Epidemiology of Buruli ulcer cases and a potential screening test for exposure by Avumegah, Michael Selorm
 
 
 
 
 
 
 
 
 
EPIDEMIOLOGY OF BURULI ULCER CASES AND A 
POTENTIAL SCREENING TEST FOR EXPOSURE 
 
 
 
 
 
by 
 
 
MICHAEL SELORM AVUMEGAH 
BSc. Biological Sciences (Hons); MSc. Biology. 
 
 
 
 
 
 
 
Submitted in fulfilment of the requirements for the degree of 
 
Doctor of Philosophy  
 
 
 
 
 
 
 
 
 
 
 
Deakin University 
 
May, 2018 


Acknowledgements 
 
 
 
 Acknowledgements 
 
I would like to express my deepest appreciation to the following institutions for their 
contribution to my PhD experience: Financial support was provided by Deakin University 
(Australian Post-graduate Award), Barwon Health and CSIRO-Australian Animal Health 
Laboratory (AAHL) (Top-up Scholarship). Deakin University and Barwon Health 
supported attendance at local and international conferences. 
For expert guidance and advice, my appreciation goes to Prof. Soren Alexandersen, Prof. 
Eugene Athan both affiliated with Deakin University, GCEID and Barwon Health, Dr 
Wojtek Michalski and Dr Anthony Keyburn from CSIRO-AAHL for their invaluable 
mentoring throughout my PhD endeavour; for their constructive critiques and advice. 
Thanks also to Dr Melanie Thomson for her support and supervison during the initial 
stages of my PhD work. It has been an absolute pleasure working under their guidance.  
Many thanks go to Dr Isabelle Jeanne for her expert advice on the software (qGIS and 
SatScan) used in data analysis and providing initial comments on the epidemiology 
chapter in this thesis. Thanks also to Ms Ee Laine Tay (Communicable Disease 
Epidemiology and Surveillance, Health Protection Branch of Department of Health and 
Human Services, Victoria, Australia) for sharing the Victoria Buruli ulcer database with 
us for this study.  
My appreciation also goes to Dr Fiona Collier, Dr Jason Hodge and Dr Anthony Chamings 
(GCEID) for their useful advice and supportive technical assistance. I wish to thank all 
staff and PhD students at GCEID and IMPACT, especially to Mr Tarka Raj Bhata for his 
assistance during my ELISA and Western blot experiments.  
Acknowledgements 
 
 
 
My thanks also go to Mr Gary Beddome and Mr Brian Shiell from AAHL’s Bioassay 
Research and Development laboratory for their assistance in protein quantitation of 
samples (GB), and for guidance and tuition in mass spectrometric analyses (BS).  
I wish to thank A/Prof. Daniel O’Brien from Barwon Health for his support in acquiring 
serum samples from Buruli ulcer patients for the research work. My gratitude also goes to 
Alana Sarah, Bree Sarah, Kate Ellis, Jo Chambers and Sue Lamb from the Clinical Trial 
Unit (Barwon Health) for their invaluable assistance during volunteers’ specimen 
collection for the serological study. Thanks also go to Dr John Stenos, Ms Chelsea Nguyen 
and Ms Kristen Larcombe from Australian Rickettsial Reference Laboratory, Geelong for 
the serum samples from Tasmania. 
My sincere appreciation also goes to Prof. Tim Stinear (Peter Doherty Institute for 
Infection and Immunity, Melbourne) for supplying me with the Mycobacterium ulcerans 
strain as well as the seven M. ulcerans gene constructs for the recombinant protein work. 
Many thanks to Ms Lydia K. Avumegah and Ms Senam Ahiaga-Dagbui for proof-reading 
the first draft of this thesis. Thanks also to Dr Derek Davey and Dr Heather Hallam (DVM) 
for proof-reading the final draft. 
My sincere appreciation goes to my family: to my parents, Uncle Raph and Auntie Naana, 
my brothers (Andrew, Eric, Kwesi, Mawuli and Kenneth) for their love, support and 
confidence in me, and constant encouragement to do my best in all my endeavours. 
Finally, I would like to express my deepest gratitude to my wife, Lydia (and my daughter, 
Edem) who has supported me immeasurably through this intense journey with patience, 
encouragement, prayers and unconditional love. 
Acknowledgements 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
...but I didn't quit because of ONE.  
I've been through hell and high waters, please let me be.  
        
        To God be the glory 
                    Efo Selorm 
 
Communications and awards 
 
i 
 
Communications 
 
Conference presentations 
 
1. Michael S. Avumegah, Brian J. Shiell, Eugene Athan, James W. Wynne, Anthony 
Keyburn, Soren Alexandersen, Wojtek P. Michalski (2017). Production and 
proteomic characterizations of protein preparations from Mycobacterium 
ulcerans cultures. Barwon Health-Deakin University Research Week Victoria, 
Australia. November 2017 (poster presentation). 
 
2. Michael S. Avumegah, Eugene Athan, Daniel P. O’Brien, Isabelle Jeanne, James 
W. Wynne, Wojtek P. Michalski, Melanie Thomson, Soren Alexandersen (2016). 
One Health Approach – The way forward to mitigate emergence and re-
emergence of Bairnsdale ulcer (poster presentation). The 4th International One 
Health Congress & 6th Biennial Congress of the International Association of 
Ecology and Health. Melbourne, Australia. December 2016 (poster presentation). 
 
3. Michael S. Avumegah, Eugene Athan, Daniel P. O’Brien, Isabelle Jeanne, James 
Wynne, Wojtek Michalski, Melanie Thomson (2015). Mapping the spatial 
distribution of Bairnsdale ulcer cases in Victoria. BacPath 13: Molecular 
Analysis of Bacteria Pathogens Conference 2015, Victoria, Australia. September 
2015 (poster presentation). 
 
4. Michael Selorm Avumegah, Eugene Athan, Daniel P. O’Brien, Isabelle Jeanne, 
James Wynne, Wojtek P. Michalski, Melanie Thomson (2015). Mapping the 
spatial distribution of Bairnsdale ulcer cases in Bellarine Peninsula. Victoria 
Infectious and Immunity Network Symposium (VIIN). Victoria, Australia. 
October 2015 (poster presentation). 
 
5. Michael S. Avumegah, Eugene Athan, Daniel P. O’Brien, Isabelle Jeanne, James 
Wynne, Wojtek P. Michalski, Melanie Thomson (2015). Bairnsdale ulcer 
disease-current trend in Victoria. Barwon Health-Deakin University Research 
Week Victoria, Australia. November 2015 (poster presentation). 
 
 
Communications and awards 
 
ii 
 
Awards 
 
June-August 
2018 
Deakin University School of Medicine write-up scholarship.      
2014-2018 Australian Postgraduate Award and Deakin University Postgraduate 
Research Scholarship.  
2014-2018 CSIRO Australian Animal Health Laboratory Top-Up PhD 
Scholarship. 
2012-2014 Master’s degree DANIDA Scholarship (Denmark). 
 
 
 
 
 
 
 
 
Abstract 
 
iii 
 
ABSTRACT 
 
Buruli ulcer (BU) is a subcutaneous necrotic infection of the skin caused by 
Mycobacterium ulcerans. It is the third most common human mycobacterial disease after 
tuberculosis and leprosy. Currently, the most common methods for diagnosis of the 
disease are polymerase chain reaction, histopathology and culture of the pathogen. These 
methods have their infrastructural and resource challenges. Additionally, BU has a 4.5 
months median incubation period. The infection rate is believed to be under-reported due 
to the lack of a rapid and easy to use screening test, among other factors. There has been 
report of increasing BU infection rate in Victoria, Australia. Development of a serological 
screening test would be beneficial to more accurately assess M. ulcerans exposure as well 
as determine the natural history of infection. This requires dedicated antigen preparations 
reproducibly derived from M. ulcerans. Descriptive and explorative epidemiology in this 
study has shown that increases in BU cases began in 2011. Cases were mainly located on 
the Bellarine and Mornington Peninsulas with increased susceptibility among the group 
of over 60 years of age. Sera from 10 confirmed BU patients and 20 healthy endemic 
controls in an initial serological survey using 12 in-house culture preparations and four M. 
ulcerans recombinant proteins for antibody responses specific to these antigens by ELISA 
and Western blot were highly variable. However, in ELISA, the M. ulcerans culture 
preparation designated Batch D and the recombinant protein hsp65 were highly reactive 
in BU patients’ sera compared to healthy controls. The ELISA test using Batch D had 
90% sensitivity (CI = 55.50 - 99.75%) and a specificity of 95% (CI = 75.13% - 99.87%) 
at the optimum cut-off. The ELISA with Hsp65 as test antigen had only 50% sensitivity 
(CI = 18.71% - 81.29%), but 95 % specificity (CI = 75.13% - 99.87%) at the optimum 
Abstract 
 
iv 
 
cut-off. Protein composition of extracts were determined by mass spectrometry analysis 
and the identity of 733 distinct M. ulcerans proteins were confirmed. Present in all samples 
were the well-known mycobacterial proteins: chaperone (dnaK), 10 kDa chaperonin 
(groS), 60 kDa chaperonin 1 and 2 (grosL1 and 2), chaperone protein (clpB) and the 
conserved secreted antigen (Wag31). In addition, comparative amino acid sequences of 
protein extracts showed that 17 M. ulcerans distinct proteins: ilvB1_1, mlsA1, mlsA2, 
mlsB, MUL_0705, MUL_0838, MUL_1269, MUL_1620, MUL_2683 MUL_2952, 
MUL_3118, MUL_3189, MUL_3300, MUL_4290, MUL_4933, MUL_4925 and 
MUL_4926 did not appear to have a homologue in the common pathogenic mycobacteria 
(M. avium subsp. paratuberculosis, M. bovis, M. leprae and M. tuberculosis). Purification 
of these proteins could be useful to determine their suitability as candidate antigens. There 
is a prospect for this protocol to be developed into a tool for disease surveillance and 
identify exposure or overt disease in at “risk communities”. More work is needed for 
validation in particular testing more BU cases and endemic and non-endemic controls. 
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CHAPTER 1 
 
1. General introduction 
 
Buruli ulcer (BU) is a skin infection caused by the bacteria Mycobacterium ulcerans. The 
progression of the disease is marked by destruction of the subcutaneous skin layer, which 
sometimes damages nerves and blood vessels (1,2). Buruli ulcer is the most common term 
for the disease, however, it is also known as Bairnsdale ulcer (2), Daintree ulcer (3), 
Kumusi ulcer (4), Mossman ulcer or Searle ulcer (5) depending on the geographical region 
of original detection (6).  
BU has been reported in over 33 countries in the tropics and sub-tropics (7), with very few 
cases reported in temperate areas (8). In Australia the sub-tropical cases are mainly within 
Queensland (3). Cases in the temperate regions include the temperate region in Australia 
(i.e. Victoria) (9). Some cases have also been reported in Asia and the Americas (10) 
(Figure 1-1).  
In the tropics, the highest prevalence is in the West and Central Africa regions, including 
countries like Ghana, Cameroon, Democratic Republic of the Congo (DRC), Cote 
d’Ivoire, Togo, Angola, Benin and Nigeria (11,12). Total reported cases of infection in 
West Africa has exceeded 30,000 in the last 20 years (11,13). A previous countrywide 
survey in 1999 of BU infections in Ghana reported an incidence rate of 20.7/100,000 
persons, which surpassed cases of leprosy. A similar incidence rate of 21.5/100,000 
persons has been reported in Benin, which is higher than cases of either tuberculosis or 
leprosy in that country (14–16). In these regions, the disease is usually associated with the 
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rural poor population, where access to medical facilities is limited and inadequate, and 
many people rely solely on alternative medicine (17). The national incidence rate in 
Australia is less than 1 in 100,000 persons. However with the current increasing trend in 
Australia, the incidence rate could be many times higher in endemic areas (18). 
 
Figure 1-1: Epidemiology of Buruli ulcer worldwide. 
World map showing BU endemic countries. Countries actively reporting cases are in red whereas previously reporting 
countries are in green. Countries with no known cases are unshaded. Adapted from BU website managed by WHO 
(http://www.who.int/mediacentre/factsheets/fs199/en/ ). 
 
The pathogen, M. ulcerans belongs to the Order-Actinomycetales, Family-
Mycobacteriaceae and genus-Mycobacterium (19). It is also a member of the atypical or 
non-tuberculous mycobacteria (NTM). Atypical, are mycobacterial species that do not 
cause tuberculosis or leprosy, e.g. M. avium, M. intracellularae, M. kansasii, M. xenopi, 
M. chelonae, M. marinum and M. fortuitum (20–22).  The disease is currently the third 
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most common mycobacterial disease in humans after tuberculosis and leprosy (23,24).  
The necrotic nature of BU has been attributed to Mycolactone, a toxin produced by M. 
ulcerans (25–27). Mycolactone, a polyketide-derived macrolide is a major secondary 
metabolite. It has been demonstrated both in vitro and in vivo in mice and guinea pigs by 
injection of 100 μg of the toxin to result in the debilitating lesions observed in the BU 
disease through cytotoxicity, immunosuppression and immunomodulation (27–29). 
The exact mode of transmission of BU is unknown; however, outbreaks  have usually 
been reported from areas close to aquatic environments (4,6,30,31). Extensive 
environmental sampling of soil, water, plants, insects etc. close to wetlands in endemic 
areas in Africa have had samples testing positive for M. ulcerans target sequence, IS2404 
(32–37). Among all the environmental samples collected in Africa, aquatic insects, in the 
Order: Hemiptera: Families Naucoridae and Belostomatidae are suspected transmission 
vectors (6,34,38,39). The involvement of mosquitoes as vectors and mammals (e.g. 
possums) as a reservoir have also been reported in Australia (40,41). Climate change as 
well as anthropogenic activities such as dam creation, new constructions, deforestation, 
agricultural activities and arsenic leakage into water bodies by mining activities have all 
been examined in relation to increase in the incidence of BU (6). Host factors such as age 
and gender in some areas are regarded as non-environmental risk factors (6,11). In Africa, 
it has been observed that children younger than 15 years and adults older than 79 years 
are more susceptible (42). In Victoria, BU is prevalent in the older population over 60 
years. This has been attributed to immunosenescence (43,44). Though gender has not 
conclusively been linked with BU, one study has reported males present more cases in 
Chapter 1 
 
7 
 
Africa. This might be due to immunological or sociocultural factors. More research is 
required to understand gender disparities (42,45). 
In terms of the anatomical presentation of BU, more ulcers have been reported on the 
lower limbs than the upper limbs. The exact reason for this differential is unknown, 
however, it has been suggested that because the lower limbs are close to the ground or soil 
exposure that could be one plausible explanation. BU has also been reported on the head, 
face, neck, buttocks, fingers and trunk (14,46). 
WHO classified BU as an emerging neglected tropical disease (NTD) in 1998 (13). NTDs 
are a subdivision of infectious diseases in the tropics that affect the world’s poorest people, 
e.g. Yaws, Trachoma, Leprosy etc. Over the years, WHO and funder agencies have 
neglected the control of some diseases to a certain degree and more attention has been 
given to diseases like malaria, HIV/AIDS and other poverty reduction projects (47,48).  
BU presents a huge socio-economic burden on affected individuals particularly those 
living in rural Africa. These areas usually lack basic social infrastructure like proper roads, 
hospitals and potable water. The inhabitants often are subsistent farmers growing crops to 
support their families. The estimated cost of treating BU per patient in Ghana as of 1996 
was USD $ 958.74 (17). In Australia, as of 2004, the estimated cost of diagnosing and 
treating BU was AUD $ 14, 608 (49). It must be mentioned that BU treatment in medical 
centres has been made free in most African countries. However, the non-medical (e.g. 
transportation and caregivers)  and socio-economical cost could be substantial on patients 
(17,50,51).  
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Due to a lack of proper social welfare programs in rural communities in Africa, patients 
have to bear the full cost of these non-medical treatment (17,50,51). The average income 
for a farm labourer is less than $1.00 (USD) per day. Since many cannot afford the cost 
of treatment, they resort to traditional healers. By the time the disease is reported to 
medical centres for proper care, it had reached an advanced lesion stage and is difficult to 
manage. This results in complications such as vasculitis and osteomyelitis, leading to 
contracture deformities or amputations. These complications mean that the individual(s) 
may not be able to work and lose income. The long-term impact of the infection leads to 
lengthy hospitalization, disruption to the income stream of breadwinners and poor school 
attendance of affected children (17,52,53).  
Currently, WHO recommended diagnostic methods of BU include: (i) the cultivation of 
M. ulcerans from a biopsy, (ii) histopathology and microscopic detection of acid fast 
bacteria in a tissue biopsy and (iii) PCR detection of M. ulcerans DNA sequence IS2404. 
Any two or more of these tests is required for a confirmed BU diagnosis. In some cases, 
external quality assurance (EQA) is encouraged and required from a reference laboratory 
(54). This is important for two main reasons: firstly, many ulcers have the same physio-
pathological features of BU and secondly, none of the diagnostic methods is of 100% 
sensitivity and specificity. Therefore, performing at least two diagnostic methods and 
EQA may remove the chance of misdiagnosis of BU (41,46,55). 
BU patients’ serum profile shows characteristic absence of inflammatory response during 
the acute phase of the disease. This has been attributed to the immunosuppressive nature 
of mycolactone (56). It has been reported that BU patients have significantly reduced 
expression of interferon gamma (γ-IFN) in their peripheral blood mononuclear cells 
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(PBMC) compared to healthy controls (57,58). IFN is an important mediator of innate and 
adaptive immunity. IFN is involved in the activation of macrophages (59,60). The reduced 
proliferation of cell mediated responses has been suggested to  account for many of the 
pathophysiological features of the disease as seen by indolent inflammation and oedema 
at the site of infection (58,61). The lack of effective cell-mediated (CMI) response has 
also been reported in other mycobacterial diseases such as tuberculosis, leprosy and 
Johne’s disease in livestock. This has made the development of screening tests based on 
CMI or humoral immunity difficult  (62–65). 
However, research to identify unique antigens specific for M. ulcerans for screening 
purposes has gained ground and many laboratories have attempted to develop culture 
filtrates as well as recombinant proteins for such purposes. More studies are therefore, 
required to optimise a test for M. ulcerans exposure or infection (11). 
1.1 Research priority by WHO 
WHO launched the Global Buruli Ulcer Initiative (GBUI) program in 1998. The mandate 
of GBUI was to co-ordinate efforts in BU research. The first International Conference on 
Buruli ulcer control and research took place in Yamoussoukro, Côte d’Ivoire. The 
Yamoussoukro communiqué brought attention to the severity of the morbidity of BU and 
concerns about its emergence. GBUI identified five key research areas as most likely to 
add to the knowledge database of the disease: 
1.  Identification of the mode of transmission; 
2.  Development of methods for early diagnosis; 
3.  Improvement of treatment;   
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4. Bacillus Calmette–Guérin (BCG) trials and development of new vaccine, and  
5. Cultural and socio-economic studies.  
Although significant research effort has been made in these five key areas, the full 
understanding of the disease is yet to be realized (24,55). It is therefore the focus of the 
current study to address the first two points of the GBUI key research areas: transmission 
and early diagnosis of BU using Australian population in the state of Victoria. 
1.2 Aims, hypothesis and objective 
Alopes and Searls reported the first case of Buruli ulcer in Bairnsdale, East area of 
Gippsland of Victoria in the late 1930s and 1940s (66). The incidence of the disease then 
became almost non-existent for several decades until there was a sudden re-emergence of 
cases in 1992-1994 around the Mornington Peninsula, Western Port Bay, Phillip Island 
and from the Bellarine Peninsula, all in Victoria (9). Current reports indicate that among 
these areas, cases from Bellarine peninsula have been rising since 2010 and the reason is 
unknown (18,67).  
The objective of this study is to understand the current trend in the distribution of BU 
cases in Victoria as well as to develop protein preparations from M. ulcerans cultures for 
use in a potential screening test of exposure to this pathogen. It was hypothesised that a 
standardised approach in protein preparations from M. ulcerans cultures could be vital for 
serological screening for M. ulcerans exposure. The aims of this study can be divided into 
three blocks: 
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Aim 1: To perform explorative and descriptive epidemiology, as well as space-time 
analyses using the Victorian Department of Health BU database to understand migration 
and transmission patterns and possibly identify local environmental risk factors. 
Aim 2: To use a standardised approach to produce protein preparations from M. ulcerans 
cultures. 
Aim 3: To assess the usefulness of in-house protein preparations as well as suggested 
recombinant proteins in a serological survey of M. ulcerans exposure. 
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CHAPTER 2 
 
2 Systematic review: in pursuit of screening tests for Mycobacterium ulcerans 
exposure 
 
2.1 Background 
 
It has been reported that not all people exposed to or infected with M. ulcerans develop 
clinical signs of BU (68,69). Currently, there is no standardised definition for M. ulcerans 
exposure, infection and BU disease. Establishing a clear epidemiological distinction has 
been difficult due in part to lack of appropriate tests. The available methods for laboratory 
detection of the bacilli in ulcers that are approved by WHO in medical centres include:  
microscopic detection of acid-fast bacteria (AFB), isolation and cultivation of M. 
ulcerans, histopathology and polymerase chain reaction (PCR) for M. ulcerans insertion 
sequence IS2404 (55,70). IS2404 PCR, considered as gold standard, is routinely used in 
laboratories for BU confirmation. Histopathology and microscopy are also used when 
necessary for quality assurance purposes (71). The only method that detects viable bacilli, 
is the isolation and cultivation of M. ulcerans (which requires 1.5 to 3 months) (54). 
Unfortunately some of these tests are not rapid enough (e.g. cultivation of bacilli) for 
direct patient care and/or require trained personnel with access to well-equipped 
laboratory facilities (e.g. PCR, histopathology and microscopy), which are usually not 
available in remote parts of West Africa. The WHO recommends two laboratory tests for 
BU confirmation in endemic settings (46,54). There is a call to develop an easy, reliable 
and rapid test for BU diagnosis and surveillance within at “risk communities” to aid rapid 
detection and treatment of the disease. (13,54,71). Screening tests based on serology have 
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been suggested but previous studies have found cross-reactivity with other mycobacterial 
infections difficult to overcome (68,72). Recent advances in TB diagnosis that could 
potentially also be useful in BU diagnosis and needs to be explored, is quantification of 
cytokine responses (cell-mediated test). Current whole-blood (cytokine) assays for TB 
diagnosis include cell mediated response assays such as interferon-gamma release assays 
(IGRAs) available as QuantiFERON and T-SPOT test (73,74). It has been suggested that 
a similar approach is one way to develop improved screening tests for M. ulcerans 
infection. This requires thorough investigation (69,72,75,76). The objective of this review 
is to discuss general immune responses among BU patients as well as to review outcome 
of studies that have aimed to develop a serological and/or cell-mediated screening test(s) 
for M. ulcerans infection or exposure. This review will also discuss the prospects and 
challenges of the development of these screening tests and provide perspective for future 
research in this important area. 
2.2 Methodology 
 
2.2.1 Data Sources and Search Strategy  
 
The following online reference search engines and databases were used to search for 
relevant articles: PubMed, PubMed central (1930 to 2017), Cochrane library, Web of 
Science /ISI Web of Knowledge (1930 to 2017) and Buruli ulcer disease database 
maintained by WHO in Geneva, Switzerland (http://www.who.int/buruli/en). The search 
terms and keywords used included the following: “Buruli ulcer”, “Mycobacterium 
ulcerans”, “Mycobacterium ulcerans culture filtrate”, “Burulin”, “mycolactone”, 
“immune response”, “interferon-gamma”, “T-cells”, “cytokines”, “Quantiferon”, 
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“interferon gamma assay”, “serology”, “BCG vaccine”, and “diagnostic test”. Some of 
the keywords were also used in combination, e.g. “diagnostic test for Buruli ulcer”. The 
keywords were chosen based on the title of this paper, as well as terminology used in 
current research towards the development of a screening test. 
2.2.2 Study selection  
 
The search strategy was constructed, using the previous systematic review on tuberculosis 
by Pai et al., 2004 (77) as a guide, to identify all available, published in English studies 
on any of the following aspects of immune responses:  
(i) assessment among patients with active BU or healed ulcers;  
(ii) assessment among those with healed BU or household contacts and healthy 
controls; 
(iii) direct comparison between active BU patients, healed patients and healthy 
controls, and  
(iv) indirect comparison between active BU patients, healed patients and healthy 
controls (e.g., correlation with exposure to M. ulcerans).  
2.2.3 Data extraction and analysis 
 
Articles that met the objective of serological or cell-mediated screening tests for M. 
ulcerans infection or exposure were reviewed. Rationale for the study, study design, year 
of study, M. ulcerans strain, participants, country and results were then extracted. Data 
collation followed the guidelines for review structure in the PRISMA checklist 
(http://www.prisma-statement.org/documents/PRISMA-P-checklist.pdf). Data was then 
summarized for each article to give an overview of current research work on the attempt 
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to develop a serological and/or cell-mediated screening test for BU disease. Because 
studies varied greatly in their design, execution and outcomes, meta-analysis was not 
conducted for this review. 
2.3 Results and discussion 
 
Out of the initial 117 publications, only eight original research studies met the criteria for 
inclusion on the development of serological and/or cell-mediated test, the earliest being 
from 1952 and the most recent from 2014. The clinical features of BU and immune 
responses of active patients were also reviewed (Table 2-1).  
Table 2-1: Selected keywords and the number of publications found by individual 
databases and search engines. 
 
Note: words and numbers in bold were the initial 117 reviewed publications from which eight studies met the criteria 
for inclusion as attempts on developing serological and/or cell-mediated screening tests. 
 
 
Keywords 
 
PubMed 
PubMed 
central 
Web of Science/ ISI 
Web of Knowledge 
Cochrane 
library 
Google  
Scholar 
Buruli ulcer 877 997 480 2 6,810 
Mycobacterium ulcerans 1,065 1,710 571 1 12,600 
Mycobacterium ulcerans 
culture filtrate 
 
8 
 
134 
 
0 
 
0 
1,040 
Burulin 4 27 1 0 151 
Mycolactone 191 388 87 1 1,690 
Immune response in Buruli 
ulcer patients 
 
22 
 
276 
 
0 
 
2 
2,340 
Diagnostic test for Buruli 
ulcer 
28 279 1 1 3,430 
Screening test for Buruli 
ulcer 
41 486 1 2 2,040 
Quantiferon for M. 
ulcerans 
0 0 0 0 226 
Serology for Buruli ulcer 
patients 
3 51 0 0 836 
BCG vaccine and Buruli 
ulcer  patients 
11 100 0 0 1,010 
Interferon-gamma 
response in Buruli ulcer 
patients 
12 82 1 0 372 
Total 2,262 4,530 1,148 9 32,545 
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2.3.1 Clinical features of BU and host immune response to M. ulcerans 
 
For the purposes of this review, it is important to define some general terms used in this 
section for clarity as there are no designated definitions for M. ulcerans exposure, 
infection and disease. The definitions used here are what has generally been reported by 
other studies (78,79). The exposure refers to contact with M. ulcerans and thus have 
developed an immunological response, the infection describes colonisation and/or the 
detection/isolation of the pathogen from the host without clinical symptoms of BU. The 
diagnosis of BU disease means the evidence of M. ulcerans infection with clinical 
symptoms. These definitions are useful to provide clinicians and researchers with a 
working framework for epidemiological purposes. With regard to M. ulcerans exposure 
and infection, effective assessment could be based on serological and/or cell-mediated 
tests and requires investigation.  
M. ulcerans is a slow growing environmental mycobacterium (62) with a 4.5 months 
median incubation period of developing BU (80). The WHO has classified BU into two 
clinical forms, namely non-ulcerative and ulcerative. The non-ulcerative form manifests 
usually with no open lesions but may progress to ulcerative form from as early as four 
weeks if not treated (46). There are four forms of the non-ulcerative stage, the first form 
initially appearing as a painless papule about 1 cm in diameter with the area around the 
papule usually reddened. This form is mostly reported in Australia (46). Another form is 
the appearance of a painless but itchy nodule or swelling protruding from the 
subcutaneous skin layer about 3 cm in diameter. The area can be distinguished by the 
unique colouration compared to the surrounding skin layer (46). The third form is called 
a plaque, usually a firm well delineated lesion on the skin more than 3 cm in diameter and 
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often also painless and characteristically reddened (46). Lastly, the oedematous form of 
the non-ulcerative stage of disease has also been described (46). This is normally an 
extensive non-pitting swelling with no clearly defined margin. Fever has been reported to 
follow this form. The ulcerative form is presented by extensive necrosis of the 
subcutaneous layer. The ulcers usually have undermined edges with peripheral 
indurations. The floor of the ulcer has a whitish appearance (46). 
Category I ulcers are defined as a single lesion less than 5 cm in diameter. Category I 
ulcers are usually treatable with antibiotics. Ulcers with a diameter of 5 to 15 cm are 
referred to as category II. They can be treated with a combination of antibiotics and 
sometimes surgery. Ulcers greater than 15 cm in diameter and/or lesions present on eyes, 
breast and genitalia, or with a complication of osteomyelitis fall into category III. 
Treatment regimen for category III ulcers includes both antibiotics and surgery (Table 2-
2) (41,55). 
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Table 2-2: Summary of categories, diagnosis and recommended treatment of Buruli 
ulcer. 
 
 
Treatment category 
 
 
Form of disease 
 
 
Diagnosis  
 
 
Recommended treatment 
regimen 
 
 
 
Category I 
Single small ulcers includes: 
- Nodules 
- Papule 
- Plaque 
- Ulcers less than 5 cm in diameter 
 
 
 
Histopathology  
Isolation  
PCR 
 
Cure without surgery but  
Complete 8 weeks antibiotic 
treatment 
 
 
 
Category II 
 
Non-ulcerative and ulcerative plaque 
and oedematous forms 
 
Single large ulcers 
5-15 cm in diameter 
 
 
Histopathology  
Isolation  
PCR 
 
Complete antibiotic treatment 
before surgery  
 
If ulcer is near a joint maintain 
same movement as on unaffected 
side 
 
 
 
 
 
Category III 
 
- Ulcers on the head, neck and on face 
 
- Mixed forms such as osteitis, 
osteomyelitis and joint involvement 
 
- Multiple lesions and osteomyelitis 
 
- Extensive lesions > 15cm diameter  
 
 
 
 
Histopathology  
Isolation  
PCR 
 
Complete antibiotic treatment 
before surgery (if possible) 
 
If ulcer is near a joint maintain 
same movement as on unaffected 
side 
 
Table 2-2 was adapted from the book “Treatment of Mycobacterium ulcerans disease (Buruli ulcer). Guidance for Health workers 
(2012) (46). 
 
Initial BU diagnosis is usually based on clinical features and experience of the clinician 
(81) and  the detection of IS2404 target sequence in specimens are used for confirmation. 
In endemic areas in Africa a second test (e.g. AFB staining and microscopy) and EQA 
may be required (54). The same cannot be said about M. ulcerans exposure or infection 
which could be asymptomatic and has been reported (68,72). There is currently no test for 
exposure to or infection with M. ulcerans. The development of a screening test based on 
cell-mediated responses for BU might be difficult as these responses are acute and 
transient due to the destructive nature of mycolactone (29,82,83). On the other hand, 
humoral responses (antibody mediated) is relatively long lasting and could detect the 
presence of exposure/infection (84,85).  
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2.3.2 Immune responses to M. ulcerans disease 
 
Immune response generation is the body’s defence mechanism against foreign agents. The 
response can be innate, as in non-specific and not acquired from encounter with a foreign 
agent, and/or adaptive which is acquired from encounter with external agents and is 
specific (86). Humoral and cell-mediated immunity (CMI) are another way of categorizing 
the defence system, the former is usually immunity in body fluids and is generally 
antibody-mediated whereas the later pertains to cytokines participation (86). Antibodies 
are produced by the B-lymphocytes (B-cells) and CMI are generated by the T-
lymphocytes (T-cells). T-cells can further be divided into e.g. T-helper cell 1 (Th1), T-
helper cell 2 (Th2) and cytotoxic T-cell (Tc). Th1 (produces e.g. gamma interferon: IFN-
ϒ and Interleukin 12: IL-12) are involved in the activation of macrophages and Th2 (e.g. 
IL-4, IL-5, IL-6, and IL-10) signals the proliferation of B-cells (antibodies) during 
infection. On the other hand, Tc are involved with the elimination of non-self or infected 
cells (86,87). 
At the cellular level in BU immunity, mycolactone has been observed to act as an 
immunosuppressive toxin and as such there is marked non-proliferation (anergy) of  Th1 
type cells compared to healthy controls (57,76,88). Various in-vitro studies on immune 
responses among active BU patients (at pre-ulcerative and ulcerative stage), healed BU 
patients and healthy household controls have come to similar conclusions 
(57,58,76,83,89–105). It has thus been suggested that high levels of Th1 cytokines may 
prevent development of BU (57,58,76,83,89–105). This requires further investigation. 
Table 2-3, shows some major cytokines assessed in BU patients and healthy controls. The 
predominant immune response observed in BU patients has usually been Th2 type 
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response, which indicates the presence of antibody against M. ulcerans in sera of BU 
patients. This antibody specific response has not been known or assessed to offer any 
protection against developing BU (57,106). 
Table 2-3: Major cytokines studied in Buruli ulcer disease. 
Name Major source Biological activity  References 
 
G-CSF (granulocyte 
colony-stimulating factor) 
 
Fibroblasts, monocytes, 
macrophages 
 
Stimulates neutrophil production in bone 
marrow 
 
(102,107) 
GM-CSF (granulocyte-
macrophage colony-
stimulating factor) 
 
T cells, macrophages, monocytes 
 
Differentiation of myeloid progenitor cells 
 
(102) 
 
IFN-α/-β 
 
Macrophages (IFN-α), fibroblasts 
(IFN-β) 
 
Antiviral 
 
(94,98) 
 
IFN-ϒ  
 
T cells, NK cells 
 
Activates macrophages, Th1 
differentiation  
 
(57,58,76,83,8
9–105) 
 
IL-1 (interleukin-1) 
 
Macrophages 
 
Cell activation, fever 
(89) 
 
IL-2 (interleukin-2) 
 
T cells 
 
T cell growth and activation 
 
(89,102,108) 
 
 
IL-3 (interleukin-3) 
 
T cells 
 
Hematopoiesis 
 
(105) 
 
 
IL-4 (interleukin-4) 
 
T cells, mast cells 
 
B cell proliferation and switching to 
immunoglobulin E (IgE) Th2 
differentiation 
 
(105) 
 
IL-5 (interleukin-5) 
 
T cells 
 
Differentiation of eosinophils, activates B 
cells 
 
(105,108) 
 
IL-6 (interleukin-6) 
 
B cells 
Differentiation; plasma cells/proliferation; 
Th1, Th2 cells/activation; CD8+  
cells/differentiation, proliferation 
 
(105,108) 
 
IL-7 (interleukin-7) 
 
Bone marrow stroma cells 
 
T cell progenitor differentiation 
 
(105,109) 
 
 
IL-8 (interleukin-8) 
 
Macrophages, T cells 
 
Chemotactic for neutrophils 
 
(105,109) 
 
IL-10 (interleukin-10) 
 
Macrophages, T cells 
 
Inhibits activated macrophages and 
dendritic cells 
 
(109,110) 
 
IL-12 (interleukin-12) 
 
Macrophages 
 
Differentiation of T cells,  activation of 
NK cells 
 
(83,94) 
 
IL-13 (Interleukin-13) 
 
Macrophages 
Monocytes,  macrophages/down-
regulation; B cells/activation,  
differentiation 
 
(105,109) 
 
M-CSF (monocyte-
macrophage colony-
stimulating factor) 
 
T cells,  macrophages,  monocytes 
 
Differentiation of myeloid progenitor cells 
 
(105,107) 
 
TNF- α (tumor necrosis 
factor alpha) 
 
Macrophages,  T cells 
 
Cell activation,  fever,  cachexia,  
antitumor 
 
 
(93,96,97,99,1
00,105,107) 
TNF-β (tumor necrosis 
factor beta),  LT 
(lymphotoxin) 
 
T cells 
 
Activates  polymorphonuclear neutrophil  
(PMNs) 
 
(93,96,97,99,1
00,105,107) 
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2.3.3 Studies that have attempted to develop a serological and/cell-mediated 
screening test 
 
A systematic review by Sakyi et al.,  2016 (71) provides an in-depth review on various 
clinical and laboratory methods of screening for M. ulcerans infection or diagnosing BU. 
Sakyi et al., 2016 reviews the sensitivity and specificity of various techniques ranging 
from microscopy, culture of the bacilli, histopathology, PCR (including dry reagent based, 
DRB; Real-Time; Nested and loop mediated isothermal amplification, LAMP assay), thin 
layer chromatography for mycolactone detection and briefly on serology.  
All the studies that have attempted the development of serological and/cell-mediated 
screening tests have always started with the production of diverse antigens of the infective 
organism - M. ulcerans. The antigen preparations were either derived from bacterial 
cultures as refined (precipitated protein derivatives-PPD) or crude (culture filtrates) 
protein preparations or prepared as individual recombinant proteins. Culture preparations 
are usually whole cell homogenate/lysates of the bacilli and therefore contain membrane 
proteins, cytoplasmic proteins,  polysaccharides,  lipids etc. (111,112). Recombinant 
proteins are generated from specific recombinant DNA and can easily be purified for 
downstream applications (113–115).  
2.3.4 Immune response to M. ulcerans derived protein preparations 
 
An earlier study to determine the antigenic structure of M. ulcerans and a group of 
Mycobacterial species (M. tuberculosis, M. muris, M. avium, M. ranae and M. phlei) done 
by Fenner et al., 1952, showed that, indeed, mycobacteria do share many anteginic 
properties. Though  Fenner et al., cell derived preparations were used in serological 
experiment, it was not directly used in BU studies. The earliest BU research using cell 
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derived protein preparation from M. ulcerans was in 1975 by Stanford (75). The antigenic 
preparation, Burulin as was called, was used in a skin-test in Zaire (now DRC) and 
Uganda. The cell-mediated delayed-type hypersensitivity (DTH) arising as induration on 
the skin was used to determine positive reaction. Dobos et al., study in 2000 later 
described an attempt in using cell derived preparations in serology and cell-mediated 
experiments. The biological activity of mycolactone was also evaluated in 1997 by Robert 
et al., (61) in serological experiment to assess it usefulness in protecting against 
developing BU disease or for diagnostic purposes. For comparative serological study, M. 
smegmatis, M. phlei, M. fortuitum and M. chelonei were also tested in this Roberts et al., 
study. Four out the eight studies used M. ulcerans cell derived preparations for their 
experiments. The outcome of these four studies indeed showed prospect, however,  the 
protein preparations used in serology and/or cell-mediated experiments were not specific 
or sensitive enough for any clinical application. Mycobacterial culture preparations are 
well studied in M. tuberculosis (116–118) and the outcome was not entirely unexpected 
due to host exposure to other environmental mycobacteria and its consequent immune 
response cross-reactivity. It is important to note that researchers understanding of immune 
responses to M. ulcerans preparations has expanded based on these previous studies 
(61,106,119,120).  
2.3.5 Immune response to M. ulcerans recombinant proteins. 
 
It is a fair assumption that since cell derived antigenic preparation is a mixture of whole 
bacterial lysate, it would be nearly impossible to elucidate the most reactive components 
in serology or cell-mediated experiments without fractionation of components. The effect 
of immuno-dominant and highly expressed proteins could cutail  the ultimate effect of 
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‘would be’ important and less expressed proteins. However, the identification and 
purification of the M. ulcerans immuno-dominant 18 kDa small heat shock protein (18 
kDa shsp) by Diaz et al., 2006 (69) has no clinical application either. Four years after the 
identification of the 18 kDa shsp, Pidot et al., 2010 identified 45 M. ulcerans-specific 
antigens through a genomic study of  20 mycobacterial species compared with M. ulcerans 
(Agy99 strain),  of which 33 (18 kDa shsp inclusive)  were successfully purified and used 
in  a serological study.  Out of the eight  studies selected for review, four studies have 
utilized the 18 kDa shsp protein (Table 4) in serology and their conclusions have been 
similar in terms of lack of specificity. Although this protein may not be useful in point-
of-care practice, it could be epidemiological relevant for monitoring M. ulcerans exposure 
within at risk communities (68,69,72,121). 
Dreyer et al., 2015 article on MUL_3720 conserved surface protein was an important 
study. Though not a serological or cell-mediated study (122), their study opens up more 
investigation into the possibility of directly detecting certain unique M. ulcerans-specific 
proteins in specimens from BU patients which could be useful in antigen-capture based 
test. Further study has been done to utilize MUL_3720 and MUL_2232 (18 kDa shsp) in 
recombinant vaccine formulation to assess its efficacy to protect against BU disease but it 
was unsuccessful  (123).   
Developing a diagnostic test for BU, a mycobacterial disease, based on serology and cell-
mediated assays has been very difficult to date, due to cross-reactivity with other 
mycobacterial infections or antigens (61,68,69,72,106,119–123). This has also been 
reported in other mycobacterial disease e.g. tuberculosis (65,116,124,125). The 
widespread use of the BCG vaccine for TB  and probably environmental exposure to other 
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mycobacteria have been thought to present a challenge due to cross reactivity in all the 
BU screening studies in Africa (106).  On the other hand, in Australia, which also reports 
BU disease, there is a prospect to develop a serological and/or cell-mediated assay as the 
population contains a significant proportion of people naïve to BCG vaccination. Due to 
public health awareness and subsequent national tuberculosis eradication program 
conducted from the late 1940s,  Australia currently has one of the lowest notification rate 
for TB worldwide and mass BCG vaccination has halted since the mid-1980s (126). This 
has created a BCG naïve population in the Australian BU cohort, providing an opportunity 
for further screening to study cross-reactivity issues. 
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Table 2-4: Summary of materials and methods used in screening test studies. 
 
Study/year  
 
Country 
 
M. ulcerans 
strain used 
 
 
Culture medium 
 
 
Brief methodology 
 
 
Method for analysis 
 
Unique  
biomarkers 
 
Samples 
used   
Fenner et al.,  
1952 
Australia SF,  RS and RT LJ,  Dubos broth Heat-killed M. ulcerans were used 
to challenge rabbit to produce 
antisera for complement fixation 
test. Guinea pigs were the source 
of complement for the test. 
Complement-fixation test  -Rabbit serum 
-Guinea pig 
-Sheep 
erythrocytes 
Stanford et al.,  
1975 
 
Uganda and  
Zaire 
Uganda: strains nos. 
297 and 298 and no.408 
from Zaire. 
LJ Lysates were made from 
ultrasonic disintegration. The 
mixture was centrifuged and the 
supernatant collected. 
Lysates were used for a skin 
test 
 Burulin Skin test 
Robert et al.,  
1997 (61) 
 
Australia  8 strains of Mu isolated 
from patients in 
Queensland 
LJ,  Dubos broth Mu were cultured under constant 
agitation. Supernatant was 
harvested for crude cultural 
filtrates (CCF).  
CCF was used for in-vitro and 
in-vivo cytotoxic assays in 
animal model (rabbits and 
mice) 
Mycolactone Mice footpad 
and serum 
Dobos et al.,  
2000 (106) 
 
Cote d’Ivoire A lyophilised 
M.ulcerans S-WT 
strain from the Centres 
for Disease Control and 
Prevention culture 
collection; Atlanta 
MB 7H9 
(OADC). 
7H9TG broth 
Mu culture filtrate (MuCF) was 
produced by centrifugation and 
supernatant was concentrated at 
4oC under Nitrogen. MUCF and 
PPD responses were compared in 
BU patients. 
Skin test, western blotting 70 kDa 
38/36 kDa  
5 kDa protein 
Skin test and  
serum 
Diaz et al.,  2006 
(69) 
 
Ghana The Mu strains used: 
Democratic Republic of 
Congo (5151),  Angola 
(960657),  Ghana (97-
483),  Australia (ITM 
5147,  ITM 9540,  ITM 
9550,  and 94-1324),  
Mexico (ITM 5114),  
Malaysia (941328),  
French Guiana (ITM 
7922),  and Japan (ITM 
8756) 
 
Modified LJ and  
MB 7H10 
Some of the procedures used for 
obtaining mycobacteria lysates 
included,  heat inactivation,  bead 
beating,  centrifugation and 
collection and analysis of 
supernatant 
Immunodominant proteins 
were recognized in the Mu 
lysates by western blot and 
ELISA on human and animal 
sera. 
18kDa Serum 
Pidot et al.,  2010 
(72) 
Benin Refer to article for 
complete list 
 
Not stated Mu lysates were also used. Using 
bioinformatics and BLAST, the 
genomes of Mu was compared 
with other mycobacteria species. 
Immunogenicity of Mu 
proteins were verified using 
ELISA 
MUP045,  MUP057,  
MUL_0513,  Hsp65,  
AT- propionate,  and 
KR A) 
Serum 
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Yeboah-Manu et 
al.,  2012 (68) 
Ghana (69)  (69) Antibodies presence in sera 
were analysed using western 
blot and ELISA 
Biomarker screened for 
was the Mu Anti-18 kDa 
protein 
Serum 
Röltgenet al.,  
2014 (121) 
Ghana and 
Cameroun 
(69)  (69) The methods used for sera 
analyses were western blot 
and ELSIA 
Biomarker screened for 
was the Mu Anti-18 kDa 
protein 
Serum 
Note: LJ= Löwenstein–Jensen medium. Mod = modified    
MB= Middlebrook media. 
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2.3.6 Proposed screening tests for M. ulcerans infection 
 
Designing appropriate serological and cell-mediated assays have been met with 
challenges. Research efforts in designing better TB  diagnostic tests have not halted 
and it should not stop for BU either. The search for an inexpensive, reliable and rapid 
screening test for M. ulcerans exposure should be explored. PCR has proven to be one 
of the most effective diagnostic methods for clinical disease in many health settings 
that can afford the testing. However, screening tests based on burulin and recombinant 
proteins expression have definitely showed promise but experimental optimisation and 
standardisation are likely to be key. 
The use of aptamers designed to bind mycolactone in swab and biopsies is being 
explored. There has been an initial study in Ghana to assess the usefulness of  aptamers 
as a screening test. The initial study identified aptamers that had 50% sensitivity and 
100% specificity (127).  
Two other methods worth investigating is based on microRNA (miRNA) and  
mycolactone for screening and potentially diagnostic purposes for BU. MiRNA are 
short non-coding RNA sequences usually between 2-22 nucleotides. They are 
synthesized from longer nucleotides from animals,  plant and viral genomes as a result 
of post-transcriptional repression of gene expression (128,129). Recent publications 
have indicated that miRNA is present in body fluids and might present a new target 
for infectious disease screening (130).  
A previous study has also observed that BU patients do have circulating mycolactone 
in their body fluids (blood/serum) (131) which might provide a new target for the 
development of a new diagnostic tool. For a potential mycolactone biosensor, 
applications using graphene template could be explored. Through computer 
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simulation,  the surface of graphene could be configured as a substrate for biomolecule 
scavenging for potential biosensor applications (132–134). Mycolactone and graphene 
interaction study using computational simulation for possible application as a 
biosensor for BU diagnosis could be explored.  
2.4 Conclusion and perspectives 
 
To attempt to resolve the M. ulcerans serological and cell-mediated conundrum, there 
is a need for better standardisation of study design. These standards ought to be agreed 
upon and be accessible to researchers globally to enable meta-analysis  and obtain 
statistically relevant results. Researchers also have to understand that once M. ulcerans 
is in a host, it may potentially up-regulate a particular protein (antigen) of serological 
importance, which might never be produced in-vitro (culture medium) due to 
differences in growth conditions. This proposition is not unwarranted as M. ulcerans 
18 kDa shsp protein and other heat shock proteins/stress biomarkers are up or down-
regulated during certain adverse conditions to protect cells (135,136). There is the  
need for genomic and proteomic evaluation among different M. ulcerans strains and 
other mycobacterial species to further assess this phenomenon. 
Based on this systematic review there has been paucity of published articles or studies 
developing some sort of antigenic reagents for M. ulcerans screening. Further 
investigations need to be undertaken to focus on the identification of biomarkers 
(antigens) and development of serological and/or CMI screening tests for M. ulcerans 
exposure and potentially diagnostic purposes. In addition, the proteins identified could 
be used in combination for screening purposes. A recent publication on M. tuberculosis 
looking at point-of-care screening for wild animals used a combination of M. 
tuberculosis specific antigens as well as PPD (64). 
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CHAPTER 3 
 
3 Descriptive analysis in time and space of recorded data for Buruli Ulcer 
occurrence in Victoria over 22 years 
 
3.1 Background 
 
Victoria reported its first case of a chronic necrotic subcutaneous infection in 
Bairnsdale, a town in East Gippsland, in the late 1930s. The condition was referred to 
as Bairnsdale ulcer (66). Ulcers with a similar appearance were first observed and 
reported by Cook in 1897 in Kampala, Uganda and by Klein Schmidt in North-East 
Congo during the 1920s (23). The Uganda Buruli Group gave the disease the name 
“Buruli ulcer” (BU) because the cases they describe were first detected in Buruli 
County in Kyoga,  Uganda (137). The causative agent,  M. ulcerans,  was not fully 
described until 1948 (138). MacCallum et al., were the first to describe and publish 
reported cases from Australia of skin ulcer caused by Mycobacterium cultivable only 
on Löwenstein-Jensen medium when the incubation temperature was set lower than 
for M. tuberculosis (2,138).  After the first case in Bairnsdale, BU cases were later 
reported in regions of Northern Territory and Queensland (Figure 3-1) affecting people 
of different age groups (Table 3-1) (2,66). Since then BU has gained public health 
interest and has been reported in different states in Australia (66,138,139). In 1992-
1994, there was a major outbreak in Victoria after several years of dormancy but the 
trigger was unknown (9).  
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Table 3-1: Distribution of BU in Australia as of 1975 
 
 
Sites 
 
Number of case 
 
Age (years) 
Gender 
M              F 
 
Victoria 
3 
3 
5 
10 
2, 13, 26 
16, 15, 45 
10 
70 
3 
 
 
                     
 
     3 
      
      
New South Wales 1 40 1  
 
 
 
Queensland 
“several” 
1 
“8-10” 
8 
6 
 
21 
43, 4 
53, 61  
9, 15, 18, 57, 70 
11/2, 6, 19, 35, 59, 66 
 
1 
 
       2 
 
       6 
 
 
2 
 
5 
 
 
Northern Territory 
 
4 
8 
13, 16, 18 
1  
3 
Table 3-1 was adapted from Radford et al., 1975 (66). 
 
In Victoria, cases were reported from the Mornington Peninsula area, Western Port, 
Phillip Island and the Bellarine Peninsula (40,67,140,141). One of the major outbreaks 
occurred in 2011-2012, when Victoria and Queensland reported 157 and 75, cases 
respectively (9,142,143) (Figure 3-1). 
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Figure 3-1: Map of Australia showing different regions and land cover. 
Numbers 1, 2, 3, 4, 5, 6, 7 represent New South Wales, Northern Territory, Queensland, South Australia, 
Tasmania, Victoria and Western Australia, respectively.   The colours represent different landcovers. For example 
all shades of green and yellow represent vegetation cover. The urban areas are shaded in red. GIS raster and 
vector map layers were from the Government of Victoria website (https://www.data.vic.gov.au/). 
 
The Department of Health and Human Services (DHHS) in Victoria  as of 2016  put 
the annual incidence rate at < 1 per 100,000 inhabitants in Australia (18),  however, in 
endemic regions, this rate can be up to 100-times higher (143).  
Though BU have been reported since the late 1930s, it only became a notifiable disease 
in Victoria in January 2004 (9,143). The Communicable Diseases Epidemiology & 
Surveillance Unit - DHHS, keeps a database of all reportable infectious and 
communicable diseases in the State including BU. Victoria is one of the states in 
Australia with the highest reports. It is geographically located in the south-eastern 
(37°S 144°E) corridor of the country with a total land size of 237,639 km2. The 2016 
population census estimated that there are 5,926,624 people living in Victoria with a 
significant concentration around the Port Philip Bay and surrounding areas (144).  In 
Victoria, all four seasons are experienced. Cool winters usually occur from June to 
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August with a windy transition to spring from September to November. Typically, hot 
summers occur from December to February followed by mild autumns from March to 
May. The north-western part of Victoria experiences much hotter summers and the 
southern part experiences much colder and wet winters (145). Currently, the highest 
burden of BU cases is found on the Bellarine and Mornington Peninsulas. BU case 
reports indicate the geographical progression of transmission within this region 
(11,146,147).  
The exact mode of transmission is unknown, however, outbreaks of BU have usually 
been reported from areas close to aquatic environments, i.e. wetlands, swamps, marshy 
areas,  ponds, streams or rivers (6). The importance of ecological sampling from 
aquatic environments have long been known and was first conducted in Uganda in the 
1970s after it was observed that most patients reporting BU infection lived close to 
aquatic environments (30). Many researchers have since then hypothesized that 
contact with an infected aquatic environment is a high risk factor (4,31,139).  In many 
endemic areas in Africa, water bodies such as rivers, streams, lakes, dams and ponds 
have many direct uses. They serve as a source of drinking water for humans and 
livestock. In addition,  they are used for bathing and washing as well as for irrigation 
(148–150). This is in contrast to Australia because not all water bodies have such direct 
usage (141). 
Extensive environmental sampling of soil, water, biofilms, detritus, snails,  fish and 
aquatic bugs in many countries in Africa have tested positive for M. ulcerans target 
sequence, IS2404 (6,32,34–37). Among all the environmental samples tested, aquatic 
insects in the Order: Hemiptera: Families Naucoridae and Belostomatidae have 
repeatedly been found IS2404 positive. Laboratory experimentation has shown that,  
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through feeding on infected prey, Belostomatidae species are able to cause BU in an 
animal model through bites (38,39,151).  
A recent report by Wallace et al., 2017 on a laboratory disease transmission model 
demonstrated that BU infected mosquitoes could also serve as mechanical 
transmission vectors of M. ulcerans (152). The proposition of the role of mosquitoes 
as vectors has only been reported in Australia. This proposition was borne from the 
following observations: in 2001, an 18 months old child was diagnosed with clinical 
BU on the ear and this was attributed to a mosquito bite (9) and in another study (140), 
mosquitoes tested positive for M. ulcerans DNA. 
BU has also been reported in mammals in Australia including koalas (Phascolarctos 
cinereus),  common ringtail possums (Pseudocheirus peregrinus), long-footed potoroo 
(Potorous longipes) and alpaca (Vicugn apacos), as well as in horses, dogs and cats  
(40,153–156). Among all these animals,  possums are suspected as a potential reservoir 
of M. ulcerans (40,157). It has been hypothesised that when an adult mosquito feeds 
on an infected possums’ wound and then went on to bite a human, transmission of 
infection could occur. Infection could also occur if a cat, dog or any other animal was 
in contact with a dead infected possum (40) 
Barker (1972) in Uganda has suggested a seasonal pattern in the transmission of M. 
ulcerans. He was working on the hypothesis that M. ulcerans thrives on vegetation 
close to slow moving streams. He proposed that when inhabitants visit the stream to 
draw water and come into contact with infected vegetation, they contract M. ulcerans 
through existing or skin trauma. He also suggested that the incidence of BU in Uganda 
would vary with seasonal variation of vegetation. After numerous seasonal sampling 
in Ibuje, an endemic area in Uganda during dry season (November-March) and the 
raining season (April-August) he validated the hypothesis. In Ibuje, dry season leads 
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to the drying out of most of the perennial grasses around riverbanks, which correlated 
with the low incidence of the disease. The raining season leads to growth of vegetation 
thereby an increase in the disease (30). Seasonal variation of aquatic insects in endemic 
areas have also been observed (34). In contrast to what Barker found in Ibuje,  where 
dry season saw reduction in BU incidence,  Marion et al., in 2010 reported the opposite 
in a study conducted in Akonolinga, Cameroun. It was observed that dry season and 
reduction of water level in the Nyong river favoured the transmission of M. ulcerans 
(158). Seasonal variation in BU cases also exists in Australia. Winter, which occurs 
from June-August records more BU diagnosis compared with other seasons (67). With 
the incubation period of BU being 4.5 months, this suggests that infection occurs in 
summer (December-February) or the fall (March-May) (159). 
Heavy rains and floods causing landscape alteration have also been reported to 
increase the incidence of BU (6,11). The first case of infection in Bairnsdale, Australia 
was attributed to a severe rainfall in 1935. There was extensive flooding and washout 
from drainages through the whole district (66). In Papua New Guinea (PNG), the onset 
of BU came to the fore after the eruption of Mount Lamington in 1951. BU was 
actually not reported until heavy rains and flooding occurred in the region; washing 
the residues of the volcanic eruption into the human settlements. Regions around 
Septik and Kumusi rivers were the most affected. The disease was named Kumusi 
ulcer after the Kumusi River in PNG (4,10). Barker (1972) also observed that cases in 
Uganda coincided with a heavy flooding, which had occurred from 1962 to 1964. The 
severe rains and flooding created many permanent swamps around Lake Victoria as 
well as increased soil fertility and grass proliferation; these floods enhanced the growth 
of M. ulcerans (30).  
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In terms of the impact of anthropogenic activities,  a study conducted in Cote d’Ivoire 
showed that people living close to a dam and/or rice plantation presented more cases 
of BU than those who lived farther away (160). Environmental alterations like dam 
creation, new constructions, deforestation, agricultural activities and arsenic leakage 
into water bodies from mining activities have also been reported to increase the 
incidence of BU. Though this information does not directly point to the mode of 
transmission,  it suggests the importance of environmental factors for an outbreak of 
BU (6, 11).  
Host factors such as age and gender are regarded as non-environmental risk factors in 
some areas (6). In Africa, it has been observed that children between the ages of 2-14 
years and older adults > 79 years are more susceptible (42). The likely explanation is 
that children aged 2-14 years tend to be engaged in many outdoor activities whereas 
immunosenescence may explain the increased risk among the over 79 age group 
(42,45). In Australia, BU is prevalent in the older population ≥ 60years. This has been 
attributed to waning immunity (43). Though gender has not conclusively been linked 
with BU, more studies report males being infected in Africa. This might be due to 
immunological or sociocultural factors (42,45). More research may be required to help 
understand gender disparities. 
Previous studies have shed some light on possible reservoirs and vectors, but many 
questions remain unanswered. These studies have failed to identify the exact 
environmental niche of M. ulcerans and ecological or biological transmission to 
humans. In addition, these studies have not resolve the potential role of intermediate 
factors such as invertebrates (6).  
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  Figure 3-2: Graph showing the rise in Buruli ulcer cases from 1940-2010. 
  The “n” represent number of BU cases. The dots and connecting grey lines depicts 
  confirmed cases and trend, respectively (18). 
 
 
BU cases are now decreasing globally (11). However, since 2010, Victoria has seen 
an increase in cases (Figure 3-2). More investigation is required into understanding 
this trend in Victoria, specifically the endemic regions (Bellarine and Mornington 
peninsulas). The main objective of this chapter is to utilise explorative and descriptive 
epidemiology and space-time analyses using the Victorian BU database to better 
understand transmission patterns and possibly identify local risk factors.  
3.2 Methodology 
 
3.2.1 Access to the BU database for Victoria 
 
The BU database used for the descriptive epidemiology and spatio-temporal analysis 
is maintained by the Department of Health and Human Services (DHHS), Victoria. 
There were two set of lists: (i) BU confirmed cases list and (ii) BU exposure list. The 
BU confirmed case involves detection of IS2404 by polymerase chain reaction (PCR) 
or isolation and culture of the organism from specimen performed by the 
Mycobacterium Reference Laboratory (MRL), Victoria. The exposure list contains 
information regarding suburbs where BU patients believed they may have been 
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exposed. Variables extracted from the database for analysis included: date, age group, 
sex, suburb of residence, meshblock, “exposure to which endemic area”, “why visit” 
and “type of contact with endemic area”. These variables were chosen based on 
previous studies identifying them to be  important risk factors: age,  occupation,  
seasonal variation,  proximity to aquatic environment etc., (6,11,44,161). These 
variables were analysed to understand the general trend in Victoria and some selected 
suburbs.  
3.2.2 Ethics Approval 
 
Ethics approval was obtained from Research Ethics, Governance & Integrity (REGI) 
Unit at Barwon Health for the use of the Victoria Buruli ulcer database. Project 
reference number:  BW HREC 14/114. 
3.2.3 Statistical analysis 
 
After the organisation of the dataset, GraphPad Prism (Version 7.03) was used to 
perform univariable and multivariable analyses. Non-parametric analysis was done 
using Kruskal–Wallis and Mann–Whitney tests on the variables at statistical 
significance at p-value of 0.05. 
3.2.4 Epidemiological calculations 
 
Basic epidemiological calculations such as cumulative incidence, proportion (rate) and 
relative risks were performed to understand disease spread in Victoria. Cumulative 
incidence is the measure of population at risk in a specified period (usually at the 
beginning of a study). When disease rate is low, this is a simple and useful 
approximation of incidence in the “at risk population”. Proportion in this study was 
the number of BU cases compared to the total population of a specified suburb in the 
year under review. Proportion is thus a measure of disease frequency in a given 
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population. The Relative risk calculated in this study was the rate of disease divided 
by the calculated rate of cases in the entire population of Victoria (Table 3-2) (162). 
 
 
Rate =
Number of BU cases in  suburb
Resident population
 x 100 
 
Table 3-2: Contingency table. 
 
  
Disease (confirmed BU 
cases) 
 
No disease 
 
     Exposed 
 
A 
 
B 
 
The rest of Victoria 
 
C 
 
D 
 
Contingency table for relative risks calculation.  For ease of calculation, exposed group “A” represent suburb(s) 
with known BU cases (i.e. everyone in this suburb with or without active BU was assumed exposed).  Exposed (no 
disease) “B” is the population of the rest of Victoria excluding the exposed (disease) suburb(s). The rest of Victoria 
(disease) “C” represents number of BU cases in Victoria from 1994-2016 and “D” represent the population of the 
rest of Victoria excluding the number of BU cases from 1994 to 2016. 
 
 
 
Relative Risk =
(A/(A + B)
(C/(C + D)
 
 
cumulative incidence/1000 =
Total number of BU cases per suburb
Year in review
 × 1000 
                                                  
0
Resident population 
 
 
3.2.5 Dataset for geographic information system 
 
To understand the distribution pattern of BU cases in space and time (spatio-temporal) 
the project acquired access to use GIS raster and vector layers from the Government 
Chapter 3 
39 
 
of Victoria website (https://www.data.vic.gov.au/ ) as well as demographic data from 
the Australian Bureau of Statistics (ABS). Some of the data sourced included: 
i. Regional boundaries (Australia and Victoria map layers) 
ii. Meshblock area of residence 
iii. Rainfall pattern data (2011-2016) 
iv. Demographic data (2016) 
 
3.2.6 Spatio-temporal analysis 
 
SatScan software was used in conjunction with quantum GIS (qGIS) software (version 
2.18.7, Las Palmas) to develop maps to represent cases in time (temporal trend), in 
space (spatial analysis) and in space and time (spatio-temporal trend).  SatScan is a 
free internet software developed by Martin Kulldorff (Department of Population 
Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute) (163). 
The software was first designed for temporal analysis to determine if occurrence of a 
disease over time in a particular group was randomly distributed or not. With a null 
hypothesis of no outbreak, the software algorithm searches the data files to discover 
areas where cases exceed expectation and report a p-value. The updated version of 
SatScan is not only able to perform temporal but also spatial and space-time analysis. 
Based on the time of studies and data type, different statistical tests can be performed 
from different in built parameters in the software. 
3.2.7 Organization of files for SatScan 
 
To conduct scan statistics on the spatial, temporal, and space-time of BU cases in 
Victoria,  a polygon map of Victoria containing meshblock (the smallest geographic 
regions in the Australian Statistical Geography Standard; ASGS) was obtained from 
ABS,  from which latitudes and longitudes of central points of each meshblock were 
created using QGIS. Meshblocks are the smallest geographical units for which census 
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data are available and that are used to preserve individuals’ privacy. Meshblock 
demographic information based on ABS population census in 2016 was also acquired. 
All BU cases and locations were geo-coded and matched to the layers by Meshblock 
points and administration code using the software QGIS 2.18.7. SatScan (version 
9.4.4) was used to conduct a retrospective temporal, purely spatial and space and time 
analysis under the Poisson probability model to detect significant clusters by 
exhaustively scanning over space,  time and both space-time using moving circular 
windows (spatial analysis) and cylindrical windows (temporal trend) or both. To 
enhance precision and statistical power, some meshblock coordinates that have not 
reported BU cases were also analysed. Those that had zero population and or no BU 
case report were removed from the geo-coordinate file (latitudes and longitudes) and 
demographic file (population file). The meshblocks removed included areas of Buloke, 
Mildura, Mildura region, West Wimmera, South Grampians, Glenelg, Kerang,  
Gannawarra, Lockington, Gunbower, Echuca, Towong, Otway, Horsham, Nhill 
region, Swan Hill region, Robinvale, Irymple, Merbein and Red Cliff - essentially all 
the North-western part of Victoria,  as well as some agricultural lands, parkland, 
transport and water geo-coordinates. 
 
3.2.8 SatScan analysis parameters 
 
The files created as input files for SatScan software were: 
1. Case file = contains BU cases with meshblock location identification (Loc. id) 
and time of diagnosis in months and years; 
2. Population file = Contains Loc. id with number of inhabitants; 
3. Co-ordinates files = contains Loc. id with latitudes and longitudes (as point 
location).  
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The files were analysed retrospectively for purely temporal, purely spatial and space-
time clusters under the discrete Poisson probability model scanning for areas with high 
rate only. SatScan was programmed to report maximum cluster size of ≥ 25% of the 
population at risk using the circular spatial window. Spatial output was set to report 
hierarchical clusters with no geographic overlaps. Monte Carlo replications were set 
at 999. In addition SatScan was programmed to generate output files of (i) cluster 
information, (ii) stratified cluster information, (iii) location information, (iv) risk 
estimates for each location and (v) simulated log likelihood ratio/test statistics where 
possible. 
3.3 Results 
 
This result section gives descriptive and explorative epidemiology of BU from 1994 
to 2016 as extracted from the Victoria BU database. In addition, the scan spatial 
statistical analysis performed using the SatScan in time and space are shown.  
3.3.1 Distribution of BU cases in Victoria-1994-2016 
 
The highest concentration of BU cases was in Southern metropolitan of Melbourne 
with 356 cases (39%). This was closely followed by Barwon South West region with 
317 cases (35%). Northern/Southern and Eastern metropolitan had 91 (10%) and 74 
(8%) respectively. Gippsland, Grampians, Lodden-Mallee and Hume regions together 
reported less than 60 cases ( 
                                              Figure 3-3). 
3.3.2 Explorative epidemiology of the BU database 
 
There were 902 BU confirmed cases from 1994-2016 from 245 suburbs in Victoria.  
From these cases, 523 (58%) thought they were exposed at their place of residence, 
335 (37%) believed they were exposed elsewhere and 44 (5%) did not know or gave 
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no information regarding exposure site. There is concentration of cases in small 
number of suburbs (Table 3-3). Out of the 245 suburbs, 232 (95%) have reported < 10 
cases from 1994-2016. Five (2%) suburbs have reported 10-20 cases, three (1%) 
suburbs have reported 21-30 cases and two (0.8%) have reported between 31-40 cases. 
Suburbs reporting over 40 cases were three (Table 3-3). 
 
Table 3-3: BU cases showing the number of suburbs with most cases. 
 
Number of 
BU cases 
Number of 
suburbs 
% of total 
suburb (245) 
1-9 232 95 
10-20 5 2 
21-30 3 1 
31-40 2 0.8 
61-70 1 0.4 
71-80 1 0.4 
100+ 1 0.4 
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                                              Figure 3-3 Distribution of BU cases within different regions in Victoria -1994-2016. 
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3.3.3 Disease cluster detection using SatScan 
 
Victoria has 81,370 meshblock units. After the removal of areas with no BU case 
reports as well as zero population, 56,327 meshblock units with 4,844,773 people were 
left for SatScan analysis (Figure 3-4).  
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        Figure 3-4: Victoria map showing geographic coordinates used in the SatScan analysis. 
          Red dots indicate geographic co-ordinates used for the SatScan analysis. 
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3.3.4 Detected purely spatial and space-time clusters 
 
The purely spatial and space-time analysis reported annual cases per 100, 000 people 
of 0.8 from 1994 to 2016 in Victoria. The space-time analysis reported five spatial 
clusters (1, 3, 4, 5 and 6) and one temporal cluster (cluster 2). The purely spatial 
analysis identified 11 clusters (Figure 3-5). Four of the space-time clusters (1, 3, 4 and 
5), as well as the purely spatial clusters (1, 2, 3 and 4) were reported to be significant 
clusters (p=0.000), meaning distribution of cases were not due to chance but followed 
a pattern. Both the purely spatial and space-time analysis had the most likely cluster 
(cluster 1), also known as the primary/candidate cluster geographically located on the 
Bellarine and Mornington peninsula (Figure 3-6). The annual incidence of 
cases/100,000 persons for the space-time and purely spatial clusters was 40.4 (2001-
2016) and 28.3, respectively (raw data in Appendix B, Table B-2).
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            Figure 3-5: Victoria map showing overlay of purely spatial and space-time clusters. 
            There were 11 and 5 detected clusters in the purely spatial and space-time analysis, respectively. Some of the clusters could not be shown  
            on the map due to their small size. The size of the circular windows (big or small radius) does not indicate significance; rather it shows the  
            proximity of cases within a cluster. Some secondary clusters could not be shown on map due to small size.  
                           (Violet circular window: purely spatial clusters and Black circular windows: space-time clusters). 
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Figure 3-6: Detected disease clusters of purely spatial and space- time analysis. 
Both primary clusters of space-time and spatial analyses labelled “1” (Indigo circular window) are located on the Bellarine and Mornington Peninsulas. The remaining circular windows 
(Violet circular window: purely spatial clusters and Black circular windows: space-time clusters) seen on the map are secondary clusters. The numbers (1, 2, 3, 4, 5, 6 and 7) represent 
the order of cluster reporting. Some secondary clusters could not be shown on map due to small size. Based on Australian Bureau of Statistics data © Commonwealth of Australia, and 
based on © The State of Victoria, Department of Environment, Land, Water & Planning 2018.
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3.3.5 Age gender and temporal trends of Buruli ulcer cases 
 
Test statistics for age (Figure 3-7), year of case report (Figure 3-8) and  month of 
diagnosis (Figure 3-10) stratified for gender was not statistically significant, p = 
0.1275, 0.2026 and 0.6059, respectively. However, more males (56.4%) have reported 
cases compared to females (43.6%) within the study period in Victoria. The three age 
groups with most cases were age 60-64, 65-69 and 70-74 years, recording 83 (9.2%), 
78 (8.7%) and 72 (8%), respectively. The remaining age groups had < 70 cases each 
(Figure 3-7). There was a general rise in BU cases from 1994-2016 (Figure 3-8). 
SatScan temporal analyses detected significant rise in BU cases from 2011 (red bars) 
(Figure 3-9). 
 
    
 
Figure 3-7: Age group stratified for gender (1994 to 2016). 
The age group was stratified for gender to ascertain if any unique trend existed in age, gender and BU cases. Males 
have reported more case compared to their female counterpart from 1994 to 2016. 
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Figure 3-8: Number of cases per year stratified for gender from 1994 to 2016. 
 
3.3.6 Temporal  trend of cases in Victoria 
 
The year with highest recorded cases was 2016 with 183 (20%) this was followed by 
2015 with 106 (12%) cases. However, from 1994 to 2014 less than 100 cases were 
recorded in each year. The month of highest BU cases was in August with 129 (14.3%) 
this was followed by September, July and October with 116 (12.9%), 110 (12.2%) and 
109 (12.1 %) cases, respectively (Figure 3-10). The rest of the month of diagnoses 
recorded < 100 cases within the study period. There appears to be similarity of trend 
in age and seasonal variation stratified for gender (Figure 3-7, Figure 3-8 and Figure 
3-10). 
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Figure 3-9: Purely temporal trend of BU cases from 1994 to 2016. 
The histograms represent observed cases across time: (i) Blue histograms show observed cases only, (ii) Red 
histograms indicate observed cases that showed significant temporal clustering across time (also highlighted in 
read). (iii) Dark green line indicates the baseline expected cases based on the total population used in the analysis 
and (iv) Light green line indicates general trend of cases across time. 
 
 
 
 
Figure 3-10: Month and number of diagnosed cases stratified for gender in each month from 1994 to 2016. 
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3.3.7 Top five residence and perceived exposure areas of BU cases 
 
The top five suburbs with most BU cases were located on the Bellarine and 
Mornington Peninsulas. The suburb with most BU cases was Point Lonsdale with 103 
(11%) cases, this was followed by Rye with 74 (8%). There were 61 (7%) cases in 
Barwon Heads. Ocean Grove and Queenscliff reported 39 (4%) and 33 (3.7%), 
respectively. All the patients in these suburbs believed they acquired their infection 
where they lived or at least in the Bellarine and Mornington Peninsulas (Figure 3-11-
A).  From the exposure list, it is clear that some patients believed the probable exposure 
site to M. ulcerans was elsewhere (not their usual place of residence). Figure 3-12-B 
shows the top five suburbs claimed to be the place of probable exposure by patients. 
However, 16 patients did not give any information or could not identify any suburb of 
exposure. After the exclusion of BU patients exposed at the place of residence from 
the exposure analysis, Point Lonsdale, is the most frequent suburb perceived to be the 
exposure area with 89 (10%) cases followed by Barwon Heads with 42 (5%) cases. 
Rye, Ocean Grove and Queenscliff followed with 32 (4%), 24 (3%) and 24 (3%) cases, 
respectively. 
   A      B 
 
Figure 3-11: Number of diagnosed cases in the top 5 residence and perceived exposure areas from 1994 to 
2016.  
Figure 3-11-A shows top five patients’ location (Residents). Figure 3-11-B shows top five perceived exposure 
site (Visitors). Residents who claimed exposed at the place of residence were not included in the analysis of “B”. 
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3.3.8 Temporal trend in the top 5 residence and perceived exposure areas 
 
The temporal trend of Residents (BU patients who lived within the top five suburbs: 
Point Lonsdale, Rye, Barwon Heads, Ocean Grove and Queenscliff) and Visitors (BU 
patients who visited the top five areas) were compared as well as years of case report 
for each of the five suburbs. The seasonal trend of BU reporting was generally similar 
in both residents and visitors (Figure 3-12) which is comparable to the result obtained 
for the entire Victoria (Figure 3-10).    
 
Figure 3-12: Number of diagnosed cases among residents and visitors in the top five residence and 
perceived exposure areas in each month from 1994 to 2016. 
 
Since 2011, Point Lonsdale, a suburb on the Bellarine peninsula has been reporting a 
decrease in cases whereas Rye, a suburb on the other side of the Port Phillip Bay, on 
the Mornington Peninsula, which had no cases previously, has consistently been 
reporting cases since 2012.  Within five years between 2012 and 2016, cases reported 
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from Rye alone (74) exceeded each of the total cases for Queenscliff, Barwon Heads 
or Ocean Grove, where cases have been reported since 2004, 2005 and 2006, 
respectively (Figure 3-13). 
 
Figure 3-13: Number of diagnosed cases in the top 5 residence and perceived exposure areas from 1994 to 
2016. 
 
3.3.9 Age and gender of residents and visitors in the top five suburbs 
 
Victoria has a total population of 5,926,624 of which 50.9% are female and 49.1% are 
male. The current median age in Victoria is 37 (144). Among the top five patient 
locations, the largest suburb is Ocean Grove (14,165), followed by Rye (8,416). The 
population in Barwon Heads, Point Lonsdale and Queenscliff records 3,875, 2,584 and 
1,315, respectively with a similar gender distribution as in Victoria. However, in BU 
case distribution, Rye was an exception having almost twice as many males to females 
among both Residents and Visitors. The proportion of males to females with BU cases 
among Resident or Visitors were similar within each of the other four suburbs (Table 
3-4). From Table 3-4, there was no statistically significant difference in gender among 
Residents (p= 0.44) as well as Visitors (p= 0.51). 
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3.3.10 Changes in demographics and physical environment of the top five 
exposure sites 
 
M. ulcerans is an environmental pathogen (62). Incidence in Buruli ulcer cases has 
often been associated with drastic environmental changes or degradation (6,62,164–
166),  therefore changes to the physical milieu were also assessed in the top five 
exposure sites.  
In terms of population, each of the suburbs has recorded some increase over the last 
10 years (2006-2016). Barwon Heads and Ocean Grove had the most population 
increase of 881 (21%) and 2891 (20%) respectively.  The population at Point Lonsdale 
increased by 207 (8%) and Rye 79 (1%) as well. There has also been an 8% decrease 
in Queenscliff’s population over the last 10 years. The population changes also 
resulted in new construction of houses and attendant road constructions. Ocean Grove 
has had the most addition of new house constructions of 1,574 (21%). Rye, which had 
only 1% increase in population had 590 (7%) increase in new constructions. In the past 
decade, there has been a 3,957 (13%) increase in the population and 2,882 (13%) new 
constructions in the suburbs combined (Table 3-5). 
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Table 3-4: Age and gender of residents and visitors in the top five suburbs. 
 
 
Character- 
istics 
 
Point Lonsdale 
Ocean 
Grove 
Barwon 
Heads 
 
Queenscliff 
 
Rye 
 
p-value 
Population 
(2016) 
 
2,684 
 
14,165 
 
3,875 
 
1,315 
 
8,416 
 
       
Sex       
Female% 54 52 51 53 50.5  
Males% 46 48 49 47 49.5  
       
Median 
age(Year) 
 
59 
 
42 
 
43 
 
59 
 
47 
 
       
Resident (n) 103 39 61 33 74  
Sex       
Female 51 (49.5%) 18 (46.2%) 26 (42.6%) 15 (45.5%) 26 (35.1%) 0.4444 
Males 52 (50.5%) 21 (53.8%) 35 (57.4%) 18 (54.5%) 48 (64.9%)  
       
Age group       
0-14 6 (5.8%) 2 (5.1%) 7 (11.5%) 3 (9.1%) 9 (12.2%) 0.0408 
15-24 7 (6.8%) 2 (5.1%) 9 (14.8%) 0 (0%) 3 (4.05%)  
25-34 5 (4.9%) 3 (7.7%) 5 (8.2%) 1 (3%) 5 (6.76%)  
35-44 9 (8.7%) 3 (7.7%) 8 (13.1%) 2 (6.1%) 9 (12.2%)  
45-54 3 (2.9%) 3 (7.7%) 2 (3.3%) 2 (6.1%) 9 (12.2%)  
55-64 20 (19.0%) 8 (20.5%) 12 (19.7%) 11 (33.0%) 13 (17.6%)  
65-74 17 (17.0%) 8 (20.5%) 9 (14.8%) 4 (12.0%) 12 (16.2%)  
75+ 36 (35.0%) 10 (25.6%) 9 (14.8%) 10 (30.0%) 14 (18.9%)  
Median age 69.5 59.5 49.5 59.5 59.5  
Age mode 75+ 75+ 55-64 55-64 75+  
       
Visitors (n) 86 22 42 23 31  
Sex       
Female 42 (48.3%) 8 (36.4%) 20 (47.6%) 12 (52.2%) 12 (38.7%) 0.5159 
Males 44 (51.7%) 14 (63.4%) 22 (52.4%) 11 (47.8%) 19 (61.3%)  
       
Age group       
0-14 23 (26.7%) 5 (22.7%) 11 (26.2%) 3 (13.0%) 5 (16.1%) 0.0023 
15-24 10 (11.6%) 4 (18.2%) 6 (14.3%) 3 (13.0%) 0 (0%)  
25-34 6 (7.0%) 2 (9.1%) 2 (4.8%) 4 (17.4%) 0 (0%)  
35-44 6 (7.0%) 5 (22.7%) 9 (21.4%) 3 (13.0%) 3 (9.7%)  
45-54 7 (8.1%) 1 (4.5%) 2 (4.8%) 2 (8.7%) 2 (6.5%)  
55-64 16 (18.6%) 1 (4.5%) 5 (11.9%) 2 (8.7%) 3 (9.7%)  
65-74 13 (15.1%) 2 (9.1%) 5 (11.9%) 4 (17.4%) 13 (41.9%)  
75+ 5 (5.8%) 2 (9.1%) 2 (4.8%) 2 (8.7%) 5 (16.1%)  
Median age 39.5 29.5 39.5 39.5 69.5  
Age mode 55-64 35-40 0-14 25-34/65-74 65-74  
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Table 3-5: Population census of the top five patients’ location and number of 
new constructions from 2006-2016. 
 
 
3.3.11 Rainfall data in the top 5 patients location from 2011-2016 
 
Since BU incidence has been linked to seasonal variations (154,158,167,168),  rainfall 
data from 2011-2016 were sourced from the Bureau of Meteorology in Victoria to 
identify if any patterns existed among the top 5 patient locations. Rainfall data are 
collected at designated weather stations across Victoria; therefore, data for Rye was 
collected from the Rosebud country club station (#086213), 5.2 km from Rye. Ocean 
Grove weather station (#087178) was also the source of Point Lonsdale and 
Queenscliff rainfall data, which are 8.9 km and 12.1 km away from the weather station 
respectively. Barwon heads rainfall data was collected from the Barwon Heads Golf 
Club station (#087135) 1.1 km away. Overall, there has been more rainfall in Rye than 
the other suburbs from 2011 to 2016 (Figure 3-15). The highest mean rainfall was 
collected at Rye in 2012 (951 mm) and again in 2013 (878 mm). The mean rainfall 
data from Ocean Grove (including Point Lonsdale and Queenscliff) and Barwon Heads 
 Point 
Lonsdale 
 
Rye 
Barwon 
Heads 
 
Ocean Grove 
 
Queenscliff 
 
Total 
Population  
census 
      
2006 2,477 8,337 2,994 11,274 1,416 26,498 
2011 2,466 8,160 3,536 12,555 1,418 28,135 
2016 2,684 8,416 3,875 14,165 1,315 30,455 
Percentage  
change 
 
207 (8%) 
 
79 (1%) 
 
881 (21%) 
 
2,891 (20%) 
 
-101 (-8%) 
 
3,957 (13%) 
       
Houses/ 
Dwellings 
      
2006 2,205 7,907 1,820 5,812 1,006 18,750 
2011 2,281 8,247 2,039 6,572 1,103 20,242 
2016 2,390 8,497 2,226 7,386 1,133 21,632 
Percentage  
change 
 
185 (8%) 
 
590 (7%) 
 
406 (18%) 
 
1,574 (21%) 
 
127 (11%) 
 
2,882 (13%) 
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were similar during the same period,  >700 mm. There is a clear variation in monthly 
rainfall with peaks generally in May and June (Figure 3-14). 
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Figure 3-14: Monthly rainfall data in the top five BU locations. 
Monthly rainfall data in the Bellarine and Mornington Peninsula from 2011-2016, shown for Rye, Ocean Grove, and Barwon Heads. The mean annual rainfall data are also shown 
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3.3.12 Relative risk of living in the top 5 or disease cluster areas 
 
The relative risks recorded for BU in each of the top five patients’ locations and cluster 
areas compared to the rest of Victoria were high. This is due to the huge number of the 
unexposed population (the rest of Victoria) used for the calculations (5,137,213 to 
5,925,309) compared to number of BU cases (14 to 399) in these areas. The risk of 
being exposed to M. ulcerans is 274.0 (range: 223.9-335.0) times higher in Point 
Lonsdale compared to the rest of Victoria. Exposure risk in Queenscliff and Barwon 
Heads are 171.1 (121.5-240.5) and 110.9 (85.7-143.3). The risk of exposure in Ocean 
Grove and Rye is greater than 100. Relative risk of those living in the top five areas 
(combined) was 101 (88.4-116.2). The highest incidence rate of BU cases was 3.8% 
in Point Lonsdale, 2.5% in Queenscliff and 1.6% in Barwon Heads, and in Ocean 
Grove and Rye the rate was less than 1%. The highest cumulative incidence of 2.8 per 
1,000 persons was observed in Point Lonsdale. Queenscliff, Rye and Barwon Heads 
had 1.9, 1.8 and 1.4 per 1,000 persons, respectively. The lowest cumulative incidence 
of 0.2 per 1,000 persons was recorded in Ocean Grove (Table 3-6). 
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Table 3-6: Relative risk of living in the top five or disease cluster areas. 
 
 
 
 
Location 
 
 
Year in 
 review 
 
 
Total 
cases 
 
 
Mean no. 
cases/ year 
 
 
Resident  
population 
 
Mean 
annual 
incidence 
 
 
Rate 
(%) 
 
 
 
Relative risk 
Barwon Heads  2006-2016 61 5.5 3,875 1.4 1.6 110.9 (85.7-143.3 
Ocean Grove 2005-2016 39 3.3 14,165 0.2 0.3 18.9 (13.7-26.0) 
Point Lonsdale 2002-2016 103 6.9 2,684 2.6 3.8 274.0 (223.9-335.0) 
Queenscliff 2004-2016 33 2.5 1,315 1.9 2.5 171.1 (121.5-240.5) 
Rye 2012-2016 74 14.8 8,416 1.8 0.9 62.9 (49.6-79.6) 
Combined (5) 2002-2016 310 20.7 30,455 0.7 1 101.4 (88.4-116.2) 
        
Space-Time        
Cluster 1 2001-2016 399 26.6 61,723 0.4 0.006 75.4 (66.1-85.9 
Cluster 2 2011 2016 598 99.6 - - - - 
Cluster 3 2005-2016 62 5.2 73,072 0.1 8.5x10-4 5.9 (4.6-7.6) 
Cluster 4 2016 50 50 638,943 0.1 7.8x10-5 0.5 (0.4-0.6) 
Cluster 5 2002-2010 14 1.6 18,033 0.1 7.8x10-4 5.2 (3.1-8.7) 
        
Purely spatial        
Cluster 1 1994-2016 402 17.5 61,723 0.28 0.651 76.4 (67.0-87.1) 
Cluster 2 1994-2016 63 2.7 64,706 0.04 0.097 6.8 (5.3-8.8) 
Cluster 3 1994-2016 24 1.0 16,140 0.06 0.149 10 (6.7-15.0) 
Cluster 4 1994-2016 53 2.3 101,677 0.02 0.052 3.6 (2.7-4.7) 
 
The Space-time and purely spatial primary cluster,  also known as the most likely 
cluster (Cluster 1), which circumscribes areas on the Bellarine and Mornington 
peninsula had a relative risk of 75.4 (66.1-85.9) and 76.4 (67.0-87.1) and cumulative 
incidence of 0.4 and 0.3 per 1,000 persons respectively. Relative risk of the remaining 
clusters was ≤ 10. Cumulative incidence recorded in cluster 2, 3 and 4 of the purely 
spatial analysis were negligible (0.0-0.06 per 1,000 persons). The same could be said 
for the remaining space-time clusters (3, 4 and 5) with 0.1 per 1,000 persons (Table 3-
6). 
3.3.13 Reasons for visiting an exposure area 
 
Out of the 335 patients in the BU database who believed they were exposed elsewhere 
from their place of residence, 202 (60%) gave reasons and activities engaged in on 
visit. However, 133 (40%) of this patient group either did not know or attribute their 
exposure to any activity (not stated). The two most common reasons given for visiting 
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an exposure site were associated with holidays. For ease of presentation and 
interpretation, the following activities: recreation, single visit and multiple visits of 
relatives were categorized as a holiday. Holiday (recreation) and Holiday House 
visitation (partial resident) recorded 93 (28%) and 82 (24%) of cases respectively. 
Work was the next reason given recording 10 (3%) of cases. The remaining reasons 
such as golf, previous resident, school, recycling depot and scout activities were less 
than 10 cases each (Figure 3-15). 
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Figure 3-15: Activities or reasons for visiting an exposure site (1994-2016). 
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3.4 Discussion 
 
Progression of disease in Victoria. Buruli ulcer continues to be reported in Victoria 
after the first cases in Bairnsdale area of East Gippsland in the 1930s (66,138,139). 
Over the years many studies have concentrated in focal areas, especially in the 
Bellarine peninsula and more specifically Point Lonsdale to understand the 
progression and transmission of the disease (9,40,44,169). There have been reports of 
gradual movement of BU case from the south-eastern to south-western of Victoria 
(8,141,170,171). These reports are observational and do not utilise any spatial testing. 
The current study has utilized the Victoria BU database to give a complete picture and 
update of BU cases in Victoria as well as provide report on top 5 patient locations 
(Point Lonsdale,  Rye,  Barwon Heads,  Ocean Grove and Queenscliff) on the Bellarine 
and Mornington peninsula which are considered BU endemic (Figure 3-6).  This study 
has used Quantum Geographical Information System (qGIS) as well as SatScan 
software, to perform a retrospective space-time and purely spatial analysis to ascertain 
whether BU cases are randomly distributed or form significant geographical clusters 
in Victoria.  
These analyses were important as the results may explain or confirm the major 
geographical shift of cases in Victoria. GIS analysis to understand BU cases in space 
identified that over the past 22 years (1994-2016), there has been a high concentration 
of cases in the Southern (356), Northern and Southern (91), Eastern (74) and Barwon 
South West (317) metropolitan areas (Figure 3-3). In addition, the most likely disease 
cluster detected by SatScan space-time and purely spatial analysis circumscribed the 
Bellarine and Mornington Peninsulas (Figure 3-6). There were three other significant 
clusters detected in both space-time and purely spatial analysis (Figure 3-6).  Although 
the reason for such a shift is not clear, it is plausible that high concentration of people 
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in metropolitan areas, general increase in population and construction of new 
settlement in these areas could play a role.  
A close look at the top five patients’ locations in the 2006-2016 population census 
discovered that there have been 3,957 (13%) increase in the population since 2006-
2016, in parallel there has been an increase in the number of houses by 2,882 (13%) 
(Table 3-5). With the incidence and prevalence of BU cases thought to be affected by 
increased constructional works, such as creation of dams, deforestation and general 
disturbance of the environment (6,13,164,172),  the trend observed in Victoria may 
not necessarily be attributed to anthropogenic activities alone. 
Age and gender disparities in BU cases in Victoria. In the current study, males (509 
cases) were more affected compared to females (392 cases) however, there was no 
statistically significant difference (p=0.1275) in age stratified for gender across 
Victoria (Figure 3-7). In Victoria, the > 60 year age group reported more cases in the 
database in the study period.  A closer look at Residents’ and Visitors’ profile of the 
top 5 endemic areas for gender, showed no significant difference as well (Table 3-4) 
indicating that gender may not be a risk factor for Residents. Though there were 
differences in Visitors’ age profile, especially in Ocean Grove, Barwon Heads and 
Queenscliff, it is not unreasonable to conclude that in the five endemic areas over 55 
year age group reported more cases (Table 3-4) which agreed with a previous study by 
Johnson et al., 2007 (9).  
The association of age and gender in BU transmission have previously been reported 
both in Africa and Australia (42,169,171). In Africa,  gender was not a risk factor  
however, age was a risk factor especially among the less than 15 and over 79 year age 
groups (42,173,174). Previous studies in Victoria also showed no difference in gender, 
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but the over 60 year age group were most affected. In Australia,  this has been 
attributed to the ageing population and the attendant immunosenescence (169,171). 
The finding agrees with previous studies in Victoria. This finding limits generalization 
of BU case reports in Victoria, because the trend observed in the State is influenced 
by only a few suburbs (Figure 3-11, Table 3-4).   
Temporal trend and seasonal variation cases. Though BU disease became notifiable 
in January 2004 in Victoria (9),  the database gives some case reports before 2004 
(1994-2003),  these were also analysed in this study. There is a general rise in BU 
cases in Victoria, with a peak in 2016 (Figure 3-8). SatScan temporal analysis 
identified that significant disease clustering began 2011 (Figure 3-9), though 
observable rise in cases was reported in 2010 (41,143). It is worth noting that the 
increase in cases has not been uniform in Victoria and there are top five locations 
(Figure 3-11). BU cases in Point Lonsdale, the most reported area among the top five 
patients’ location (Figure 3-13) has been decreasing steadily since 2011, whereas Rye, 
which never reported any cases until 2012, has shown a steady rise in cases. It must be 
mentioned that Point Lonsdale is on the Bellarine peninsula and Rye is on the 
Mornington Peninsula, geographically on opposite sides of the Port Phillip Bay. The 
reason for such a trend is unclear however, the general increase in rainfall in Rye since 
2012 compared to the other suburbs (Figure 3-14) followed by the 3rd hottest year on 
record in Victoria in 2013 (data not shown) may account for some of this trend. This 
agrees with previous studies that reported that seasonal variation such as increase in 
rainfall and flooding and subsequent hotter season have been associated with high 
incidence in some countries in Africa  (6,141,158,167,169).   
The month with the highest diagnosis in the BU database was August with 129 (14%) 
cases followed by September with 116 (13%). Previous studies have reported the 
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median incubation period of BU to be 4.5 months (range: 1 to 9 months) after infection. 
This suggests that more people would have been exposed or infected in autumn, 
March-April (4.5 months median lag period) or November-February (9 months 
maximum lag period) the summer period in Victoria. This has also been reported in 
previous studies (67,80). This is not surprising as more outdoor activities are held 
within the summer and autumn periods and therefore more contact with the 
environment. This is also evident from the activities undertaken by Visitors in the 
perceived exposure site were mostly holiday related (Figure 3-15). Comparison of the 
month of diagnosis among Residents and Visitors (Figure 3-12) showed close 
similarity to the trend in Victoria. This confirms that the exposure site of M. ulcerans 
could well be in the top five Residents’ location. (Figure 3-11-A). Future 
environmental studies for risk factors could begin in any of the top five suburbs 
described in this study. 
3.5 Conclusion 
 
After the identification of the first BU cases 86 years ago, BU still present a significant 
public health concern. There has been an increase in the number of BU cases since 
2010. This study has provided an update on the epidemiology of BU cases in Victoria 
using the BU database (1994-2016). Total of 902 laboratory confirmed BU cases from 
245 suburbs were analysed. The age group most affected in Victoria were the ≥ 60 
years; however, in the top five areas the ≥ 55 years reported more cases. This could be 
attributed to immunosenescence. In addition the top five location are also retirement 
areas. Incidence of BU cases has shifted from South-eastern (Bairnsdale, 1930s). 
Currently, there is high concentration in the South-western and central, around the Port 
Philip Bay. It has been observed in this study the effect of anthropogenic activities and 
seasonal variation in rainfall on the incidence of BU cases in Victoria as described in 
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Rye and Point Lonsdale. The distribution pattern of BU cases or emergence observed 
in this study could not be random as have previously been reported (141).  For the first 
time, four significant spatial disease clusters have been detected in Victoria. The most 
likely cluster is on the Bellarine and Mornington Peninsulas which is not new. 
However, the other clusters could describe new emerging foci in M. ulcerans 
transmission in Victoria. The incidence rate observed in the most likely disease cluster 
area was 40.4/100,000 persons from 1994 to 2016 (space-time analyses). The relative 
risk for the top five locations combined was 101.4 (Table 3-6). There is a strong 
confirmation of the top five patients’ location (Residents) being the environmental 
source of M. ulcerans exposure. Nevertheless identification of specific factors is 
lacking. This study recommends exhaustive environmental sampling to identify 
possible environmental risk factors. It is plausible that behavioural patterns of 
Residents and Visitors could provide key information regarding the identification of 
specific risk factors. Analysing the daily activities or lifestyle pattern of Residents may 
be challenging but this might not be difficult among Visitors who visit for a short 
period. Therefore, future case control studies could be designed to describe the daily 
activities of Visitors (e.g. hiking or swimming, where and when) during their stay. 
This could provide valuable information regarding identification of possible risk 
factors. 
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CHAPTER 4 
4 Production and proteomic characterization of protein preparations from 
Mycobacterium ulcerans 
 
4.1 Background 
 
Although mycobacteria as a group of microorganism have long been studied (175,176)  
many questions about this genus remain unanswered (116,125). Currently what is well 
known is that acid fastness is one property all mycobacteria have in common due to 
the presence of mycolic fatty acid chains in their cell wall (20,125,177); they also share 
chemical properties of their lipids,  proteins and carbohydrates contents. It has also 
been observed that some metabolic mechanisms are also shared in this group, an 
example is the specialised entry mechanism that enables them evade lysosomal fusion 
in macrophages (178).  Immunogenic similarity revealed by cross-skin reactions is 
also well studied. A previous study found that an exposure even to non-pathogenic 
mycobacteria could make an individual have a positive response to a tuberculin 
prepared from tubercle bacilli (175).  
To address the challenge of easy, reliable and rapid screening tests,  the development 
of a serological or cell-mediated tests have been suggested as a possible screening tool 
for M. ulcerans exposure within ‘at risk’ populations and to aid understanding 
exposure globally. Such tools have been used in previous studies in endemic and non-
endemic areas (68,72,75,106). Following previous studies researchers have suggested 
that a dedicated approach in the cultivation of M. ulcerans,  standardisation and 
optimisation in protein preparations utilising proteomics and genomics bioinformatics 
could provide the tools for diagnostic development (65,72,116,125). The lack of 
standardisation in M. ulcerans protein preparations for screening tests has made 
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comparing research difficult. Therefore, the current study has employed a standardised 
approach in producing and characterising M. ulcerans protein preparations for a 
serological screening test in an Australian cohort. 
4.2 Materials and method 
 
4.2.1 Biosafety and Biocontainment 
 
All molecular cloning, bacteria transformation works for protein expression 
experiment as well as for antigen production were conducted within a Biosafety 
cabinet 2 (BSC2) at the Geelong Centre for Emerging Infectious Diseases (GCEID) 
and the CSIRO Australian Animal Health Laboratory (AAHL) certified Physical 
Containment Level (PC) 2 laboratories. Specific experiments like enzyme-linked 
immunosorbent assay (ELISA) and Western blotting were conducted in accordance 
with regulatory requirements; namely, Australia/New Zealand Standard™ 
2243.3:2010 - Microbiological Safety and Containment (Standards Australia); 
Security Sensitive Biological Agents standards,  2013 (Department of Health,  
Australian Government). All transfer of infectious material from Deakin University to 
GCEID and/or AAHL was in accordance with Australian Standard 4834–2007 - 
Packaging for surface transport of biological material that may cause disease in 
humans, animals and plants (Standards Australia). The Laboratory & Biosafety 
Committee (LBC) gave approval for the culture of M. ulcerans in Deakin University 
PC2 laboratory. Work safety assessment (WSA) was approved by the School of 
Medicine Laboratory Technical Committee. All procedures used in the culture of M. 
ulcerans were in accordance with the guidelines of Safety in Laboratories, AS2243.3 
Microbiology 2002. 
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4.2.2 Gene ontology 
For ease of presentation and interpretation, the locus_tag was used in naming genes 
and proteins. Names referring to genes are italicised (e.g. hsp65) and all names 
referring to proteins have no italics (e.g. Hsp65). Genes and proteins annotations were 
adapted from GenBank M. ulcerans Agy99, complete genome, accession number: 
CP000325.1 (https://www.ncbi.nlm.nih.gov/nuccore/118568029) submited by Stinear 
et al., 2007 (179).  
4.2.3 Bacteria Strains 
 
M. ulcerans isolate from a BU patient in Victoria (Australia) and M. ulcerans gene 
constructs: mul_0513, mup045, mup057, AT propionate, KRA, mul_2232 and hsp65 in 
Escherichia coli TOPO10 competent cells  for recombinant protein expression were 
obtained from Prof. Tim Stinear from the Peter Doherty Institute for Infection and 
Immunity in Melbourne (PDI). M. ulcerans isolate from Australia was used and not 
the sequenced strain Agy99 isolate from Ghana because of the genomic and immune 
response differences reported in different M. ulcerans geographical isolates (25,99). 
He generously provided M. ulcerans (strain Agy99) genomic DNA to be used as 
positive control for polymerase chain reaction (PCR). The seven gene constructs 
(mul_0513, mup045, mup057, AT propionate, KRA, mul_2232 and hsp65) were 
selected because previous study by Pidot et al., 2010 described them to have shown 
prospect in a serological survey in an African cohort. Therefore, the gene constructs 
were included in this study for two reasons i) for recombinant protein expression and 
purification to assess its usefulness in an Australian cohort and ii) for comparative 
serological experiment with a panel of cell derived protein preparations from M. 
ulcerans. The Gateway entry vector used for the cloning of the constructs was 
pENTR/SD-TOPO. The destination vector pET-DEST42  was used for cloning all 
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constructs except for mup045 where pET28a vector was used. They all had a C-
terminal V5 epitope and 6xHis-tag; pET-DEST42 vector was ampicillin (amp) and 
chloramphenicol (cam) resistant whereas pET-28 was kanamycin (kan) resistant.  
The M. ulcerans strain received was grown on a 6 ml Löwenstein–Jensen (LJ) slope. 
For antigen production and immune cross-reactivity comparative study, 
Mycobacterium smegmatis strain (180) (ATCC700084) was purchased from Invitro 
technologies, Australia. All mycobacterial species used in this study were sub-cultured 
on Brown and Buckle Agar (BBA) slopes from the Media Preparation Unit, Melbourne 
(MPU). BBA was used for M. ulcerans subculture because, a report from WHO 2014 
suggested that M. ulcerans grow best on BBA media (54). Middlebrook 7H9 (BD 
Difco, Australia) broth supplemented with tryptose and glucose was also prepared by 
MPU and was used for the enrichment of M. ulcerans and M. smegmatis for protein 
production. The media supplemented with tryptose and glucose was adapted from a 
previous study by Dobos et al., 2000. Their study indicated the tryptose and glucose 
did not have any affect on M. ulcerans protein produced (106). Middlebrook 7H9 
medium supplemented with only glucose was also used for enrichment of M. ulcerans 
as production control.  Sterile Middlebrook 7H9 broth (in 500 ml autoclavable bottles) 
received from MPU were used fresh upon receipt. Unused media were stored at 4oC 
and discarded after 6 months as prescribed by the manufacturer.  
4.2.4 Confirmation of bacterial strains 
 
To confirm that the cultures received were M. ulcerans and the TOPO10 had the 
correct M. ulcerans genes, DNA extraction and PCR were performed. Table 4-1 shows 
primers used for PCR amplifications. 
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Table 4-1: Primers for M. ulcerans plasmid constructs. 
 
 
CDS 
 
Forward primer 5’ – 3’ 
 
Reverse primer 5’ – 3’ 
 
Reference 
MUL_0513 CACCATGGCCGTACCTCTGC
TTC 
GAGGGTGAACAGGTTC
TTCAG 
(72) 
MUL_2232 CACCATGTTGATGCGTACCG GGCTTCTATCACCTCAG
GAT 
(72) 
MUP045 CACCATGATTTGGAATGACA CTACGAAGTGGAGTGTC
CGG 
(72) 
MUP057 CACCATGCAATCAACGACTG
CCTCCGTCCCGG 
GCCTTCGCACAGCGCAA
GTCCGCGC 
(72) 
KRA CACCATGAGGGGGACCGTGT
TAATC 
GGCGAGCGAATCTAAG
AATG 
(72) 
AT-P CACCATGGCAGTGGGTGTAC
TGGTG 
CATTGTGGTGGTGTCGT
AGG 
(72) 
Hsp65 CCGAAGGTGTTGGACTCCTC CCGAGAAGGTCCGTAA
CTCG 
NCBI 
 
T7 Promoter 
 
TAATACGACTCACTATAGGG 
 Life 
technologies
, Australia 
MU_VNTR9N
R_F 
ACTGCCCAGACAGGGCGA ACGCGAGGTGGAACAA
AGC 
(181,182) 
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4.3 Production of protein preparations from M. ulcerans culture 
 
4.3.1 Mycobacterial culture media 
 
To produce protein preparations from M. ulcerans isolate from Australia (Victoria), 
bacteria were sub-cultured on Brown and Buckle agar (BBA) and grown at 32.5oC for 
8 to10 weeks, after which cultures were seeded into Middlebrook 7H9 liquid medium 
supplemented with 0.1% w/v tryptose and 2% w/v glucose (7H9TG). Middlebrook 
7H9 medium supplemented with only 2% w/v glucose (7H9G) was also used for 
culture. With the exception of tryptose, all Middlebrook 7H9 media prepared for 
bacteria growth did not contain albumen or any other protein supplement. 
4.3.2 M. ulcerans  batch setup 
 
M. ulcerans is a slow growing mycobacterium and takes between 6 to 24 weeks to 
grow in a medium. To produce sufficient quantities of protein preparations for analysis 
and downstream application, a number of cultures had to be setup and pooled. The 
wet-weight of 8 weeks M. ulcerans cells scraped using a sterile loop from a single 
BBA slope weighed approximately 0.350 mg (initial inoculum). Ten slopes of 8 weeks 
M. ulcerans culture were pooled by scraping using a sterile loop from BBA slope and 
seeded into 500 ml Erlenmeyer flasks containing 200 ml either 7H9TG or 7H9G media 
and incubated at 32.5oC without disturbance for days to make a single batch setup. 
After the first 10 days, sub-cultures were made from each 200 ml 7H9TG/7H9G 
cultures unto fresh BBA slopes to check for cell viability and contamination. Ziehl–
Neelsen (ZN) staining was also done to check the presence of acid fast bacteria (AFB). 
The cultures were checked daily for contamination and after 30 days, 4 x 200 ml 
cultures were pooled/harvested for production of protein preparations (batch). Three 
different batches were prepared this way (4 x 200 ml of culture) and 4 different 
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preparations were  made from 200 ml media only. M. smegmatis was grown on BBA 
slope for only 7 days. Two BBA slopes of M. smegmatis served as the initial inoculum 
for 200 ml 7H9TG. This was incubated at 32.5oC until a thick dominant pellicle was 
observed (approximately 2 weeks). Heat treatment procedure was also used for protein 
production from M. smegmatis. M. ulcerans and M. smegmatis cultures showing 
contamination were discarded.   
 
4.3.3 Production of mycobacterial protein preparations 
 
The procedure used for protein production was adapted from Wynne et al., 2012 for 
the production of precipitated protein derivatives (PPDs) from M. avium subsp. 
paratuberculosis (MAP) the causal agent of Johne’s disease (65). Wynne et al. 2012 
procedure was adapted because, it used a defined approcah to prepare PPDs from MAP 
to address the lack of standardisation in antigen preparation for the potential diagnosis 
of the Johne’s disease. Based on the systematic review in chapter 2, there was the need 
for such standardisation in M. ulcerans antigen preparations. There were slight 
modifications in protein production due to logistical constraint in the facility where the 
samples were processed and included,  i) Time for culture inactivatation in autoclave, 
ii) introduction of preparation from M. smegamtis and M. ulcerans without heat 
inactivation treatment and iii) the resultant supernatant was generated using 0.22 µm 
pore size bottle-top filters (Corning Life Sciences) without centrifugation step. For 
protein preparation, M. ulcerans cultures were treated with or without heat. For the 
heat treated cultures,  cells were autoclaved at 105oC for 90 min to inactivate cells. 
Inactivated cultures were then cooled at 4oC for 18 h. Then filtered through 0.22 µm 
bottle-top filters (Corning Life Sciences) into a sterile 1 litre bottle and 40 % (w/v) 
trichloroacetic acid (Sigma Aldrich) solution in distilled water was added to 4% final 
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concentration in mixture; this was stirred for  30 min with a magnetic stirrer (set to 
speed 10 ) to ensure even precipitation of protein in supernatant. The suspension was 
then kept (without stirring) in the dark at room temperature for 18 h. After this period, 
the proteins were completely precipitated with TCA and the suspension was 
transferred to fresh sterile centrifuge bottles and centrifuged at 3,000 x g for 15 min. 
The supernatant was decanted and the pellet was retained. The pellet was washed with 
5% NaCl (w/v) + 0.5% (w/v) phenol in dH20 (pH 3.0 adjusted with 40% TCA). 
Centrifugation and washing were repeated thrice until pH of supernatant was 2-3. The 
amount of wet-weight was measured and noted at this point. The pellet was later 
resuspended in 100 mM Na2HPO4 x2H2O at pH 11. The amount of resuspension 
solution (100 mM Na2HPO4 x2H2O at pH 11) added was approximately 3 to 3.5-fold 
the wet-weight of the pellet and vortexed using MO-BIO Vortex-Genie2 (speed was 
set to 8) until all pellets were resuspended (approximately 90-120 min), pH was 
measured to be within the 6.7-6.9 range. After the pellet had resuspended it was further 
clarified by centrifugation at 3,000 x g for 10 min to remove any unsuspended 
particles,  the supernatant was then mixed with an equal volume of 1.5% (w/v) KH2PO4 
+ 3% (w/v) Na2HPO4 x2H2O + 19.4% (w/v) glucose + 0.5% (w/v) phenol in dH2O pH 
6.7-6.9. Protein concentration of precipitated proteins was determined by 2D-quant kit 
(VWR). Aliquots of protein preparations were stored at -80oC. The above protocol was 
also used for protein preparations from M. smegmatis and M. ulcerans unheated 
cultures. Protein preparation control was made from 200 ml of 7H9TG (heat treated) 
to assess whether the tryptose supplement could be preciptated by the TCA. 
 There was also a separate protein preparation that was a sample pool from each of the 
two approaches of culture treatment (heated and unheated cell treatments). Therefore, 
50 µl aliquots from all heat-inactivated preparations were pooled in to a separate 2 ml 
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sterile tube (designated: heat-inactivated combined). The pool from the unheated 
protein preparations was designated “unheated combined”. The pool was done to 
ascertain if the protein profile of the combined preparations would be representative 
of the individual batches. 
4.3.4 Protein preparations of homogenate 
 
Live M. ulcerans cells from the unheated cultures were separated from medium by 
filtration through 0.22 µm filters and suspended in 20 ml of 7H9TG media containing 
1% phenol. This was then incubated at 37oC overnight to inactivate the cells. Cells 
were then centrifuged at 3,000 x g for 15 min at 4oC in a pre-weighed tube. The 
supernatant was discarded and the cell pellet was washed four times with 1 x PBS. The 
weight of the pellet was determined at this point and was resuspended in 10 ml of 
phosphate buffer pH 6.7-6.9 (1.5% (w/v) KH2PO4 + 3% (w/v) Na2HPO4) containing 
19.4% (w/v) glucose, 0.5% (w/v) phenol and a tablet of protease inhibitors (Pierce). 
The cells were then homogenized using glass beads and vortexed for 90 min. 
Homogenate was centrifuged at 3,000 x g for 30 min at 4oC to pellet out insoluble 
debris as well as the beads. Aliquots of supernatants were stored at – 80oC. Protein 
concentration was determined by 2D-quant kit (VWR, Australia). 
4.3.5 Proteomic characterisation of M. ulcerans protein preparations 
 
Fifty micrograms (50 µg) of all protein preparations and recombinant proteins were 
subjected to proteolytic digestion to generate peptides suitable for mass spectrometric 
analysis. Aliquots of each sample (50 µl) were reduced with 100 mM dithiothreitol 
(DTT) in 50 mM NH4HCO3 (pH 8.5) for 30 min at 56°C.  After samples were cooled, 
5 µl of 250 mM iodoacetamide (IAM) in 50 mM NH4HCO3 was added and incubated 
at room temperature for 20 min in the dark.  Digestion was done using trypsin (20 µg 
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in 200 µl) in 50 mM NH4HCO3/5% v/v acetonitrile. The preparations were incubated 
overnight at 37oC. After the incubation, the enzymatic activity of trypsin was quenched 
with 10% formic acid to give a final concentration of 1% v/v formic acid.  To remove 
any large or undigested proteins (also trypsin), samples were passed through 10 kDa 
MWCO filter (Amicon Ultracel) following the manufacturer’s protocol. Filtrates 
containing peptides were kept and lyophilised by vacuum centrifugation (Thermo 
Speedivac) and resuspended in 25 µl 0.1% formic acid for mass spectrometry. 
4.3.6 Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
 
Mass spectrometry of the protein digests were performed by Dr Nick Williamson at 
the Bio21 Mass Spectrometry and Proteomics Facility, the University of Melbourne. 
Brian Shiell of the Bio-Assay R&D group at CSIRO AAHL conducted primary MS 
data analysis. Protein digests were subjected to LC-MS/MS analysis on a Q Exactive 
Plus Hybrid Quadrupole - Orbitrap mass spectrometer (Thermo Scientific) coupled to 
an Ultimate 3000 RSLC nanosystem (Dionex). The nanoLC system was equipped with 
an Acclaim Pepmapnano-trap column (Dionex) and an Acclaim Pepmap analytical 
column (Dionex). Mobile phase buffers were 0.1% (v/v) formic acid in water (A) and 
0.1% (v/v) formic acid in acetonitrile (B), run at a flow rate of 1.2 μl per min with a 
linear gradient of 3-80% B over 25 min. The mass spectrometer was operated in the 
data-dependent mode, whereby spectra were acquired first in positive mode followed 
by MS/MS fragmentation using high energy collision-induced dissociation (HCD). 
Fifteen of the most intense peptide ions with charge states ≥ 2 were isolated and 
fragmented using normalized collision energy of 30 V. For identification of proteins 
in the samples, the resulting MS/MS spectra were searched against M. ulcerans (strain 
Agy99) protein database in GenBank, accession number: CP000325. M. ulcerans 
FASTA protein database (M. ulcerans strain Agy99, comprising 4,206 protein 
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sequences downloaded from UniProt) using MASCOT algorithm, version 2.4.1 (183). 
Searches for protein identification were performed with the following parameters: 
Enzyme: semi-trypsin; Fixed modifications: Carbamidomethyl (Cys); Variable 
modifications: Oxidation (Met); MS peptide tolerance: 10 parts per million (ppm); 
MS/MS tolerance: 0.5 Da; Number of missed cleavages: up to one. Peptide identity 
was only accepted for Mascot scores ≥ 20 and proteins were reported only if ≥ 2 unique 
peptides were identified (65).  
4.3.7 Plasmid extraction for recombinant proteins expression 
 
A TOPO10 E. coli colony from each of the gene construct plates were inoculated in 
50 ml Luria-Bertani (LB) broth containing amp (final concentration = 100 µg/ml) and 
cam (final concentration = 30 µg/ml) with exception of mup045 where kan was used 
(final concentration = 100 µg/ml). All cultures were incubated at 37oC on an orbital 
shaker (190 rpm) until an OD600 of 0.5 was obtained. After incubation, cultures were 
centrifuged in 50 ml tubes at 2,500 x g for 15 min at 4oC to collect cell pellets. Plasmid 
DNA was extracted from the cell pellets using Qiagen spin miniprep kits (Qiagen) 
following the manufacturer protocol. Genomic DNA was also extracted from M. 
ulcerans isolate from Victoria as described (182,184,185) after sub-culturing on BBA. 
There were no DNA extracts from M. smegmatis (ATCC700084) used in this study. 
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4.3.8 Determination of plasmid concentration 
 
NanoDrop ND-1000 Spectrophotometer (Thermofisher Scientific) was used to 
determine DNA concentrations of extracts. Two microliters (2 μl) elution buffer was 
used as a blank measurement on the spectrophotometer prior to sample (2 μl of DNA 
extracts) measurement to ensure a low level of background. 
4.3.9 Polymerase chain reaction of DNA extracts 
 
DNA extracts of M. ulcerans isolate and M. ulcerans gene constructs were verified 
using M. ulcerans specific primers (Table 4-1) in a polymerase chain reaction (PCR) 
as well as Sanger sequencing. Primers and oligonucleotides probes used in the study 
were sourced from Integrated DNA Technologies (IDT) and Applied Biosystems 
(AB). To ensure that M. ulcerans gene constructs were in frame, T7 promoter primers 
were also used in amplification. With the exception of hsp65 primers which were 
designed in-house,  primers used for PCR and sequencing of mul_0513, mup045, 
mup057, ATP, mul_2232 and KRA included 5’ CACC sequence (Table 4-1) as 
published in the Pidot et al.,  2010 (72). 
 
4.3.10 DNA amplification conditions 
 
Amplification of sequence-specific target in M. ulcerans and M. ulcerans gene 
constructs were done by PCR using GoTaqMasterMix (Promega) (Table 4-2).  
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Table 4-2: PCR MasterMix components. 
 
 
Components 
Volume per PCR 
reaction tube 
PCR Mastermix 12.5 µl 
Forward primer 1 µl 
Reverse primer 1 µl 
dH2O 9.5 µl 
DNA extracts 1 µl 
Total reaction volume 25 µl 
 
To each PCR reaction tube, 1 μl (DNA extract or PCR positive control) was added 
except for the PCR negative control where 1 μl dH2O was added. Total PCR reaction 
volume was 25 μl (Table 4-2). PCR condition used in amplification were as follows: 
 
Initiation-        1 cycle of 95°C for 5 min  
Denaturation-   1 cycle of 94°C for 30 sec  
Annealing -       1 cycle of 60°C for 1 min            35 cycles 
Elongation -     1 cycle of 72°C for 1 min 
Final elongation -  1 cycle of 72oC for 10 min 
 
4.3.11 Gel electrophoresis of DNA amplicons 
 
Electrophoretic separation of amplicons was done using 1% agarose in 1 x Tris- 
Borate-EDTA buffer (TBE) pH 7.0. DNA stain SybrSafe (Invitrogen), was added and 
microwaved prior to pouring into the gel-casting frame. Electrophoresis was 
performed at 100 V for 30 to 50 min in 1x TBE. Aliquots of 10 µl PCR amplicons 
were loaded into each gel well and stained nucleic acids were visualized using 
MSMajor science transilluminator light box. 
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4.3.12 Sanger sequencing of M. ulcerans gene constructs 
 
Sanger Sequencing of the seven M. ulcerans gene constructs were done prior to further 
use to verify if constructs were in-frame as well as to confirm the correct gene insert 
in the cloning vectors. Geelong Centre for Emerging Infectious diseases (GCEID), 
Victoria, did the DNA sequencing. For Sanger sequencing, 0.5-1.0 µg of plasmid DNA 
was used for the reaction in a 96 well plate. Table 4-3 shows the reaction 
components/Master Mix per reaction. 
Table 4-3: Sanger sequence MasterMix. 
 
 
Component     
Volume per PCR 
reaction tube 
BigDye Sequencing Buffer    4 µl 
Ready Reaction Premix    2 µl 
Primer (3.2 µM) (forward and reverse 
primers in separate wells) 
2 µl 
Template 2 µl 
H2O    10 µl 
Total volume per well 20 µl 
 
The plate was sealed with MicroAmp clear adhesive film (Life technologies, Australia) 
and placed in thermal cycler (Applied Biosystems) and ran under the following 
conditions: 
Initiation-         1 cycle of 95°C for 5 min  
Denaturation-   1 cycle of 96°C for 10sec  
Annealing -      1 cycle of 50°C for 4 min                   25 cycles 
Elongation -     1 cycle of 60°C for 1 min 
Hold -                               4o C 
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4.3.13 BigDye XTerminator purification 
 
After PCR run, clean-up of primers, salts and unincorporated BigDye terminators were 
performed per well using the BigDye XTerminator purification kit (Life Technologies, 
Australia) following manufacturer’s protocol. Plate was sealed and vortexed at 1, 800 
x g for 30 min to ensure thorough cleanup and centrifuged at 1,000 x g for 2 min. After 
the cleanup, the seal was carefully removed so as not to cross contaminate wells and 
replaced with a septum before running it in the DNA sequence analyzer under the 
BigDye XTerminator run module.   
4.4 Bioinformatics analysis 
 
Molecular Evolutionary Genetics Analysis (MEGA) software version 7 was used to 
edit the DNA sequence data of the M. ulcerans gene constructs. In addition, ExPASY 
(https://www.expasy.org/), UniProt (http://www.uniprot.org/) and National Center for 
Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) were used for DNA sequence translation and 
protein searches by BLASTN algorithm. The online bioinformatics tools were also 
used for amino acid sequence comparison of proteins identified in the culture 
preparations. In addition, Bioinformatics and Evolutionary Genomics online Venn 
diagram resource (http://bioinformatics.psb.ugent.be/webtools/Venn/) was used to 
perform multiple comparative analyses of proteins identified in each of the 
preparations. This was to assess similarities and differences in protein compositions of 
each of the preparations.  
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4.5  Competent cell production and expression of recombinant proteins 
 
Dr Melanie Thomson at Deakin University (School of Medicine) was generous in 
supplying the E. coli (BL21) (186) from her laboratory from which competent cells 
were made. BL21 competent cells were produced using the Hanahan method for 
competent cell production (187). Detailed protocol is in Appendix A. Aliquots of 100 
µl BL21 competent cells in cyrotubes were stored at -80oC for future use. 
4.5.1 BL21 Competent cell transformation 
 
Plasmid DNA concentration of constructs were normalized for transformation. 
Transformation was done by the heat shock method. Chemically competent E. coli 
strain BL21 cells were transformed with 40-50 ng plasmid per 100 μl of cells (OD600 
~0.5), for the over-expression of the seven M. ulcerans recombinant proteins. Cells 
were transformed by incubation on ice for 30 min, followed by heat shock at 42°C for 
42 sec and incubation on ice for 5 min. For cell recovery, 950 μl SOC media (10 mM 
NaCl, 2.5 mM KCL, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose supplemented 
with 2% tryptone and 0.5% yeast extract) was added to the cells and incubated for 1 h 
at 37°C with agitation (190 rpm).  One hundred microliters (100 µl) of cells were 
streaked onto selective LB-antibiotic agar plates. 
4.5.2 Stock preparation of BL21 competent cells 
 
A single visible colony of transformed BL21 was used to inoculate 5 ml of LB broth 
containing appropriate antibiotics (i.e., amp + cam or kan) for each of the seven gene 
constructs and incubated overnight at 37oC. After OD600 of 0.5 was read using Biowave 
Cell Density Meter CO8000 (VWR), 50% glycerol stocks were prepared for 
mul_0513, mup057, mup045, ATP, KRA, mul_2232 (18 kDa shsp) and hsp65 in the 
ratio of 1:1. Glycerol stocks were stored at -80oC for future use.  
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4.5.3 Protein expression protocol 
 
Single colonies of each of the seven M. ulcerans expression clones were inoculated in 
LB-antibiotic medium. All bacteria cultures were incubated at 37oC on an orbital 
shaker (190 rpm) until OD600 of 0.45-0.5.  Expression of the recombinant proteins was 
done by inducing cells with 1 M isopropyl-β-D- thiogalactoside (IPTG) to a final 
concentration of 1 mM.  
4.5.4 Pilot recombinant proteins expression 
 
From overnight LB culture plates, a single colony for each expression clone was 
inoculated into 50 ml LB/Ab broth and incubated at 37°C overnight with shaking. An 
aliquot (2 ml) of the overnight culture was seeded in 100 ml LB/Ab (1:50 dilution) and 
incubated at 37oC with shaking (190 rpm) for 3 h (OD600 ~0.4-0.5).  Protein expression 
was induced by treatment of cells with 1 M IPTG to a final concentration of 1 mM. 
After 4 - 4.5 h (OD600 ~0.8) of post-induction, cells were harvested by centrifugation 
at 3,000 x g for 30 min at 4oC.  
4.5.5 Large-scale expression and purification of recombinant proteins 
 
BL21 expression clone stocks were retrieved from -80oC and streaked on LB plates 
containing amp + cam or kan. Plates were incubated overnight at 37oC. A single colony 
of overnight cells was inoculated into 10 ml LB-amp + cam or kan broth and incubated 
overnight at 37oC on an orbital shaker (190 rpm). After incubation the 10 ml LB culture 
was passaged into 500 ml LB-antibiotic broth (1:50 dilution) and incubated at 37oC on 
a shaker for 3 h (OD600 ~0.4-0.5) and 1 ml culture taken after 3 h from each 
recombinant protein culture and centrifuged at 16, 000 x g for 5 min. The supernatant 
was discarded, but the pellet was retained and labelled as un-induced (pre-induced) 
sample and stored at -20oC for SDS-PAGE analysis. For protein induction and 
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expression,  500 µl 1M IPTG was added to each sample (final concentration ~1 mM 
IPTG) and incubated at 37oC on a shaker (190 rpm) for 4 h (OD600 ~0.8). Cells were 
harvested after 4 h by centrifugation at 3,500 x g for 30 min at 4oC. Harvested cells 
(post-induced) were labelled and stored at -80oC for SDS-PAGE analysis and His-
tagged protein purification. 
4.5.6 Verification of His-tagged proteins 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
verify expression of the M. ulcerans gene constructs followed by Western blot to 
confirm presence of His-tagged proteins. 
4.5.7 Electrophoretic separation of proteins 
 
All SDS-PAGE and Western blot analysis were performed under reducing conditions. 
One ml of sample reducing buffer (SRB) (250 µl 4x Laemmli sample buffer, 100 µl 
0.5 M DTT and 650 µl MES) was prepared for protein denaturing following Laemmili 
method (188). For protein pellet denaturing, 100 µl SRB was added to 1 ml pre- and 
post-induction pellets whereas for cell lysates and partially purified recombinant 
proteins, 20 µl protein sample was added to 50µl SRB (1:2.5 dilution). All samples 
were denatured at 100°C for 10min prior to SDS-PAGE and Western blot analysis. 
Samples were loaded onto pre-cast 15 well NuPAGE 4-12% Bis-Tris-polyacrylamide 
gels (Life Technologies, Australia). Molecular weight markers used were pre-stained 
PageRuler Standard and BenchMark His-tagged Standard (Life Technologies, 
Australia). Electrophoresis was performed at 200 V for 30 min in 1x MES buffer at 
pH 7.7 (Life Technologies, Australia). 
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4.5.8 Protein visualization on polyacrylamide gels 
 
The staining buffer of choice for protein visualization was Coomassie Brilliant Blue 
(CBB) (Life Technologies, Australia). The CBB buffer prepared for protein staining 
contained 0.25% (w/v) CBB R-250 dissolved in 45% (v/v) methanol, 10% (v/v) acetic 
acid. Proteins within gels were stained with CBB at room temperature (RT) on a 
rocking platform mixer for 1h after which gels were de-stained in 10% (v/v) acetic 
acid, 40% (v/v) methanol and 50% (v/v) dH2O. SilverXpress silver staining kit 
(Invitrogen) was used on selected gel to enable visualization of all proteins within 
culture preparations. This technique is known to exhibit a higher degree of sensitivity 
than the standard CBB for detecting proteins present in low concentrations. All 
procedures used in protein staining were as described by the manufacturer’s protocol. 
Colour Image CanoscanLiDE 120 scanner was used for gel documentation. Digital 
Images of stained gels were saved as TIF files. 
4.5.9 Pilot Western blot for His-tagged verification 
 
For the verification of His-tagged proteins, 20 µl of pre and post-induced cell lysates 
were separated on NuPAGE 4-12% SDS-PAGE. PageRuler pre-stained protein 
standard was included in each run. SDS-PAGE was performed using 1x MES buffer 
at 200 V for 30 min. After that the gel was transferred onto a nitrocellulose membrane 
(NC) (Life Technologies, Australia) using the iBlot dry transfer system (Invitrogen) 
module for 7 min. Transfer was deemed successful upon visualization of complete 
transfer of the pre-stained protein standard onto the membrane. The membrane was 
blocked at room temperature in 5% skim milk in 1x PBS-T for h with slight agitation 
using an orbital shaker (50 rpm). After blocking,  it was washed with 1x PBS-T 
(repeated 4 times) and later probed with Anti-His6 antibody conjugated to Horseradish 
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Peroxidase (Sigma Aldrich) at 1 in 500 dilution in blocking buffer and incubated for 1 
h. Washing was repeated as described above. His-tagged proteins on membranes were 
detected by Chemiluminescence using Pierce SuperSignal kit (Life Technologies, 
Australia) following the manufacturer’s protocol. Digital image was captured or 
recorded by the UVP chemidoc (Scientifix, Australia). 
4.5.10 Purification of recombinant proteins 
 
Expressed recombinant proteins were partially purified using an ÄKTA Pure 
Chromatography apparatus connected to UV and conductivity monitors for detection 
of proteins and salts, respectively. The purification procedure was done according to 
the inbuilt protocol for His-tagged protein purification using a 1 ml HisTrap HP 
column (GE Healthcare Life Science). Post-induced pellets were resuspended in 10 ml 
wash buffer (300 mM NaCl, 20 mM imidazole, 50 mM NaH2PO4, 8 M urea; pH 7.0). 
After the pellet has resuspended, 50 µl of lysozyme, 10 µl DNase and 1 tablet of Pierce 
protease inhibitor (Life Technologies) was added to 10 ml suspension and sonicated 
on ice for 3 x 30 sec with pulse. The lysate was then centrifuged at 16,000 x g for 30 
min at 4oC. The clarified lysate was added to 1ml HisTrap HP column after it was 
equilibrated with 5 column volumes (CV) of wash buffer solution (300 mM NaCl, 20 
mM imidazole, 50 mM NaH2PO4, 8 M urea; pH 7.0). The cell lysate was applied to 
the column at a flow rate of 2 ml/min using the Super loop system (8 ml volume).  
Flow-through sample was taken for SDS-PAGE analysis. The column was washed 
with 10 CV of wash buffer to wash away unbound and non-specific proteins (sample 
was taken for SDS-PAGE analysis). Isocratic elution of His-tagged proteins were 
performed with 5 ml of elution buffer (500 mM imidazole,  50 mM NaH2PO4 xH2O,  
300 mM NaCl at pH 8.0) at a flow rate of 1 ml/min. Salts and imidazole were removed 
by 10 kDa molecular weight cut-off (MWCO) Amicon Ultra centrifugal filter units 
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(Merck Millipore) with two Tris-buffer (pH 8.0) exchanges. Purified proteins were 
stored at -80oC in 30% glycerol. 2-D Quant Kit (VWR) following the manufacturer’s 
protocol was used to quantitate the concentration of purified proteins after the addition 
of glycerol.  
4.6 Results 
 
4.6.1 Protein preparation setup and quantitation  
 
Batch D was the only preparation in 7H9G media. With the exception of homogenate 
preparation and the recombinant gene constructs, all culture preparations were in 
7H9GT media. The wet-weight recovered for the homogenate preparation was 1.4 g 
with protein concentration of 0.82 mg/ml. Among all the precipitated preparations, 
Batches C, G and H  which were a pool of 4 x 200 ml culture had similar wet-weight 
of ≥ 0.333 g (range: 0.333 - 0.453 g)  with protein concentration of  ≥ 1.02 mg/ml 
(range:1.78 - 2.04 mg/ml). The 10 slope preparations (Batches A, B, D, E and F) had 
wet-weight ≥ 0.162 g (range: 0.162 - 0.334 g) with protein concentration of ≥ 0.92 
mg/ml (range: 0.92 - 1.82 mg/ml). M. smegmatis preparation had the highest wet-
weight of precipitated pellet of 0.908 g and protein concentration of 2.3 mg/ml. 
The concentration of all four recombinant proteins were determined after the addition 
of glycerol to be over 1.4 mg/ml (range: 1.4 - 1.8 mg/ml) (Table 4-4).
Chapter 4 
89 
 
Table 4-4: Protein preparation setup and quantitation. 
 
 
Protein 
preparation 
 
Culture 
medium 
(200 ml) 
 
Number of 
pooled slopes 
 
Wet-weight of 
precipitated 
pellet  
(g) 
 
Final volume 
after 
resuspension   
(ml) 
 
Protein 
concentration 
(mg/ml) 
Batch A 7H9GT 10 slopes  
(200 ml 
culture) 
0.234 1.5 1.30 
Batch B 7H9GT 10 slopes  
(200 ml 
culture) 
0.334 2.0 1.52 
Batch C 7H9GT 4 x 200 ml 
culture 
0.453 2.0 1.82 
Batch D 7H9G 10 slopes  
(200 ml 
culture) 
0.174 0.7 1.50 
Batch E 7H9GT 10 slopes  
(200 ml 
culture) 
0.292 1.5 0.92 
Batch F 7H9GT 10 slopes  
(200 ml 
culture) 
0.162 1.5 1.50 
A+B+C+D+E+F - - - - 0.90 
Batch G#  7H9GT 4 x 200 ml 
culture   
0.400 2.5  2.04 
Batch H# 7H9GT 4 x 200 ml 
culture 
0.333 2.5 1.76 
Batch G+H# - - - - 0.90 
 
Homogenate# 
20 ml of 
7H9GT 
with 1% 
phenol 
 
Batch H cells 
after filtration  
 
1.4* 
 
5.00 
 
0.82 
M. smegmatis 7H9GT 2 slopes (200 
ml culture) 
0.908 3.00 2.3 
MUL_2232 LB  - - 0.80 1.5 
MUP057 LB - - 1.50 3.0 
ATP LB - - 1.50 1.0 
Hsp65 LB - - 2.00 1.0 
 
4 x 200 ml culture = four of 10 slopes seeded in 200 ml culture medium (incubated for 30 days) were pooled together to that 
preparation only. 
7H9GT = Middlebrooks media supplemented with glucose and tryptose. 
7H9G =   Middlebrooks media supplemented with glucose only (Batch D only). 
Final volume after resuspension = for easy of measurement all volumes were rounded to nearest whole number. 
LB medium= each of the four M. ulcerans gene construct was cultured in 500 ml LB broth. 
Protein concentration of recombinant proteins were done after the addition of glycerol solution. 
# = these were the unheated culture preparations. 
* = the homogenate wet-weight was not a precipitate but the weight of cells recovered from Batch H after          
filtration through the 0.22 µm pore size filter (Merck Millipore). 
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4.6.2 Mycobacterial cultures 
 
Mycobacterial cell viability was verified by subculture on BBA after 10 days in 
7H9GT/7H9G media (Figure 4-1). In addition, ZN staining was performed to check 
for the presence of Acid-fast bacteria (AFB) (Figure 4-2). Cultures that showed fungal 
contaminations were always discarded. 
 
 
Figure 4-1: Colonies of M. ulcerans on BBA after 2 weeks of incubation at 32.5oC. 
To show that cells used for the protein production were viable and not contaminated, subcultures were made from 
liquid media (i.e. 7H9GT and 7H9G) on to BBA to check M. ulcerans viability as well as screen for contaminants. 
 
 
 
A       B 
 
 
 
Figure 4-2: Ziehl–Neelsen staining showing acid fast bacilli. 
Image “A” is showing M. ulcerans clumped colonies at x20 magnification and “B” is showing single rod-shaped 
cells of M. ulcerans at x50 magnification. 
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4.6.3 Protein production and identification 
 
Electrophoretic separation of CBB and silver stained culture preparations by SDS-
PAGE is shown in Figure 4-3. Mass spectrometry (LC-MS/MS) analysis was then used 
for protein identification in all batches. Proteins can be categorized as functional or 
structural. Functional proteins describe groups of proteins involved in metabolic 
activities of the cell (e.g., heat shock proteins and toxins). Structural proteins on the 
other hand, form components of the cell wall and organelles within the cell (e.g., 
ribosomal proteins) (189). In total, 733 M. ulcerans proteins were identified across all 
12 culture preparations (Table 4-4). There are 4,362 protein-coding DNA sequences 
(CDSs) in the M. ulcerans (Agy99) genome (179), 733 proteins represents 16.8% of 
the CDSs. All of the 733 proteins were identified with at least two peptides with LC-
MS/MS size tolerance level of 0.5 Da. Present in all samples were well-known 
mycobacterial functional proteins: chaperone (dnaK), 10 kDa chaperonin (groS), 60 
kDa chaperonin 1 and 2 (grosL1 and 2), chaperone protein (clpB) and the conserved 
secreted antigen (Wag31). Molecular chaperone (Small heat shock protein, 
MUL_2232) and chaperone protein (htpG) were only found in M. ulcerans 
preparations and not in M. smegmatis. Chaperon proteins (DnaJ, molecular weight 
(MW):41,980 and 40,546) were only found in the M. ulcerans homogenate.  
Proteins identified involved in biosynthesis included pks12-16, Mas and PpsA. Among 
the well-known elongation factors used in cell cycle were the tuf, tsf, greA, fusA and 
typA proteins. There were 27 (3.7%) flavin adenine dinucleotide (FAD) proteins 
identified. These proteins (FADs) are important prosthetic proteins involved in 
enzymatic reactions, these included, different categories of FadA, FadB, FadD and 
FadE. Various types of transport or export proteins were identified, especially in the 
homogenate including the ATP-binding component (ABC) transporter (MUL_1269, 
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MUL_1864, MUL_3059, MUL_3149, MUL_3757, and MUL_4925), ctpC, ctpF, ctpl 
and MmpL3. The housekeeping protein translocase subunit SecA1 and SecA2 were 
only identified in M. ulcerans preparations. Interestingly, none of the 11 (1.5%) 
lipoproteins (LpqW, Lpql, OppA, DppA, LprG, LppX, DsbF, LprL, LppZ, LpqE and 
LpqN) identified were in the M. smegmatis preparation. There was only one tuberculin 
related peptide (MUL_1378) found in two M. ulcerans preparations. The conserved 
M. ulcerans surface protein MUL_3720 which has been investigated for antigen-
capture assay in BU patients’ specimen for screening test purposes (122) was present 
in two M. ulcerans preparations as well as in M. smegmatis. 
With the exception of M. ulcerans homogenate, all proteins present in the culture 
supernatants were precipitated by TCA, therefore the study sought to identity secreted 
proteins in preparations. There were a total of 16 (2.2%) secreted proteins of which the 
conserved secreted mycobacterial antigen (Wag31) was found in all preparations. 
Interestingly Wag31 antigen was the only secreted protein common to M. ulcerans and 
M. smegmatis. The remaining 15 secreted proteins (Alanine and proline rich secreted 
protein (Apa), FbpA-D, MUL_0125, MUL_0607, MUL_1085, MUL_1142, 
MUL_1413, MUL_3189, MUL_3206, MUL_3300, MUL_4290 and MUL_4846) 
were only found in M. ulcerans preparations. There were 28 (3.8%) membrane 
associated proteins across all preparations. Surprisingly only one (conserved 
membrane protein, MUL_416) was common to both M. ulcerans and M. smegmatis. 
None of the 11 (1.5%) transmembrane proteins identified was in the M. smegmatis 
preparation. There was one cytoplasmic protein (cytoplasmic peptidase, PepQ) in two 
M. ulcerans preparations (Batches C and E) and three cold shock proteins (cspA, 
cspA_1 and cspB) in all preparations except in Batches D and F. Cytoplasmic 
peptidase (PepQ) is involved in hydrolysis of various bonds (190) and cspA-B helps 
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regulate temperature downshift during extreme conditions (136).  Overall, 58 (7.9%) 
and 137 (18.7%) identified proteins could be classified as synthases and conserved 
proteins, respectively.  
 
Figure 4-3: SDS-PAGE analysis of 12 protein preparations. 
Gel A is CBB staining of culture preparations and lanes 1 and 15 are pre-stained PageRuler protein molecular mass 
marker (Life Technologies, Australia). Lane 14 on Gel A is empty. Gel B is silver staining of culture preparations 
and lanes 1 and 14 are pre-stained PageRuler protein marker. Lane 2 on both gels show M. ulcerans homogenate 
preparation. Lanes 3, 4, 5, 6, 7, 8, show M .ulcerans heated protein preparations of batches A, B, C, D, E and F, 
respectively. Lanes 9 and 10 are batches G and H, respectively (unheated preparations). M. smegmatis preparation 
is shown in lane 11. Lanes 12 and 13 are showing M. ulcerans heated preparations combined (batches 
A+B+C+D+E+F) and unheated preps combined (G+H), respectively. Twenty microlitres (20 µl) and 2 µl of 
proteins were separated on 4–12% NuPAGE precast (Life Technologies, Australia) for Gel A (CBB stained gel) 
and Gel B (silver stained gel), respectively. 
 
 
4.6.4 Comparative analysis of M. ulcerans proteins  
 
The amino acid sequences of M. ulcerans proteins categorized in Table 4-4 were 
compared with M. marinum, M. liflandii, M. smegmatis, M. bovis, M. leprae, M. avium 
subspecies paratuberculosis (MAP) and M. tuberculosis. M. marinum and M. liflandii 
were included in the comparison because some researchers have advocated that these 
should be classified with M. ulcerans as a single species as they share 98.3% DNA 
sequence similarity and are all mycolactone producing mycobacteria (MPM) (191). 
With the exception of M. smegmatis, the remaining mycobacterial species were used 
for comparison because they are well-known pathogens of humans (M. leprae and M. 
Chapter 4 
94 
 
tuberculosis) and animals (M. bovis and MAP) (116,176). The following 17 proteins: 
ilvB1_1, mlsA1, mlsA2, mlsB, MUL_0705, MUL_0838,, MUL_1269, MUL_1620, 
MUL_2683, MUL_2952, MUL_3118, MUL_3189, MUL_3300, MUL_4290, 
MUL_4933, MUL_4925 and MUL_4926 (Table 4-6) did not have homologues in M. 
smegmatis and the pathogenic mycobacterial species considered. In addition, there was 
no homologue of MUL_3189 and MUL_3300 in M. liflandii (Table 4-5). Out of the 
17 M. ulcerans unique proteins identified, three (mlsA1, mlsA2 and mlsB) are 
polyketide synthases found on the M. ulcerans virulence plasmid pMUM001 and 
encode for the toxin mycolactone with orthologues in M. marinum and M. liflandii. 
Four proteins (MUL_1142, MUL_3189, MUL_3300 and MUL_4290) are classified 
as secretory proteins. Bacterial secretory proteins are involved in various activities of 
the cell some of which is for manipulating the host immune system to establishing a 
replicative niche (192). MUL_0838 and MUL_1269 are ion and transmembrane 
carbohydrate transport proteins, respectively. There was only one membrane protein 
(MUL_4926) and three conserved proteins (MUL_1620, MUL_2952 and MUL_4933) 
(Table 4-6). Figure 4-4 to Figure 4-16 show secreted M. ulcerans proteins with 
orthologues in mycobacterial species used for the comparison. Mycolactone producing 
mycobacteria (MPM) protein sequences were not included in these figures.
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Table 4-5: Number of proteins identified by LC-MS/MS and housekeeping protein categories identified in protein batches. 
 
 
Batches 
 
Total 
proteins  
 
Percentage  
of 733 
 M. ulcerans 
proteins 
 
FadD 
proteins 
 
Elongation 
proteins 
 
Lipo- 
protein 
 
Transport 
proteins 
 
Sec 
proteins 
 
ATP 
protein 
 
Tuberculin 
peptide 
 
Secreted 
proteins  
 
Membrane 
proteins 
 
Trans- 
membrane 
 
Cytoplasm 
protein 
 
Synthase 
 
Cold 
shock 
proteins 
 
Conserved 
proteins 
Batch A 125 17.1 1 3 0 0 0 3 0 5 2 0 0 14 3 17 
Batch B 123 16.8 0 2 2 0 0 4 0 6 3 0 0 12 1 18 
Batch C 223 30.4 2 3 8 1 0 6 1 10 6 2 1 20 2 49 
Batch D 128 17.5 1 2 5 0 0 4 0 2 3 0 0 18 0 22 
Batch E 291 39.7 2 4 7 1 0 5 0 10 5 2 1 28 2 56 
Batch F 76 10.4 0 1 0 0 0 4 0 4 2 0 0 12 0 7 
Batch combined 175 36.6 1 3 2 1 0 4 0 8 2 2 0 19 1 30 
Batch G 268 37.2 2 3 5 1 0 5 0 8 2 1 0 26 2 43 
Batch H 273 84.2 2 4 3 0 1 4 1 7 3 0 0 30 2 34 
G+H 329 18.7 2 4 5 2 2 9 0 8 4 0 0 33 2 56 
M. smegmatis 137 23.9 0 3 0 2 0 9 0 1 1 0 0 15 1 11 
Homogenate 617 44.9 5 5 11 12 2 21 0 13 27 7 0 49 1 11 
Total proteins  2,765 
 
5 5 12 14 2 24 1 16 28 11 1 58 3 137 
percentage of 
733 M. ulcerans 
proteins 
  
 
3.7 
 
0.7 
 
1.6 
 
1.9 
 
0.3 
 
3.3 
 
0.1 
 
2.2 
 
3.8 
 
1.5 
 
0.1 
 
7.9 
 
0.4 
 
18.7 
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Table 4-6: Percentage similarity of amino acid sequences in the 16 secreted proteins with other mycobacterial species. 
 
 
Accession number 
 
M. ulcerans 
 
M. marinum 
 
M. liflandii 
 
M. smegmatis 
 
M. tuberculosis 
 
MAP 
 
M. leprae 
tr|A0PWZ6|A0PWZ6_MYCUA 100 98.5 98.8 0 83.4 88.1 79.6 
tr|A0PSB1|A0PSB1_MYCUA 100 98.8 98.8 0 88 0 80.9 
tr|A0PWI8|A0PWI8_MYCUA 100 100 100 0 88.9 0 82.9 
tr|A0PWZ5|A0PWZ5_MYCUA 100 100 100 0 85 85 78.8 
tr|A0PTH9|A0PTH9_MYCUA 100 100 100 0 87.9 89 83.1 
tr|A0PWM8|A0PWM8_MYCUA 100 98.6 98.6 0 0 0 0 
tr|A0PN03|A0PN03_MYCUA 100 98.6 98.6 0 0 0 0 
tr|A0PNN4|A0PNN4_MYCUA 100 99.3 99.3 0 81.2 75.3 65.8 
tr|A0PT23|A0PT23_MYCUA 100 100 0 0 57.4 53.7 0 
tr|A0PKL5|A0PKL5_MYCUA 100 99.6 99.6 76.4 85.5 88.5 78.9 
tr|A0PST8|A0PST8_MYCUA 100 99 0 0 0 0 0 
tr|A0PMV7|A0PMV7_MYCUA 100 97.1 98.9 0 85.6 0 0 
tr|A0PVD8|A0PVD8_MYCUA 100 99.5 99.6 0 80.4 76.9 81.6 
tr|A0PLR0|A0PLR0_MYCUA 100 99.6 99.6 55.6 67.5 0 0 
tr|A0PSV4|A0PSV4_MYCUA 100 99.1 99.1 53 52.1 0 0 
tr|A0PSE9|A0PSE9_MYCUA 100 90.2 92.9 51.8 67.3 0 65.9 
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Figure 4-4: Alanine and proline rich secreted protein (Apa). 
Comparison of amino acid sequences of the Alanine and proline rich secreted protein (Apa) of different 
mycobacterial species. Identity with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference 
sequence is indicated by (.). The GenBank accession numbers were as follows: M. leprae, OX1297123; M. 
smegmatis, OX246196; and M. tuberculosis, OX419947. MEGA software version 7, was used to perform the 
comparsion. 
 
 
 
Figure 4-5: Secreted antigen 850A (fbpA). 
Comparison of amino acid sequences of the secreted antigen 850A (fbpA) different mycobacterial species. Identity 
with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference sequence is indicated by (.). The 
GenBank accession numbers were as follows: MAP, OX1391998; M. leprae, OX272631and M. tuberculosis, 
OX419947. MEGA software version 7, was used to perform the comparsion. 
 
 
 
 
 
 
tr|A0PSE9|A0PSE9 MYCUA 
M. ulcerans M H E V D P N K R R R H G L W T T L A L A A V S S A S V V S I A L P A T A S A D P A P A P A P S T T A A P P A D P N A A  [ 60]
M. leprae . N Q . . L D S T H . K . . . A I . . I . V . A . . . A F T M P . . . A . N . . . . . L . P S T A . . . . S P A Q E I I  [ 60]
M. smegmatis . Y . S . S M S H . . S . . S K K . T . . . . T G M T A . A V . . . S V . H . . . E . P . P . P G N T F L . . P . P . D  [ 60]
M. tuberculosis . . Q . . . . L T . . K . R L A A . . I . . M A . . . L . T V . V . . . . N . . . E . . . P V P . . . . S . P S T A . .  [ 60]
M. ulcerans P P P A D P N A P P P P V V D P N A P E P G R V N N A V G G F S S V V P A G W V E S D A S H L D Y G S A L L S K M T G E  [120]
M. leprae T . L P G A P V S S E A Q P G D P N A P S L D P . A P Y P L A V D P N A G R I T N A V G G F S F V L P . G W V E S E A S  [120]
M. tuberculosis . . A P A T P V A . . . P A A A . T . N A Q P G D P N A A P P P A D P N . P P P P V I . P N A P Q P V R I D N P V G . F  [120]
M. smegmatis . N A P A . A P A . A . A P A . A P A P A L A P A P . P . A P A P A P A P A P A P A . P N A P A P A P . D P N A P A P A  [120]
M. ulcerans P P M P G Q A P P I A N D T R V V L G R L D Q K L Y A S A E A T N P K A A V R L G S D M G E F F M P Y P G T R I N Q E T  [180]
M. leprae H L D Y . S V L L S K A I E Q P P V L G Q P T V V A T D T R I V L G R L D Q K . Y A S A E A D N I K A A V R L G S D M G  [180]
M. tuberculosis S F A L P A G W V E S D A A H F D Y . S A L L S K T T G D P P F P G Q P P P V A N D T R I V L G R L D Q K L Y A S A . A  [180]
M. smegmatis . A E E P P . . E P G R V D N A A G . F S Y V V P E G W Q V S D A T Q L S Y G Q A L L T K T V A E G A E P P N D T S V L  [180]
M. ulcerans I P L N A N G I T G S A S Y Y E V K F S D E S K P N G Q I W T G V V G T P A G S T P N E G P P Q R W F V V W L G T S N D  [240]
M. leprae E F Y L P Y P G . R I N Q E T I P L H A N G I A G S A S Y Y E V K F S D . N K P I G Q I C T S V V G S P A A S T P D V G  [240]
M. tuberculosis T D S K . A A R L . . D M G E F Y M P Y P G T R I . Q E T V S L D A N G V S . . A S Y Y E V K F S D P S K P N . Q I W T  [240]
M. smegmatis L G R L D L K L F A G . E P D N N . A A V R L A S D M G E F F M P F P G T R V N Q Q T V Q L N A D G M P G V A S Y Y E V  [240]
M. ulcerans P V D K G A A K V L A E S I R P W M P P P A P A P A P A P G E P A P Q P G A P E P V P A P A P A P A A G V A P T V A P A  [300]
M. tuberculosis G . I G S P . A N A P D A G P . Q R W F V V W L G T A N N P V D K G A A K . L A E S I R . L V . . P P A P . . A P . E P  [300]
M. smegmatis K F T D A N K P A G Q I W A G V V G Q . V . . G T P R G Q R T . E R W F V V W L G T A N N P I D K D . A . . L A N S I R  [300]
M. leprae E F Y L P Y P G . R I N Q E T I P L H A N G I A G S A S Y Y E V K F S D . N K P I G Q I C T S V V G S P A A S T P D V G  [240]
M. ulcerans - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
M. tuberculosis A P A P A P A G E V A P T P T T P T P Q R T L P A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
M. smegmatis P W A P P P P P P P A P A D P A D P N A A P P P P D P N A P P A R P G V G V P V P V T D A P P E M M P P A - - - - - - -  [360]
M. leprae - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
tr|A0PWZ6|A0PWZ6 MYCUA
M. ulcerans M K L V D R F R G A A T G T S R R L M V G A V G A A L L S G L V G F V G G S A T A S A F S R P G L P V E Y L Q V P S V A  [ 60]
MAP . T . . . . L . . . V A . M P . . . V . . . A . . . . . . . . I . A . . . . . . . G . . . . . . . . . . . . . . . . A .  [ 60]
M. leprae . . F . . . . . . . V A . M L . . . V . E . M . V . . . . A . I . V . . S A P A E A F S R P G L P V E Y L Q V P S P S M  [ 60]
M. tuberculosis . Q . . . . V . . . V . . M . . . . V . . . . . . . . V . . . . . A . . . T . . . G . . . . . . . . . . . . . . . . P S  [ 60]
M. ulcerans M G R N I K V Q F Q S G G A N S P A L Y L L D G M R A Q D D F S G W D I N T P A F E W Y Y Q S G I S V A M P V G G Q S S  [120]
MAP . . . D . . . . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . . . . . . N . . . . . . . . . . . . . . .  [120]
M. leprae G R D I K V Q F Q N G . A N S P A L Y L . D G L R A Q D . F S G W D I N T . A F E W Y . Q S G I S V . M P V G . Q S . F  [120]
M. tuberculosis . . . D . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . D . . . L . . V . . . . . . . .  [120]
M. ulcerans F Y S D W Y N P A C G K A G C T T Y K W E T F L T S E L P Q Y L S A N K G V K P T G S G V V G L S M A G S S A L I L A A  [180]
MAP . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . Q . Q . . . . . . . . . . . . . . . . . . . . . . .  [180]
M. leprae Y S D W Y S P A C G K A G C Q . Y K W E T F L T S E L P Q Y L Q . N K Q I K P T G S A A . G L S M A G L . A L T L A I Y  [180]
M. tuberculosis . . . . . . Q . . . . . . . . Q . . . . . . . . . . . . . G W . Q . . R H . . . . . . A . . . . . . . A . . . . T . . I  [180]
M. ulcerans Y H P D Q F V Y S G S L S A L L D P S Q G I G P S L I G L A M G D A G G Y K A S D M W G P K D D P A W A R N D P M L Q V  [240]
MAP . . . . . . . . A . . . . . . . . S . . . M . . . . . . . . . . . . . . . . . A . . . . . . E . . . . . . . . . S . . .  [240]
M. leprae H P D Q F I Y V G S M S G L . D P S N A M G P S L I G L A M G D A G . Y K A . D M W G P S T . P A W K R N D P T V N V G  [240]
M. tuberculosis . . . Q . . . . A . A M . G . . . . . . A M . . T . . . . . . . . . . . . . . . . . . . . . E . . . . Q . . . . L . N .  [240]
M. ulcerans G K L V A N N T R I W V Y C G N G K P S D L G G D N L P A K F L E G F V R T S N M K F Q A A Y N A A G G H N A V W N F D  [300]
MAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . D . . . G . . . . . . . . . . .  [300]
M. leprae T L I A N . T R I W M Y C G N G K P T E L G . N N L P A K L L E G L V R T S N I K F Q D G Y N A G G . H N A V F N F P .  [300]
M. tuberculosis . . . I . . . . . V . . . . . . . . . . . . . . N . . . . . . . . . . . . . . . I . . . D . . . . G . . . . G . F D . P  [300]
M. ulcerans D N G T H S W E Y W G A Q L N A M R P D L Q H T L G A T P N T G D T Q G A - - - - - - - - - - - - - - - - - - - - - - -  [360]
MAP A . . . . D . P . . . . . . Q . . K . . . . S V . . . . . G A . P A T A . A T N A G N G Q G T - - - - - - - - - - - - -  [360]
M. leprae S G T H S W E Y W G E Q L N D M K P D L Q . Y L G A T P G A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
M. tuberculosis . S . . . . . . . . . . . . . . . K . . . . R A . . . . . . . . P A P Q G A - - - - - - - - - - - - - - - - - - - - - -  [360]
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Figure 4-6: conserved secreted protein (fbpB). 
Comparison of amino acid sequences of the conserved secreted protein (fbpB) of different mycobacterial species. 
Identity with the M. ulcerans (Agy99 strain, accession number; OX362242) reference sequence is indicated by (.). 
The GenBank accession numbers were as follows: M. leprae, OX1297123 and M. tuberculosis, OX419947. MEGA 
software version 7, was used to perform the comparsion. 
 
 
 
Figure 4-7: secreted antigen 850C (fbpC). 
Comparison of amino acid sequences of the secreted antigen 850C (fbpC) different mycobacterial species. Identity 
with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference sequence is indicated by (.). The 
GenBank accession numbers were as follows: M. leprae, OX272631 and M. tuberculosis, OX419947. MEGA 
software version 7, was used to perform the comparsion. 
 
 
 
 
 
Figure 4-8: secreted Mpt51/Mpb51 antigen (fbpD). 
Comparison of amino acid sequences of the secreted Mpt51/Mpb51 antigen (fbpD) different mycobacterial species. 
Identity with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference sequence is indicated by (.). 
The GenBank accession numbers were as follows: MAP, OX1391998; M. leprae, OX272631and M. tuberculosis, 
OX419947. 
tr|A0PSB1|A0PSB1 MYCUA 
M. ulcerans M T D V S G K I R T W G R R L L I G A A A A I T L P G L V G V A G G A P A A K A F S R P G L P V E Y L Q V P S A A M G R  [ 60]
M. leprae . I . . . . . . . A . . . W . . V . . . . T L P S L I S L A G G A A T A S . F S R P G L P V E Y L Q V P S E A M G R S I  [ 60]
M. tuberculosis . . . . . R . . . A . . . . . M . . T . . . V V . . . . . . L . . . . A T . G . . . . . . . . . . . . . . . . P S . . .  [ 60]
M. ulcerans S I K V Q F Q S G G D N S P A V Y L L D G L R A Q D D Y N G W D I N T P A F E W Y Y Q S G L S V I M P V G G Q S S F Y A  [120]
M. leprae K V Q F . N G G N . S P A V Y L L D G L R A Q D D Y N G W D I N T S A F E W Y Y Q S G L S V V M P V G G Q S S F Y S D W  [120]
M. tuberculosis D . . . . . . . . . N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I V . . . . . . . . . . S  [120]
M. ulcerans N W Y Q P A C G K S G C S T Y K W E T F L T S E L P E W L S A N R S V K P T G S A A I G I S M S G S S A M I L A V Y H P  [180]
M. leprae Y S P A C G K A G C T T Y K W E T F L T S E L P K W L S A N R S V K S T G S A V V G L S M A G . S A L I L A A Y H P D Q  [180]
M. tuberculosis D . . S . . . . . A . . Q . . . . . . . . . . . . . Q . . . . . . A . . . . . . . . . . L . . A . . . . . . . . A . . .  [180]
M. ulcerans Q Q F V Y A G S L S A L L D P S Q G M G P F L I G L A M G D A G G Y K A G D M W G P S S D P A W Q R N D P T I Q I P A L  [240]
M. leprae F I Y A G S L . A L M D S S Q G I E P Q L I G L A M G D A G G Y K A A D M W G P P N D P A W Q R N D P I L Q A G K L V A  [240]
M. tuberculosis . . . I . . . . . . . . . . . . . . . . . S . . . . . . . . . . . . . . A . . . . . . . . . . . E . . . . . Q . . . K .  [240]
M. ulcerans V S N N T R L W V Y C G N G T P S E L G G A S L P A E F L E N F V R S S N L K F Q D A Y N A A G G H N A V F N F N D N G  [300]
M. leprae N N T H L W V Y C G N . T P S E L G G T N V P A E F L E N F V H G S N L K F Q D A Y N G A G G H N A V F N L . A D G T H  [300]
M. tuberculosis . A . . . . . . . . . . . . . . N . . . . . N I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P P . .  [300]
M. ulcerans T H S W E Y W G A Q L N A M K G D L Q T S L G A A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
M. leprae S W E Y W G A Q L N A M K P D L Q N T L M A V P R S G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
M. tuberculosis . . . . . . . . . . . . . . . . . . . S . . . . G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
tr|A0PWI8|A0PWI8 MYCUA
M. ulcerans M K F V E K L R G A A A G A P R R L T I A A I G A A L L S G L V G A V G G A A T A G A F S R P G L P V E Y L Q I P S A A  [ 60]
M. leprae . . . L Q Q M . K L F G L . A K F P A R L T . A V I G T A L . A . L . . V V G D T A I A V A F S K . G L P V E Y L Q V P  [ 60]
M. tuberculosis . T . F . Q V . R L R S A . T T L P R R L . . A . M G A V L V Y . L . . T F G G P A T A G A F S R . G L P V E Y L Q V P  [ 60]
M. ulcerans M G R D I K V Q F Q G G G A H S V Y L L D G L R A Q D D Y N G W D I N T P A F E E Y Y N S G L S V V M P V G G Q S S F Y  [120]
M. leprae S P S M G H D I K I Q F Q G G G Q H A V Y L . D G L R A Q E D Y N G W D I N T P A F E E Y Y H . G L S V I M P V G G Q S  [120]
M. tuberculosis S A S M G R D I K V Q F Q G G G P H A V Y L . D G L R A Q D D Y N G W D I N T P A F E E Y Y Q . G L S V I M P V G G Q S  [120]
M. ulcerans S D W Y Q P S Q G N G Q G Y T Y K W E T F L T R E M P A W L Q A N K G V S P T G N A A V G L S M S G G S A L V L A A Y Y  [180]
M. leprae . F Y S N W Y . P S Q G N G Q H Y T Y K W E . F L T Q E M P S W L Q A N K N V L P T G N A A V G L S M . G S S A L I L A  [180]
M. tuberculosis . F Y T D W Y . P S Q S N G Q N Y T Y K W E . F L T R E M P A W L Q A N K G V S P T G N A A V G L S M . G G S A L I L A  [180]
M. ulcerans P Q Q F P Y A A S L S G F L N P S E G W W P T L I G L A M N D S G G Y N A N S M W G P S T D P A W K R N D P M V Q I P R  [240]
M. leprae S Y Y P Q Q F P Y A A S L S G F L N P S E G W W P T M I G L A M N D S G G Y N A N S M W G P S T D P A W K R N D P M V Q  [240]
M. tuberculosis A Y Y P Q Q F P Y A A S L S G F L N P S E G W W P T . I G L A M N D S G G Y N A N S M W G P S S D P A W K R N D P M V Q  [240]
M. ulcerans L V A N N T R I W V Y C G N G T P S D L G G D N M P A K F L E G L T L R T N Q T F R D T Y L A S G G R N G V F N F P T N  [300]
M. leprae I P R L V A N N T R I W V Y C G N G A P N E L G G D N I P A K F . E S L . L S . N E I F Q N T Y A A S G . R N G V F N F  [300]
M. tuberculosis I P R L V A N N T R I W V Y C G N G T P S D L G G D N I P A K F . E G L . L R . N Q T F R D T Y A A D G . R N G V F N F  [300]
M. ulcerans G T H S W P Y W N Q Q L V A M K G D I L K V L N G P A V P A A P A A P E A P A A P V A P A A - - - - - - - - - - - - - -  [360]
M. leprae P P N G T H S . P Y W N Q Q L V A M K P D I Q Q I L N G S N N N . - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
M. tuberculosis P P N G T H S . P Y W N E Q L V A M K A D I Q H V L N G A T P . . . . A . . . . - - - - - - - - - - - - - - - - - - - -  [360]
tr|A0PWZ5|A0PWZ5 MYCUA
M. ulcerans M E V D M R G V S V V T R L L C V A V L S V T L G G I T V A T G S T G K A N A A P Y E T L M V P S G A M G R D I P V A F  [ 60]
MAP . D M T V V R G V S A L L R V F C I A V L A A G L . V A L Q P A A V T G . A R . A G Y E S L M V P S . A M G R D I P V A  [ 60]
M. leprae . R G L S A V . R . L C V A A L A V G V F A A A V L L A G T A . N A K A . G Y E S L M V P S N A M . R D I P V A F M . G  [ 60]
M. tuberculosis . K G R S A L L R A L W I A A L S F G . G G V A V A A E P T A K A A P Y E . L M V P S P S . G R D I P V A F L A G G P H  [ 60]
M. ulcerans L A G G P H A A Y L L D A F N A G P D V S N W V T A G N A M N T L G G K G I S V V A P A G G A F S M Y T D W E Q D G S K  [120]
MAP F L A . G P H . V Y . L D A F N A A P D V S N W V T A G N A M N T L . G K G I S . V A P A . G A W S M Y T N W E Q D G S  [120]
M. leprae G P H A V Y L L D A F N . A L D V S N W V T A G N . M T T L G G R . I S V V A P A G G . Y S M Y T N W E N D G S K Q W D  [120]
M. tuberculosis A V Y L L D . F N A G P D V S N W V T A G . A M N T L A G K G I S V V A P A G G A Y S M Y T N W E Q D G S K Q W . T F L  [120]
M. ulcerans Q W D T F L S S E L P D W L A A N K G L A P G G H A A V G A S Q G G Y G A M A L A A F H P D R F G F A G S L S G F L Y P  [180]
M. tuberculosis S A E L P D W L A A N R G . . P G G H A . V . A A Q G G Y G A M A L A A F H P D R F G F A G S M S G F L Y P . N T T T N  [180]
MAP K Q W D T F L . S E L P D W L . A N K G L A P . G H . A V G A S Q . G Y G A M A L . A F H P D R F G F A G S L S G F L Y  [180]
M. leprae T F L S S E L P D W L A T K R G L A P D G H A A V G . S Q G G Y A A L A L A . F H P D R F G F A . S L S G F V Y P S S T  [180]
M. ulcerans S S T T T N G A I L A G M Q Q F G G V D G N G M W G A P Q L G R W K W H D P W V H A A L L A Q N N T R V W V W S P T N P  [240]
MAP P . S . N Y N G A I L A G L . Q Y . G V D G N G M W G V P Q L G R W K W H D P Y V H . S . L A Q . N T R V W V W S P T N  [240]
M. leprae N Y N G A I L . G . Q Q F G G I D . N G M W . A P Q L G R W K W H D P Y V H A S L L . Q N N T R V W V Y S P M T M G G D  [240]
M. tuberculosis G A I A A G M Q Q F G . V D T N . M W G A P Q L G R W K W H D P . V H A S L L A Q N N T R V W V W S P T N P G A S D P A  [240]
M. ulcerans G A S D P A A M I G Q A G A A M G D S R S F Y Q Q Y R N V D G H N G H F D F P G G G D N G W G S W S A Q L G A M S G D I  [300]
MAP M G G . D . . . . . . . . . . . . S . . E . . . . . . S N G . . . . . . . . . . . . . . . . . . . A G . . . . . . . . .  [300]
M. leprae I D A M I G Q A V A S M . S S R E F Y Q Q Y R S V G G H N G H F D F S G G G D N . W G A W A P Q L A . M S . D I V . A .  [300]
M. tuberculosis A M I G Q . . E A M G N S R M F Y N Q Y R S V G G H N G H F D F P A S G . N G W . S W A P Q L G A M S G D I V G A I R -  [300]
M. ulcerans V G A I R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
MAP . . . . . - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
M. leprae R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
M. tuberculosis - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
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Figure 4-9: Conserved secreted protein (MUL_0125). 
Comparison of amino acid sequences of the Conserved secreted protein (MUL_0125) different mycobacterial 
species. Identity with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference sequence is 
indicated by (.). The GenBank accession numbers were as follows: M. leprae, OX272631; MAP, OX1391998; M. 
smegmatis, OX246196; and M. tuberculosis, OX419947. MEGA software version 7, was used to perform the 
comparsion. 
 
 
 
Figure 4-10: Conserved hypothetical secreted protein (MUL_0607). 
Comparison of amino acid sequences of the conserved hypothetical secreted protein (MUL_0607) different 
mycobacterial species. Identity with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference 
sequence is indicated by (.). The GenBank accession numbers were as follows: M. smegmatis, OX246196; and M. 
tuberculosis, OX419947. 
 
 
 
 
tr|A0PKL5|A0PKL5_MYCUA
M. ulcerans M I P L W F T L S A L C F V S A V V L L Y V D I D R R R G R S R R R K S W A R S H G F D Y E R E S T D I L Q R W T R G V  [ 60]
MAP . V . . . . . . . . . . . . G . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . K . . .  [ 60]
M. leprae . V . . . . . . . . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E . . . . . K . . .  [ 60]
M. smegmatis . V . . . . . . . . . . . . G . A . . . . . . . . . . . . L G . . . . . . . K . . . . . . . Y . . E . L . K . . K . . .  [ 60]
M. tuberculosis . V . . . . . . . . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E . . K . . . . . .  [ 60]
M. ulcerans M S T V G E V P A K N V V L G Q I R G E A V Y I F D L E E V A T V I A L H R K V G T N V V V D L R L K G L K E P R E S D  [120]
MAP . . . . . D . A . Q . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [120]
M. leprae . . . . . D I S . H . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . . . . . . .  [120]
M. smegmatis . . . . . D . T . . . . . . . . . . . . . . F . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N .  [120]
M. tuberculosis . . . . . D . A . H . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [120]
M. ulcerans I W L L G A I G P R M V Y S T N L D A A R R A C D R R M V T F A H T A P D C A E I M W N E Q N W T L V S M P I A S S R A  [180]
MAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . T . T . T  [180]
M. leprae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . . . . . . . . . G . T . V  [180]
M. smegmatis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . V T . N . .  [180]
M. tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . .  [180]
M. ulcerans Q W D E G L R T V R Q F N D L L R V L P P L P Q E S P Q E A E E S E P A Q S G N R S L T P S R R P E L P P R R A Q V D P  [240]
MAP . . . . . . . . . . . . . . . . . . . . . . . E . T . . . . P A A P R N S . P S . P . A . A - - - - - - - - - - - - - -  [240]
M. leprae . . . . . . . . . . . . . . . . . . . . . . . A D T S . . . G A . A R N A A P S . P . A S V G . A . . . . D . G V E S D  [240]
M. smegmatis . . . . . . . . . . . . . . . . . . . . . V . . N G S . A . L P R R G G S P S R P L A P T P A G R R E L . P G R A D V .  [240]
M. tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . . M . . Q T G V G P R G A A P G . P V A . G G P A . . . . . . . . P . .  [240]
M. ulcerans A A G L L P D A S R R T P E P M R R E E G R S E G S R R P P L G G R N G Q Q A T K Y Q R - - - - - - - - - - - - - - - -  [300]
MAP - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [300]
M. leprae V . . . . G S G V Q A G R S A E P I S R D E G R W D G I R R P P S V E R N G H Q T T N Y Q Y - - - - - - - - - - - - - -  [300]
M. smegmatis P . R G D V S R F A P R . . A G . S D A F . R P P P A . N G R E A S H F . R - - - - - - - - - - - - - - - - - - - - - -  [300]
M. tuberculosis . T T V . . . P A . . A . . . I . . D . . . . . . V . . . . P A . . . . . . . . N . . H - - - - - - - - - - - - - - - -  [300]
tr|A0PLR0|A0PLR0 MYCUA 
M. ulcerans . I C V R H T M . R S V V E . V V S R L V M V V I G L T L L V G V V V G F S L R P L H P A R A R A Y D A L T V D Y R L .  [ 60]
M. tuberculosis M S R P G T Y V I G L T L L V G L V V G N P G C P R S Y R P L T L D Y R L N P V A V I G D S Y T T G T D E G G L G S K S  [ 60]
M. smegmatis . . . L T . F L V A V A . . . . V F . N V . T Q R Y V T S G . D P K I F H I A . I G D S Y T T G A A E G G Q . A K G W P  [ 60]
M. ulcerans H I . V I G D S Y T T G T D E G G R G P N . W T S L A W R E L A Q R . M R I N A D V . A E G R A G Y G M P G D H . . V F  [120]
M. tuberculosis W T A R T W Q M L A A R G V R I A A D V A A E G R A G Y G V P G D H G N V F E D L T A R A V Q P D D A L V V F F G S R N  [120]
M. smegmatis T L . W Q T L A R R G V Q I N A D V V A E G G A G Y V V R G N R G S I F A D L T P R . V K P D D S L V V F Y G S R N D K  [120]
M. ulcerans E D L T A G A V K P D D . L V . F F G S R N D Q G V D L G L L G D R A R N A F D L . H R V A . S A . L L V I G P P W P T  [180]
M. tuberculosis D Q G M D P E D P E M L A E K V R D T F D L A R H R A P S A S L L V I A P P W P T A D V P G P M L R I R D V L G A Q A R  [180]
M. smegmatis . A D P V A I T R M S H D A L A L A Q R I A P T A . M L V I G P P W P T A D V . V S V L R I R D I L R D Q A E Q V G . S  [180]
M. ulcerans P D V P I P . L Q . R . V V R A A A G F A Q A E F V D P I A E G W F F D R P . L . G A D G V H P N D A G H A Y L A D K I  [240]
M. tuberculosis A A G A V F V D P I A D H W F V D R P E L I G A D G V H P N D A G H E Y L A D K I A P L I S M E L V G - - - - - - - - -  [240]
M. smegmatis F Y D P I A A G W F V G R P D L I G G D G . H P T D A G H A Y M A D K I A T I I G D E . P R W V - - - - - - - - - - - -  [240]
M. ulcerans A P L I G A R L A G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [300]
M. tuberculosis - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [300]
M. smegmatis - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [300]
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Figure 4-11: Conserved secretory protein (MUL_1085). 
Comparison of amino acid sequences of conserved secretory protein (MUL_1085) different mycobacterial species. 
Identity with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference sequence is indicated by (.). 
The GenBank accession numbers for M. tuberculosis is OX419947. MEGA software version 7, was used to perform 
the comparsion. 
 
 
 
 
Figure 4-12: Conserved hypothetical secreted protein (MUL_1413). 
Comparison of amino acid sequences of the conserved hypothetical secreted protein (MUL_1413) different 
mycobacterial species. Identity with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference 
sequence is indicated by (.). The GenBank accession numbers were as follows: MAP, OX1391998; M. leprae, 
OX272631and M. tuberculosis, OX419947. MEGA software version 7, was used to perform the comparsion.  
 
 
 
 
Figure 4-13: Conserved hypothetical secreted protein (MUL_3206). 
Comparison of amino acid sequences of the Conserved hypothetical secreted protein (MUL_3206) of different 
mycobacterial species. Identity with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference 
sequence is indicated by (.). The GenBank accession numbers were as follows: M. smegmatis, OX246196 and M. 
tuberculosis, OX419947. MEGA software version 7, was used to perform the comparsion. 
  
 
 
 
tr|A0PMV7|A0PMV7_MYCUA
M. ulcerans M S R W M R G R I R G S L F A A V N A A G V V G V L L L G A G P A V A D P D D A P G D P P V I A P A E P A P D P L A P P  [ 60]
M. tuberculosis . P H . A E E . H . R E S N Y V A L E . . L D E G E S I R R S E H S R S G C G . D A G C W R C R G G P G R G S R R S R R  [ 60]
M. ulcerans P G P L A L P P M P D P L A P P P L V P V A A G P V A G Q D P T P F F G P P P F R P P S F N P V D G A M V G V A K P I I  [120]
M. tuberculosis S R G P G G T A G . V D P P A V D . L A P P P D . L . L P P A L D P L A . . . P D . L A P P . P . P L A . P . . A G P V  [120]
M. ulcerans I N F Q V P I A D Q A M A E S A I H I S S I P P V P G K F Y W M T P T Q V R W R P F Q F W P A N T A V N I D A A G T K S  [180]
M. tuberculosis A G Q D P T S F V G P P P F R P P T F N P V D G A M V G V A K P I V I N F A V P I A D R A M . E S . I H . S S I P P V P  [180]
M. ulcerans S F R T G D S L V A T A D D A T H Q M T I T R N G V V E Q T F P M S M G M A A G N H Q T P N G T Y Y V L E K M P T V V M  [240]
M. tuberculosis G K F Y W M . P T Q V R W R P F E F W P A N T A V N I D A A G T K . S F R T G D S L V A T A D D A T H Q M T I T R N G V  [240]
M. ulcerans D S S T Y G V P V N S P Q G Y K V T V A D A V R I D N S G N F V H S A P W S V G D Q G K R D V S H G C I N L S P T N A K  [300]
M. tuberculosis V Q K . F P M S M G M V S . G H Q . P N G T Y Y V L E K F A T . V M D S S T Y . V P V N S A Q G Y K L T V S D A V R I D  [300]
M. ulcerans W F F D N F G S G D P I V V K N S V G T Y N K N D G A Q D W Q I - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [360]
M. tuberculosis N S G N F V H . A P W S . A D Q G K R N V T H G C I N L S P A N A K W F Y D N F G S G D P V V V K N S V G T Y N K N D G  [360]
M. ulcerans - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [395]
M. tuberculosis A Q D W Q I - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [395]
tr|A0PNN4|A0PNN4_MYCUA
M. ulcerans M S R L S S S L R A G A V F L A I G I A A A V F P K T A A A D S T D D F P I P R R I I A T S C D A E Q V L A A T R D T S  [ 60]
MAP . . . . . R G . . . . . A . V . L . V T . . I . . S . . V . . . . E . . . . . . . M . N . T . . . . . I . . . . . . . .  [ 60]
M. leprae . . . . . T . . C K . . . . . V F . . I P V A . . T . . V . . G S T E D F P I P . R Q I A T T C D A E Q Y L . A V R D T  [ 60]
M. tuberculosis . . . . . . I . . . . . A . . V L . . . . . T . . Q S . . . . . . E . . . . . . . M . . . T . . . . . Y . . . V . . . .  [ 60]
M. ulcerans P V Y Y Q R Y M I D Y N N H P Q F Q Q A T Q D K A H W F F S L S P A D R R D Y S E H F Y D S I D P L W W G W R N H M K I  [120]
MAP . . . . . . . . . . F . . . . N V . . . . I . . . . . . Y A . . . Q . . . N . . . N . . A P Q A D P L . E A W P N H M K  [120]
M. leprae S P I . Y Q R Y M I D M H N K P T D I Q Q A A V N R I H W F Y . L S P T D R R Q Y S E D T A T N V Y Y E Q M A T . W G N  [120]
M. tuberculosis . . . . . . . . . . F . . . A N L . . . . I N . . . . . . . . . . . E . . . . . . . . . N G D P L T F A W V N H M K I F  [120]
M. ulcerans F F N N K G V V A K S T E V C N Q Y P A G D M S V W N W A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [180]
MAP I . W . N K G . V A K A T D I C N Q Y P P G D M S V W N W S - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [180]
M. leprae W A K I F F N N K G V V A K A T E V C N Q Y Q A G D M S V W N W P - - - - - - - - - - - - - - - - - - - - - - - - - - -  [180]
M. tuberculosis . N . K G V . A K G T E V C N G Y P A G D M S V W N W A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [180]
tr|A0PSV4|A0PSV4 MYCUA 
M. ulcerans M S L S A P A V H R R I A V G A F S A A L L F G S A A I A V A D P P A N C T A A D L A R T A S G V S N A T A D Y L F N H  [ 60]
M. smegmatis . L . . . Q N A R . V V . G A . G A G . V A G A M L F G . I P S A L . D P A P N P P N C . . A D L A G V A S G V S A G T  [ 60]
M. tuberculosis . V S F V R P A A . V V . G A M A A G . V G V A M L F A T A G S A A . D W P M D . P E P A P . S Q P . C . . A D . A Q V  [ 60]
M. ulcerans P D V N D F F T G L R G Q D R D A M S A N T Q N Y L D A N P S V K A D L Q G I R Q P L V D F K G R C Q - - - - - - - - -  [120]
M. smegmatis S A Y L F T H P Q V N D F F T S L E G L P R E E V K P K V A D Y L . A N P Q V K D E . T A V R Q P L V D L K N R C G T A  [120]
M. tuberculosis S S G V A A A . S A Y L F T H P D V N . Y F T S L K G Q P R D D M R A Q L K Q Y M D A N P Q T H T D L E G I R Q P L T D  [120]
M. ulcerans - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [180]
M. smegmatis P A P E L P - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [180]
M. tuberculosis F Q N R C R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [180]
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Figure 4-14: Conserved secreted protein (MUL_3300). 
Comparison of amino acid sequences of the conserved secreted protein (MUL_3300) of different mycobacterial 
species. Identity with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference sequence is 
indicated by (.). The GenBank accession numbers were as follows: MAP, OX1391998 and M. tuberculosis, 
OX419947. MEGA software version 7, was used to perform the comparsion. 
 
 
 
Figure 4-15: Conserved hypothetical secreted protein (MUL_4290). 
Comparison of amino acid sequences of the conserved hypothetical secreted protein (MUL_4290) different 
mycobacterial species. Identity with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference 
sequence is indicated by (.). The GenBank accession numbers were as follows: MAP, OX1391998; M. leprae, 
OX272631and M. tuberculosis, OX419947. MEGA software version 7, was used to perform the comparsion. 
 
 
 
Figure 4-16: conserved secreted antigen (Wag31). 
Comparison of amino acid sequences of the conserved secreted antigen (Wag31) different mycobacterial species. 
Identity with the M. ulcerans (Agy99 strain, Accession number; OX362242) reference sequence is indicated by (.). 
The GenBank accession numbers were as follows: MAP, OX1391998; M. leprae, OX272631and M. tuberculosis, 
OX419947. MEGA software version 7, was used to perform the comparsion. 
  
 
 
tr|A0PT23|A0PT23 MYCUA
M. ulcerans M K L L V G V T G L A V M V G L A A P A H A D A N D D A F L V A L G K A G I T Y P D A A R A I A A A K W I C Q Q V N N G  [ 60]
MAP . L C K N H R F M K L F L I V A G F A . V I G L A V P . R A D S T D D . F V A S L . K . G I K Y G D A D K A A G A G K W  [ 60]
M. tuberculosis . . Y . L T L A S . . T V L . T . . . . Y . . G A . . I . . G S . R A . . . . F . . P E . . . . . G . . V . S A . H G .  [ 60]
M. ulcerans T Q T V D V V K Q V Q S S N S G L Q E D G A A K F T A I A A N A Y C P A I L S G H G A N P P G - - - - - - - - - - - - -  [120]
MAP V C . T L Q G G K Q M . D V V S T L Q S K N S N L S D D H . . T F A A I A V N A Y C P D Q A S S I T P A T P T D T P P S  [120]
M. tuberculosis N A M . . . . . T . . N E . P . . R G . N . . Q . . . . . . . T . . . T T . A . N T H - - - - - - - - - - - - - - - - -  [120]
M. ulcerans - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [180]
MAP T S - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [180]
M. tuberculosis - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [180]
tr|A0PVD8|A0PVD8 MYCUA 
M. ulcerans M S A A S P G M I G L M T S P T L M R P A L A A A L L G L G V T A S L V A S P A L A N P S D P G V V S Y A V L G K G S V  [ 60]
MAP . . R V L K A G G A W H D R C M T . . I T R V R R A V L F V G V . A V G . V A L P V A A A H . S E P G V V N Y A V L G K  [ 60]
M. leprae . . W V I R I S A V V . S V G L G L G V P V . S . R P S E P G V V . Y A V L G K G S V G N I I . R P M G W E S L L T E P  [ 60]
M. tuberculosis . R I . A A V V S I G L A V I A G F A V P V . D . H P S E P G V V . Y A V L G K G S V G N I V . A P M G W E A V F T R P  [ 60]
M. ulcerans G N I V G A P M G W E S V F T E P F Q A Y S V D L P V C N N W A D I G L P E V F N D P D L A S F N G A T T Q T S A T D Q  [120]
MAP . S V G N I V G . P M G W E S V F T . P G Q G . W V D L P E C N N W A D I G L P E V F N D P D L A S F N G A V T Q . S A  [120]
M. leprae L Q A Y S V D L P M C N N W A D I G L P E V Y H D V D L A S F N G A I T Q T S A . . Q T H F V K Q A V G V F A T N D A A  [120]
M. tuberculosis F Q A F W V E L P A C N N W V D I G L P E V Y . D . D L A S F N G A T T Q T S A T . Q T H L V K Q A V G V F A . N D A A  [120]
M. ulcerans T H Y V K Q A V G V F A T T D A A S R A F H R V V D R T V G C S G Q T T A M H L D N G T T Q V W S F D G P A P T A T D A  [180]
MAP . D Q T H L V K Q A V G V F A T N D A . D R A F H R V V D R T V . C S G Q T T A I H L D N G S T Q V W S F D G G P A G P  [180]
M. leprae V R A F H R V . D R T V G C S G Q T T . M . L D N G T . Q V W . F V G G T P T Y A D A N W T K Q E A G T D R R C F V Q T  [180]
M. tuberculosis D R A F H R V . D R T V G C S G Q T T . I . L D D G T . Q V W . F A G G P S T G T D E A W T K Q E A G T D R R C F V Q T  [180]
M. ulcerans A W T K Q E A D T D R R C F N Q T R L R E N V L L Q A K V C Q S S N G G P A V N V L A G A M Q N T L G Q - - - - - - - -  [240]
MAP . D E N W T K Q E A G T D R R C F N Q T R L R E N V V L Q A K V C Q S . N . G P A V N V L A G A M Q N A L G Q - - - - -  [240]
M. leprae R L R E N V L L Q T K V . Q P G N A G P A V N V . A G A M Q N A L G Q - - - - - - - - - - - - - - - - - - - - - - - - -  [240]
M. tuberculosis R L R E N V L L Q A K V . Q S G N A G P A V N V . A G A M Q N T L G - - - - - - - - - - - - - - - - - - - - - - - - - -  [240]
tr|A0PTH9|A0PTH9 MYCUA
M. ulcerans M P L T P A D V H N V A F S K P P I G K R G Y N E D E V D A F L D L V E N E L T R L I E E N S D L R Q R I A E L D Q E L  [ 60]
MAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . E . . . . . .  [ 60]
M. leprae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Q . . . . . . . . . . . . E . . . H . .  [ 60]
M. tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . .  [ 60]
M. ulcerans A A G A G G G A A V T A Q P T Q A M P V Y E P E P E P A K P A A P V A S A A T N E E Q A M K A A R V L S L A Q D T A D R  [120]
MAP . . . G . A A . P A A . A . . . . I . . A . . . . V K . A . . . A . S N E E Q A I K A . R V L S L A Q D T . D R L T S T  [120]
M. leprae . . . G . T . . G P V I A V Q P T Q A L S T F . . . L V S A K Q A P V A . V A E T A E E L A M K A T R V . S L A Q D T A  [120]
M. tuberculosis . . . G . A . V T P Q . T Q A I P A Y E P . . G K P A P A A V S A G M N E E Q A L K A . R V L S L A Q D T . D R L T N T  [120]
M. ulcerans L T S T A K A E S D K M L S D A R A N A D Q I L S E A R H T A E T T V T E A R Q R A D G M L A D A Q A R S E S Q L R Q A  [180]
MAP A Q A E S E K M L A D A R A N . D Q I L S E A R . T . E T . V A E A R Q R . D A M L A D A Q . R S E . Q L R Q A Q E K .  [180]
M. leprae D Q L . S T . K V E S D K M L . D . R V N A D Q I L G E A R L T A E A . V . E A Q Q R A D A M L . D . Q T R . E V Q S R  [180]
M. tuberculosis A K A E S D K M L A D A R A N . E Q I L G E A R H T . D A . V A E A R Q R . D A M L A D A Q S R S E . Q L R Q A Q E K .  [180]
M. ulcerans Q E K A D A L Q A D A E R K H S E I M G T I N Q Q R T V L E G R L E Q L R T F E R E Y R T R L K T Y L E S Q L E E L G Q  [240]
MAP D A L Q A D A E R K H S E I M G T . N Q Q R T V L E G R . . Q L R T F E . E Y R T R L K . Y . E S Q . . E L G Q R G S A  [240]
M. leprae . A Q E K . D A L Q . . A E R K H S E I M G A I S Q Q R T V L E G R L E Q L R T F . R E Y . T R L K T Y L E S Q L E E L  [240]
M. tuberculosis D A L Q A D A E R K H S E I M G T . N Q Q R A V L E G R . . Q L R T F E . E Y R T R L K . Y . E S Q . . E L G Q R G S A  [240]
M. ulcerans R G S A A P V D S S A D A G G F E Q F N R G N N - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [300]
MAP A P V D S S A . A G G F D Q F N R G N . - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [300]
M. leprae G Q R G S A A P V D S N . D A G G F D Q F N R G N N - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [300]
M. tuberculosis A P V D S N A . A G G F D Q F N R G K . - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  [300]
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4.6.5 General overview of proteins identified in all preparations 
Generally, there were more proteins identified in the homogenate and the three 
unheated preparations (G, H and G+H) compared to the eight heat inactivated ones 
(Table 16). Some proteins were identified in more than one batch. This is designated 
shared, and unique refers to proteins identified only in one batch (Figure 4-19). Out of 
the six M. ulcerans heat inactivated preparation analysed by LC-MS/MS, four batches 
(A, B, D and “A+B+C+D+E+F”) had similar numbers of proteins. In addition, 
comparison of the protein profiles in the three unheated batches G, H and G+H also 
showed that two out of the three had similar numbers of proteins. Overall, the 
precipitated proteins from M. ulcerans in this study could be divided into two groups 
of five batches in terms of similarity of number of proteins; Group 1 (batches A, B, D, 
F and “A+B+C+D+E+F”) and Group 2 (batches C, E, G, H and “G+H”).
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Table 4-7: M. ulcerans unique proteins with no homologues in pathogenic mycobacteria and their representation in the 12 protein 
preparations. 
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tr|A0PMA7|A0PMA7_MYCUA Transmembrane carbohydrate transport protein   Mul_0838  54,635                       + 
tr|A0PNB7|A0PNB7_MYCUA Conserved ion transport protein   MUL_1269  27,124                       + 
tr|A0PWU3|A0PWU3_MYCUA ATP binding protein ABC transporter   MUL_4925  34,435                       + 
tr|A0PT23|A0PT23_MYCUA Conserved secreted protein   MUL_3300  10,810         +             + 
tr|A0PN03|A0PN03_MYCUA Conserved secreted protein   MUL_1142  7,427   + +   +   +   +       
tr|A0PWM8|A0PWM8_MYCUA Conserved secreted protein   MUL_4846 7,693  + +  + + + + + +  + 
tr|A0PST8|A0PST8_MYCUA Conserved secreted protein   MUL_3189  40,246                       + 
tr|A0PWU4|A0PWU4_MYCUA Conserved membrane protein   MUL_4926  25,430     +   +             + 
tr|Q6MZ72|Q6MZ72_MYCUA Type I modular polyketide synthase   mlsB  1,501,507 + + + + + + + +   +   + 
tr|Q6MZA5|Q6MZA5_MYCUA Type I modular polyketide synthase   mlsA2  256,810     + + + + + +       + 
tr|Q6MZA4|Q6MZA4_MYCUA Type I modular polyketide synthase   mlsA1  1,803,727     +     + +   + +   + 
tr|A0PR16|A0PR16_MYCUA Acetolactate synthase (Large subunit)  ilvB1_1  59,867                       + 
tr|A0PP52|A0PP52_MYCUA Conserved protein   MUL_1620  14,370 +   +   +   + + + +   + 
tr|A0PS97|A0PS97_MYCUA Conserved protein   MUL_2952  27,434                       + 
tr|A0PWV1|A0PWV1_MYCUA Conserved protein   MUL_4933  43,937                       + 
tr|A0PSN6|A0PSN6_MYCUA Uncharacterized protein   MUL_3118  15040         +         +   + 
tr|A0PRN5|A0PRN5_MYCUA Uncharacterized protein   MUL_2683  45973                       + 
tr|A0PLZ0|A0PLZ0_MYCUA Imidazolonepropionase   MUL_0705  44386 +       +   + + + +   + 
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4.6.6 Heat inactivated preparations 
 
There were eight heat inactivated protein preparations, seven batches A, B, C, D, E, F, 
‘A+B+C+D+E+F’ from M. ulcerans and one from M. smegmatis. The total number of 
proteins identified in M. ulcerans preparations was similar in batches A,  B,  D and 
‘A+B+C+D+E+F’ (range: 123-175).  However, batch E and F had the highest and 
lowest number of 291 and 76 identified proteins, respectively. There were no unique 
proteins in Batch F. Nevertheless a five-way Venn diagram of the top five M. ulcerans 
preparations (batches A, B, C, D and E) shows that 55 proteins  representing 15% of 
the total 367 identified M. ulcerans  proteins are across the five batches. In addition 
there were several shared and unique proteins (Figure 4-17). There were 137 identified 
proteins in M. smegmatis that were homologous to M. ulcerans proteins (Table 4-4). 
 
Figure 4-17: Five-way Venn diagram of top five heat inactivated preparations. 
Protein composition shared between the top five in-house M. ulcerans heat inactivated protein preparations. 
Numbers within each segment represent the total number of proteins shared by those preparations. 
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4.6.7 Unheated protein preparations 
 
Generally, there were more similarities in the protein profiles of the three unheated 
preparations (G, H and ‘G+H) compared to the heat inactivated preparations. Out of 
the 268 and 273 proteins identified in G and H, respectively (Table 16), 207 are shared 
representing 62% of the total 334 M. ulcerans proteins identified in the two batches 
(Figure 4-18). 
 
 
Figure 4-18: Venn diagram of unheated protein preparations. 
Number protein composition shared by the two M. ulcerans unheated protein preparations. Number within each 
segment represents the total number of proteins. 
 
4.6.8 Homogenate preparation 
 
The homogenate preparation had the highest number of proteins of 617 representing 
84.2% of the 733 M. ulcerans identified proteins. Unsurprisingly, it also had the 
highest number of shared and unique proteins of 389 and 228, respectively (Figure 4-
19). 
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4.6.9 Common mycobacterial proteins  
 
The Venn diagram comparative analysis of all proteins identified by LC-MS/MS in 
the 12 batches found 25 shared proteins,  which included the 60 kDa chaperone protein 
(dnaK) as well as the 60 kDa chaperonin 1 and 2 (Hsp65) (Table 4-7 and Table 4-8),  
well known mycobacterial immunogenic antigens. M. ulcerans-specific18 kDa shsp 
protein (MUL_2232) was among the 27 proteins shared by 11 batches. Most of the 
unique proteins, 287 (39.2%), were found only in the homogenate.  Overall, there was 
an inverse relationship between shared proteins and the number of batches (Table 4-
7). Table 4-8 shows twenty (20) proteins common to the 12 batches as identified by 
mass spectrometry. A detailed overview of all shared and unique proteins in all batches 
could be found in Appendix B, Table B-3. 
 
Table 4-8: Number of shared proteins in protein preparation batches. 
 
 
 
 
 
 
 
 
 
 
Number  
of proteins shared  
 
Number of 
Batches 
 
Common 
immunogenic antigens 
25 (3.4%) 12 Hsp65 
27 (3.7%) 11 MUL_2232 
22 (3.0%) 10 mlsB 
23 (3.1%) 9  
21 (2.9%) 8  
30 (4.1%) 7 mlsA2 
40 (5.5%) 6 mlsA1 
47 (6.4%) 5  
60 (8.2%) 4  
50 (6.8%) 3 MUL_3720 
101(13.8%) 2  
287 (39.2%) 1  
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Figure 4-19: The number of proteins identified by LC-MS/MS within each preparation. 
Light grey bars denote proteins identified in two or more preparations and dark grey bars denote proteins identified 
as unique to individual preparations. Mass spectrometry (LC-MS/MS) analysis identified 2,765 proteins in all 12 
preparations. 
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Table 4-9: Most common M. ulcerans proteins observed in all 12 preparations. 
 
 
 
 
 
 
 
 
 
 
 
 
Accession number 
 
Protein description 
 
Gene 
 
Molecular weight 
sp|A0PLQ1|DNAK_MYCUA Chaperone protein  dnaK 66,362 
sp|A0PM24|RPOB_MYCUA DNA-directed RNA polymerase subunit beta   rpoB 129,751 
sp|A0PM25|RPOC_MYCUA DNA-directed RNA polymerase subunit beta~   rpoC 147,465 
sp|A0PM42|EFTU_MYCUA Elongation factor Tu tuf 43,779 
sp|A0PM71|RL29_MYCUA 50S ribosomal protein L29   rpmC 9,151 
sp|A0PME8|CH10_MYCUA 10 kDa chaperonin   groS 10,741 
sp|A0PME9|CH601_MYCUA 60 kDa chaperonin 1   groL1  55,852 
sp|A0PNL7|CH602_MYCUA 60 kDa chaperonin 2   groL2  56,524 
sp|A0PQE7|PNP_MYCUA Polyribonucleotide nucleotidyltransferase pnp 80,837 
sp|A0PSI5|MASZ_MYCUA Malate synthase G   glcB 79,657 
sp|A0PUK0|ATPB_MYCUA ATP synthase subunit beta   atpD 52,768 
sp|A0PUK2|ATPA_MYCUA ATP synthase subunit alpha   atpA 59,643 
sp|A0PW55|ENO_MYCUA Enolase   eno 44,709 
tr|A0PKL7|A0PKL7_MYCUA Chaperone protein clpB 92,765 
tr|A0PM20|A0PM20_MYCUA 50S ribosomal protein L7/L12   rplL 13,348 
tr|A0PNE9|A0PNE9_MYCUA Pyruvate dehydrogenase E1 component   aceE 103,472 
tr|A0PNT7|A0PNT7_MYCUA Aconitate hydratase can acn 102,363 
tr|A0PP44|A0PP44_MYCUA Ribosomal protein S1 RpsA rpsA 53,072 
tr|A0PPN2|A0PPN2_MYCUA Glyceraldehyde-3-phosphate dehydrogenase   gap  36,091 
tr|A0PPW0|A0PPW0_MYCUA Electron transfer flavoprotein (Beta-subunit) FixA fixA 27,779 
tr|A0PSD3|A0PSD3_MYCUA Alkyl hydroperoxide reductase C protein AhpC ahpC 21,582 
tr|A0PTH9|A0PTH9_MYCUA Conserved secreted antigen Wag31   wag31  28,715 
tr|A0PTQ1|A0PTQ1_MYCUA Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex   sucB 60,749 
tr|A0PVX3|A0PVX3_MYCUA Isocitratelyase icl 47,440 
tr|A0PNE6|A0PNE6_MYCUA Acyl carrier protein   acpM 12,479 
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4.6.10 Amplification and sequencing of M. ulcerans gene constructs 
 
Figure 4-20 demonstrates gel electrophoresis of plasmid extracts from E. coli for 
protein expression. PCR results of the M. ulcerans gene constructs (Figure 4-21) 
showed amplification in all plasmid DNA extracts (mul_0513, mup045, mup057, ATP, 
mul_2232 and hsp65) except for KRA where no amplification was visualized on the 
gel. There was also a successful amplification of the variable-number tandem repeat 
(VNTR) locus 9 (515 bp) (182) in the DNA extract of the M. ulcerans isolate, therefore 
confirming it as M. ulcerans (Figure 4-21). 
 
 
Figure 4-20: Gel electrophoresis of plasmids extracts from E. coli. 
Lane L is the 100 dp DNA marker (Life technologies, Australia) and lanes 1, 2, 3, 4, 5, 6 and 7 are showing extracts 
from mup045, mup057, mul_2232, mul_0513, KR_A, ATP and hsp65, respectively. Ten microliters (10 µl) of 
plasmid DNA were separated on 0.5% agarose. The gel was stained with SybrSafe DNA dye (Life Technologies 
Australia). 
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Figure 4-21: PCR amplification of gene constructs and M. ulcerans (Parkin strain). 
Image A: Lanes 1 is a 100 dp DNA ladder (Life technologies, Australia). Lanes 2, 3, 4, 5, 6, 7 and 8 are showing 
PCR amplification products of  mup045, mup057, mul_2232, mul_0513, KRA, ATP and hsp65, respectively.  
Image B : Lanes 1 and 8 are showing 100 bp DNA ladder (Life technologies, Australia). Lane 2-4 are showing 
PCR amplicons of the  (VNTR) locus 9  from (M. ulcerans isolate from Victoria) and 5-6 are PCR positive controls 
from Agy99 strain. Lane 7 is DNA extraction control (empty lysis tube with no sample). 
 
 
Although amplification of all the constructs was possible with the exception of KRA, 
sequencing results showed that mup045, mul_0513 were not in-frame after DNA 
consensus sequence alignment and translation.  The following construct, KRA, mup045 
and mul_0513 were therefore excluded from protein expression and purification work. 
The remaining constructs, ATP, mup057, mul_2232 and hsp65, which gave correct 
sequence results (Figure 4-22), were retained for downstream application.   
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Figure 4-22: M. ulcerans gene constructs and protein consensus sequences. 
The letters in red in show the T7 promoter sequence of the gateway expression vector (pET-DEST42/pET-28),  
while the blue letters are artefacts of the gateway entry vector (pENTR/SD-TOPO) ending with 5’- CACC- 
3’sequences. Letters in black show the M. ulcerans genes and amino acid sequences to be expressed and green 
highlight shows the C-terminal V5 epitope, which contains the His-tagged sequence 5’- CAT-CAT-CAC-CAT-
CAC-CAT-3’. All the M. ulcerans gene constructs begin with a start codon ‘ATG’ with no stop codon within to 
ensure the expression of the recombinant protein. But there is a stop codon ‘TGA’ at the end of the V5 sequence. 
The DNA sequences were translated into amino acid and the aqua letters HHHHHH shows the six histidine (6xHis) 
amino acids and one asterisk (*) as the stop codon. 
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4.6.11 Pilot-scale expression of recombinant proteins 
 
SDS-PAGE and preliminary Western blot analysis showed protein bands that were 
greater than the theoretical molecular weight (MW). Western blot analysis of cell 
lysates and purified samples using anti-His tag HRP conjugated antibody revealed the 
presence of His-tagged proteins in cell lysates in the post-induced samples and the 
purified samples. Though, other proteins seem to have been co-induced as well as co-
purified in all samples. These extra bands were faint in the cell lysate Western blot. 
But in the purified samples they have become more prominent. For example, cell lysate 
for ATP (Figure 4-23, lanes 1 and 5) has a co-induced protein of 80 kDa. The cell 
lysate for MUP057 (Figure 4-23, lanes 2 and 6) showed a 60 kDa co-induced protein. 
There are other smaller protein bands of less than 20 kDa in ATP (lanes 5) and 
MUP057 (lane 6). The cell lysate of MUL_2232 (Figure 4-23, lane 3) has an extra 
band similar to that of 30 kDa size protein similar to MUP057 (lane 2). Yet in the 
purified sample of MUL_2232 (Figure 4-23, lane 7), this was not co-purified (Figure 
4-23).    
   
Figure 4-23: Anti His-tagged peroxidase Western blot of post induced proteins. 
Lane L is showing BenchMark His-tagged standard. Lanes 1-4 are post-induced cell lysates of ATP, MUL_2232, 
MUP057 and Hsp65 respectively. Lanes 5-8 are partially purified proteins of post-induced cell lysates of ATP, 
MUL_2232, MUP057 and Hsp65, respectively. 
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4.6.12 Large-scale expression and purification of M. ulcerans recombinant 
proteins 
 
SDS-PAGE analysis of M. ulcerans recombinants proteins,  purified from 500 ml 
cultures of BL21 E. coli AKTA Pure chromatography system using 1 ml HisTrap HP 
columns, revealed protein bands that were higher for MUP057,  MUL_2232 and ATP 
except for Hsp65 (Figure 4-24). Figure 4- 25 shows His-tagged positive Western blot 
image of partially purified recombinant proteins.  
 
Figure 4-24: Expression of soluble recombinant four M. ulcerans recombinant proteins and purification by 
affinity chromatography. 
Coomassie Brilliant blue-stained gels of proteins present during expression and purification of (A) HSP65 and ATP 
and (B) MUL_2232 and MUP057. Lanes 1 and 8 of (A) and Lanes 1and 9 of (B) are pre-stained PageRuler protein 
molecular mass marker (Life Technologies). For gel (A), lanes 2 and 9 show cell lysates before induction of protein 
expression. Lanes 3 and 10 are lysates of post-induced cultures. Lanes 4 and 11 are unbound protein flow-throughs 
of post-induced lysates. Lanes 5 and 12 unbound proteins in five CV wash. Lane 6 and 14 are partially purified 
proteins of HSP65 and ATP, respectively. Lane 7 is empty whereas lane 13 was supposed to have shown partially 
purified ATP. Lanes in gel (B) are in the same format as (A) except that lanes 1 and 2 are cell lysates of MUL_2232 
before induction and lane 7 should have shown stained partially purified protein of MUL_2232. Red arrows are 
showing the partially purified protein bands. 
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Figure 4- 25: Anti His-tagged peroxidase Western blot of large-scale partially purified proteins. 
Lanes 1-4 are showing MUP057, Hsp6, MUL_2232 and ATP, respectively. No His-tagged standard was included 
in this Western blots as Figure 4-29 has already confirmed presence of His-tagged proteins in all samples. There 
was visible smearing in MUP057 and Hsp65 lanes which might be due to protein fragmentation. Black arrows are 
pointing to protein bands on NC membrane. 10 µl of each partially purified sample was loaded into each lane to 
confirm presence of His-tagged proteins in the large-scale protein purification. 
 
 
4.7 Discussion 
 
This study has attempted to use a standardised approach to produce and characterize 
protein preparations from M. ulcerans cultures for potential use in serological tests to 
understand exposure. Based on the LC-MS/MS results on protein extracts, all were of 
high quality and indicative of the infective organism. The protein production procedure 
from bacterial cultures did not seem to compromise proteins identified, as many 
housekeeping mycobacterial proteins were present in all batches. In addition, the 
credibility of the procedure was authenticated as many common M. ulcerans antigens 
(mlsA1, mlsA2, mlsB, Hsp65, MUL_2232 and MUL_3720) were present in extracts.  
Although this does not affect the use of the protein extracts in serology, it was indeed 
a shortfall in the study by not including an internal control standard in the LC-MS/MS 
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analysis to give an idea of the concentration of expressed proteins in each of the 
extracts as performed in Wynne et al., 2012 article (65). 
This study is not the first to establish a protocol for protein preparation from 
mycobacteria cultures because many studies have previously reported some form of 
protein preparations and characterization from M. ulcerans cultures (56, 62, 102, 126, 
179) as well as other mycobacteria (176, 180, 181). The approach used in this study in 
protein production from M. ulcerans culture was unique, in the way the bacterium was 
cultured to the wash buffers and precipitation of proteins with TCA.  This study has 
for the first time identified 17 distinct M. ulcerans proteins (17 proteins including: 
mlsA1, mlsA2 and mlsB) from culture preparations, two of which have no homologues 
in the frog pathogen M. liflandii. All 14 proteins have no homologue in M. smegmatis 
nor the pathogenic mycobacteria used for the comparison.  
 It must be mentioned that the Type I modular polyketide synthases (mlsA1, mlsA2 
and mlsB) though absent in MAP, M. leprae, M. smegmatis and M. tuberculosis was 
not considered new in this study (29). Purification of these 14 proteins could be 
important candidate antigens for serological screening test for M. ulcerans exposure 
or antigen-capture assay similar to Dreyer et al., 2015 (122). The secreted proteins 
described in Table 4-5 and Figure 4-4 to Figure 4-16 could also be explored for the 
same purpose. 
Proteins identified in batch preparations varied, nevertheless, there were shared as well 
as unique proteins.  Previous studies have also identified that it is very difficult to 
produce the same protein profile of mycobacteria from two or more separate batches 
due to subtle differences in protein preparations and growth conditions. With 
optimisation and standardisation, preparations could be similar (65,193,194) as 
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evident in the current study (Table 4-4). Also with optimisations and streamlining of 
the current standardised protocol, there could be finalization of this approach as a 
standard in protein production from M. ulcerans secreted proteins. 
Comparison of the two methods, being the heat inactivated and unheated protein 
preparations is very interesting, in terms of which approach produces consistent 
protein number and similarity. This warrants further investigation. These two methods 
could not be directly compared in this study because though from the same bacteria 
strain and production procedure, they were prepared from different batches. There 
were also six batches (A, B, C, D, E and F) of the heat-inactivated preparations and 
only two unheated batches (G and H). In order to clearly present which method may 
be superior in terms of generating similar protein profiles and number,  a single culture 
batch could be split and treated differently (heated or unheated treatments) to ascertain 
which method could be a better choice. A previous study that used unheated cultures 
for protein production from M. bovis reports generated more reliable antigenic and 
immunogenic proteins (195). 
There were 137 (5.0%) proteins shared by M. ulcerans and M. smegmatis. This was 
expected as previous studies have reported protein similarities among mycobacterial 
species (72,124,125,196).  M. smegmatis batch searched against M. smegmatis protein 
database revealed 753 M. smegmatis proteins (data not shown). M. smegmatis is 
among the fast growing mycobacteria therefore, it is not unusual to identify more  
proteins in culture medium compared to M. ulcerans, which is a slow growing bacillus 
(62,197). 
 Four His-tagged proteins (MUP057, MUL_2232, ATP and Hsp65) were expressed 
out of seven M. ulcerans gene constructs. The following gene constructs: mul_0513, 
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mup045 and KRA were excluded from the study due to lack of PCR amplification 
(KRA) and/or out-of-frame of gene constructs in the gateway expression vector 
revealed by sequencing and bioinformatics analysis (mul_0513 and mup045). In the 
case of KRA, the lack of amplification could be due to mismatch of primers used.  
However, sequencing from the T7 promoter region of the vector did not show M. 
ulcerans DNA insert either.  The reasons for the out-of-frame nature of the other two 
constructs could be due to glycerol shock that could have resulted in plasmid instability 
and therefore rearrangement of gene inserts. A previous study in Agrobacterium 
mediated transformation has also reported this phenomenon (198). In addition, as 
single colonies were used as inoculum for cultivation of each gene construct it is likely 
that these two (mup045 and KRA) had heterogeneous plasmid preparations. Therefore, 
the inoculum was either transformed with plasmid without insert and or with plasmid 
with an insert out of frame. 
4.8 Conclusion 
 
This study describes a standardised procedure for production and characterisation of 
proteins from mycobacteria cultures. The approach used in this chapter for protein 
preparations from M. ulcerans has been described here for the first time. Through LC-
MS/MS analysis it has also been verified that proteins identified in each batch were 
indicative of the microorganism. It is worth noting that the two methods used in the 
protein production namely heated inactivated and unheated procedures could be 
investigated further to potentially establish a final standardization protocol for protein 
production for M. ulcerans. This study has also replicated the M. ulcerans recombinant 
protein expression experiment by Pidot et al., 2010 (72).  
The antigenicity and immunogenicity of the14 proteins identified in this study with no 
homologues in the pathogenic mycobacteria as well as the 16 secreted proteins (Figure 
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4-4 to Figure 4-16) could be explored in serology or cell-mediated tests for BU 
diagnosis.  It would also be useful to investigate which of the 12 batches (A, B, C, D, 
E, F, G, H, “A+B+C+D+E+F”, “G+H”, homogenates and M. smegmatis) may be the 
best candidate reagent for screening M. ulcerans exposure in at “risk communities”. 
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CHAPTER 5 
 
5 Initial serological screening test for Mycobacterium ulcerans exposure in 
Victoria 
 
5.1 Background 
 
Buruli ulcer (BU) is a subcutaneous necrotic infection of the skin caused by M.  
ulcerans (2,63,199). It is the third most common mycobacterial disease after 
tuberculosis and leprosy (12). Currently, the most common methods for diagnosis of 
the disease are PCR,  histopathology and culture of the organism (54,71). These 
methods have their infrastructural and resource limitations. The global infection rate 
is believed to be under-reported due in part to lack of an easy, reliable and rapid to use 
screening test (54). Development of a serological screening test has been suggested 
and could be beneficial to more rapidly and accurately assess M. ulcerans exposure, 
as well as determine the natural history of infection in humans and animals (68,69,72).  
Many researchers have shown that BU patients and laboratory BU murine models are 
seemingly unable to raise specific antibodies against M. ulcerans antigens or 
mycolactone (29,76,200). At the cellular level, mycolactone has been observed to act 
as an immunosuppressive toxin during the acute phase of the disease (57,76,201,202). 
The acute phase is the early stage of infection where the host produces a complex series 
of immune responses to destroy the infective organism to return the host to normality 
(60,82). Because this response is absent or inadequate in individuals infected with M. 
ulcerans, mycolactone usually leads to advanced forms of BU,  marked by a gradual 
progression of reddened swelling,  nodules,  papule or plaque to necrotic and 
debilitating lesions (56,88). Immune responses to mycobacteria antigens in general, 
have long been studied and M. tuberculosis has been the exemplar. This led to the 
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development of the tuberculin skin test (TST) (116,125). TST measures the size of 
induration on the skin as a result of cell-mediated immunity arising from exposure to 
M. tuberculosis (77). Based on the TST, researchers have proposed a similar test might 
offer rapid, easy and inexpensive screening for M. ulcerans exposure. Stanford et al., 
1975 was the first to attempt skin test using burulin, M. ulcerans protein preparation 
in 1975 (75). Since then research to discover unique antigens specific for M. ulcerans 
for serological assays has gained ground and many have attempted developing culture 
filtrates as well as recombinant proteins for such purposes (68,69,72,75,106,122).  
It has been suggested that M. ulcerans may only cause BU in specific individuals with  
host susceptibility (203) but this requires further investigation. There has been further 
report of asymptomatic exposure to M. ulcerans in BU endemic communities in a 
study in West Africa (68,69). A study by Yeboah-Manu et al., 2012 discovered that 
healthy controls from the same BU endemic communities had antibodies against the 
18 kDa specific-M. ulcerans antigen. This suggests that not all individuals exposed or 
infected will develop BU (68).  
The development of a test for screening purposes for exposure to, infection of, or for 
diagnostic purposes for detecting acute stages of the disease would require a dedicated 
antigen or protein preparation from the infective organism and blood or serum samples 
from “at risk communities” (65,117,175,194). 
The main objective of this section is to make such an attempt by using a panel of 
antigens produced from M. ulcerans in a pilot serologically based screening test in BU 
patients and healthy endemic controls from the City of Greater Geelong and non-
endemic controls from Tasmania. At the end of the serological survey, it is 
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hypothesized that the antigens would be useful in distinguishing between the surveyed 
groups exposure to M. ulcerans. 
5.2 Materials and methods 
 
Attempt was made to utilize all the protein preparations  from Figure 4-25 and the four 
partially purified M. ulcerans recombinant proteins (Figure 4-30) in a pilot serological 
survey. 
5.2.1 Ethics approval 
 
Low risk ethics approval was obtained from Research Ethics, Governance & Integrity 
(REGI) Unit, Barwon Health for the recruitment of participants for serum collection 
to be used in serological assays. Project reference number: HREC 16/166. 
5.2.2 Study area and populations 
 
BU is a notifiable disease in Victoria, Australia, so, there is a database of BU cases 
(143). For the purpose of this project, we have permission to access and use the BU 
database from the Victoria health department. The area selected for participants’ 
recruitment was based on the primary cluster detected in the space-time analysis 
(Figure 3-6). City of Greater Geelong was the study area. Areas of critical interest 
(where the disease is mostly found) included the surrounding areas of Point Lonsdale, 
Barwon Heads, Ocean Grove, Queenscliff, and Rye. 
5.2.3 Inclusion criteria 
 
It was the aim of the current study to recruit the following groups of people for the 
study area. 
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1. Group 1 
These have active BU disease. Individuals who have had the disease before were also 
included in this group provided they had been diagnosed within 1 year. Therefore, a 
Group 1 participant could be a resident in City of Greater Geelong or any of the areas 
of critical interest, which are, Point Lonsdale, Barwon Heads, Ocean Grove, 
Queenscliff and Rye. It is expected that this group of participants would have a positive 
reaction with the M. ulcerans protein preparations. 
2. Group 2 
These do not have BU clinical disease and are living in the primary cluster area. 
These could be described as endemic healthy controls (EC). A participant assigned to 
Group 2 could be a resident in any of the areas of critical interest. This group may test 
positive to the M. ulcerans protein preparations because as endemic healthy controls, 
they may have been exposed to the pathogen.  
3. Group 3 
These are participants living in an area in Victoria or outside Victoria where BU 
has never been reported. This group could be described as non-endemic controls 
(NEC).  It is expected that participants in this group would test negative to the M. 
ulcerans protein preparations because as non-endemic healthy controls, they should 
be naïve to the pathogen. The results from this group will reveal the performance of 
the screening test. 
4. Group 4 
One challenge with developing a blood/serology based test for a disease caused by 
mycobacteria has always been the issue of cross-reactivity of their proteins. 
Tuberculosis (TB) being one of the most common mycobacterial diseases, it was also 
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the aim of this study to recruit participants with a known diagnosis of TB infection 
when possible to assess the similarities between immune responses to TB and BU 
diseases. This group may test positive to the M. ulcerans protein preparations. 
5.2.4 Exclusion criteria 
 
Buruli ulcer disease affects all age groups and gender. This study did not have any 
strict exclusion criteria for participation.  
5.2.5 Experimental group considerations. 
 
All Group 1 participants used in the serological screening are supposed to have 
laboratory confirmed BU, therefore 100% prevalence of disease as well as antibodies 
against M. ulcerans was assumed. Because this study has not been done in Victoria 
before, defining an appropriate healthy control size was a challenge. Available 
literature suggests the sample size for a pilot study of similar nature be 10% of the 
parent population (204), this being the entire population within the primary cluster 
which is 61,723. Therefore 10% would be 6,172 people for each of the remaining sub-
groups described. This sample size was not logistically feasible for the current study. 
Other literature have proposed 10-30 participants for a pilot in survey research 
(205,206). From the descriptive and explorative analysis on the BU database from 
1994 -2016, there were 902 laboratory confirmed cases, of which 10% would be 90 
participants. The research timeline for the entire projects did not make recruitment of 
90 participants feasible.  
For proof of principle,  the current study aims to recruit a minimum of 10 and a 
maximum of 30 participants in each of the healthy control (EC and NEC) and TB 
infection groups as proposed in previous studies (207). 
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5.2.6 Participants recruitment 
 
Recruitments of all groups of participants were done through convenience sampling. 
Group 1 recruitment was done through the BU clinic run by A/Prof. Daniel O’Brien 
and Prof. Eugene Athan at the University Hospital, Geelong (UHG). Group 2 
participants were healthy volunteers interested in participating and met the inclusion 
criteria specified in this group. Recruitment of staff members was undertaken by “word 
of mouth” and electronic mail (email) correspondence.  This was a good option 
because many of the staff members are also residents of the study area. For the 
recruitment of participants in Group 3, serum samples from Tasmania was sourced 
from the Australian Rickettsial Reference Laboratory, Geelong. This laboratory has a 
serum storage facility from different states in Australia. Tasmania was chosen as a 
non-endemic state for BU comparison, as there have been no known BU cases. Though 
Group 4 is important to test for similarity of immune responses between BU and TB 
participants, it is not the primary goal of this project. To recruit this group, Prof. 
Eugene Athan and A/Prof. Daniel O’Brien at UHG were consulted to facilitate the 
recruitment of TB infection participants.   
5.2.7 Requirements from study participants 
 
To determine antibody responses to M. ulcerans protein preparations, after signing a 
consent form the study required 8 ml samples of blood from the four groups for use in 
ELISA and Western blot assays. Trained personnel collected the blood samples at the 
Clinical Trial Unit, UHG, Barwon Health, following the procedure described in Figure 
5-1.  All participants recruited received i) a participant information sheet/Consent form 
(PICF), ii) plain language statement (PLS) of the project and iii) participants survey 
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questionnaires form (Figure 5-2). Study questionnaires were designed to give a brief 
history of participants’ association or knowledge of BU as well as to determine which 
Group (1, 2, 3 or 4) to assign them for further analysis. The questionnaires were also 
important in discussing the nature of results to be obtained from the ELISA and 
Western blot assays regarding exposure. 
This is a low-risk non-identifiable study. Therefore all information collected that had 
potential to identify any individual was removed e.g. all names were replaced with 
identification reference number (ID REF) as in Figure 5-1 . However, information that 
was kept about a participant included: 
a. Participants ID REF 
b. Gender 
c. Age group   
d. Post code/suburb 
 
5.2.8 Data storage 
 
Data from the study were stored on a locked computer in a secured room at GCEID 
office. All serum samples were stored in a -80oC lockable freezer at GCEID laboratory 
for the studies. It was the intention of this study to store data for five years after 
completion of the current study for future projects. Consent was sought from all 
participants for this. 
5.2.9 Data deletion or destruction 
 
Electronic data stored on GCEID secured computers regarding this will be destroyed 
by deleting them from the computer. Serum samples stored for five years after 
collection will be destroyed by deactivation by either autoclaving or chemical 
destruction. Destruction by chemical shall follow the procedure below: 
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a) Chemically destroy blood or serum samples with a 1:10 final dilution (vol/vol) 
of household bleach. 
b) Swirl flask contents and allow a contact time of 30 min. 
c) Pour down a sink drain connected to the GCEID laboratory sewage system and 
flush the plumbing with an excess of water. 
Alternatively, blood samples and serum samples to be autoclaved for 30 min at 
121°C and 15 psi. In the event that serum samples need to be stored for more than 
five years, new human ethics application shall be made to REGI, Barwon Health. 
 
Figure 5-1: Blood collection standard operation procedure. 
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Blood were collected by trained personnel from the Clinical trial Unit at University Hospital Geelong for the 
serological survey. Each participant is supposed to be given an identification reference number to de-identify them. 
 
Figure 5-2: Participants survey questionnaires. 
Survey questionnaires to be given to each participant who has consented to take part in the study. The questions 
are designed to give a brief history and participant knowledge about the disease. The questionnaires are also to 
assist in grouping participants for the serological analysis. 
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5.2.10 Development of enzyme-linked immunosorbent assay (ELISA)  
 
5.2.11 ELISA protocol 
 
For standardisation, all protein preparations used as test antigens for immune-detection 
assays in this chapter were normalized using protein concentration results from Table 
4-4. 
Unless stated otherwise, all experiments with protein preparations from bacteria 
cultures included a blank well and 79HGT/79HG media controls against test sera. All 
samples were prepared in duplicate in 96-well microtitre plates. Microplate wells were 
coated with 100 μl per well of antigen (A, B, C, D, E, F, G, H,  homogenate and M. 
smegmatis) diluted in coating buffer (100 mM carbonate-bicarbonate, pH 9.6) and 
incubated overnight at 4oC. Wells were manually washed four times with 300 µl per 
well of phosphate buffered saline (PBS) pH 7.3, 0.05% (v/v) Tween-20 (PBS-T) and 
hand-pad on paper towel to dry. After drying, wells were blocked with 100 µl 10% 
normal goat serum (NGS) in PBS and incubated at room temperature for 2 h. Plates 
were washed and dried prior to addition of 50 µl human sera dilutions and an overnight 
incubation at 4oC. Microplates were washed, dried and 50 µl of goat anti-human 
immunoglobulin G (IgG)-horseradish peroxidase (HRP) dilutions were added to each 
well and incubated at room temperature for 2 h followed by manual washing. Plates 
were developed by the addition of 50 µl of 3, 3’, 5, 5’-tetramethylbenzidine substrate 
(TMB, Invitro technologies) to each well and incubated for 10 min. The reaction was 
stopped by the addition of 50 µl of 2 N sulphuric acid and optical density (OD450) was 
read by an Epoch 2 microplate reader (Millennium Science, Austalia). To reduce non-
specific binding resulting from the goat derived secondary antibody and media, 
dilutions of human sera comprised of 1x PBS with 1% NGS + 1% culture media 
(7H9TG/7H9G). In addition, dilutions of the secondary antibody was in 1 x PBS + 1% 
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79HGT/7H9G. This was to reduce non-specific binding arising from the culture media. 
Homogenate and the four M. ulcerans partially purified recombinant proteins 
(MUL_2232, MUP057, ATP and Hsp65) were diluted in 1x PBS with 1% NGS only.  
5.2.12 Determination of antigen coating concentration and absorbance 
maximum by direct ELISA 
 
To determine an appropriate concentration of primary and secondary antibodies for 
the ELISA assay a checkerboard titration was set up using Batch C as test antigen and 
7H9GT culture media control against a test primary antibody from participant with 
active BU and healthy control. There were wells with no antigen coating as well. Batch 
C was used as test antigen because from the mass spectrometric analysis and 5-way 
Venn diagram analysis of the composition of proteins in all batches, its was a better 
representation in number and variability of proteins. Antigens and media control used 
in coating 96 well plates were kept at 2 µg, however there were 4 serial dilutions of 
primary antibody (serum samples) of 1:1,000, 1:2,000, 1:4,000 and 1:8,000 and 4 serial 
dilutions of the secondary antibody of 1:1,500, 1:3,000, 1:6,000 and 1:12,000 (Figure 
5-3). The assays were run without duplicates following the ELISA protocol above. 
There was no optimal concentration determination for the partially purified M. 
ulcerans proteins since it is from published work. The protocol in Pidot et al., 2010 
study (72) was followed with modifications in antigens, primary and secondary 
antibody concenrtrations for the ELISA. 
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Figure 5-3: Checkboard ELISA template. 
A checkerboard template to determine optimal dilutions for serum samples and secondary antibody for the ELISA 
assay. Microplate wells designated “no coating” were not coated with test antigens, whereas wells with Batch C 
and 7H9GT were coated with test antigens and media control, respectively. Wells with yellow and pink highlight 
received 1:1,000, 1:2,000, 1:4,000 and 1:8,000 dilutions (in green highlight) of test sera from BU patient and 
healthy endemic control respectively. The secondary antibody dilutions were in the range of 1:1,500, 1:3,000, 
1:6,000 and 1:12,000 (in blue highlight). 
 
5.2.13 Detection of human antibodies against potential M. ulcerans antigens by 
ELISA 
The dilutions with the optimum absorbance values in the checkerboard was used as 
the final dilution ratio for all detection of human antibodies against M. ulcerans 
antigens in this study. For the detection of M. ulcerans specific antibodies in serum 
samples, the ELISA protocol for the protein preparations was as described in the 
checkerboard section. For the homogenate and recombinant proteins, 1 µg in 100 µl 
carbonate coating buffer was adsorbed per well in a 96 well plates (pH 9.6) instead of 
the 2 µg adsorption for the mycobacteria protein preparations. The remaining ELISA 
procedure was the same as described above.   
5.2.14 Recombinant proteins immune-reactivity by Western blotting 
 
For the analysis of partially purified M. ulcerans recombinant proteins, 10 µg of each 
protein (MUL_2232, MUP057, ATP, and Hsp65) was separated on NuPAGE 4-12% 
Sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) (Life Technologies, 
Australia) under reducing conditions (as described previously). PageRuler pre-stained 
protein standard (Life Technologies, Australia) was included in each run. SDS-PAGE 
1:1000 1:2000 1:4000 1:8000 1:1000 1:2000 1:4000 1:8000 1:1000 1:2000 1:4000 1:8000
1 2 3 4 5 6 7 8 9 10 11 12
1:1500 A no c oa ting no c oa ting no c oa ting no c oa ting Batch C Batch C Batch C Batch C 7H9GT 7H9GT 7H9GT 7H9GT
1:3000 B no c oa ting no c oa ting no c oa ting no c oa ting Batch C Batch C Batch C Batch C 7H9GT 7H9GT 7H9GT 7H9GT Test serum from participant with  active BU
1:6000 C no c oa ting no c oa ting no c oa ting no c oa ting Batch C Batch C Batch C Batch C 7H9GT 7H9GT 7H9GT 7H9GT
1:12000 D no c oa ting no c oa ting no c oa ting no c oa ting Batch C Batch C Batch C Batch C 7H9GT 7H9GT 7H9GT 7H9GT
1:1500 E no c oa ting no c oa ting no c oa ting no c oa ting Batch C Batch C Batch C Batch C 7H9GT 7H9GT 7H9GT 7H9GT
1:3000 F no c oa ting no c oa ting no c oa ting no c oa ting Batch C Batch C Batch C Batch C 7H9GT 7H9GT 7H9GT 7H9GT Test serum from health control
1:6000 G no c oa ting no c oa ting no c oa ting no c oa ting Batch C Batch C Batch C Batch C 7H9GT 7H9GT 7H9GT 7H9GT
1:12000 H no c oa ting no c oa ting no c oa ting no c oa ting Batch C Batch C Batch C Batch C 7H9GT 7H9GT 7H9GT 7H9GT
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was run at 180V for 30 min in 1x MES buffer (Life Technologies, Australia). After 
completion, gels were transferred onto nitrocellulose membranes (NC) using the iblot 
dry transfer system (Invitrogen) module for 7 min. Transfer was deemed successful 
upon visualization of complete transfer of the PageRuler prestained protein standard 
onto the membrane. Membranes were blocked at room temperature in 5% NGS in 1x 
PBS-T (pH 7.2) for 1 h with slight agitation using an orbital shaker. After blocking, 
membranes were probed with human sera at 1/500 dilution in blocking buffer (5% 
NGS in 1x PBS-T) and incubated for 1 h and washed four times with 1x PBS-T.  
Membranes were incubated with goat anti-human IgG-HRP conjugated secondary 
antibody in a 1/3,000 dilution in blocking buffer for 1 h, after which membranes were 
washed as described above. Bands were detected by Chemiluminescence using Pierce 
SuperSignal kit (Life Technologies, Australia) following the manufacturer’s protocol. 
Digital image documentation was by the UVP chemidoc system (Scientifix, Australia). 
5.2.15 Quantitation of total immunoglobulin G in serum samples 
 
The most abundant immunoglobulin found in human serum and mammals in general, 
is immunoglobulin G (IgG). IgG possesses important immune functions including 
antimicrobial properties which helps bacterial killing by host cells during infections 
(86). IgG (Total) Human ELISA Kit (Life Technologies) was used to determine the 
total concentration of IgG in serum samples collected for the study following the 
manufacturer’s protocol with a slight dilution modification. The reagents supplied in 
the kits included: two microwell plates coated with monoclonal antibody to human 
total IgG, a vial of HRP-Conjugate anti-human total IgG monoclonal antibody and a 
vial of human total IgG Standard (lyophilized). Present in the kit were also an assay 
buffer for diluting samples and wash buffer for washing plates. TMB substrates, as 
well as phosphoric acid stop solutions were among the items supplied. For IgG 
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quantitation, 0.5 µl serum sample was diluted in 1 ml assay buffer (0.5:1,000) (pre-
dilution A). Then 5 µl of the pre-dilution A was further diluted in 1,000 assay buffer 
to make a “pre-dilution B” (1:200). Aliquots of 100 µl of pre-dilution B were applied 
across 96 microwell plates for the detection of IgG. After the blank subtraction, ELISA 
mean absorbance value was compared to a standard curve to estimate the mean IgG 
concentration in samples. The estimated concentration was then multiplied by the 
dilution factors (200 x 2,000) to get the actual mean IgG concentration in each serum 
sample. 
5.2.16 Data analysis 
 
ELISA test results were analysed using GraphPad Prism version 7 (GraphPad 
Software, San Diego California USA). The average absorbance value of the media 
controls were subtracted from all study samples. ELISA absorbance values were then 
analysed with One-way ANOVA using the non-parametric Kruskal- Wallis test with 
Dunn’s post-test values for BU patient, endemic controls (EC) and non-endemic 
control (NEC). This test was used because there were more than two independent 
groups (BU patients, EC and NEC) to be compared. Under the assumption that 
asymptomatic exposure is plausible among EC,  the absorbance values of EC and BU 
patients in the ELISA were combined (designated BU-endemic), and compared to 
NEC in unpaired-t test using Mann–Whitney nonparametric testing for each of the 
antigens similar to what was reported in Pidot et. al 2010 (72). This test was used 
because there were now only two groups (BU-endemic and NEC) to be compared. 
5.2.17 Receiver-operator characteristics (ROC) 
 
To identify the optimum cut-off value for declaring positive and negative test results 
as well as performance for each of the antigens used in this study, Receiver-Operator 
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Characteristics (ROC) analysis was done (208,209). BU patients’ samples were used 
to calculate sensitivity for the protein preparations and specificity for EC and NEC. 
Sensitivity and specificity is the ability of the antigens to discriminate true positives 
and true negatives respectively. From the ROC analysis, the study also reported the 
area under the curve (AUC) and likelihood ratio for each of the antigens both of which 
are indicators of the performance of the assay. 
5.3 Results 
 
5.3.1 Participants demographics and history 
 
As a proof of principle, 50 participants were recruited for the pilot serological study. 
Ten participants were eligible for Group 1 (designated: BU patients) which was evenly 
split in females and males. Twenty participants fit the criteria for Group 2 (designated: 
Endemic controls; EC) with 19 (95%) females and 1 (5%) male.  There were 20 sera  
[female to male = 8 (40%) to 12 (60%)] from Tasmania representing Group 3 
(designated: Non-endemic controls; NEC). The study could not secure serum samples 
for Group 4, representing participants with active tuberculosis (TB) within the research 
timeline. Six (60%) out of the ten BU patients recruited came from the City of Greater 
Geelong (Barwon Heads, Belmont, East Geelong, Ocean Grove, Point Lonsdale and 
St Leonard),  the remaining  4 (40%) were from Ballarat, Kooyong, Tyabb and 
Queenscliff outside Geelong region. All endemic controls (EC) were located in the 
City of Greater Geelong and Group 3 participants’ sera were from Tasmania (Table 
19). Results from the participants’ questionnaires (Figure 35) showed that all BU 
patients answered “Yes” to question 1 (do you have BU now?) representing 100% and 
all EC responded “NO”. Only one person in Group 1 responded “Yes” to question 3 
(has any member of your family had BU?).  Four (40%) BU patients responded in the 
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affirmative to question 4 (have you shared an accommodation with a BU patient?). 
Regarding having an ulcer, not necessarily BU (question 5), 2 (10%) EC responded 
“Yes”. Five (50%) and six (30%) answered “Yes” to question 7 (do you encounter 
possums in your home or around your house often) among BU patients and EC 
respectively. For BCG vaccination, only one person answered “Yes” among BU 
patients, whereas 14 (70%) in EC responded in the affirmative (Table 5-1).
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Table 5-1: Demographics and brief BU history of participants recruited for the 
serological survey. 
 
 
N/A= Not applicable 
 
 
 
 
Group 1 Group 2 Group 3 Group 4 Total 
Total number 10 20 20 0 50 
Sex 
     
Females 5 (50%) 19 (95%) 8 (40%) - 32 (64%) 
Males 5 (50%) 1 (5%) 12 (60%) - 18 (36%) 
    
- 
 
Suburbs of participants 
   
- 
 
Barwon Heads 1 (10%) 0 - - 1 (2%) 
Ballarat 1 (10%) 0 - - 1 (2%) 
Belmont 1 (10%) 0 - - 1 (2%) 
East Geelong 1 (10%) 0 - - 1 (2%) 
Kooyong 1(10%) 0 - - 1 (2%) 
Ocean Grove 1 (10%) 1 (5%) - - 2 (4%) 
Point Lonsdale 1 (10%) 0 - - 1 (2%) 
Queenscliff 1 (10%) 0 - - 1 (2%) 
Rye 0 0 - - 0 
St Leonards 1 (10%) 0 - - 1 (2%) 
Tyabb 1 (10%) 0 - - 1 (2%) 
City of Greater Geelong 6 (60%) 19 (95%) - - 25 (50%) 
Tasmania - - 20 (100%) - 20 (40%) 
      
Survey questions 
     
Question 1 Yes=10 (100%) No= 20 (100%) N/A N/A 
 
Question 2 
  
N/A N/A 
 
Question 3 Yes = 1 (10%) 
 
N/A N/A 
 
Question 4 Yes = 4 (40%) 
 
N/A N/A 
 
Question 5 
 
Yes = 2 (10%) N/A N/A 
 
Question 6 
  
N/A N/A 
 
Question 7 Yes = 5 (50%) 
No = 1 (10%) 
Yes = 6 (30%) N/A N/A 
 
      
BCG vaccinated Yes = 1 (10%) Yes = 14 (70%) N/A N/A 
 
      
Rickettsia detected N/A N/A 4 (20%) N/A  
      
Remarks from participants Mosquito bite= 1 person none N/A N/A 
 
 
1 person goes bowling at Point 
Lonsdale 
Queenscliff 
Portarlington 
Ocean Grove and 
Barwon Heads 
    
 
 
 
 
 
 
 
 
 
 
  
  
1 person goes skating in Ocean 
Grove and Barwon Heads 
 
  
 
 
1 person = contact with possum 
faeces as well as recycled water 
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Four (20%) of the Tasmania sera tested positive for Rickettsia (additional information 
obtained from the Rickettsial reference laboratory where the sera was sourced). 
Additional remarks from participants revealed that 3 (30%) BU patients have had close 
association with areas of critical interest (Barwon Heads, Ocean Grove, Point 
Lonsdale, Queenscliff and Rye). One (10%) person among the BU patients attributed 
infection to a mosquito bite (Table 5-1). 
5.3.2 Participants mean Immunoglobulin concentrations 
 
The Immunoglobulin G (IgG) quantitation in the sera used for the studies revealed a 
mean IgG content of 12,429 µg/ml, 5,194 µg/ml and <1,080 µg/ml in BU patients, EC 
and NEC, respectively (Figure 5-4). The IgG in the NEC samples were low compared 
to the mean normal IgG level which is ≥7,000 µg/ml in healthy adults (210). 
 
 
Figure 5-4: Total IgG concentration of study sera. 
Total IgG concentration of BU patients, endemic controls and non-endemic controls sera. IgG concentration in 
microgram per millilitre (µg/ml) for each group and standard error of the mean are shown. 
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5.3.3 Diagnostic potential of protein preparations 
 
From the checkerboard results, all dilutions of primary and secondary antibodies used 
for direct ELISA were in the ratio of 1:1,000 and 1:1,500, respectively, as these ratios 
produced the highest OD450 values. To evaluate the potential of the protein 
preparations to be used as a screening test to access exposure or possibly M. ulcerans 
infection, sera from the 10 BU patients, 20 EC and 20 NEC were used in a direct 
ELISA as well as Western blot. The rational for screening for EC and not only NEC 
was borne from the fact that a previous study had reported that asymptomatic exposure 
to the bacterium is highly probable in BU endemic localities (69). Screening of the 10 
culture preparations uncovered significantly higher antibody responses in BU patients 
compared to NEC among the following six protein: batches A, B, D, F, homogenate 
and M. smegmatis (p < 0.05, Figure 5-5). However, because of questionable quality 
arising from the low IgG concentration in the NEC sera and the fact that they had been 
stored for significant time, they unfortunately had to be excluded them from the study. 
From this point onward, comparison was therefore made between the BU patients and 
EC ELISA OD450 values. Only three out of 10 protein preparations (batches D, E and 
M. smegmatis) had the potential to discriminate among BU patients and EC (p< 0.05, 
Figure 5-5). Among the three, batch D had a greater screening potential as illustrated 
by the ROC curve analysis (Figure 5-6). The performance of the assay in BU patients 
against EC showed that at a cut-off of > 0.9930, Batch D has 90% (CI: 55.50% - 
99.75%) sensitivity and a specificity of 95% (CI: 75.13% - 99.87%), with AUC of 
0.910 (CI: 0.7863 - 1.034) (Figure 5-6). At this cut-off (> 0.9930), BU patients were 
18.0 times likely to test positive in ELISA with batch D as test antigen compared to 
EC in the same BU endemic region. ELISA results of the other two batches varied 
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considerably in sensitivity and specificity for BU patients and EC (Figure 5-6) 
(detailed overview of all ROC results is in Appendix C, Table C-1).  
When screening using the M. ulcerans recombinant proteins, none could significantly 
discriminate among BU patients and EC (p>0.05, Figure 5-7). Nevertheless, among 
the four recombinant proteins, Hsp65 was better in differentiating between BU patients 
and EC with a sensitivity of 50% (CI: 18.71% - 81.29%) and specificity of 95% (CI: 
75.13% - 99.87%) at OD450 cut-off >1.548, with AUC of 0.875 (CI: 0.7102 - 1.040). 
BU patients were 10.0 more times likely to test positive in ELISA with Hsp65 as test 
antigen compared to EC in the same BU endemic region. (Figure 5-8, Appendix C, 
Table C-2). 
ROC analysis of BU-endemic (a pool of OD values for both BU patients and EC) 
against NEC was used to ascertain if any of the antigens could differentiate sera of 
participants from BU endemic areas (i.e., City of Greater Geelong) compared to NEC 
(i.e., Tasmania). Screening of all the 14 antigens uncovered higher antibody responses 
among the BU-endemic group compared to NEC for the following 10 protein 
preparations: batches A, B, D, E, F, H,  homogenate, M. smegmatis, MUP057 and 
Hsp65 (p < 0.05). These antigens produced sensitivity ≤ 93.33% and specificity ≥ 
89.47% at OD450 cut-off ≥ 0.5715, with AUC ≥ 0.6883 (Figure 5-6, Figure 5-8 and 
Appendix C Table C-1 and 2).  
The best performing antigen preparations able to distinguish between BU-endemic 
against NEC was batch A, with the highest likelihood ratio of 15.0 at OD450 cut-off < 
0.5715. In addition, Hsp65 produced the highest likelihood ratios of 14.0 in “BU-
endemic against NEC” at OD450 cut-off ≥ 0.6218. However, as mentioned above, the 
low IgG levels in the NEC sera, and thus the questionable quality of these sera, 
unfortunately excludes any conclusion as to the validity of this comparison. 
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A detailed summary of all the ROC analysis can be found in Appendix C, Table C-1 
and 2. 
 
Figure 5-5: ELISA results for protein preparations. 
ELISA results for the 10 mycobacteria protein preparations (batches A, B, C, D, E, F, G, H, homogenate and M. 
smegmatis). ELISA results of these proteins were compared with sera from BU patients, endemic controls (EC) 
and non-endemic controls (NEC).  Mean OD450 readings for each group and standard error of the mean are shown.  
The asterisk “*” is showing where there was significant distinction (p < 0.05). 
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Figure 5-6: Evaluation of the sensitivity and specificity of the ELISA. 
Receiver Operator Characteristic (ROC) analysis of 10 mycobacteria protein preparations (Batches A, B, C, D, E, 
F, G, H, homogenate and M. smegmatis) in a direct ELISA evaluating BU patients, endemic control (EC) and non-
endemic control sera. 
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Figure 5-7: ELISA results for the four M. ulcerans recombinant proteins. 
ELISA results for the 4 M. ulcerans recombinant proteins (Hsp65, MUP057, MUL_2232 and ATP). Proteins were 
compared with BU patients’, endemic controls (EC) and non-endemic controls (NEC) sera. Mean OD450 readings 
for each group and standard error of the mean are shown. The asterisk “*” is showing where there was significant 
distinction (p < 0.05). 
 
 
Figure 5-8: Evaluation of the sensitivity and specificity of the ELISA (recombinant proteins). 
Receiver Operator Characteristic (ROC) analysis of 4 M. ulcerans recombinant proteins (Hsp65, MUP057, 
MUL_2232 and ATP) in a direct ELISA evaluating BU patients, endemic control (EC) and non-endemic control 
sera. 
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5.3.4 Immunoblotting of the M. ulcerans recombinants proteins 
 
Western blot analysis for the four recombinant proteins showed some clear positive 
bands and some lanes that had ambiguous bands (Figure 5-9). To avoid visualization 
bias, Western blot result collation and summary was performed double-blinded (Table 
5-1) using Figure 4-31 and Figure 5-9 as template guide. Hsp65 was the most 
discriminatory antigen, with eight (80%) of BU patients having antibodies specific for 
this antigen in their sera. However, 11 (55%) and 12 (60%) of sera from EC and NEC 
also responded positively to Hsp65 antigens respectively. MUL_2232, MUP057 and 
ATP did not perform well at differentiating in any group (Table 5-2). Western blot 
images can be found in Appendix D.  
Table 5-2: Summary of Western blot results showing serum reactivity with the 
four M. ulcerans recombinant proteins. 
 
Recombinant  
proteins 
BU patients 
(n=10) % 
EC  
(n=20) % 
NEC 
(n=20)% 
 
Hsp65 
 
8 (80%) 
 
11 (55%) 
 
12 (60%) 
 
MUP057 
 
5(50%) 
 
11 (55%) 
 
9 (45%) 
 
ATP 
 
5 (50%) 
 
13 (65%) 
 
9 (45%) 
 
MUL_2232 
 
6 (60%) 
 
11 (55%) 
 
10 (50%) 
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5.4 Discussion 
 
The number of BU patients recruited compared to the control groups assessed for 
antibody responses against protein preparations was smaller than planned. This was 
because as of the time of participants’ recruitment and laboratory analysis, these were 
the number of BU patients that had recently reported as cases to the BU clinic at UHG. 
Due to time constraints of the research project, the study could not recruit new Non-
endemic controls for comparison. As a proof of principle for a first pilot serological 
study in the City of Greater Geelong using these protein preparations, the goal of this 
study was achieved. The goal: to produce M. ulcerans protein preparations for a 
potential use in serological study to understand exposure to the bacterium.  
BCG mass vaccination was halted in the late 1980s in Australia (126), therefore it was 
an undocumented hope to recruit BCG free healthy controls (i.e. EC and NEC) in the 
study area for the serological survey. This was ideal because cross-reactivity in M. 
ulcerans serological surveys in Africa has usually been attributed to mass BCG 
vaccination (106). Nevertheless, from the survey questionnaires, 70% of EC (Table 5-
1) had BCG and the study could not authenticate the BCG status of the NEC.  
Still, some of the protein preparations were able to distinguish among study groups. 
Despite the fact that there were many shared proteins (e.g. 60 kDa chaperonin 1 and 
2; Hsp65), the ELISA test using the Batch D preparation was better at discriminating 
between BU patients from EC. This could potentially be developed to demonstrate 
asymptomatic exposure. The total proteins identified in batch D was 128 (Table 4-4). 
Furhermore, it was the only control batch prepared with Middlebrooks media 
supplemented with glucose only and no tryptose (79HG) (Table 4-4).  
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 A follow-up search in the five-way Venn diagram in Figure 4-17, showed that there 
were 7 proteins (A0PSH5, A0PLD3, A0PMN1, A0PW61, A0PLY3, A0PNP3 and 
A0PPL5; Appendix B, Table B-3) identified in batch D, not present in the other four 
(batches: A, B, C and E). With the exception of A0PSH5 (conserved protein, 
MUL_3044, MW: 31,113 Da), the other six proteins were also found in the 
homogenate (Appendix B, Table B-3). Amino acid sequence comparison of the 
A0PSH5 found similar protein in pathogenic mycobacteria (e.g. M. tuberculosis and  
MAP). The only protein in batch D not found in the homogenate was A0PKR2 
(conserved protein, MUL_0178, MW= 28,132 Da). Interestingly, MUL_0178 was also 
found in batch C and did not have any homologue in M. liflandii, M. smegmatis nor 
the pathogenic bacteria used in this study. Though MUL_0178 was absent in MAP, M. 
leprae, M. liflandii, M. smegmatis and M. tuberculosis it had orthologues in M. avium, 
M. avium subsp. avium, M. avium subsp. hominissuis and M. avium subsp. silvaticum 
which are not human pathogens. Further review of all proteins in batch D discovered 
A0PUR1 (Citrate (Pro-3s)-lyase (Beta subunit) CitE_1; MW: 30,016 Da) protein 
which was also present in batch C, batch E, batch H and homogenate. Amino acid 
sequence comparison showed that there was no homologue of CitE_1 in the well-
known human pathogenic mycobacterial species. Though protein-BLAST and UniProt 
search did not produce a hit of A0PUR1 for MAP, M. bovis, M. leprae and M. 
tuberculosis, the BLAST results indicated that A0PUR1 is a  MULTISPECIES: CoA 
ester lyase [Mycobacterium] (with 99% sequence identity) and in other bacteria. 
Therefore, it is not unlikely orthologues may be  present in these pathogenic 
mycobacteria. The complete reasons that batch D was a better antigen in the 
serological survey remains conjecture, so further investigation is would be required to 
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purify and assess the usefulness of these two proteins (A0PUR1 and A0PKR2) as 
candidate antigens for BU diagnosis.  
There has not been any study on M. ulcerans using a similar standardised protein 
preparation as described by Wynne et al, 2012) (65) approach for serology in BU 
research, therefore there is no comparison. Some of the results obtained in this study 
seem to validate and optimise previous studies that had attempted developing a test for 
screening purposes (68,69,72,127). A previous study was Tafelmeyer et al.,  2008; but, 
their protein preparations were never used in any immune-detection assays (211). 
Another similar standardised approach was Wynne et al., 2012 in protein preparations 
from M. avium subsp. paratuberculosis (MAP) for use in Johne’s disease (JD) in 
animals (65).  
Regarding the four recombinant proteins (Table 5-2), the Hsp65 ELISA results 
obtained agreed with a previous study using an African cohort by Pidot et al. 2010. 
They reported that ELISA test using Hsp65 was far better at differentiating between 
BU endemic group and non-endemic control with 84.1% sensitivity and 93.3% 
specificity at OD cut-off 0.6930 (72). The current study went further to also use the 
four recombinant proteins in Western blot analysis which was not performed in Pidot 
et al., 2010 (72). Nevertheless the results were quite comparable to the results obtained 
in the ELISA.  
It must be noted that, Hsp65 has been reported to be an immune-dominant protein in 
mycobacteria and the presence of anti-Hsp65 proteins in all sera is very likely due to 
exposure to environmental mycobacteria (72,212,213). Therefore, ELISA test using 
Hsp65 was not expected to show any distinction compared to the other three M. 
ulcerans recombinant proteins. The elevated antibody response to Hsp65 antigen 
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among the BU case patients could be due to their disease state. It is not unusual to 
develop hypergammaglobulinemia (a condition of elevated immunoglobulin) during 
active infection with pathogenic bacteria (214,215) and the actual IgG levels observed 
in the BU patients were higher than in the EC sera.  
There have been numerous studies on the description of mycobacteria protein 
composition through bacteria culture, DNA and/or protein bioinformatics 
(65,69,72,106,116,119,120,122,194). Therefore, this study is not the first to use 
protein preparations from mycobacteria, nor even from M. ulcerans in some form of 
serological experiments. However, it has been the first study to express novel proteins 
through culture and perform comprehensive proteomic comparison for further 
investigation as candidate antigens. In addition, the standardised approach in culturing 
the bacterium, protein production procedure and profiling of batches by LC-MS/MS 
to understand variations in proteins generated before usage are unique to this study. 
There is no doubt that more work is needed in the optimisation of bacterial culture, 
protein production standardisation, reducing the background signal of the ELISA 
assays and using quality non-endemic control serum samples.  
There was a pre-decision to only recruit BCG free-controls in the study. But due to 
ethical constrain regarding dissemination of initial study findings, convenience 
sampling was deemed sufficient for a pilot survey. None of the protein preparations is 
at the mature stage of diagnostic potential, however, there is prospect for this 
standardised approach to be used for generating quality antigens for exposure 
screening purposes within at ‘‘at risk community’’. 
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5.5 Conclusion 
 
This study has attempted to use the M. ulcerans proteins prepared in chapter four for 
a serological based screening test recruiting BU case patients and healthy endemic 
controls from the City of Greater Geelong region and non-endemic controls from 
Tasmania. There were two groups of antigens. Group 1 was culture preparations 
(Batches, A, B, C, D, E, F, G, H, homogenates and M. smegmatis) and group 2 
(MUP057, MUL_2232, ATP and Hsp65)  was M. ulcerans recombinant proteins. 
Antibody responses of human sera against these antigens were highly variable. 
Nevertheless, ELISA tests using Batch D and Hsp65 were able to successfully 
distinguish between some of the study groups. Purification of A0PUR1 and A0PKR2 
proteins and securing more non-endemic control samples for further study is highly 
recommended.  
This study cannot decide on the diagnostic potential of any of the batches since this 
was a pilot survey and will require further screening and validation of different serum 
samples. Nevertheless, there are prospects in using the methodology employed in this 
study for protein production and screening for M. ulcerans exposure within at ‘risk 
communities’. This study has been  cognizant of the challenges of cross-reactivity 
associated with developing a serologically based diagnostic test for BU (evident even 
from the M. smegmatis results, Figure 5-5 and Figure 5-6) and previous mycobacterial 
disease studies (68,72,75,106,117,124). But considering the fact that mycobacteria 
cause different forms of disease in humans and animals (62), a dedicated antigen 
preparation should be used to identify a unique antigen of diagnostic potential.
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CHAPTER 6 
 
6 Concluding discussions and perspectives 
 
To date researchers have faced hurdles in the development of a serological screening 
test for M. ulcerans exposure or infection due to cross-reactivity. Some have become 
sceptical of the serological test based screening approach (61,68,72,106,116,119,120). 
This scepticism is not unreasonable because even the well-studied mycobacteria 
species,  the Tubercle bacilli that cause tuberculosis in humans has no agreed point of 
care or clinically useful serological or cytokine screening tests (216,217). From the 
systematic review presented in this thesis, the challenge associated with serological 
and cell-mediated studies has led to the paucity of protein preparation work to date. 
There seems to be a lack of research continuity in a particular approach to arrive at any 
meaningful conclusions. For example, Stanford’s skin test study with burulin in 
Uganda and Zaire (now the Democratic Republic of Congo) was not replicated 
anywhere else (119). The same could be said about Dobos et al., 2000 skin test study 
in Côte d’Ivoire with M. ulcerans culture filtrates (106). They were both based on skin 
tests. But the approach used in these two studies were different regarding the M. 
ulcerans strains used as well as protein preparation procedure. Therefore, results were 
not comparable.  
After 70 years of its identification and description by MacCallum (138), the exact 
mode of M. ulcerans transmission remains speculative (6). Environmental sampling 
and molecular epidemiology to date have only confirmed M. ulcerans is an 
environmental mycobacterium (36,62,139,218). There is no doubt that in order to 
understand M. ulcerans transmission dynamics an effective population screening tool 
would be useful (62,117,175). To this end,  the current study has used a standardised 
Chapter 6 
 
149 
 
approach in protein preparation from M. ulcerans with minor modifications in the 
protocol reported in Wynne et al., 2012 in protein preparation from Mycobacterium 
avium subsp. paratuberculosis (MAP) (65). This study was also able to partially purify 
four M. ulcerans recombinant proteins from Pidot et al., 2010 (72) for comparative 
study. The results obtained have shown that it is possible to produce proteins 
representative of the infective organism using the standardised protocol.  
In order to test the usefulness of such protein preparations as a screening test for 
exposure, quality serum samples from BU patients and healthy controls living in the 
same area are crucial as well as healthy individuals living in areas where BU has never 
been reported. In addition, the preparation from the bacterium must be able to 
distinguish to some degree M. ulcerans exposed sera from unexposed in a potential 
screening test (68,69).  The pilot screening test demonstrated in this study using the 
protein preparations against BU patients and healthy control sera from the City of 
Greater Geelong, showed that some of the preparations could in an ELISA test 
distinguish BU patients from healthy endemic controls. Though the results from non-
endemic controls (Tasmania) require further validation, the fact that the ELISA test 
dichotomised BU patients and endemic controls sera, shows prospect for the use of 
such preparations as a screening test for exposure and or disease. There is however, 
the need for optimisation in the protein preparations and immunoblotting experiments. 
Despite many efforts in BU research, the development of a rapid, reliable and easy to 
use diagnostic test is yet to materialise. The importance of such a test to global 
surveillance and control cannot be overemphasised because such a test, if 
discovered/developed holds the potential of accurately assessing the global 
infection/exposure rate of M. ulcerans (11,54,71). 
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This study recommends purification of all the newly identified M. ulcerans proteins: 
ilvB1_1, CitE_1, MUL_0178, MUL_0705, MUL_0838, MUL_1269, MUL_1620, 
MUL_2683, MUL_2952, MUL_3118, MUL_3189, MUL_3300, MUL_4290, 
MUL_4933, MUL_4925 and MUL_4926 with no homologues in the human 
pathogenic mycobacteria: MAP, M, bovis, M. leprae, and M. tuberculosis for a 
potential use in serology, cell-mediated or antigen-capture assay to assess their 
usefulness in BU diagnosis or M. ulcerans exposure. The 16 secreted antigens 
described in Table 4-6 could also be explored for the same purpose. 
Some researchers have held the view that some mycobacterial carbohydrate 
components also have prospects of being useful in a screening test. An example is the 
arabinomannan (AM) polysaccharide (125,219,220). Arabinomannan has been 
reported as one of the ubiquitous carbohydrates in mycobacterial species accounting 
for 70-80% of the total polysaccharide in the cell capsule. Though common,  many 
researchers have also indicated that AM is specific for different mycobacteria species 
(125,221) and might be useful. 
Future protein production from M. ulcerans using the standardised approached should 
investigate the effect of heated and unheated preparations on the quality and quantity 
of protein produced. Such work is crucial to not deactivate any important secreted 
proteins through the preparation procedure. 
The current pilot serological screening survey did not fractionate protein preparations 
into any components (e.g. by molecular weight, proteins or polysaccharides). 
However, it would have also been very informative to ascertain which fraction of the 
preparation was more antigenic. Future study using this approach should also 
investigate protein or polysaccharide fractions and antigenicity. In addition, future 
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research efforts need to investigate the usefulness of recombinant proteins and culture 
preparations in antibody adsorption experiments for screening purposes. Antibody 
absorption experiments, could still be relevant in BU research, in the wake of 
recombinant protein expression technologies.  
Explorative and descriptive analysis of the Victoria BU database has highlighted the 
importance of tailoring research in BU to suit endemic localities. The nature of BU 
spread in Victoria is very focal (i.e. centred on Bellarine and Mornington Peninsulas) 
and this investigation require a dedicated and local attention. Recent review articles 
have also intimated that geographical variations in transmission and probable 
environmental risk factors may exist; therefore geographical regions may require 
specific attention (6,11). These geographical differences also co-exist with similarities 
in rainfall patterns,  anthropogenic activities such as new constructional works and 
may all be involved in incidence of BU (6,11,139). It must be stated that BU focalized 
studies must be performed with the aim of understanding the local as well as global 
transmission, distribution pattern and potential implications. In regards to tracking the 
environmental risk factors in the Bellarine and Mornington Peninsulas, this study 
recommends that tourists to the areas could be encouraged to keep a diary of daily 
activities (e.g. swimming-where and when) which could be valuable in tracking 
potential sources of infection. This study recommends an investigation that 
incorporates molecular epidemiology, a serological screening test and social 
epidemiology to arrive at a contextual framework for possible intervention during an 
outbreak. This approach has previously been utilized in research regarding 
tuberculosis transmission (222) and could be valuable for BU. 
The results obtained in the current study definitely adds to the body of knowledge in 
the scientific literature.  The attempt made in this study on  developing a screening test 
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for M. ulcerans exposure or infection has a huge implication for accurately assessing 
the infection rate in Australia, Ghana, Benin, and other endemic countries around the 
world for rapid, reliable and appropriate treatment. However, for the proteins prepared 
in this study to be used as a diagnostic test, diligent optimisation and validation would 
be required. 
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Appendices 
Appendix A 
 
Hanahan method for competent cells 
 
1. Grow E coli strain (BL21 received from Dr Melanie Thomson) colonies on 
plate (no amp) overnight 37oC. Streak the plate so that single colonies will be 
visible. 
2. The following day, inoculate 10ml of LB with a single colony; incubate 
overnight at 37oC shaking at 200 rpm. 
3. The following day, inoculate 50 ml LB (no amp) with 500 µl of culture 
(1/100 dilution) in an Erlenmeyer flask. Scale up if desired. 
4. Incubate at 37oC shaking at 200 rpm until OD600 reaches 0.3-0.6. Generally 
OD of  ~0.3 is achieved after 3 h growth and an OD600 of  ~0.6 after 4 h 
5. Harvest the culture by spinning at 4000 rpm for 20 min at 4oC. 
6. Pour off the supernatant and resuspend the pellet in 15ml of ice-cold buffer 
RF1. 
7. Incubate for 15 mins on ice, then centrifuge at 4000 rpm for 10 min at 4oC. 
8. Resuspend the pellet in 5 ml of ice-cold buffer RF2 
9. Incubate on ice for 15 min, then flash freeze 100 µl aliquots on dry ice. Store 
at -80oC. 
10. This study did not test the competency of the cells. 
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Reagents 
Composition RF1 RF2 
KCL 2.4 g 0.3 g 
MnCL2.4H2O 2.0 g - 
CH3CO2K 0.6 g - 
CH3CL2.2H2O 0.3 g 2.2 g 
Glycerol 30 ml (37.8 g) 30 ml (37.8 g) 
0.5M MOPS - 4.0 ml 
H2O To 200 ml To 200 ml 
 
RF1- Dissolve in 140 ml H2O. Adjust pH to 5.8 (~7 drops 1 M HCL) and make up 
to 200 ml. filter sterilise and store at 4oC. 
RF2- Dissolve in 140 ml H2O. Adjust pH to 6.8 and make up to 200 ml. filter 
sterilise and store at 4oC. 
0.5 M MOPS 
Dissolve 10.47 g in 80 ml of H2O, pH 6.8 using 10 M NaOH or tablets and bring to 
100 ml 
Dr Kathryn Matthews (Member of Prof Tania De Koning-Ward research team, 2015) 
supplied this protocol and the reagents (RF1 and RF2) for the competent cell 
preparation. 
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Appendix A.1 
 
The Middlebrook media recipe from Media Preparation Unit is described below. 
Media composition Amount 
7H9GT media  
Middlebrook 7H9 Broth (271310) 4.7 g 
50% Glycerol  4 ml 
Glucose (D-) 20 g 
Tryptose - (Bacto 211713) 1 g 
Distilled Water 1,000 ml 
pH 6.6 ± 0.2  
  
7H9G media  
Middlebrook 7H9 Broth (271310) 4.7 g 
50% Glycerol  4 ml 
Glucose (D-) 20 g 
Distilled Water 1,000 ml 
pH 6.6 ± 0.2  
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Appendix B 
 
The following tables comprise the large datasets that were obtained throughout the 
project. 
Table B-1 describes the SatScan purely spatial and space-time detected clusters. The 
table also describes suburbs allocations within the clusters.  
Table B- 2 is showing raw data obtained from the SatScan purely spatial and space-
time analysis. 
Table B- 3 is the overview of proteins identified by LC-MS/MS in all protein 
preparations. The table also describes unique proteins and shared proteins in all 
preparations.  
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Table B-1: SatScan purely spatial and space-time detected clusters with 
suburb allocations within the clusters. 
 
 
Cluster 
Number 
 
Suburbs in Space time clusters 
 
Suburbs in Purely spatial clusters 
 
 
Cluster 1 
Barwon Heads,  Ocean Grove,  Point Lonsdale,  
Queenscliff,  Portsea,  Sorrento 
Blairgowrie,  Rye,  Tootgarook,  Leopold 
Curlewis,  Drysdale,  Clifton Springs 
St Leonards,  Indented Heads 
Portarlington 
Barwon Heads,  Ocean Grove,  Point 
Lonsdale,  Queenscliff,  Portsea,  
Sorrento,  Blairgowrie,  Rye,  
Tootgarook,  Leopold 
Curlewis,  Drysdale,  Clifton Springs 
St Leonards,  Indented Heads 
Portarlington 
Cluster 2 Seaford,  Frankston,  Frankston South,  Frankston 
North 
Seaford,  Frankston,  Frankston South,  
Frankston North 
 
 
 
 
 
 
Cluster 3 
Beaumaris,  Black Rock,  Cheltenham,  Highett,  
Sandringham,  Clarinda,  Hampton 
Hampton East,  Bentleigh East,  Bentleigh   
Brighton,  Brighton East,  Ormond 
Hughesdale,  Murrumbeena,  Caulfield 
Caulfield East,  Elwood,  Malvern East 
Caulfield North,  Malvern,  Ashwood 
Ashburton,  Glen Iris,  Armadale,  Albert Park 
Middle Park,  Prahran,  South Yarra,  Toorak 
Kooyong,  Camberwell,  Hawthorn 
Hawthorn East,  Richmond,  East Melbourne 
Collingwood 
Beaumaris,  Black Rock 
 
Cluster 4 
Cann River,  Mallacoota,  Swan Reach,  Oakleigh 
East,  Raymond Island,  Wiseleigh 
Hawthorn,  Hawthorn East,  Toorak,  
Kooyong,  Camberwell,  Armadale,  
Malvern 
Glen Iris 
 
 
 
 
 
Cluster 5 
Mernda,  Doreen,  Diamond Creek 
Lalor,  Bundoora,  Greensborough,  Briar Hill 
Eltham,  Montmorency,  Lower Plenty 
Viewbank,  Rosanna,  Bulleen,  Doncaster,  
Ivanhoe,  Ivanhoe East,  Balwyn North,  Doncaster 
East,  Box Hill,  Blackburn,  Mitcham,  Ringwood,  
Croydon,  Croydon South,  Warranwood,  
Bayswater North 
Mount Evelyn 
Empty 
Cluster 6 N/A Mallacoota 
Cluster 7 N/A Hastings,  Bittern 
Cluster 8 N/A Empty 
 
Cluster 9 
N/A Wiseleigh,  Nicholson,  Swan Reach,  
Oakleigh East,  Raymond Island,  
Paynesville 
Cluster 10 N/A Empty 
Cluster 11 N/A Empty 
Appendices 
 
174 
 
Table B-2: Table B-2: Raw data of SatScan purely spatial and space-time analysis.  
 
 
Space-Time SatScan summary 
           
               
CLUSTER LOC_ID LATITUDE LONGITUDE RADIUS START_DATE END_DATE NUMBER_LOC LLR P_VALUE OBSERVED EXPECTED ODE REL_RISK GINI_CLUST 
1 20534960000 -38.26974 144.65904 21.351073 1/01/2001 31/12/2016 1325 1272.07 1.00E-17 399 7.97618696 50.0239026 89.066891 F 
2 All 
   
1/01/2011 31/12/2016 56327 320.506 1.00E-17 598 234.829187 2.54653183 5.6088697 F 
3 20178740000 -38.12862 145.12445 5.3121823 1/01/2005 31/12/2016 941 81.3198 1.00E-17 62 7.08207557 8.75449569 9.32821732 F 
4 20045422000 -37.89876 145.00192 10.2517944 1/01/2016 31/12/2016 8213 69.7603 1.00E-17 50 5.17108044 9.6691592 10.1791097 F 
5 20161871000 -37.56671 149.13164 131.815332 1/01/2002 31/12/2010 347 20.5596 0.00450933 14 1.31070748 10.6812544 10.8342313 F                
 
Purely spatial SatScan summary 
           
               
CLUSTER LOC_ID LATITUDE LONGITUDE RADIUS START_DATE END_DATE NUMBER_LOC LLR P_VALUE OBSERVED EXPECTED ODE REL_RISK GINI_CLUST 
1 20534960000 -38.26974 144.65904 21.351073 N/A N/A 1325 1141.61 1E-17 402 11.46611 35.0598417 62.5539307 T 
2 20172190000 -38.13288 145.1223 4.81688848 N/A N/A 853 54.8746 1E-17 63 12.0202536 5.24115399 5.56038063 T 
3 20050160000 -37.97932 145.01805 2.42578491 N/A N/A 186 29.1664 2.5806E-08 24 2.99828289 8.00458158 8.19648792 T 
4 20066890000 -37.83659 145.04449 3.31312994 N/A N/A 1350 21.2401 3.2068E-05 53 18.8882534 2.80597676 2.91898357 T 
5 20318210000 -37.98792 145.08124 0.17322582 N/A N/A 4 12.8917 0.052 4 0.05963128 67.0788924 67.3738874 F 
6 20160670000 -37.56669 149.75595 53.0066489 N/A N/A 33 11.0329 0.262 5 0.21177463 23.6100049 23.7363177 F 
7 20479510000 -38.29163 145.18946 6.81780787 N/A N/A 211 10.3209 0.45 15 3.52511872 4.25517584 4.31034831 F 
8 20529640000 -37.8373 144.95554 0.06908769 N/A N/A 2 10.0295 0.552 3 0.03956842 75.8180438 76.0682714 F 
9 20158672000 -37.82421 147.82771 15.0209123 N/A N/A 170 9.44463 0.731 10 1.70274232 5.87287924 5.92763069 F 
10 20066130000 -37.86729 145.08023 0 N/A N/A 1 8.79599 0.89 2 0.00910259 219.717596 220.204718 F 
11 20637800000 -37.78853 144.975 0 N/A N/A 1 7.89721 0.996 2 0.01430408 139.820289 140.129465 F 
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Table B-3: Proteins identified by LC-MS/MS in all culture preparations. 
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sp|A0PLQ1|DNAK_MYCUA Chaperone protein  dnaK               
66,362  
+ + + + + + + + + + + + 
sp|A0PM24|RPOB_MYCUA DNA-directed RNA polymerase subunit beta   rpoB             
129,751  
+ + + + + + + + + + + + 
sp|A0PM25|RPOC_MYCUA DNA-directed RNA polymerase subunit beta~   rpoC             
147,465  
+ + + + + + + + + + + + 
sp|A0PM42|EFTU_MYCUA Elongation factor Tu   tuf               
43,779  
+ + + + + + + + + + + + 
sp|A0PM71|RL29_MYCUA 5-S ribosomal protein L29   rpmC                 
9,151  
+ + + + + + + + + + + + 
sp|A0PME8|CH10_MYCUA 1- kDa chaperonin   groS               
10,741  
+ + + + + + + + + + + + 
sp|A0PME9|CH601_MYCUA 6- kDa chaperonin 1   groL1               
55,852  
+ + + + + + + + + + + + 
sp|A0PNL7|CH602_MYCUA 6- kDa chaperonin 2   groL2               
56,524  
+ + + + + + + + + + + + 
sp|A0PQE7|PNP_MYCUA Polyribonucleotide nucleotidyltransferase   pnp               
80,837  
+ + + + + + + + + + + + 
sp|A0PSI5|MASZ_MYCUA Malate synthase G   glcB               
79,657  
+ + + + + + + + + + + + 
sp|A0PUK0|ATPB_MYCUA ATP synthase subunit beta   atpD               
52,768  
+ + + + + + + + + + + + 
sp|A0PUK2|ATPA_MYCUA ATP synthase subunit alpha   atpA               
59,643  
+ + + + + + + + + + + + 
sp|A0PW55|ENO_MYCUA Enolase   eno               
44,709  
+ + + + + + + + + + + + 
tr|A0PKL7|A0PKL7_MYCUA Chaperone protein clpB               
92,765  
+ + + + + + + + + + + + 
tr|A0PM20|A0PM20_MYCUA 5-S ribosomal protein L7/L12   rplL               
13,348  
+ + + + + + + + + + + + 
tr|A0PNE6|A0PNE6_MYCUA Acyl carrier protein   acpM               
12,479  
+ + + + + + + + + + + + 
tr|A0PNE9|A0PNE9_MYCUA Pyruvate dehydrogenase E1 component   aceE             
103,472  
+ + + + + + + + + + + + 
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tr|A0PNT7|A0PNT7_MYCUA Aconitate hydratase Acn   acn             
102,363  
+ + + + + + + + + + + + 
tr|A0PP44|A0PP44_MYCUA Ribosomal protein S1 RpsA   rpsA               
53,072  
+ + + + + + + + + + + + 
tr|A0PPN2|A0PPN2_MYCUA Glyceraldehyde-3-phosphate dehydrogenase   gap               
36,091  
+ + + + + + + + + + + + 
tr|A0PPW0|A0PPW0_MYCUA Electron transfer flavoprotein (Beta-subunit) FixA   fixA               
27,779  
+ + + + + + + + + + + + 
tr|A0PSD3|A0PSD3_MYCUA Alkyl hydroperoxide reductase C protein AhpC   ahpC               
21,582  
+ + + + + + + + + + + + 
tr|A0PTH9|A0PTH9_MYCUA Conserved secreted antigen Wag31   wag31               
28,715  
+ + + + + + + + + + + + 
tr|A0PTQ1|A0PTQ1_MYCUA Dihydrolipoamide acetyltransferase component of 
pyruvate dehydrogenase complex   
sucB               
60,749  
+ + + + + + + + + + + + 
tr|A0PVX3|A0PVX3_MYCUA Isocitrate lyase  icl               
47,440  
+ + + + + + + + + + + + 
sp|A0PM98|KAD_MYCUA Adenylate kinase   adk               
20,083  
+ + + + + + + + + +   + 
sp|A0PP28|TRPC_MYCUA Indole-3-glycerol phosphate synthase   trpC               
28,202  
+ + + + + + + + + +   + 
sp|A0PPN4|TPIS_MYCUA Triosephosphate isomerase   tpiA               
27,479  
+ + +   + + + + + + + + 
sp|A0PQ11|Y1987_MYCUA Uncharacterized oxidoreductase   MUL_1987               
30,043  
+ + + + + + + + + +   + 
sp|A0PRT4|HTPG_MYCUA Chaperone protein  htpG               
73,011  
+ + + + + + + + + +   + 
sp|A0PSD4|AHPD_MYCUA Alkyl hydroperoxide reductase  ahpD               
18,841  
+ + + + + + + + + +   + 
sp|A0PVV1|MDH_MYCUA Malate dehydrogenase   mdh               
34,646  
+ + + + + + + + + +   + 
tr|A0PKM7|A0PKM7_MYCUA 5-methyltetrahydropteroyltriglutamate--homocysteine 
methyltransferase   
metE               
85,417  
+ + + + + + + + + +   + 
tr|A0PKR9|A0PKR9_MYCUA Acyl-[acyl-carrier protein] desaturase desA2               
31,500  
+ + + + + + + + + +   + 
tr|A0PKU0|A0PKU0_MYCUA Enoyl-CoA hydratase  echA9               
36,345  
+ + + + + + + + + +   + 
tr|A0PKU1|A0PKU1_MYCUA Enoyl-CoA hydratase echA8               
27,250  
+ + + + + + + + + +   + 
tr|A0PLA3|A0PLA3_MYCUA 29 kDa antigen cfp29               
29,066  
+ + + + + + + + + +   + 
tr|A0PN26|A0PN26_MYCUA 3-oxoacyl-[acyl-carrier protein] reductase FabG4   fabG4               
46,872  
+ + + + + + + + + +   + 
tr|A0PPJ4|A0PPJ4_MYCUA Integration host factor MihF   mihF               
11,529  
+ + +   + + + + + + + + 
tr|A0PQ30|A0PQ30_MYCUA Multifunctional mycocerosic acid synthase 
membrane-associated Mas   
mas             
223,924  
+ + + + + + + + + +   + 
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tr|A0PQ35|A0PQ35_MYCUA Phenolpthiocerol synthesis type-I polyketide synthase 
PpsE   
ppsE             
158,830  
+ + + + + + + + + +   + 
tr|A0PQH1|A0PQH1_MYCUA 4-hydroxy-tetrahydrodipicolinate synthase   dapA               
30,833  
+ + + + + + + + + +   + 
tr|A0PQK0|A0PQK0_MYCUA Molecular chaperone (Small heat shock protein)   MUL_2232               
16,546  
+ + + + + + + + + +   + 
tr|A0PSH7|A0PSH7_MYCUA Conserved protein   MUL_3046               
17,148  
+ + +   + + + + + + + + 
tr|A0PUJ7|A0PUJ7_MYCUA Cobalamin adenosyltransferase   MUL_3951               
21,340  
+ + + + + + + + + +   + 
tr|A0PUP1|A0PUP1_MYCUA Carbonic anhydrase   MUL_3998               
17,928  
+ + + + + + + + + +   + 
tr|A0PUU7|A0PUU7_MYCUA Short-chain type dehydrogenase/reductase   MUL_4065               
30,447  
  + + + + + + + + + + + 
tr|A0PV44|A0PV44_MYCUA ATP-dependent protease ATP-binding subunit   clpC1               
93,660  
+   + + + + + + + + + + 
tr|A0PVN3|A0PVN3_MYCUA Fusion of enoyl-CoA hydratase, EchA21 and lipase, 
LipE   
MUL_4410               
75,844  
+ + + + + + + + + +   + 
tr|A0PVQ4|A0PVQ4_MYCUA Phosphate-binding protein  phoS2               
37,829  
+ + + + + + + + + +   + 
tr|A0PVY0|A0PVY0_MYCUA Iron-regulated heparin binding hemagglutinin  hbhA               
22,478  
+ + + + + + + + + +   + 
tr|A0PWM8|A0PWM8_MYCU
A 
Conserved secreted protein   MUL_4846                 
7,693  
+ + + + + + + + + +   + 
sp|A0PMB7|RPOA_MYCUA DNA-directed RNA polymerase subunit alpha   rpoA               
37,776  
  + + + +   + + + + + + 
sp|A0PPY3|ILVC_MYCUA Ketol-acid reductoisomerase (NADP(+))   ilvC               
36,038  
  + + + +   + + + + + + 
sp|A0PQ80|EFTS_MYCUA Elongation factor Ts   tsf               
28,614  
+   + + +   + + + + + + 
sp|A0PU35|TIG_MYCUA Trigger factor   tig               
52,417  
+ + + + +   + + + +   + 
sp|A0PVP6|Y4430_MYCUA Putative S-adenosyl-L-methionine-dependent 
methyltransferase    
MUL_4430               
32,613  
+ + +   + + + + + +   + 
tr|A0PKD3|A0PKD3_MYCUA Conserved protein   MUL_0024               
57,106  
+ + +   + + + + + +   + 
tr|A0PKS0|A0PKS0_MYCUA Serine hydroxymethyltransferase   glyA               
45,131  
+ + + + +   + + + +   + 
tr|A0PKX9|A0PKX9_MYCUA Conserved protein   MUL_0263               
16,227  
+ + + + +   + + + +   + 
tr|A0PLQ2|A0PLQ2_MYCUA Protein GrpE   grpE              
22,812  
 
+ + + + + + + + +   + 
tr|A0PLZ7|A0PLZ7_MYCUA Enoyl-CoA hydratase, EchA3   echA3               
24,539  
+ + +   + + + + + +   + 
tr|A0PP51|A0PP51_MYCUA Iron-regulated conserved protein   MUL_1619               
15,251  
  + + + +   + + + + + + 
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tr|A0PPW1|A0PPW1_MYCUA Electron transfer flavoprotein (Alpha-subunit) FixB   fixB               
31,698  
+ + +   +   + + + + + + 
tr|A0PPY5|A0PPY5_MYCUA D-3-phosphoglycerate dehydrogenase   serA1               
54,246  
+ + + + +   + + + +   + 
tr|A0PQ25|A0PQ25_MYCUA Polyketide synthase    Pks15/1            
218,474  
+ +   + + + + + + +   + 
tr|A0PRA4|A0PRA4_MYCUA Conserved protein   MUL_2530                 
8,556  
+   + + + + + + + +   + 
tr|A0PRJ6|A0PRJ6_MYCUA Bifunctional protein acetyl-/propionyl-coenzyme a 
carboxylase (Alpha chain) AccA3   
accA3               
63,896  
+ + +   +   + + + + + + 
tr|A0PRM9|A0PRM9_MYCUA Conserved protein   MUL_2677               
48,589  
+ + + + +   + + + +   + 
tr|A0PS53|A0PS53_MYCUA Probable thiol peroxidase   tpx               
17,099  
+ + +   + + + + + +   + 
tr|A0PSE9|A0PSE9_MYCUA Alanine and proline rich secreted protein Apa   apa               
31,142  
+ + +   + + + + + +   + 
tr|A0PU25|A0PU25_MYCUA Conserved membrane protein   MUL_3722               
44,591  
+ + + + +   + + + +   + 
tr|A0PWG0|A0PWG0_MYCUA Short-chain type dehydrogenase/reductase   MUL_4759               
29,881  
+ + +   + + + + + +   + 
tr|Q6MZ72|Q6MZ72_MYCUA Type I modular polyketide synthase   mlsB          
1,501,50
7  
+ + + + + + + +   +   + 
sp|A0PLS0|GSA_MYCUA Glutamate-1-semialdehyde 2,1-aminomutase   hemL               
45,997  
  +   + + + + + + +   + 
sp|A0PLW6|Y671_MYCUA UPF-234 protein  MUL_0671               
18,097  
+   + + +   + + + +   + 
sp|A0PPN3|PGK_MYCUA Phosphoglycerate kinase   pgk               
43,118  
+   + + +     + + + + + 
tr|A0PKJ1|A0PKJ1_MYCUA Conserved protein   MUL_0093               
19,315  
    + + +   + + + + + + 
tr|A0PKR5|A0PKR5_MYCUA Fumarate hydratase class II   fum               
50,303  
+       + + + + + + + + 
tr|A0PKT2|A0PKT2_MYCUA Transcription elongation factor greA               
18,003  
+ + +   +   + + + +   + 
tr|A0PKX4|A0PKX4_MYCUA Citrate synthase   gltA2               
48,330  
+ +   + +     + + + + + 
tr|A0PL48|A0PL48_MYCUA Conserved protein   MUL_0343               
36,574  
  + + + +   + + + +   + 
tr|A0PL98|A0PL98_MYCUA Phosphoribosylformylglycinamidine synthase subunit  purS                 
8,734  
+   +   +   + + + + + + 
tr|A0PLZ9|A0PLZ9_MYCUA Glyoxalase II, GloB   gloB               
26,101  
+ + +   +   + + + +   + 
tr|A0PM06|A0PM06_MYCUA Transcription termination/antitermination protein 
NusG   
nusG               
25,543  
  + +   +   + + + + + + 
tr|A0PM19|A0PM19_MYCUA 5-S ribosomal protein L1-   rplJ               
21,066  
+ + + + +   +   + +   + 
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tr|A0PN27|A0PN27_MYCUA Acetyl-CoA acyltransferase FadA2   fadA2               
46,708  
+ + +   +   + + + +   + 
tr|A0PNH4|A0PNH4_MYCUA Glutamine synthetase   glnA1               
53,617  
+   +   +   + + + + + + 
tr|A0PPL4|A0PPL4_MYCUA Conserved lipoprotein LprG   lprG               
24,556  
  + + + +   + + + +   + 
tr|A0PPP6|A0PPP6_MYCUA Transketolase   tkt               
75,366  
+ +     +   + + + + + + 
tr|A0PQ38|A0PQ38_MYCUA Phenolpthiocerol synthesis type-I polyketide synthase 
PpsB   
ppsB             
161,008  
+ + +   +   + + + +   + 
tr|A0PSB1|A0PSB1_MYCUA Secreted antigen 85-B FbpB   fbpB               
34,657  
  + +   + + + + + +   + 
tr|A0PU39|A0PU39_MYCUA Ribose/galactose isomerase RpiB   rpiB               
17,213  
  + + + +   + + + +   + 
tr|A0PU41|A0PU41_MYCUA Aminopeptidase N PepN   pN               
94,366  
  +   + + + + + + +   + 
tr|A0PUI7|A0PUI7_MYCUA Thioredoxin   MUL_3937               
31,968  
  + + + +   + + + +   + 
tr|A0PWZ2|A0PWZ2_MYCUA Polyketide synthase  pks13             
191,304  
    + + + + + + + +   + 
tr|A0PX60|A0PX60_MYCUA Thioredoxin reductase   trxB2               
35,361  
+ + +     + + + + +   + 
sp|A0PP18|HIS4_MYCUA Phosphoribosyl isomerase A   priA               
25,587  
    + + +   + + + +   + 
sp|A0PP30|TRPA_MYCUA Tryptophan synthase alpha chain   trpA               
27,987  
  + + + +   +   + +   + 
sp|A0PTJ7|MRAZ_MYCUA Transcriptional regulator  mraZ               
16,041  
    +   +   + + + + + + 
tr|A0PKB7|A0PKB7_MYCUA DNA gyrase subunit A   gyrA               
92,743  
      + +   + + + + + + 
tr|A0PKC2|A0PKC2_MYCUA Peptidyl-prolyl cis-trans isomerase   ppiA               
19,219  
  + +   +   + + + +   + 
tr|A0PKH5|A0PKH5_MYCUA 3-S ribosomal protein S6   rpsF               
10,890  
+   +   +     + + + + + 
tr|A0PKR4|A0PKR4_MYCUA Fructose-1,6-bisphosphatase   glpX               
38,118  
+ + +   +   + + + +     
tr|A0PQ37|A0PQ37_MYCUA Phenolpthiocerol synthesis type-I polyketide synthase 
PpsC   
ppsC             
233,120  
+ 
  
+ + 
 
+ + + + 
 
+ 
tr|A0PMH3|A0PMH3_MYCUA GMP synthase [glutamine-hydrolyzing]   guaA               
56,602  
+     + +   + + + +   + 
tr|A0PNU5|A0PNU5_MYCUA Enoyl-[acyl-carrier-protein] reductase [NADH]   inhA               
28,718  
+   +   + +   + + +   + 
tr|A0PP52|A0PP52_MYCUA Conserved protein   MUL_1620               
14,370  
+   +   +   + + + +   + 
tr|A0PPX6|A0PPX6_MYCUA Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase 
subunit B   
gatB               
54,687  
+   +       + + + + + + 
Appendices 
 
180 
 
tr|A0PQ36|A0PQ36_MYCUA Phenolpthiocerol synthesis type-I polyketide synthase 
PpsD   
ppsD             
192,217  
    + + +   + + + +   + 
tr|A0PQ46|A0PQ46_MYCUA Conserved protein   MUL_2028               
27,204  
+   +   +   + + + +   + 
tr|A0PQI0|A0PQI0_MYCUA Conserved protein   MUL_2197               
19,753  
+ +     +   + + + +   + 
tr|A0PSC7|A0PSC7_MYCUA Bacterioferritin   bfrA               
18,413  
    +   +   + + + + + + 
tr|A0PU34|A0PU34_MYCUA ATP-dependent Clp protease proteolytic subunit   clpP1               
21,621  
  +   + +     + + + + + 
tr|A0PVW1|A0PVW1_MYCUA Serine protease HtrA (DegP protein)   htrA               
51,953  
    + + +   + + + +   + 
tr|A0PWB1|A0PWB1_MYCUA Pterin-4-alpha-carbinolamine dehydratase  moaB2               
18,395  
+ + + +     + + + +     
tr|A0PWI8|A0PWI8_MYCUA Secreted antigen 85-C  fbpC               
36,702  
+ + +   +     + + +   + 
tr|A0PWV6|A0PWV6_MYCUA Isocitrate dehydrogenase [NADP] icd2               
82,557  
    + + +   + + + +   + 
tr|A0PWZ6|A0PWZ6_MYCUA Secreted antigen 85-A fbpA               
35,791  
+   +   +   + + + +   + 
sp|A0PQ87|RRF_MYCUA Ribosome-recycling factor   frr               
20,926  
  + +       + + + +   + 
sp|A0PRF5|SAHH_MYCUA Adenosylhomocysteinase   ahcY               
54,137  
      + +     + + + + + 
sp|A0PTP9|AMPA_MYCUA Probable cytosol aminopeptidase   pA               
53,775  
    +   +   + + + +   + 
sp|A0PWD1|SUCC_MYCUA Succinate--CoA ligase [ADP-forming] subunit beta   sucC               
40,837  
        +   + + + + + + 
tr|A0PKB3|A0PKB3_MYCUA DNA polymerase III subunit beta   dnaN               
42,299  
  +     +     + + + + + 
tr|A0PKJ8|A0PKJ8_MYCUA Fructose-bisphosphate aldolase fba               
36,746  
  +     +   + + + +   + 
tr|A0PL11|A0PL11_MYCUA Fatty oxidation protein B fadB               
75,640  
+       +   + + + +   + 
tr|A0PL12|A0PL12_MYCUA Acyl-CoA thiolase  fadA               
42,513  
    + + +   +   + +   + 
tr|A0PLZ0|A0PLZ0_MYCUA Imidazolonepropionase   MUL_0705               
44,386  
+       +   + + + +   + 
tr|A0PM96|A0PM96_MYCUA Conserved protein   MUL_0825               
25,963  
    + + +     + + +   + 
tr|A0PNA1|A0PNA1_MYCUA Conserved membrane protein   MUL_1250               
48,597  
  + +   + +     + +   + 
tr|A0PPZ8|A0PPZ8_MYCUA DNA-binding protein Hu HupB-like protein   hupB               
23,632  
    +   +   +   + + + + 
tr|A0PQ24|A0PQ24_MYCUA Fatty-acid-CoA ligase FadD22   fadD22               
75,823  
+     + +     + + +   + 
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tr|A0PQ26|A0PQ26_MYCUA Conserved lipoprotein LppX   lppX               
24,134  
    + + +     + + +   + 
tr|A0PRC0|A0PRC0_MYCUA Iron-regulated short-chain dehydrogenase/reductase   MUL_2546               
30,191  
  + +   +     + + +   + 
tr|A0PT95|A0PT95_MYCUA Conserved 35 kDa alanine rich protein   MUL_3386               
29,198  
  + + + +   +     +   + 
tr|A0PTM0|A0PTM0_MYCUA Conserved protein   MUL_3540               
16,197  
  + +       + + + +   + 
tr|A0PTN8|A0PTN8_MYCUA Conserved protein   MUL_3561               
12,655  
    +   +   + + + +   + 
tr|A0PTW5|A0PTW5_MYCUA Ferredoxin-dependent nitrite reductase, NirA_2   nirA_2               
62,256  
  + +   +     + + +   + 
tr|A0PU90|A0PU90_MYCUA Bacterioferritin comigratory protein  bcp               
17,097  
    + + +   + + + +     
tr|A0PUF3|A0PUF3_MYCUA 3-oxoacyl-[acyl-carrier protein] reductase  fab               
26,435  
+   + +       + + +   + 
tr|A0PV05|A0PV05_MYCUA Conserved lipoprotein  dsbF               
19,514  
  + + + +     +   +   + 
tr|A0PV30|A0PV30_MYCUA Conserved transcriptional regulatory protein   MUL_4159               
17,896  
    + +     + + + + +   
tr|A0PV59|A0PV59_MYCUA Epoxide hydrolase  ephA               
35,599  
    + + +     + + +   + 
tr|A0PV69|A0PV69_MYCUA Inorganic pyrophosphatase   ppa               
18,559  
      + +   + + + +   + 
tr|A0PVB1|A0PVB1_MYCUA Conserved protein with endoribonuclease L-PSP 
domain   
MUL_4252               
15,290  
    +   +   + + + +   + 
tr|A0PWZ3|A0PWZ3_MYCUA Fatty-acyl AMP ligase  fadD32               
69,577  
    +   +   + + + +   + 
tr|A0PX20|A0PX20_MYCUA Ferritin   bfrB               
20,364  
    +   +   + + + +   + 
tr|A0PX61|A0PX61_MYCUA Thioredoxin   trxC               
12,684  
  + + + +   + +       + 
tr|Q6MZA5|Q6MZA5_MYCUA Type I modular polyketide synthase   mlsA2             
256,810  
    + + + + + +       + 
sp|A0PNP3|FOLD_MYCUA Bifunctional protein  folD               
29,911  
      +       + + + + + 
sp|A0PPX4|GATA_MYCUA Glutamyl-tRNA(Gln) amidotransferase subunit A   gatA               
51,631  
    +   +     + + + +   
sp|A0PQ79|RS2_MYCUA 3-S ribosomal protein S2   rpsB               
30,020  
    +         + + + + + 
sp|A0PQH6|KATG_MYCUA Catalase-peroxidase   katG               
81,114  
        +     + + + + + 
sp|A0PU19|NDK_MYCUA Nucleoside diphosphate kinase   ndk               
14,673  
        +     + + + + + 
sp|A0PVU7|KGD_MYCUA Multifunctional 2-oxoglutarate metabolism enzyme   kgd             
137,113  
    +   +       + + + + 
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sp|A0PW79|ARCA_MYCUA Arginine deiminase   arcA               
43,572  
  +     + +   +   +   + 
sp|A0PWI9|MAK_MYCUA Maltokinase   mak               
49,439  
      + +   + + +     + 
tr|A0PKD1|A0PKD1_MYCUA Serine/threonine phosphatase  pstP               
54,721  
    +   +     + + +   + 
tr|A0PKH6|A0PKH6_MYCUA Single-stranded DNA-binding protein   ssb               
17,706  
        +     + + + + + 
tr|A0PKW1|A0PKW1_MYCUA Enoyl-CoA hydratase echA6               
26,241  
    + + +     + + +     
tr|A0PL90|A0PL90_MYCUA Cold shock protein a,  cspA                 
7,453  
+ + +   +     +   +     
tr|A0PLN0|A0PLN0_MYCUA Conserved protein   MUL_0567               
13,567  
    +   +     + + +   + 
tr|A0PLN6|A0PLN6_MYCUA Aspartate aminotransferase AspC   aspC               
47,860  
    +   +   +   + +   + 
tr|A0PNA0|A0PNA0_MYCUA Conserved protein   MUL_1249               
54,672  
  + +   +         + + + 
tr|A0PNQ2|A0PNQ2_MYCUA O-acetylhomoserine sulfhydrylase MetC   metC               
47,356  
      + +     + + +   + 
tr|A0PNU1|A0PNU1_MYCUA Transcriptional regulatory protein, MoxR1   moxR1               
39,987  
    + +       + + +   + 
tr|A0PNY6|A0PNY6_MYCUA Conserved protein   MUL_1544               
15,325  
    +   +     + + +   + 
tr|A0PP41|A0PP41_MYCUA Two-component system transcriptional regulator   MUL_1608               
22,955  
    +   +     + + +   + 
tr|A0PPR1|A0PPR1_MYCUA Conserved ATP-binding protein ABC transporter   MUL_1864               
28,013  
    +   +   + +   +   + 
tr|A0PQ16|A0PQ16_MYCUA Pyruvate carboxylase   pca             
121,562  
+       +     + + +   + 
tr|A0PQ39|A0PQ39_MYCUA Phenolpthiocerol synthesis type-I polyketide synthase 
PpsA   
ppsA             
170,199  
      + +     + + +   + 
tr|A0PQJ0|A0PQJ0_MYCUA Dihydrolipoyl dehydrogenase   lpd               
49,530  
        +     + + + + + 
tr|A0PR34|A0PR34_MYCUA Two-component system response regulator   MUL_2453               
14,364  
    +   +     + + +   + 
tr|A0PT66|A0PT66_MYCUA Iron-dependent repressor and activator IdeR   ideR               
25,356  
    +   +     + + +   + 
tr|A0PTP7|A0PTP7_MYCUA Branched-chain-amino-acid aminotransferase   ilvE               
39,942  
      + +     + + +   + 
tr|A0PTS7|A0PTS7_MYCUA Glycine--tRNA ligase   glyS               
52,428  
    +   +   +   + +   + 
tr|A0PU94|A0PU94_MYCUA Fatty acid synthase  fas             
326,538  
        +     + + + + + 
tr|A0PUL5|A0PUL5_MYCUA Threonine synthase   thrC               
37,567  
        +     + + + + + 
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tr|A0PUR1|A0PUR1_MYCUA Citrate (Pro-3s)-lyase (Beta subunit)  citE_1               
30,016  
    + + +   + +       + 
tr|A0PUW6|A0PUW6_MYCUA Conserved hypothetical oxidoreductase   MUL_4089               
45,492  
+   + + +         +   + 
tr|A0PV47|A0PV47_MYCUA Lysine--tRNA ligase   lysS               
55,680  
        +     + + + + + 
tr|A0PV86|A0PV86_MYCUA Cold shock protein A  cspA_1                 
7,338  
+           + + + + +   
tr|A0PVD1|A0PVD1_MYCUA PadR-like transcriptional regulatory protein   MUL_4279               
27,638  
+   +   +     +   +   + 
tr|A0PVE4|A0PVE4_MYCUA Aspartokinase   ask               
44,789  
        +   + + + +   + 
tr|A0PVX4|A0PVX4_MYCUA 3-hydroxybutyryl-CoA dehydrogenase  fadB2               
30,942  
        +   + + + +   + 
tr|A0PWJ1|A0PWJ1_MYCUA Serine protease PepA   pA               
33,358  
+   +   +   + +       + 
tr|A0PX01|A0PX01_MYCUA UDP-galactopyranose mutase glf               
45,973  
  + +       +   + +   + 
tr|A0PX67|A0PX67_MYCUA Conserved protein   MUL_5073               
19,840  
    +   +   + + + +     
tr|Q6MZA4|Q6MZA4_MYCUA Type I modular polyketide synthase   mlsA1          
1,803,72
7  
    +     + +   + +   + 
sp|A0PLZ1|Y706_MYCUA Putative S-adenosyl-L-methionine-dependent 
methyltransferase MUL_-7-6   
MUL_0706               
34,674  
    +   +     + + +     
sp|A0PM41|EFG_MYCUA Elongation factor G   fusA               
77,061  
        +       + + + + 
sp|A0PPI7|PYRR_MYCUA Bifunctional protein   pyrR               
20,059  
    + + +   +     +     
sp|A0PPJ8|METK_MYCUA S-adenosylmethionine synthase   metK               
43,071  
        +       + + + + 
sp|A0PPP5|TAL_MYCUA Transaldolase   tal               
40,195  
        +       + + + + 
sp|A0PPY6|LEU3_MYCUA 3-isopropylmalate dehydrogenase   leuB               
36,151  
      + +   +   +     + 
sp|A0PQC4|IF2_MYCUA Translation initiation factor IF-2   infB               
98,050  
            + + + +   + 
sp|A0PU27|MOBA_MYCUA Probable molybdenum cofactor guanylyltransferase   mobA               
21,057  
+ + +   +   +           
sp|A0PWG3|Y4762_MYCUA Putative S-adenosyl-L-methionine-dependent 
methyltransferase   
MUL_4762               
34,627  
+       +       + +   + 
tr|A0PKY2|A0PKY2_MYCUA Phosphoserine aminotransferase   serC               
40,032  
        +     + + +   + 
tr|A0PKZ5|A0PKZ5_MYCUA Cold shock-like protein B cspB               
20,660  
+   +   +       +     + 
tr|A0PL46|A0PL46_MYCUA Oxidase   MUL_0341               
58,825  
        +     + + +   + 
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tr|A0PLA6|A0PLA6_MYCUA Phosphoribosylformylglycinamidine synthase subunit 
PurL   
purL               
81,420  
        +       + + + + 
tr|A0PMH9|A0PMH9_MYCUA Conserved protein   MUL_0920               
30,661  
+       +     +   +   + 
tr|A0PMR4|A0PMR4_MYCUA Ferredoxin FdxC   fdxC               
12,376  
        +     +   + + + 
tr|A0PN03|A0PN03_MYCUA Conserved secreted protein   MUL_1142                 
7,427  
  + +   +   +   +       
tr|A0PP34|A0PP34_MYCUA Pyruvate kinase   pykA               
51,052  
    +         +   + + + 
tr|A0PP73|A0PP73_MYCUA N-acetyl-gamma-glutamyl-phosphate reductase   argC               
36,412  
        +     + + +   + 
tr|A0PPA7|A0PPA7_MYCUA Uncharacterized protein   MUL_1687               
32,015  
+   + + +             + 
tr|A0PPD9|A0PPD9_MYCUA 4-aminobutyrate aminotransferase GabT   gabT               
47,470  
        +     + + +   + 
tr|A0PPF6|A0PPF6_MYCUA Aspartyl-tRNA synthetase AspS   aspS               
64,762  
+       +       + +   + 
tr|A0PPR0|A0PPR0_MYCUA Conserved protein   MUL_1863               
42,677  
        +     + + +   + 
tr|A0PPY2|A0PPY2_MYCUA Acetolactate synthase (Small subunit) IlvN   ilvN               
18,246  
    +   +   + +       + 
tr|A0PQ28|A0PQ28_MYCUA Fatty-acyl AMP ligase FadD28   fadD28               
62,745  
        +     + + +   + 
tr|A0PQ53|A0PQ53_MYCUA Nitrogen regulatory protein P-II GlnB   glnB               
12,222  
        +       + + + + 
tr|A0PQ77|A0PQ77_MYCUA Mycobactin utilization protein ViuB   viuB               
30,656  
  +         + + +     + 
tr|A0PQI5|A0PQI5_MYCUA Conserved protein   MUL_2205               
17,254  
        +     + + +   + 
tr|A0PQS3|A0PQS3_MYCUA Dipeptidase PepE                  
39,208  
        +     + + +   + 
tr|A0PQT5|A0PQT5_MYCUA Conserved protein   MUL_2333               
55,052  
    +       +   + +   + 
tr|A0PRE3|A0PRE3_MYCUA Conserved protein   MUL_2573               
17,298  
    +   +   +     +   + 
tr|A0PSH9|A0PSH9_MYCUA Conserved protein   MUL_3048               
17,988  
    + + +     +     +   
tr|A0PT09|A0PT09_MYCUA Uncharacterized protein   MUL_3277               
10,052  
        +     + + +   + 
tr|A0PT41|A0PT41_MYCUA Conserved protein   MUL_3320               
17,667  
        +     + + +   + 
tr|A0PU28|A0PU28_MYCUA Pyruvate:ferredoxin oxidoreductase PorB, beta 
subunit   
porB               
39,233  
    +   +       + +   + 
tr|A0PU33|A0PU33_MYCUA ATP-dependent Clp protease proteolytic subunit   clpP2               
23,304  
  +       +       + + + 
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tr|A0PU91|A0PU91_MYCUA Acetylornithine deacetylase argE               
46,157  
    +       +   + +   + 
tr|A0PUI8|A0PUI8_MYCUA Acetyl-CoA acetyltransferase  fadA4               
40,579  
        +     +   + + + 
tr|A0PUI9|A0PUI9_MYCUA Glyoxalase gloA_1               
17,244  
        +     + + +   + 
tr|A0PUL6|A0PUL6_MYCUA Homoserine dehydrogenase   thrA               
45,836  
        +     + + +   + 
tr|A0PUR4|A0PUR4_MYCUA Acyl-CoA dehydrogenase  fadE3               
42,404  
    +       + +   +   + 
tr|A0PUX4|A0PUX4_MYCUA 2-keto-4-pentenoate hydratase   MUL_4097               
34,872  
  +     +     +   +   + 
tr|A0PVA1|A0PVA1_MYCUA Acetyl-coenzyme A synthetase   acs               
72,544  
        +     + + +   + 
tr|A0PVA9|A0PVA9_MYCUA Conserved regulatory protein   MUL_4250               
24,677  
    +   +     +     + + 
tr|A0PVD3|A0PVD3_MYCUA Glycerol kinase   glpK               
55,393  
        +     +   + + + 
tr|A0PVD8|A0PVD8_MYCUA Conserved hypothetical secreted protein   MUL_4290               
24,290  
    +   +     +   +   + 
tr|A0PVZ5|A0PVZ5_MYCUA Two component sensory transduction protein  regX3               
24,845  
    +         +   + + + 
tr|A0PW04|A0PW04_MYCUA Pyrroline-5-carboxylate reductase   proC               
30,059  
  +   +         + +   + 
sp|A0PKG2|SYL_MYCUA Leucine--tRNA ligase   leuS             
107,290  
        +     +     + + 
sp|A0PM69|RS3_MYCUA 3-S ribosomal protein S3   rpsC               
30,248  
          + +       + + 
sp|A0PM81|RL18_MYCUA 5-S ribosomal protein L18   rplR               
13,317  
  + +       +         + 
sp|A0PMB4|RS13_MYCUA 3-S ribosomal protein S13   rpsM               
14,370  
    +   +   +         + 
sp|A0PMB6|RS4_MYCUA 3-S ribosomal protein S4   rpsD               
23,322  
    +   +         +   + 
sp|A0PMX1|PCKG_MYCUA Phosphoenolpyruvate carboxykinase [GTP]   pckG               
68,258  
        +     + + +     
sp|A0PPA8|PYRG_MYCUA CTP synthase   pyrG               
63,933  
        +       + + +   
sp|A0PPZ7|LEUD_MYCUA 3-isopropylmalate dehydratase small subunit   leuD               
21,889  
            + + + +     
sp|A0PQT2|PSA_MYCUA Proteasome subunit alpha   prcA               
29,315  
        +         + + + 
sp|A0PQT3|PSB_MYCUA Proteasome subunit beta   prcB               
30,284  
                + + + + 
sp|A0PT52|DUT_MYCUA Deoxyuridine 5~-triphosphate nucleotidohydrolase   dut               
15,779  
        +       + +   + 
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sp|A0PTS1|THIC_MYCUA Phosphomethylpyrimidine synthase   thiC               
59,865  
        +     +   +   + 
sp|A0PUI6|GLGB_MYCUA 1,4-alpha-glucan branching enzyme  glgB               
81,651  
              + + +   + 
sp|A0PUX3|ACDH2_MYCUA Acetaldehyde dehydrogenase 2   MUL_4096               
32,366  
              + + +   + 
sp|A0PVE6|LEU1_MYCUA 2-isopropylmalate synthase   leuA               
62,362  
              + + + +   
sp|A0PVN7|G6PI_MYCUA Glucose-6-phosphate isomerase   pgi               
60,309  
                + + + + 
sp|A0PVW4|Y4520_MYCUA Putative O-methyltransferase    MUL_4520               
23,104  
    +   +   +         + 
tr|A0PL08|A0PL08_MYCUA Conserved protein   MUL_0292               
34,839  
  +   +     +         + 
tr|A0PLB3|A0PLB3_MYCUA Phosphoribosylformylglycinamidine cyclo-ligase   purM               
41,149  
              + + +   + 
tr|A0PLR0|A0PLR0_MYCUA Conserved hypothetical secreted protein   MUL_0607               
26,685  
    +       + +       + 
tr|A0PLU3|A0PLU3_MYCUA 1,4-dihydroxy-2-naphthoyl-CoA synthase   menB               
33,553  
    +   +         +   + 
tr|A0PM09|A0PM09_MYCUA Methoxy mycolic acid synthase 4, MmaA4   mmaA4               
36,379  
              + + +   + 
tr|A0PM77|A0PM77_MYCUA 5-S ribosomal protein L5   rplE               
21,301  
  + +       +         + 
tr|A0PMK6|A0PMK6_MYCUA 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-
succinyltransferase   
dapD               
32,217  
              + + +   + 
tr|A0PMN1|A0PMN1_MYCUA Short-chain type dehydrogenase/reductase   MUL_0987               
26,320  
      +       +   +   + 
tr|A0PN32|A0PN32_MYCUA Succinate dehydrogenase (Iron-sulfur subunit), 
SdhA_1   
sdhA_1               
70,885  
        +       + +   + 
tr|A0PNE3|A0PNE3_MYCUA Acetyl/propionyl-CoA carboxylase (Beta subunit) 
AccD6   
accD6               
50,456  
        +       + +   + 
tr|A0PNG2|A0PNG2_MYCUA Conserved protein   MUL_1323               
27,116  
    +   +     +       + 
tr|A0PNJ6|A0PNJ6_MYCUA Succinate dehydrogenase flavoprotein subunit   sdhA               
64,621  
    +   +           + + 
tr|A0PNK5|A0PNK5_MYCUA Superoxide dismutase [Cu-Zn]   sodC               
23,817  
+   +       +   +       
tr|A0PNP9|A0PNP9_MYCUA Exported protein   MUL_1435               
12,091  
    + + +             + 
tr|A0PNY3|A0PNY3_MYCUA Lipoprotein, LprL   lprL               
23,293  
    + + +             + 
tr|A0PNZ9|A0PNZ9_MYCUA Inv protein   MUL_1557               
27,394  
              + + +   + 
tr|A0PP74|A0PP74_MYCUA Arginine biosynthesis bifunctional protein ArgJ   argJ               
41,568  
    +   +         +   + 
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tr|A0PPS6|A0PPS6_MYCUA Ribonucleoside-diphosphate reductase subunit beta   nrdF2               
36,915  
        +     +   +   + 
tr|A0PPX7|A0PPX7_MYCUA Conserved lipoprotein LppZ   lppZ               
40,729  
    +       + +       + 
tr|A0PQ97|A0PQ97_MYCUA 4-hydroxy-3-methylbut-2-en-1-yl diphosphate 
synthase (flavodoxin)   
ispG               
38,417  
        +       + +   + 
tr|A0PQG6|A0PQG6_MYCUA Alanine rich hydrolase   MUL_2177               
26,790  
        +     + + +     
tr|A0PQS2|A0PQS2_MYCUA Uncharacterized protein   MUL_2320               
80,620  
      + +   +         + 
tr|A0PQW7|A0PQW7_MYCUA Conserved protein   MUL_2372               
18,291  
+   +             +   + 
tr|A0PQW8|A0PQW8_MYCUA Conserved protein   MUL_2373               
49,087  
              + + +   + 
tr|A0PR01|A0PR01_MYCUA Conserved protein   MUL_2418               
15,786  
        +       + +   + 
tr|A0PR60|A0PR60_MYCUA Uncharacterized protein   MUL_2484               
41,883  
              + + +   + 
tr|A0PRG4|A0PRG4_MYCUA Phosphomannomutase PmmA   pmmA               
49,055  
+             + + +     
tr|A0PRN4|A0PRN4_MYCUA Probable allantoicase   alc               
35,001  
              + + +   + 
tr|A0PRW9|A0PRW9_MYCUA Aminotransferase (Adenosylmethionine-8-amino-7-
oxononanoate) BioA   
MUL_2791               
49,347  
    +   +         +   + 
tr|A0PT46|A0PT46_MYCUA TRK system potassium uptake protein CeoB   ceoB               
24,274  
        +     +   +   + 
tr|A0PT47|A0PT47_MYCUA TRK system potassium uptake protein CeoC   ceoC               
23,776  
              + + +   + 
tr|A0PT56|A0PT56_MYCUA Extragenic suppressor protein SuhB   suhB               
29,865  
              + + +   + 
tr|A0PT77|A0PT77_MYCUA Conserved transmembrane alanine and glycine rich 
protein   
MUL_3364               
80,737  
        +   + +       + 
tr|A0PTB8|A0PTB8_MYCUA Acyl-CoA dehydrogenase FadE22   fadE22               
76,939  
              + + +   + 
tr|A0PU29|A0PU29_MYCUA Pyruvate:ferredoxin oxidoreductase, PorA, alpha 
subunit   
porA               
69,300  
+       +         +   + 
tr|A0PU65|A0PU65_MYCUA Acyl-CoA dehydrogenase FadE19   fadE19               
41,338  
        +   + +       + 
tr|A0PU68|A0PU68_MYCUA Succinyl-CoA:3-ketoacid-coenzyme a transferase 
(Alpha subunit) ScoA   
scoA               
26,452  
        +     +   +   + 
tr|A0PUI4|A0PUI4_MYCUA Alpha-1,4 glucan phosphorylase   glgP               
95,902  
        +     +     + + 
tr|A0PV11|A0PV11_MYCUA 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate 
hydrolase  
bphD               
32,621  
  +           +   +   + 
tr|A0PV31|A0PV31_MYCUA Conserved hypothetical lipoprotein  lpqE               
19,491  
    +   +         +   + 
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tr|A0PVF3|A0PVF3_MYCUA Nucleoid-associated protein MUL_4307               
14,545  
              + + +   + 
tr|A0PVG1|A0PVG1_MYCUA Conserved transcriptional regulator   MUL_4316               
46,774  
              + + +   + 
tr|A0PX24|A0PX24_MYCUA Superoxide dismutase [fe]  sodA               
23,182  
        +       + +   + 
sp|A0PMV4|ILVD_MYCUA Dihydroxy-acid dehydratase   ilvD               
59,046  
  + +                 + 
sp|A0PP79|ASSY_MYCUA Argininosuccinate synthase   argG               
44,032  
                  + + + 
sp|A0PPI8|PYRB_MYCUA Aspartate carbamoyltransferase   pyrB               
33,817  
              + +     + 
sp|A0PQC5|RBFA_MYCUA Ribosome-binding factor A   rbfA               
18,524  
              +   +   + 
sp|A0PQZ6|RF2_MYCUA Peptide chain release factor 2   prfB               
41,587  
        +         +   + 
sp|A0PR79|Y2505_MYCUA UPF-182 protein MUL_2505             
108,179  
    +       +         + 
sp|A0PSH1|SECA2_MYCUA Protein translocase subunit secA2               
88,166  
                + +   + 
sp|A0PX17|PHEA_MYCUA Prephenate dehydratase   pheA               
32,977  
                + +   + 
tr|A0PKG6|A0PKG6_MYCUA Oxidoreductase   MUL_0062               
29,343  
  +           +       + 
tr|A0PLD3|A0PLD3_MYCUA Acyl-[acyl-carrier protein] desaturase DesA1   desA1               
39,062  
      +           +   + 
tr|A0PLE7|A0PLE7_MYCUA Conserved membrane protein   MUL_0462               
24,791  
      + +             + 
tr|A0PLH3|A0PLH3_MYCUA Adenylosuccinate lyase   purB               
51,340  
                + +   + 
tr|A0PLU0|A0PLU0_MYCUA Conserved protein   MUL_0645               
15,204  
+ +                   + 
tr|A0PMG0|A0PMG0_MYCUA Inosine-5~-monophosphate dehydrogenase   guaB2               
55,587  
                + + +   
tr|A0PMT3|A0PMT3_MYCUA Conserved protein   MUL_1057               
16,748  
        +       + +     
tr|A0PMX5|A0PMX5_MYCUA Conserved protein   MUL_1107               
35,834  
              +   +   + 
tr|A0PN77|A0PN77_MYCUA Conserved protein   MUL_1221               
17,452  
        +     +   +     
tr|A0PND4|A0PND4_MYCUA Zinc-dependent alcohol dehydrogenase AdhE2   adhE2               
38,410  
                + + +   
tr|A0PNR0|A0PNR0_MYCUA Uncharacterized protein   MUL_1447               
77,804  
              +   +   + 
tr|A0PNZ1|A0PNZ1_MYCUA Conserved protein   MUL_1549               
18,401  
        +         +   + 
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tr|A0PPE6|A0PPE6_MYCUA Peptidyl-prolyl cis-trans isomerase B PpiB   ppiB               
34,288  
    +           +     + 
tr|A0PPL5|A0PPL5_MYCUA Riboflavin synthase alpha chain RibC   ribC               
21,976  
      +       +       + 
tr|A0PQ43|A0PQ43_MYCUA Thioesterase TesA   tesA               
27,755  
        +     +   +     
tr|A0PQV7|A0PQV7_MYCUA Monophosphatase CysQ   cysQ               
28,578  
  +   +         +       
tr|A0PRA0|A0PRA0_MYCUA Uncharacterized protein   MUL_2526               
32,914  
              + +     + 
tr|A0PRF1|A0PRF1_MYCUA Two component sensory transduction transcriptional 
regulatory protein MtrA   
mtrA               
25,278  
              + + +     
tr|A0PRI6|A0PRI6_MYCUA N5-carboxyaminoimidazole ribonucleotide mutase   purE               
17,609  
              + + +     
tr|A0PRU8|A0PRU8_MYCUA Conserved protein   MUL_2763               
21,686  
      + +             + 
tr|A0PSE5|A0PSE5_MYCUA Probable phosphoketolase   xfp               
89,506  
  +           +       + 
tr|A0PSH6|A0PSH6_MYCUA Glycine cleavage system H protein   gcvH               
14,216  
    +   +         +     
tr|A0PSI1|A0PSI1_MYCUA Glycine dehydrogenase (decarboxylating)   gcvB             
101,046  
              + +     + 
tr|A0PSK6|A0PSK6_MYCUA Conserved protein   MUL_3081               
32,460  
+                 +   + 
tr|A0PSN6|A0PSN6_MYCUA Uncharacterized protein   MUL_3118               
15,040  
        +         +   + 
tr|A0PSP9|A0PSP9_MYCUA Uncharacterized protein   MUL_3142               
14,401  
              +   +   + 
tr|A0PST4|A0PST4_MYCUA Uncharacterized protein   MUL_3184               
14,193  
              +   +   + 
tr|A0PT57|A0PT57_MYCUA Polyphosphate glucokinase PpgK   ppgK               
27,438  
        +         +   + 
tr|A0PTB9|A0PTB9_MYCUA Short-chain type dehydrogenase/reductase   MUL_3412               
26,310  
+               +     + 
tr|A0PTI4|A0PTI4_MYCUA Cell division protein FtsZ   ftsZ               
39,357  
        +           + + 
tr|A0PTI9|A0PTI9_MYCUA UDP-N-acetylmuramoylalanine--D-glutamate ligase   murD               
50,303  
    +           +     + 
tr|A0PTJ2|A0PTJ2_MYCUA UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-
diaminopimelate ligase   
murE               
57,764  
              + + +     
tr|A0PTK4|A0PTK4_MYCUA Conserved regulatory protein   MUL_3518               
14,593  
    + + +               
tr|A0PTV9|A0PTV9_MYCUA Acyl-[acyl-carrier protein] desaturase DesA1_1   desA1_1               
39,159  
    + + +               
tr|A0PU22|A0PU22_MYCUA Valine--tRNA ligase   valS               
98,459  
                +   + + 
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tr|A0PU23|A0PU23_MYCUA Conserved protein   MUL_3720               
21,844  
        +   +       +   
tr|A0PUL7|A0PUL7_MYCUA Diaminopimelate decarboxylase   lysA               
50,726  
                + +   + 
tr|A0PUY6|A0PUY6_MYCUA Short-chain type dehydrogenase/reductase   MUL_4110               
30,497  
        +       +     + 
tr|A0PV65|A0PV65_MYCUA Hypoxanthine-guanine phosphoribosyltransferase  hpt               
22,430  
                + +   + 
tr|A0PVV9|A0PVV9_MYCUA Iron-sulfur cluster carrier protein   mrp               
40,775  
        +         +   + 
tr|A0PW61|A0PW61_MYCUA Ribose-phosphate pyrophosphokinase   prsA               
35,779  
      +           +   + 
tr|A0PWU4|A0PWU4_MYCUA Conserved membrane protein   MUL_4926               
25,430  
    +   +             + 
sp|A0PM08|RL1_MYCUA 5-S ribosomal protein L1   rplA               
24,798  
                    + + 
sp|A0PM40|RS7_MYCUA 3-S ribosomal protein S7   rpsG               
17,604  
    +                 + 
sp|A0PM62|RS10_MYCUA 3-S ribosomal protein S1-   rpsJ               
11,467  
                    + + 
sp|A0PM82|RS5_MYCUA 3-S ribosomal protein S5   rpsE               
22,978  
    +                 + 
sp|A0PMD2|RS9_MYCUA 3-S ribosomal protein S9   rpsI               
16,953  
                    + + 
sp|A0PME7|TSAD_MYCUA tRNA N6-adenosine threonylcarbamoyltransferase   tsaD               
35,254  
                + +     
sp|A0PP15|HIS8_MYCUA Histidinol-phosphate aminotransferase   hisC               
40,820  
    +   +               
sp|A0PPE4|APT_MYCUA Adenine phosphoribosyltransferase   apt               
19,019  
        +       +       
sp|A0PPG6|SYA_MYCUA Alanine--tRNA ligase   alaS               
96,452  
+                     + 
sp|A0PPZ6|LEUC_MYCUA 3-isopropylmalate dehydratase large subunit   leuC               
50,797  
              +       + 
sp|A0PQB8|SYP_MYCUA Proline--tRNA ligase   proS               
63,588  
                  + +   
sp|A0PQF8|DAPB_MYCUA 4-hydroxy-tetrahydrodipicolinate reductase   dapB               
25,678  
                  +   + 
sp|A0PQS8|TATA_MYCUA Sec-independent protein translocase protein TatA   tatA                 
9,514  
                  +   + 
sp|A0PQT9|ARC_MYCUA Proteasome-associated ATPase   mpa               
67,672  
                  + +   
sp|A0PRE5|SECA1_MYCUA Protein translocase subunit secA1             
106,317  
                  +   + 
sp|A0PSY4|Y3246_MYCUA Probable transcriptional regulatory protein  MUL_3246               
26,855  
        +             + 
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sp|A0PT74|NRDR_MYCUA Transcriptional repressor  nrdR               
17,514  
        +   +           
sp|A0PUK3|ATPFD_MYCUA ATP synthase subunit b-delta   atpFH               
47,798  
    +                 + 
sp|A0PUK4|ATPF_MYCUA ATP synthase subunit b   atpF               
18,145  
    +                 + 
sp|A0PV26|Y4155_MYCUA Uncharacterized tRNA/rRNA methyltransferase  MUL_4155               
32,592  
    +   +               
sp|A0PVW7|GLGC_MYCUA Glucose-1-phosphate adenylyltransferase   glgC               
43,800  
              +       + 
sp|A0PWH2|MSRA_MYCUA Peptide methionine sulfoxide reductase  msrA               
19,307  
              +       + 
tr|A0PKG4|A0PKG4_MYCUA Transcriptional regulatory protein   MUL_0058               
17,938  
    +                 + 
tr|A0PKR2|A0PKR2_MYCUA Conserved protein   MUL_0178               
28,132  
    + +                 
tr|A0PKX2|A0PKX2_MYCUA Conserved protein   MUL_0253               
10,083  
              +       + 
tr|A0PL93|A0PL93_MYCUA 5-methyltetrahydrofolate--homocysteine 
methyltransferase 
metH             
140,369  
                    + + 
tr|A0PLF0|A0PLF0_MYCUA Conserved protein   MUL_0465               
14,848  
        +         +     
tr|A0PLG4|A0PLG4_MYCUA Phosphoribosylamine--glycine ligase   purD               
43,513  
        +       +       
tr|A0PLH7|A0PLH7_MYCUA Aldehyde dehydrogenase   MUL_0494               
55,276  
                    + + 
tr|A0PLY3|A0PLY3_MYCUA Uncharacterized protein   MUL_0695               
30,003  
      +               + 
tr|A0PLY7|A0PLY7_MYCUA Conserved lipoprotein, LpqN   lpqN               
23,327  
    +   +               
tr|A0PM02|A0PM02_MYCUA UPF-336 protein MUL_-72-   MUL_0720               
17,452  
        +             + 
tr|A0PM22|A0PM22_MYCUA Dioxygenase   MUL_0744               
55,377  
        +             + 
tr|A0PMI8|A0PMI8_MYCUA Pyrroline-5-carboxylate dehydrogenase, RocA   rocA               
60,427  
                  +   + 
tr|A0PMJ7|A0PMJ7_MYCUA Fatty-acid-CoA synthetase, FadD36   fadD36               
49,799  
    +                 + 
tr|A0PML5|A0PML5_MYCUA Conserved protein   MUL_0962                 
7,944  
                    + + 
tr|A0PMV9|A0PMV9_MYCUA Zinc metalloprotease   MUL_1088               
74,362  
              +   +     
tr|A0PN28|A0PN28_MYCUA Acyl-CoA dehydrogenase FadE5   fadE5               
67,478  
        +             + 
tr|A0PNK4|A0PNK4_MYCUA Tuberculin related peptide   MUL_1378               
16,991  
    +           +       
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tr|A0PNN4|A0PNN4_MYCUA Conserved secreted protein   MUL_1413               
17,125  
        +             + 
tr|A0PNS1|A0PNS1_MYCUA Cysteine synthase   cysK1               
32,529  
              +   +     
tr|A0PNU4|A0PNU4_MYCUA 3-oxoacyl-[acyl-carrier protein] reductase, FabG1   fabG1               
26,740  
            +         + 
tr|A0PP14|A0PP14_MYCUA Histidinol dehydrogenase   hisD               
46,498  
        +             + 
tr|A0PP86|A0PP86_MYCUA Conserved protein   MUL_1661                 
8,678  
              +   +     
tr|A0PPH5|A0PPH5_MYCUA Cytoplasmic peptidase PepQ   pQ               
39,280  
    +   +               
tr|A0PPJ2|A0PPJ2_MYCUA Carbamoyl-phosphate synthase large chain   carB             
120,537  
                    + + 
tr|A0PPJ6|A0PPJ6_MYCUA DNA-directed RNA polymerase subunit omega   rpoZ               
11,889  
              +       + 
tr|A0PPL2|A0PPL2_MYCUA Bifunctional riboflavin biosynthesis protein RibG   ribG               
35,479  
        +             + 
tr|A0PPP4|A0PPP4_MYCUA Glucose-6-phosphate 1-dehydrogenase   zwf2               
57,829  
                  +   + 
tr|A0PPQ2|A0PPQ2_MYCUA Quinone reductase Qor   qor               
34,559  
                +     + 
tr|A0PPS7|A0PPS7_MYCUA Conserved protein   MUL_1884               
12,046  
                  +   + 
tr|A0PPS8|A0PPS8_MYCUA NADP-dependent alcohol dehydrogenase Adh   adh               
37,642  
                    + + 
tr|A0PPU3|A0PPU3_MYCUA Conserved membrane protein   MUL_1902               
32,626  
                  +   + 
tr|A0PQ50|A0PQ50_MYCUA Conserved protein   MUL_2032               
25,370  
                +     + 
tr|A0PQA1|A0PQA1_MYCUA Methionine aminopeptidase   mapB               
30,007  
                  +   + 
tr|A0PQI4|A0PQI4_MYCUA Conserved protein   MUL_2202               
20,798  
        +             + 
tr|A0PQU9|A0PQU9_MYCUA ATP phosphoribosyltransferase   hisG               
30,986  
                    + + 
tr|A0PQV9|A0PQV9_MYCUA Conserved protein   MUL_2364               
21,476  
                  +   + 
tr|A0PR15|A0PR15_MYCUA Acyl-CoA dehydrogenase FadE23   fadE23               
43,486  
                    + + 
tr|A0PR83|A0PR83_MYCUA Conserved protein   MUL_2509                 
7,980  
        +             + 
tr|A0PRB9|A0PRB9_MYCUA RNA polymerase sigma factor   sigH               
24,486  
        +     +         
tr|A0PRD9|A0PRD9_MYCUA Oxidoreductase   MUL_2566               
41,590  
        +             + 
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tr|A0PRG2|A0PRG2_MYCUA Mannose-6-phosphate isomerase ManA   manA               
43,777  
              +   +     
tr|A0PRH8|A0PRH8_MYCUA Metal cation-transporting p-type ATPase C CtpC   ctpC               
78,050  
                  + +   
tr|A0PRI5|A0PRI5_MYCUA Acyl-CoA dehydrogenase FadE25   fadE25               
41,693  
                    + + 
tr|A0PRJ1|A0PRJ1_MYCUA Propionyl-CoA carboxylase beta chain 5 AccD5   accD5               
59,201  
                  +   + 
tr|A0PS21|A0PS21_MYCUA Nitroreductase   MUL_2854               
24,165  
                  +   + 
tr|A0PSD8|A0PSD8_MYCUA Conserved protein   MUL_3004               
14,548  
    +                 + 
tr|A0PSG9|A0PSG9_MYCUA Inosine-5~-monophosphate dehydrogenase GuaB1   guaB1               
50,021  
                +     + 
tr|A0PSY8|A0PSY8_MYCUA Pyridoxal 5~-phosphate synthase subunit PdxS   snzP               
33,506  
                    + + 
tr|A0PSZ3|A0PSZ3_MYCUA Conserved protein   MUL_3255               
21,330  
    +                 + 
tr|A0PT23|A0PT23_MYCUA Conserved secreted protein   MUL_3300               
10,810  
        +             + 
tr|A0PT30|A0PT30_MYCUA Uncharacterized protein   MUL_3308               
16,701  
                    + + 
tr|A0PT32|A0PT32_MYCUA Uncharacterized protein   MUL_3310               
26,551  
        +     +         
tr|A0PT49|A0PT49_MYCUA Uncharacterized protein   MUL_3332               
13,681  
    +                 + 
tr|A0PTA0|A0PTA0_MYCUA Conserved protein   MUL_3391               
11,026  
              +   +     
tr|A0PTJ1|A0PTJ1_MYCUA UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-
alanine ligase   
murF               
53,267  
        +             + 
tr|A0PTZ1|A0PTZ1_MYCUA Acyl-CoA dehydrogenase FadE17_1   fadE17_1               
42,670  
                  +   + 
tr|A0PTZ2|A0PTZ2_MYCUA Acyl-CoA dehydrogenase FadE18_2   fadE18_2               
39,884  
                +     + 
tr|A0PU42|A0PU42_MYCUA Conserved protein   MUL_3743               
15,924  
        +             + 
tr|A0PU51|A0PU51_MYCUA ATP-binding component of an ABC transporter   MUL_3757               
62,006  
                    + + 
tr|A0PU63|A0PU63_MYCUA Citrate (Pro-3s)-lyase (Beta subunit) CitE   citE               
29,199  
        +     +         
tr|A0PUL3|A0PUL3_MYCUA Transcription termination factor  rho               
66,924  
        +             + 
tr|A0PUV9|A0PUV9_MYCUA Coenzyme F42--dependent oxidoreductase   MUL_4079               
37,385  
            +         + 
tr|A0PUY8|A0PUY8_MYCUA Enoyl-CoA hydratase  echA20               
26,523  
                  +   + 
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tr|A0PV12|A0PV12_MYCUA Acyl-CoA dehydrogenase   MUL_4141               
43,407  
              +       + 
tr|A0PV33|A0PV33_MYCUA Conserved membrane protein   MUL_4163               
28,172  
                    + + 
tr|A0PV84|A0PV84_MYCUA DNA topoisomerase 1   topA             
102,190  
                +     + 
tr|A0PVB8|A0PVB8_MYCUA Cysteine synthase  cysK               
40,215  
                +     + 
tr|A0PVX5|A0PVX5_MYCUA Mycolic acid synthase  umaA               
33,175  
                +     + 
tr|A0PW65|A0PW65_MYCUA 5-S ribosomal protein L25   rplY               
22,291  
                  +   + 
tr|A0PW73|A0PW73_MYCUA Methionine--tRNA ligase   metS               
58,138  
                  +   + 
tr|A0PWB2|A0PWB2_MYCUA Serine protease PepD   pD               
47,713  
    +   +               
tr|A0PWE2|A0PWE2_MYCUA NAD(P) transhydrogenase (Subunit alpha) pntAa               
37,380  
              +       + 
tr|A0PWW3|A0PWW3_MYCU
A 
Acyl-CoA dehydrogenase fadE25_2               
43,856  
                  +   + 
tr|A0PWY2|A0PWY2_MYCUA Oxidoreductase   MUL_4969               
50,322  
                    + + 
tr|A0PWY5|A0PWY5_MYCUA Integral membrane indolylacetylinositol 
arabinosyltransferase EmbC   
embC             
117,057  
    +                 + 
tr|A0PWZ5|A0PWZ5_MYCUA Secreted Mpt51/Mpb51 antigen protein  fbpD               
31,450  
    +       +           
tr|A0PX27|A0PX27_MYCUA Conserved protein   MUL_5021               
14,911  
          +         +   
tr|A0PX31|A0PX31_MYCUA 4-hydroxy-4-methyl-2-oxoglutarate aldolase   menG               
17,036  
                +     + 
tr|A0PRM0|A0PRM0_MYCUA Dihydrolipoamide dehydrogenase LpdA   lpdA               
49,398  
              
 
+     + 
tr|A0PX64|A0PX64_MYCUA Chromosome partitioning protein  parB               
34,820  
                  +   + 
sp|A0PKQ3|ISPH_MYCUA 4-hydroxy-3-methylbut-2-enyl diphosphate reductase   ispH               
36,180  
                      + 
sp|A0PL16|KDC_MYCUA Alpha-keto-acid decarboxylase   kdc               
60,573  
                      + 
sp|A0PM07|RL11_MYCUA 5-S ribosomal protein L11   rplK               
14,995  
                      + 
sp|A0PM63|RL3_MYCUA 5-S ribosomal protein L3   rplC               
23,079  
                      + 
sp|A0PM64|RL4_MYCUA 5-S ribosomal protein L4   rplD               
23,846  
                      + 
sp|A0PM66|RL2_MYCUA 5-S ribosomal protein L2   rplB               
30,397  
                      + 
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sp|A0PM68|RL22_MYCUA 5-S ribosomal protein L22   rplV               
18,639  
                      + 
sp|A0PM72|RS17_MYCUA 3-S ribosomal protein S17   rpsQ               
13,118  
                      + 
sp|A0PM75|RL14_MYCUA 5-S ribosomal protein L14   rplN               
13,490  
                      + 
sp|A0PM79|RS8_MYCUA 3-S ribosomal protein S8   rpsH               
14,384  
                      + 
sp|A0PM80|RL6_MYCUA 5-S ribosomal protein L6   rplF               
19,446  
                      + 
sp|A0PMB2|IF1_MYCUA Translation initiation factor IF-1   infA                 
8,484  
                      + 
sp|A0PMB5|RS11_MYCUA 3-S ribosomal protein S11   rpsK               
14,677  
                    +   
sp|A0PMB8|RL17_MYCUA 5-S ribosomal protein L17   rplQ               
20,241  
                      + 
sp|A0PNM3|RSKA_MYCUA Anti-sigma-K factor  rskA               
23,947  
                      + 
sp|A0PNM4|SIGK_MYCUA ECF RNA polymerase sigma factor  sigK               
21,047  
                      + 
sp|A0PP77|OTC_MYCUA Ornithine carbamoyltransferase   argF               
33,559  
                      + 
sp|A0PP80|ARLY_MYCUA Argininosuccinate lyase   argH               
49,865  
                  +     
sp|A0PPE8|SYH_MYCUA Histidine--tRNA ligase   hisS               
45,401  
                      + 
sp|A0PPH0|AROC_MYCUA Chorismate synthase   aroC               
42,593  
                      + 
sp|A0PPL7|RISB_MYCUA 6,7-dimethyl-8-ribityllumazine synthase   ribH               
16,562  
                      + 
sp|A0PPN8|CAPP_MYCUA Phosphoenolpyruvate carboxylase   ppc             
102,948  
                    +   
sp|A0PPY8|SYE_MYCUA Glutamate--tRNA ligase   gltX               
53,800  
                    +   
sp|A0PQ63|RS16_MYCUA 3-S ribosomal protein S16   rpsP               
17,388  
                    +   
sp|A0PQ65|RIMM_MYCUA Ribosome maturation factor RimM   rimM               
18,666  
                      + 
sp|A0PQT1|PAFA_MYCUA Pup--protein ligase   pafA               
51,656  
                      + 
sp|A0PQT4|PUP_MYCUA Prokaryotic ubiquitin-like protein Pup   pup                 
6,938  
                      + 
sp|A0PST9|GABD2_MYCUA Putative succinate-semialdehyde dehydrogenase 
[NADP(+)] 2   
gabD2               
55,601  
                      + 
sp|A0PSZ4|SYT_MYCUA Threonine--tRNA ligase   thrS               
77,372  
                      + 
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sp|A0PT34|DCUP_MYCUA Uroporphyrinogen decarboxylase   hemE               
37,641  
                      + 
sp|A0PTI7|MURG_MYCUA UDP-N-acetylglucosamine--N-acetylmuramyl-
(pentapeptide) pyrophosphoryl-undecaprenol N-
acetylglucosamine transferase   
murG               
41,112  
                      + 
sp|A0PTM6|TRPD_MYCUA Anthranilate phosphoribosyltransferase   trpD               
37,916  
    +                   
sp|A0PU04|PROA_MYCUA Gamma-glutamyl phosphate reductase   proA               
44,564  
                      + 
sp|A0PU16|RL27_MYCUA 5-S ribosomal protein L27   rpmA                 
9,262  
                      + 
sp|A0PUK1|ATPG_MYCUA ATP synthase gamma chain   atpG               
33,807  
                      + 
sp|A0PUL1|RF1_MYCUA Peptide chain release factor 1   prfA               
39,183  
                    +   
sp|A0PUX2|HOA2_MYCUA 4-hydroxy-2-oxovalerate aldolase 2   MUL_4095               
37,034  
                      + 
sp|A0PV57|GCH1_MYCUA GTP cyclohydrolase 1   folE               
22,373  
                      + 
sp|A0PVF2|RECR_MYCUA Recombination protein  recR               
22,422  
                    +   
sp|A0PVN0|PATR_MYCUA Putative phenylalanine aminotransferase   pat               
38,792  
                      + 
sp|A0PVZ3|GPMA_MYCUA 2,3-bisphosphoglycerate-dependent phosphoglycerate 
mutase   
gpmA               
27,517  
                      + 
sp|A0PWB4|MPRA_MYCUA Response regulator  mprA               
26,082  
                      + 
sp|A0PWC5|PUR9_MYCUA Bifunctional purine biosynthesis protein  purH               
55,888  
                      + 
sp|A0PX13|SYS_MYCUA Serine--tRNA ligase   serS               
45,411  
                    +   
sp|A0PX66|RSMG_MYCUA Ribosomal RNA small subunit methyltransferase G   rsmG               
18,550  
+                       
tr|A0PKB6|A0PKB6_MYCUA DNA gyrase subunit B   gyrB               
76,192  
                      + 
tr|A0PKB8|A0PKB8_MYCUA Conserved hypothetical membrane protein   MUL_0007               
34,475  
                      + 
tr|A0PKC7|A0PKC7_MYCUA Serine/threonine-protein kinase  pknB               
66,663  
                      + 
tr|A0PKC8|A0PKC8_MYCUA Serine/threonine-protein kinase a pknA               
48,122  
                      + 
tr|A0PKG8|A0PKG8_MYCUA Myo-inositol-1-phosphate synthase  ino1               
40,455  
                      + 
tr|A0PKK3|A0PKK3_MYCUA Membrane oxidoreductase   MUL_0111               
24,066  
                      + 
tr|A0PKL5|A0PKL5_MYCUA Conserved secreted protein   MUL_0125               
32,401  
                      + 
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tr|A0PKP8|A0PKP8_MYCUA Uncharacterized protein   MUL_0161                 
6,582  
                      + 
tr|A0PKT3|A0PKT3_MYCUA Cystathionine gamma-synthase (Cgs)   metB               
40,812  
                +       
tr|A0PKT8|A0PKT8_MYCUA Beta-ketoacyl CoA thiolase fadA3               
42,647  
                    +   
tr|A0PKW8|A0PKW8_MYCUA Two component response transcriptional regulatory 
protein   
prrA               
25,345  
    +                   
tr|A0PKW9|A0PKW9_MYCUA Two component sensor histidine kinase  prrB               
48,143  
                      + 
tr|A0PKY8|A0PKY8_MYCUA Conserved protein   MUL_0272               
17,092  
    +                   
tr|A0PL04|A0PL04_MYCUA Uncharacterized protein   MUL_0288               
79,259  
+                       
tr|A0PL13|A0PL13_MYCUA Aminotransferase   MUL_0297               
42,487  
+                       
tr|A0PL56|A0PL56_MYCUA Nitrate/nitrite response regulator protein narL               
22,946  
                      + 
tr|A0PLB4|A0PLB4_MYCUA Uncharacterized protein   MUL_0419                 
6,842  
                      + 
tr|A0PLB9|A0PLB9_MYCUA Amino acid aminotransferase, PabC   pabC               
31,641  
                      + 
tr|A0PLC3|A0PLC3_MYCUA Sulfurtransferase   cysA2               
30,992  
                    +   
tr|A0PLC8|A0PLC8_MYCUA Phosphate-binding protein PstS   phoS3               
38,040  
                      + 
tr|A0PLD1|A0PLD1_MYCUA Phosphate-specific transport system accessory protein 
PhoU   
phoY2               
24,811  
                      + 
tr|A0PLE8|A0PLE8_MYCUA Two component system response phosphate regulon 
transcriptional regulator, PhoP   
phoP               
26,624  
                      + 
tr|A0PLH8|A0PLH8_MYCUA Zn-dependent alcohol dehydrogenase, AdhX   adhX               
37,427  
                      + 
tr|A0PLK5|A0PLK5_MYCUA Transcriptional regulatory protein   MUL_0525               
29,087  
                      + 
tr|A0PLQ3|A0PLQ3_MYCUA Chaperone protein DnaJ   dnaJ               
41,980  
                      + 
tr|A0PLQ4|A0PLQ4_MYCUA Heat shock protein transcriptional repressor HspR 
(MerR family)   
hspR               
17,919  
                      + 
tr|A0PLR5|A0PLR5_MYCUA Metal cation-transporting p-type ATPase F, CtpF   ctpF               
95,259  
                      + 
tr|A0PLS2|A0PLS2_MYCUA Thioredoxin protein (Thiol-disulfide interchange 
protein)   
MUL_0625               
22,255  
                      + 
tr|A0PLT2|A0PLT2_MYCUA Conserved membrane protein   MUL_0636               
58,025  
                      + 
tr|A0PLX0|A0PLX0_MYCUA Carveol-like dehydrogenase   MUL_0676               
28,560  
                      + 
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tr|A0PM00|A0PM00_MYCUA Conserved protein   MUL_0716                 
7,719  
                  +     
tr|A0PM03|A0PM03_MYCUA Conserved protein   MUL_0721               
14,939  
                  +     
tr|A0PM04|A0PM04_MYCUA UPF-336 protein MUL_-722   MUL_0722               
18,729  
                      + 
tr|A0PM23|A0PM23_MYCUA Ribonucleotide-transport ATP-binding protein ABC 
transporter, Mkl   
mkl               
35,958  
                      + 
tr|A0PM29|A0PM29_MYCUA Acyl-CoA dehydrogenase   MUL_0753               
60,570  
                      + 
tr|A0PM50|A0PM50_MYCUA L-lactate dehydrogenase (Cytochrome) LldD1   lldD1               
41,754  
                      + 
tr|A0PM53|A0PM53_MYCUA Dehydrogenase   MUL_0777               
50,131  
+                       
tr|A0PMA4|A0PMA4_MYCUA 3-hydroxyisobutyrate dehydrogenase   mmsB               
29,908  
                      + 
tr|A0PMA5|A0PMA5_MYCUA Acyl-CoA dehydrogenase, FadE9   fadE9               
42,005  
                      + 
tr|A0PMA6|A0PMA6_MYCUA Methylmalonate semialdehyde dehydrogenase, 
MmsA   
mmsA               
54,540  
                      + 
tr|A0PMA7|A0PMA7_MYCUA Transmembrane carbohydrate transport protein   MUL_0838               
54,635  
                      + 
tr|A0PME0|A0PME0_MYCUA Bifunctional NAD(P)H-hydrate repair enzyme   MUL_0877               
47,352  
                      + 
tr|A0PMG1|A0PMG1_MYCUA Inosine-5~-monophosphate (Imp) dehydrogenase, 
GuaB3   
guaB3               
39,161  
                    +   
tr|A0PMG3|A0PMG3_MYCUA Cholesterol oxidase ChoD   choD               
63,613  
                      + 
tr|A0PMG4|A0PMG4_MYCUA Taurine catabolism dioxygenase, TauD   tauD               
32,954  
                      + 
tr|A0PMN5|A0PMN5_MYCUA Uncharacterized protein   MUL_0991               
23,508  
                      + 
tr|A0PMQ2|A0PMQ2_MYCUA GTP-binding translation elongation factor TypA   typA               
67,700  
                      + 
tr|A0PMQ3|A0PMQ3_MYCUA Conserved lipoprotein LpqW   lpqW               
65,762  
                      + 
tr|A0PMU3|A0PMU3_MYCUA Conserved Mce associated membrane protein   MUL_1068               
23,932  
                      + 
tr|A0PMU4|A0PMU4_MYCUA Conserved Mce associated transmembrane protein   MUL_1069               
36,358  
                      + 
tr|A0PMV7|A0PMV7_MYCUA Conserved secretory protein   MUL_1085               
35,000  
                  +     
tr|A0PMW6|A0PMW6_MYCU
A 
Conserved transmembrane transport protein MmpL3   mmpL3             
102,249  
                      + 
tr|A0PMY5|A0PMY5_MYCUA Enoyl-CoA hydratase   MUL_1121               
27,804  
                      + 
Appendices 
 
199 
 
tr|A0PMZ0|A0PMZ0_MYCUA Conserved membrane protein   MUL_1126               
45,652  
                      + 
tr|A0PN04|A0PN04_MYCUA Uncharacterized protein   MUL_1143               
40,512  
                      + 
tr|A0PN22|A0PN22_MYCUA Conserved lipoprotein LpqI   lpqI               
40,921  
                      + 
tr|A0PN25|A0PN25_MYCUA Conserved membrane protein   MUL_1165               
30,535  
                      + 
tr|A0PN31|A0PN31_MYCUA Succinate dehydrogenase (Iron-sulfur subunit), 
SdhB_1   
sdhB_1               
29,224  
                      + 
tr|A0PN36|A0PN36_MYCUA PEP phosphonomutase   MUL_1177               
24,225  
                    +   
tr|A0PN42|A0PN42_MYCUA Aminoglycoside 2~-N-acetyltransferase Aac   aac               
19,730  
                      + 
tr|A0PN60|A0PN60_MYCUA Conserved protein   MUL_1204               
67,212  
        +               
tr|A0PN62|A0PN62_MYCUA Conserved membrane protein   MUL_1206             
146,221  
                      + 
tr|A0PN68|A0PN68_MYCUA Conserved transmembrane protein   MUL_1212               
48,008  
    +                   
tr|A0PN94|A0PN94_MYCUA Ornithine aminotransferase RocD1 and RocD2   rocD               
43,609  
                      + 
tr|A0PNA3|A0PNA3_MYCUA Uncharacterized protein   MUL_1253               
10,727  
                      + 
tr|A0PNB7|A0PNB7_MYCUA Conserved ion transport protein   MUL_1269               
27,124  
                      + 
tr|A0PNE1|A0PNE1_MYCUA Glycerol-3-phosphate dehydrogenase   glpD1               
53,856  
                      + 
tr|A0PNE4|A0PNE4_MYCUA 3-oxoacyl-[acyl-carrier protein] synthase 2 KasB   kasB               
44,322  
                      + 
tr|A0PNE5|A0PNE5_MYCUA 3-oxoacyl-[acyl-carrier protein] synthase 1 KasA   kasA               
43,767  
                    +   
tr|A0PNF1|A0PNF1_MYCUA Conserved protein   MUL_1310               
16,087  
                      + 
tr|A0PNH0|A0PNH0_MYCUA Glutamine synthetase GlnA2   glnA2               
49,925  
                      + 
tr|A0PNJ7|A0PNJ7_MYCUA Succinate dehydrogenase (Iron-sulphur protein 
subunit) SdhB   
sdhB               
30,377  
                      + 
tr|A0PNL0|A0PNL0_MYCUA Conserved ATPase   MUL_1384               
75,402  
                  +     
tr|A0PNN6|A0PNN6_MYCUA Aldehyde dehydrogenase   MUL_1416               
54,879  
                      + 
tr|A0PNV7|A0PNV7_MYCUA Methylmalonyl-CoA mutase small subunit, MutA   mutA               
65,842  
                      + 
tr|A0PNX6|A0PNX6_MYCUA Isoleucine--tRNA ligase   ileS             
119,774  
                      + 
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tr|A0PNZ4|A0PNZ4_MYCUA tR-family transcriptional regulator   MUL_1552               
45,521  
                      + 
tr|A0PNZ7|A0PNZ7_MYCUA Glycogen operon protein GlgX homolog   treX               
81,708  
                    +   
tr|A0PP12|A0PP12_MYCUA Nicotinate-nucleotide pyrophosphatase NadC   nadC               
30,353  
                      + 
tr|A0PP29|A0PP29_MYCUA Tryptophan synthase beta chain   trpB               
45,305  
                  +     
tr|A0PP53|A0PP53_MYCUA Conserved protein   MUL_1621               
24,212  
                      + 
tr|A0PP66|A0PP66_MYCUA Phenylalanine--tRNA ligase alpha subunit   pheS               
38,290  
                      + 
tr|A0PPH3|A0PPH3_MYCUA 3-dehydroquinate dehydratase   aroD               
15,724  
                      + 
tr|A0PPI9|A0PPI9_MYCUA Dihydroorotase   pyrC               
45,643  
                      + 
tr|A0PPJ7|A0PPJ7_MYCUA DNA/pantothenate metabolism flavoprotein Dfp-like 
protein   
dfp               
43,532  
                      + 
tr|A0PPM5|A0PPM5_MYCUA Diacylglycerol O-acyltransferase   MUL_1818               
50,650  
                      + 
tr|A0PPM6|A0PPM6_MYCUA Esterase LipO   lipO               
46,841  
                      + 
tr|A0PPP2|A0PPP2_MYCUA 6-phosphogluconolactonase DevB   devB               
26,031  
                      + 
tr|A0PPR5|A0PPR5_MYCUA Acyl-CoA dehydrogenase FadE15   fadE15               
65,944  
                  +     
tr|A0PPU1|A0PPU1_MYCUA Uncharacterized protein   MUL_1900               
36,300  
                      + 
tr|A0PPX5|A0PPX5_MYCUA ATP-dependent 6-phosphofructokinase   pfkA               
37,505  
                      + 
tr|A0PPY1|A0PPY1_MYCUA Acetolactate synthase   ilvB1               
66,321  
                      + 
tr|A0PPZ0|A0PPZ0_MYCUA Uncharacterized protein   MUL_1961               
34,074  
                      + 
tr|A0PQ13|A0PQ13_MYCUA Lipase/esterase LipN   lipN               
39,538  
                      + 
tr|A0PQ14|A0PQ14_MYCUA Conserved membrane protein   MUL_1990               
27,351  
                      + 
tr|A0PQ48|A0PQ48_MYCUA Ribonuclease 3   rnc               
25,546  
              +         
tr|A0PQ58|A0PQ58_MYCUA Transmembrane serine/threonine-protein kinase I 
PknI   
pknI               
63,079  
        +               
tr|A0PQ59|A0PQ59_MYCUA D-amino acid aminohydrolase   MUL_2043               
65,449  
                      + 
tr|A0PQ64|A0PQ64_MYCUA UPF-1-9 protein MUL_2-48   MUL_2048                 
8,550  
                    +   
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tr|A0PQ69|A0PQ69_MYCUA Sial peptidase I   lepB               
31,116  
                      + 
tr|A0PQ82|A0PQ82_MYCUA Transcriptional regulatory protein   MUL_2070               
15,209  
                      + 
tr|A0PQC2|A0PQC2_MYCUA Transcription termination/antitermination protein 
NusA   
nusA               
37,962  
                      + 
tr|A0PQF0|A0PQF0_MYCUA Alanine dehydrogenase   ald               
38,841  
                      + 
tr|A0PQF2|A0PQF2_MYCUA Conserved protein   MUL_2156               
16,847  
                      + 
tr|A0PQF3|A0PQF3_MYCUA Uncharacterized protein   MUL_2157               
34,685  
                      + 
tr|A0PQG3|A0PQG3_MYCUA Short-chain type dehydrogenase/reductase   MUL_2173               
26,980  
                      + 
tr|A0PQG9|A0PQG9_MYCUA Uncharacterized protein   MUL_2180               
44,434  
                +       
tr|A0PQH0|A0PQH0_MYCUA Flavin-dependent thymidylate synthase   thyX               
28,029  
                      + 
tr|A0PQI2|A0PQI2_MYCUA Membrane-anchored serine/threonine-protein kinase   MUL_2200               
69,796  
                      + 
tr|A0PQJ7|A0PQJ7_MYCUA Conserved protein   MUL_2228                 
8,206  
                      + 
tr|A0PQK2|A0PQK2_MYCUA Conserved membrane protein   MUL_2234               
31,306  
                      + 
tr|A0PQK3|A0PQK3_MYCUA Conserved hypothetical transmembrane protein   MUL_2236               
31,076  
                      + 
tr|A0PQM7|A0PQM7_MYCUA Polyketide synthase, Pks12   pks12             
435,681  
                  +     
tr|A0PQM9|A0PQM9_MYCUA RNA polymerase-binding protein RbpA   rbpA               
12,978  
                    +   
tr|A0PQN4|A0PQN4_MYCUA Uncharacterized protein   MUL_2272               
25,016  
                      + 
tr|A0PQQ8|A0PQQ8_MYCUA Conserved protein   MUL_2300               
15,038  
                      + 
tr|A0PQY5|A0PQY5_MYCUA Conserved protein   MUL_2397               
30,827  
                      + 
tr|A0PQZ3|A0PQZ3_MYCUA Cell division ATP-binding protein FtsE   ftsE               
25,551  
                      + 
tr|A0PR14|A0PR14_MYCUA Acyl-CoA dehydrogenase FadE24   fadE24               
49,921  
                      + 
tr|A0PR16|A0PR16_MYCUA Acetolactate synthase (Large subunit) IlvB1_1   ilvB1_1               
59,867  
                      + 
tr|A0PR42|A0PR42_MYCUA NADH dehydrogenase I (Chain E) NuoE (NADH-
ubiquinone oxidoreductase chain E)   
nuoE               
26,882  
                      + 
tr|A0PR44|A0PR44_MYCUA NADH-quinone oxidoreductase   nuoG               
86,004  
                      + 
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tr|A0PR92|A0PR92_MYCUA NADH pyrophosphatase NudC   nudC               
33,972  
                      + 
tr|A0PRA9|A0PRA9_MYCUA Soj/ParA-related protein   MUL_2535               
28,483  
                      + 
tr|A0PRB2|A0PRB2_MYCUA Acetyltransferase   MUL_2538               
17,967  
                  +     
tr|A0PRI7|A0PRI7_MYCUA N5-carboxyaminoimidazole ribonucleotide synthase   purK               
45,453  
                      + 
tr|A0PRJ8|A0PRJ8_MYCUA Transcriptional regulatory protein   MUL_2639               
20,468  
                      + 
tr|A0PRK4|A0PRK4_MYCUA L-lysine-epsilon aminotransferase Lat   lat               
49,115  
                      + 
tr|A0PRK6|A0PRK6_MYCUA Uncharacterized protein   MUL_2646               
45,323  
                      + 
tr|A0PRL9|A0PRL9_MYCUA Glycerol-3-phosphate dehydrogenase   glpD2               
63,453  
                      + 
tr|A0PRN5|A0PRN5_MYCUA Uncharacterized protein   MUL_2683               
45,973  
                      + 
tr|A0PRP8|A0PRP8_MYCUA Ferredoxin FdxC_1   fdxC_1               
12,256  
                      + 
tr|A0PRT5|A0PRT5_MYCUA Uncharacterized protein   MUL_2745               
34,861  
                      + 
tr|A0PRT7|A0PRT7_MYCUA Rubredoxin   rubB_1                 
7,166  
                      + 
tr|A0PRV7|A0PRV7_MYCUA Conserved membrane protein   MUL_2774             
103,875  
                      + 
tr|A0PRY1|A0PRY1_MYCUA Thiamine biosynthesis oxidoreductase ThiO   thiO               
36,321  
                      + 
tr|A0PRY9|A0PRY9_MYCUA F42--dependent glucose-6-phosphate dehydrogenase   fgd1               
37,346  
                    +   
tr|A0PS18|A0PS18_MYCUA Methyltransferase   MUL_2851               
21,754  
    +                   
tr|A0PS73|A0PS73_MYCUA Acyl-CoA ligase FadD31   fadD31               
66,615  
                      + 
tr|A0PS78|A0PS78_MYCUA Conserved membrane protein   MUL_2927               
15,853  
                      + 
tr|A0PS94|A0PS94_MYCUA Conserved protein   MUL_2948               
16,647  
                      + 
tr|A0PS97|A0PS97_MYCUA Conserved protein   MUL_2952               
27,434  
                      + 
tr|A0PSD0|A0PSD0_MYCUA Conserved protein   MUL_2996               
16,057  
                      + 
tr|A0PSD5|A0PSD5_MYCUA Trehalose synthase TreS_1   treS_1               
50,481  
                      + 
tr|A0PSD6|A0PSD6_MYCUA L-lactate dehydrogenase (Cytochrome) LldD2   lldD2               
45,716  
                      + 
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tr|A0PSD7|A0PSD7_MYCUA Lon protease   lon               
83,054  
+                       
tr|A0PSF6|A0PSF6_MYCUA Oxidoreductase   MUL_3023               
23,419  
                      + 
tr|A0PSF8|A0PSF8_MYCUA NADH dehydrogenase Ndh   ndh               
49,713  
                      + 
tr|A0PSG8|A0PSG8_MYCUA 6-phosphogluconate dehydrogenase, decarboxylating   gnd1               
51,617  
                      + 
tr|A0PSH0|A0PSH0_MYCUA Acetolactate synthase IlvG   ilvG               
58,723  
                +       
tr|A0PSH5|A0PSH5_MYCUA Conserved protein   MUL_3044               
31,113  
      +                 
tr|A0PSI7|A0PSI7_MYCUA Drug-transport transmembrane ATP-binding protein 
ABC transporter   
MUL_3059               
71,515  
                      + 
tr|A0PSK3|A0PSK3_MYCUA Conserved membrane protein   MUL_3078               
44,109  
                      + 
tr|A0PSK4|A0PSK4_MYCUA Proline rich membrane-anchored mycosin MycP5   mycP5               
59,861  
                      + 
tr|A0PSK5|A0PSK5_MYCUA Conserved membrane protein   MUL_3080               
53,739  
                      + 
tr|A0PSL7|A0PSL7_MYCUA Conserved FtsK/SpoIIIE family protein   MUL_3092             
152,935  
                      + 
tr|A0PSL8|A0PSL8_MYCUA Conserved membrane protein   MUL_3093               
54,256  
                      + 
tr|A0PSN9|A0PSN9_MYCUA Conserved membrane protein   MUL_3123               
43,535  
    +                   
tr|A0PSP7|A0PSP7_MYCUA Conserved short-chain dehydrogenase   MUL_3139               
26,968  
                      + 
tr|A0PSQ6|A0PSQ6_MYCUA Conserved transmembrane ATP-binding protein ABC 
transporter   
MUL_3149               
94,399  
                      + 
tr|A0PST8|A0PST8_MYCUA Conserved secreted protein   MUL_3189               
40,246  
                      + 
tr|A0PSV4|A0PSV4_MYCUA Conserved hypothetical secreted protein   MUL_3206               
11,746  
                      + 
tr|A0PSW2|A0PSW2_MYCUA Uncharacterized protein   MUL_3215               
45,901  
                    +   
tr|A0PSX6|A0PSX6_MYCUA Uncharacterized protein   MUL_3236               
30,476  
                    +   
tr|A0PSX7|A0PSX7_MYCUA ATPase involved in chromosome partitioning (Soj 
family)   
MUL_3237               
34,626  
                      + 
tr|A0PSY7|A0PSY7_MYCUA Acyl-CoA thioesterase II TesB2   tesB2               
31,180  
                      + 
tr|A0PT02|A0PT02_MYCUA Methyltransferase   MUL_3266               
29,225  
                      + 
tr|A0PT03|A0PT03_MYCUA Uncharacterized protein   MUL_3267               
31,478  
                      + 
Appendices 
 
204 
 
tr|A0PT07|A0PT07_MYCUA Uncharacterized protein   MUL_3275               
40,702  
                      + 
tr|A0PT08|A0PT08_MYCUA Uncharacterized protein   MUL_3276               
46,326  
                      + 
tr|A0PT58|A0PT58_MYCUA RNA polymerase sigma factor SigA   sigA               
54,770  
                      + 
tr|A0PTA2|A0PTA2_MYCUA S-adenosyl-L-methionine-dependent 
methyltransferase   
MUL_3393               
33,396  
                      + 
tr|A0PTE8|A0PTE8_MYCUA Citrate lyase beta subunit, CitE_2   citE_2               
33,483  
                    +   
tr|A0PTF8|A0PTF8_MYCUA Conserved hypothetical regulatory protein   MUL_3464               
28,429  
+                       
tr|A0PTI3|A0PTI3_MYCUA Laccase domain protein   yfiH               
27,284  
                      + 
tr|A0PTI5|A0PTI5_MYCUA Cell division protein FtsQ   ftsQ               
34,052  
    +                   
tr|A0PTL3|A0PTL3_MYCUA Phospho-2-dehydro-3-deoxyheptonate aldolase   aroG_1               
50,792  
                      + 
tr|A0PTM2|A0PTM2_MYCUA Long-chain-fatty-acid-CoA ligase FadD15   fadD15               
64,981  
                      + 
tr|A0PTM8|A0PTM8_MYCUA Ubiquinol-cytochrome C reductase QcrC   qcrC               
31,724  
                      + 
tr|A0PTN6|A0PTN6_MYCUA Carbohydrate kinase CbhK   cbhK               
34,581  
                +       
tr|A0PTU1|A0PTU1_MYCUA Chaperone protein DnaJ   dnaJ               
40,546  
                      + 
tr|A0PTW0|A0PTW0_MYCUA Uncharacterized protein   MUL_3647               
27,486  
                      + 
tr|A0PU11|A0PU11_MYCUA Glutamine-dependent NAD(+) synthetase NadE   nadE               
75,250  
                    +   
tr|A0PU18|A0PU18_MYCUA Ribonuclease E Rne   rne             
107,016  
                      + 
tr|A0PU21|A0PU21_MYCUA Folylpolyglutamate synthase protein FolC   folC               
50,574  
    +                   
tr|A0PU64|A0PU64_MYCUA Conserved protein   MUL_3777               
18,475  
                      + 
tr|A0PU67|A0PU67_MYCUA Succinyl-CoA:3-ketoacid-coenzyme a transferase 
(Beta subunit) ScoB   
scoB               
22,810  
                      + 
tr|A0PU73|A0PU73_MYCUA Short-chain type dehydrogenase/reductase   MUL_3788               
27,946  
                      + 
tr|A0PU87|A0PU87_MYCUA Uncharacterized protein   MUL_3808               
32,112  
                      + 
tr|A0PU99|A0PU99_MYCUA Conserved protein   MUL_3824               
16,542  
                      + 
tr|A0PUH9|A0PUH9_MYCUA L-aminopeptidase/D-esterase  dmpA               
36,076  
                      + 
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tr|A0PUJ5|A0PUJ5_MYCUA Methylated-DNA--protein-cysteine methyltransferase   ogt               
18,870  
                      + 
tr|A0PUN8|A0PUN8_MYCUA Bifunctional enzyme CysN/CysC: sulfate 
adenyltransferase (Subunit 1) + adenylylsulfate kinase   
cysN               
68,118  
                      + 
tr|A0PUP5|A0PUP5_MYCUA Periplasmic oligopeptide-binding lipoprotein oppA               
58,506  
                      + 
tr|A0PUR2|A0PUR2_MYCUA Conserved dehydratase   MUL_4022               
19,434  
                      + 
tr|A0PUR3|A0PUR3_MYCUA Acetyl-CoA hydrolase/transferase   MUL_4023               
48,810  
                      + 
tr|A0PUT2|A0PUT2_MYCUA Conserved hypothetical membrane protein   MUL_4047               
29,411  
                      + 
tr|A0PUU9|A0PUU9_MYCUA Acyl-CoA dehydrogenase  fadE26               
43,147  
                      + 
tr|A0PUV0|A0PUV0_MYCUA Acyl-CoA dehydrogenase  fadE27               
38,143  
                      + 
tr|A0PUV6|A0PUV6_MYCUA Enoyl-CoA hydratase  echA19               
30,844  
                      + 
tr|A0PUV7|A0PUV7_MYCUA Cytochrome P45- 142A3  cyp142A3               
45,699  
                      + 
tr|A0PUY4|A0PUY4_MYCUA Acetyl-CoA acetyltransferase fadA5               
41,692  
                      + 
tr|A0PV02|A0PV02_MYCUA Aminotransferase   aspB               
42,310  
                      + 
tr|A0PV10|A0PV10_MYCUA Biphenyl-2,3-diol 1,2-dioxygenase  bphC               
33,469  
                      + 
tr|A0PV34|A0PV34_MYCUA Carbonic anhydrase   MUL_4164               
21,665  
                      + 
tr|A0PV46|A0PV46_MYCUA Iron-regulated Lsr2 protein   lsr2               
12,058  
                      + 
tr|A0PV52|A0PV52_MYCUA Conserved transmembrane protein rich in alanine, 
arginine and proline   
MUL_4186               
48,876  
    +                   
tr|A0PVA0|A0PVA0_MYCUA Periplasmic dipeptide-binding lipoprotein  dppA               
63,047  
                      + 
tr|A0PVB3|A0PVB3_MYCUA Anion transporter ATPase   MUL_4254               
35,857  
                      + 
tr|A0PVC6|A0PVC6_MYCUA Conserved protein   MUL_4274               
40,878  
                      + 
tr|A0PVC7|A0PVC7_MYCUA Methanol dehydrogenase transcriptional regulatory 
protein   
moxR2               
34,730  
                      + 
tr|A0PVD9|A0PVD9_MYCUA Catalase  katE               
54,733  
                      + 
tr|A0PVG3|A0PVG3_MYCUA Enoyl-CoA hydratase echA3_1               
26,842  
                      + 
tr|A0PVJ5|A0PVJ5_MYCUA Hydrolase   MUL_4362               
46,438  
                      + 
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tr|A0PVP2|A0PVP2_MYCUA Conserved hypothetical membrane protein   MUL_4424               
35,550  
                      + 
tr|A0PVP3|A0PVP3_MYCUA Monooxygenase   MUL_4425               
43,272  
                      + 
tr|A0PVU8|A0PVU8_MYCUA Short-chain type dehydrogenase/reductase   MUL_4501               
29,189  
                      + 
tr|A0PVX2|A0PVX2_MYCUA Uncharacterized protein   MUL_4535               
30,615  
        +               
tr|A0PVY4|A0PVY4_MYCUA Conserved membrane protein   MUL_4547               
31,360  
                      + 
tr|A0PW30|A0PW30_MYCUA Uroporphyrin-III C-methyltransferase  hemD               
58,223  
                      + 
tr|A0PW31|A0PW31_MYCUA Delta-aminolevulinic acid dehydratase   hemB               
34,758  
                      + 
tr|A0PW68|A0PW68_MYCUA Polyketide synthase  pks16               
58,698  
                      + 
tr|A0PWC4|A0PWC4_MYCUA Maesium chelatase   MUL_4711               
50,070  
                  +     
tr|A0PWD0|A0PWD0_MYCUA Succinate--CoA ligase [ADP-forming] subunit alpha   sucD               
30,861  
                  +     
tr|A0PWE6|A0PWE6_MYCUA Uncharacterized protein   MUL_4741               
14,001  
                      + 
tr|A0PWG1|A0PWG1_MYCUA Aldehyde dehydrogenase   MUL_4760               
53,568  
                      + 
tr|A0PWH4|A0PWH4_MYCUA Conserved protein   MUL_4776                 
7,280  
                      + 
tr|A0PWJ6|A0PWJ6_MYCUA Oxalyl-CoA decarboxylase  oxcA               
61,579  
                      + 
tr|A0PWL2|A0PWL2_MYCUA Conserved protein   MUL_4825                 
7,507  
                      + 
tr|A0PWL3|A0PWL3_MYCUA Cation-transporter ATPase I  ctpI             
167,322  
                      + 
tr|A0PWP0|A0PWP0_MYCUA Non-ribosomal peptide synthetase   MUL_4858             
151,086  
+                       
tr|A0PWU3|A0PWU3_MYCUA ATP-binding protein ABC transporter   MUL_4925               
34,435  
                      + 
tr|A0PWU5|A0PWU5_MYCUA Conserved protein   MUL_4927               
19,240  
                      + 
tr|A0PWU7|A0PWU7_MYCUA Glutamate decarboxylase   MUL_4929               
53,095  
                      + 
tr|A0PWV1|A0PWV1_MYCUA Conserved protein   MUL_4933               
43,937  
                      + 
tr|A0PWW7|A0PWW7_MYCU
A 
Transcriptional regulator   MUL_4952               
17,588  
                      + 
tr|A0PX38|A0PX38_MYCUA Uncharacterized protein   MUL_5033               
32,463  
                      + 
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tr|A0PX42|A0PX42_MYCUA Ferredoxin-dependent glutamate synthase [NADPH] 
(Large subunit)  
gltB             
166,373  
                      + 
tr|A0PX57|A0PX57_MYCUA Conserved transmembrane protein   MUL_5063             
122,123  
            +           
 
tr|Q6MZ99|Q6MZ99_MYCUA 
 
Possible chromosome partitioning protein 
 
parA  
        
34,828  
                      + 
 
 
 
Appendices 
 
208 
 
Appendix C 
 
Table C- 1 and Table C 2comprise of the large datasets that were obtained from the ROC analysis of crude protein preparations and 
partially purified recombinants proteins.  
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Table C-1: ROC analysis of culture preparations.   
 
BU_EC 
        
Antigen AUC CI 95% Cut-off Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
Batch A 0.740 0.5348 - 0.9452 > 1.175 40 12.16% - 73.76% 95 75.13% - 99.87% 8.0 
Batch B 0.500 0.2689 - 0.7311 > 1.296 20 2.521% - 55.61% 95 75.13% - 99.87% 4.0 
Batch C 0.635 0.4171 - 0.8529 > 0.7130 40 12.16% - 73.76% 85 62.11% - 96.79% 2.7 
Batch D 0.910 0.7863 - 1.034 > 0.9930 90 55.50% - 99.75% 95 75.13% - 99.87% 18.0 
Batch E 0.885 0.7655 - 1.004 > 1.170 40 12.16% - 73.76% 95 75.13% - 99.87% 8.0 
Batch F 0.515 0.2889 - 0.7411 > 0.6760 70 34.75% - 93.33% 50 27.20% - 72.80% 1.4 
Batch G 0.655 0.4608 - 0.8492 < 0.8905 90 55.50% - 99.75% 60 36.05% - 80.88% 2.3 
Batch H 0.505 0.2757 - 0.7343 > 1.369 20 2.521% - 55.61% 95 75.13% - 99.87% 4.0 
M. smegmatis 0.825 0.6645 - 0.9855 > 1.430 50 18.71% - 81.29% 95 75.13% - 99.87% 10.0 
Mu homogenate 0.705 0.4780 - 0.9325 > 1.410 50 18.71% - 81.29% 94.74 73.97% - 99.87% 9.5 
BU_NEC 
        
Antigen AUC CI 95% Cut-off Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
Batch A 0.87 0.7271 - 1.017 > 1.105 50 18.71% - 81.29% 94.44 72.71% - 99.86% 9 
Batch B 0.91 0.8010 - 1.009 > 0.8750 50 18.71% - 81.29% 95 75.13% - 99.87% 10 
Batch C 0.57 0.3454 - 0.7846 > 0.7175 40 12.16% - 73.76% 80 56.34% - 94.27% 2 
Batch D 0.93 0.8306 - 1.033 > 0.9725 90 55.50% - 99.75% 94.74 73.97% - 99.87% 17.1 
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Batch E 0.9 0.7839 - 1.016 > 1.076 80 44.39% - 97.48% 89.47 66.86% - 98.70% 7.6 
Batch F 0.8 0.6027 - 0.9917 > 0.8360 50 18.71% - 81.29% 94.44 72.71% - 99.86% 9 
Batch G 0.52 0.3104 - 0.7317 < 1.037 100 69.15% - 100.0% 31.58 12.58% - 56.55% 1.462 
Batch H 0.69 0.4938 - 0.8862 > 1.190 30 6.674% - 65.25% 95 75.13% - 99.87% 6 
M. smegmatis 0.85 0.7062 - 0.9885 > 1.232 70 34.75% - 93.33% 89.47 66.86% - 98.70% 6.65 
Mu homogenate 0.81 0.6426 - 0.9674 > 1.318 70 34.75% - 93.33% 90 68.30% - 98.77% 7 
EC_NEC 
        
Antigen AUC CI 95% Cut-off Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
Batch A 0.81 0.6581 - 0.9586 > 0.9160 45 23.06% - 68.47% 88.89 65.29% - 98.62% 4.05 
Batch B 0.91 0.8100 - 1.000 > 0.8925 50 27.20% - 72.80% 95 75.13% - 99.87% 10 
Batch C 0.54 0.3530 - 0.7220 < 0.2755 45 23.06% - 68.47% 75 50.90% - 91.34% 1.8 
Batch D 0.79 0.6339 - 0.9398 < 0.4965 57.89 33.50% - 79.75% 95 75.13% - 99.87% 11.58 
Batch E 0.69 0.5197 - 0.8645 < 0.5750 42.11 20.25% - 66.50% 95 75.13% - 99.87% 8.421 
Batch F 0.85 0.7278 - 0.9778 > 0.8385 40 19.12% - 63.95% 94.44 72.71% - 99.86% 7.2 
Batch G 0.57 0.3855 - 0.7566 < 0.4500 26.32 9.147% - 51.20% 90 68.30% - 98.77% 2.632 
Batch H 0.69 0.5187 - 0.8563 > 1.153 20 5.733% - 43.66% 95 75.13% - 99.87% 4 
M. smegmatis 0.63 0.4424 - 0.8102 > 0.7495 70 45.72% - 88.11% 63.16 38.36% - 83.71% 1.9 
Mu homogenate 0.72 0.5533 - 0.8835 > 1.215 47.37 24.45% - 71.14% 85 62.11% - 96.79% 3.158 
 
 
 
 
        
Appendices 
 
211 
 
BU+EC vrs NEC 
Antigen AUC CI 95% Cut-off Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
Batch A 0.83 0.6938 - 0.9655 < 0.5715 50 26.02% - 73.98% 96.67 82.78% - 99.92% 15 
Batch B 0.91 0.8144 - 0.9956 > 0.8750 50 31.30% - 68.70% 95 75.13% - 99.87% 10 
Batch C 0.5 0.3351 - 0.6716 < 0.2755 36.67 19.93% - 56.14% 75 50.90% - 91.34% 1.467 
Batch D 0.84 0.7073 - 0.9629 > 0.9410 43.33 25.46% - 62.57% 94.74 73.97% - 99.87% 8.233 
Batch E 0.57 0.3855 - 0.7566 > 1.264 10 1.235% - 31.70% 94.74 73.97% - 99.87% 1.9 
Batch F 0.83 0.7091 - 0.9594 > 0.8360 43.33 25.46% - 62.57% 94.44 72.71% - 99.86% 7.8 
Batch G 0.54 0.3580 - 0.7227 > 0.7465 66.67 47.19% - 82.71% 52.63 28.86% - 75.55% 1.407 
Batch H 0.69 0.5273 - 0.8494 > 1.153 23.33 9.934% - 42.28% 95 75.13% - 99.87% 4.667 
M. smegmatis 0.7 0.5400 - 0.8600 > 1.265 30 14.73% - 49.40% 89.47 66.86% - 98.70% 2.85 
Mu homogenate 0.76 0.6033 - 0.9090 > 1.318 40 22.66% - 59.40% 89.47 66.86% - 98.70% 3.8 
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Table C-2: ROC analysis of recombinants proteins. 
 
BU_EC 
        
Antigen AUC CI 95% Cut-off Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
Hsp65 0.88 0.7102 - 1.040 > 1.548 50 18.71% - 81.29% 95 75.13% - 99.87% 10 
MUP057 0.56 0.3337 - 0.7813 > 1.645 30 6.674% - 65.25% 85 62.11% - 96.79% 2 
MUL_2232 0.53 0.2707 - 0.7893 < 0.1470 30 6.674% - 65.25% 90 68.30% - 98.77% 3 
AT propionate 0.69 0.4970 - 0.8830 < 0.0325 30 6.674% - 65.25% 90 68.30% - 98.77% 3 
BU_NEC 
        
Antigen AUC CI 95% Cut-off Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
HSP65 0.99 0.9720 - 1.015 > 0.6278 100 69.15% - 100.0% 93.33 68.05% - 99.83% 15 
MUP057 0.79 0.5902 - 0.9965 > 1.322 50 18.71% - 81.29% 93.33 68.05% - 99.83% 7.5 
MUL_2232 0.53 0.2498 - 0.8169 < 0.1510 30 6.674% - 65.25% 93.33 68.05% - 99.83% 4.5 
AT propionate 0.51 0.2637 - 0.7629 > 1.190 30 6.674% - 65.25% 93.33 68.05% - 99.83% 4.5 
EC_NEC 
        
Antigen AUC CI 95% Cut-off Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
Hsp65 0.97 0.9235 - 1.016 > 0.6218 90 68.30% - 98.77% 93.33 68.05% - 99.83% 13.5 
MUP057 0.79 0.6463 - 0.9404 > 1.332 50 27.20% - 72.80% 93.33 68.05% - 99.83% 7.5 
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MUL_2232 0.6 0.4105 - 0.7895 > 1.578 35 15.39% - 59.22% 93.33 68.05% - 99.83% 5.25 
AT propionate 0.68 0.5022 - 0.8578 > 1.345 45 23.06% - 68.47% 93.33 68.05% - 99.83% 6.75 
 
BU+EC vrs NEC 
        
Antigen AUC CI 95% Cut-off Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
Hsp65 0.98 0.9437 - 1.012 > 0.6218 93.33 77.93% - 99.18% 93.33 68.05% - 99.83% 14 
MUP057 0.79 0.6610 - 0.9256 > 1.322 50 31.30% - 68.70% 93.33 68.05% - 99.83% 7.5 
MUL_2232 0.56 0.3896 - 0.7215 > 1.578 36.67 19.93% - 56.14% 93.33 68.05% - 99.83% 5.5 
ATP 0.62 0.4596-0.7893 > 1.190 40 22.66% - 59.40% 93.33 68.05% - 99.83% 6 
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Appendix D 
 
Appendix D is showing all Western blot images. 
 
Image A: Anti His-tagged peroxidase Western blot of post induced proteins. 
Lane L is showing BenchMark His-tagged standard. Lanes 1-4 are post-induced cell lysates of ATP, MUL_2232, MUP057 and Hsp65 
respectively. 
 
Image B: Anti His-tagged peroxidase Western blot of large-scale partially purified proteins. 
Lanes 1-4 are showing MUP057, Hsp6, MUL_2232 and ATP, respectively. No His-tagged standard was included in this Western blots as 
Image A has already confirmed presence of His-tagged proteins in all samples. There was visible smearing in MUP057 and Hsp65 lanes 
which might be due to protein fragmentation. Black arrows are pointing to protein bands on NC membrane. 10 µl of each partially purified 
sample was loaded into each lane to confirm presence of His-tagged proteins in the large-scale protein purification. 
 
Image C: Panel of Western blot immune-reactivity with recombinant proteins.  
The number below each NC is participant’s ID REF.  
Image C 1-10 are BU patients’ sera and C11-30 are healthy control sera from the same endemic region. Image C31-48 are non-endemic 
control sera from Tasmania. 9-10 µg of protein was loaded in each lane.  
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Appendix E 
 
1. One Health Approach to investigate Mycobacterium ulcerans Disease in Victoria. 
This work was conducted by me (Michael Selorm Avumegah). It comprised of literature 
review, proposed research design and preliminary results and discussion. It was 
submitted to Deakin Univeristy on 13th August, 2015 in fullfilment of Confirmation of 
Candidature requirement as PhD Student. 
 
2. Descriptive analysis in time and space of recorded data for Buruli Ulcer occurrence 
in Victoria over 22 years. 
This work was conducted by me (Michael Selorm Avumegah). This was a publication 
manuscript prepared from the Confirmation of candidature document and Chapter 3 of  
this PhD document. Preprint (non-peer reviewd version) of the manuscript was made 
available on the 10th of September, 2018 on  BioRxiv 
(doi: https://doi.org/10.1101/413542). 
 
3. The changing epidemiology worldwide of Mycobacterium ulcerans. 
This review article was not part of my PhD work. It was a review manuscript I 
contributed to as co-author during my PhD studies at Deakin univeristy. It was submitted 
to Epidemiology and Infection journal and was made available online 8th October 2018. 
(https://doi.org/10.1017/S0950268818002662). 
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 SUMMARY 
 
Diseases that plague humans come from diverse sources, as such finding solutions requires 
multi-disciplinary approach from diverse fields: epidemiology, microbiology, veterinary 
medicine, ecology, medicine, etc. Recognising that human health may be connected to animal 
health and environment, together this is called One Health concept. Bairnsdale ulcer is one 
such disease that calls for this approach. 
 Bairnsdale ulcer also called Buruli ulcer (BU) is a subcutaneous necrotic infection of the skin 
caused by Mycobacterium ulcerans (Mu). The pathogenesis of Mu is due to the 
immunosuppressive toxin-mycolactone. BU has been reported in the tropics, mainly in West 
Africa. Some cases are also found in the subtropics of Australia (e.g. Queensland) and also in 
temperate Australia, especially in the Bellarine Peninsula of Victoria, with sporadic cases in 
other temperate regions outside Australia. 
The exact mode of transmission is unknown, however more cases have been reported from 
areas close to wetlands. In the tropics aquatic bugs belonging to the families Belostomatidae 
and Naucoridae have been suggested as possible hosts whereas in Australia, possums and 
mosquitoes have been implicated as reservoir and vector respectively. 
Barwon Health BU data from 1998-2014 revealed sixteen (16) affected towns in the Bellarine 
Peninsula, the top five towns include: Point Lonsdale, Barwon Heads, Queenscliff, Ocean 
Grove and St. Leonards. July was the month of highest cases and 2012 the year that had more 
cases. The mean and median age of patients reporting cases were 53.6 and 57.5 years old 
respectively. 
In Victoria, BU is mainly found on the Bellarine Peninsula and cases have been increasing 
since 1998 in the region. For this reason we will study this area with the One Health approach 
to determine temporo-spatial pattern, level of susceptibility and precisely identify risk factors 
mediating the spread. A historical large database will be described by a geographic information 
system (GIS) and epidemiological analysis. Microbial cultures and a serological survey will be 
designed and undertaken on the human population, as environment sample will be studied as 
the same time. 
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CHAPTER 1- INTRODUCTION  
 
1.1-1   History and Epidemiology  
Buruli ulcer disease (BU) is a necrotizing infection of the skin caused by bacteria called 
Mycobacterium ulcerans (Mu) (Hayman, 1991). It has been reported in about 33 countries in 
the tropics and sub-tropics (WHO, 2003), with very few cases reported in temperate areas (Fig 
1) (Johnson et al., 1996). In the tropics, highest prevalence is in the West Africa regions, 
including countries like Ghana, Cote d’Ivoire, Benin and Nigeria among others. The disease is 
usually associated with the rural poor population, where access to medical facilities is limited 
and inadequate, and many people rely solely on alternative medicine.  The sub-tropical cases 
are mainly within the Queensland in Australia (Fig 2). Cases in the temperate regions include: 
temperate region in Australia (e.g. Victoria) (Fig 2). Some cases have also been reported in 
Asia and the Americas ( Zinsou,1995;Asiedu et al., 1998; Duker et al., 2006; Morris et al., 
2014).  
BU has been classified as an emerging neglected tropical disease (NTD) by WHO in 1997. 
NTDs are subdivision of infectious diseases in the tropics that burden the world’s poorest 
people, e.g. Yaws, Trachoma, Leprosy etc. Over the years, these diseases to a certain degree 
have been neglected by WHO, Funder and researchers, and more attention is given to diseases 
like Malaria, HIV/AIDS and other poverty reduction projects. (Feasey et al., 2010).  
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Figure 1-Distribution of Buruli ulcer worldwide 2011 (WHO, 2012). 
 
Ulcers with similar description like BU was observed and first reported by Cook in 1897 at 
Kampala, Uganda and by Klein Schmidt in North-East Congo during the 1920s (Meyers, 1995) 
but the causative agent was not fully described until 1948. MacCallum et al., were the first to 
describe and publish reported cases from Australia of skin ulcer caused by Mycobacterium 
cultivable only on Löwenstein-Jensen medium when the incubation temperature was set lower 
than for Mycobacterium tuberculosis (MacCallum et al., 1948). The Uganda Buruli Group gave 
the disease the name “Buruli ulcer” because the cases they describe were first detected in Buruli 
County in Kyoga, Uganda (Clancey et al., 1962). 
New focus of BU has been emerging in different areas since 1980s. Some recent foci include; 
Cameroon, Togo and Angola. Total reported cases of infection in West Africa has exceeded 
30,000 in the last 20 years (Rondini, 2005; WHO, 2000). A country wide survey in 1999 of 
BU infection in Ghana reported a prevalence rate of 20.7/100,000 which surpassed cases of 
leprosy in this region. A similar prevalence rate of 21.5/100,000 per year has been reported in 
Benin which is higher than cases of either tuberculosis or leprosy. In other endemic areas in 
Côte d’Ivoire and Ghana, prevalence rate have been as high as 16.3% and 22% in affected 
population respectively (Amofah et al., 2002; Debacker et al., 2004; Noeske et al., 2004). In 
Australia, though prevalence is low compared to cases in Africa, cases are steadily rising 
(Hughes et al., 2007; Vic Health, 2015)(Fig 2). 
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Australia reported it first case of the disease in Bairnsdale, area of East Gippsland in Victoria 
in the late 1930s, therefore the disease was referred to as Bairnsdale ulcer. Since then BU has 
gained public health interest and has been reported in different regions of Victoria (Fig 3, Table 
1) (MacCallum et al., 1948; Radford, 1975; Merritt et al., 2005). Later in the years the disease 
became more common in Cairns and suburbs in Queensland affecting both gender and different 
age groups (Table 1) (Radford, 1975). 
 
 
Figure 2-Map show cases of Buruli ulcer in Australia from 2004-2014: Graph shows the rise of buruli ulcer cases 
from 1940-2010 (Vic Health, 2015; WHO, 2015). 
 
Table 1-Distribution of Buruli ulcer in Australia as at 1975 
Sates Number of case Age (years) Gender 
M              F 
Victoria 3 
3 
5 
10 
2,13,26 
16,15,45 
10 
70 
3  
3 
New South Wales 1 40 1  
 
 
 
Queensland 
“several” 
1 
“8-10” 
8 
6 
 
21 
43,4 
53,61  
9,15,18,57,70 
11/2,6,19,35,59,66 
 
1 
      
      2 
 
       6 
 
 
2 
 
5 
 
Northern Territory  
4 
8 
13,16,18 
1  
3 
 
Table modified from (Radford, 1975) 
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In 1992-1994, there was a major outbreak in Victoria after several years of dormancy. Cases 
were reported from the Mornington Peninsula area, Western Port, Phillip Island and from the 
Bellarine Peninsula (Fig 3).  
Recently, Victoria and Queensland reported 157 and 75 cases in 2011-2012 respectively. 
(Johnson et al., 2007; Nielsen et al., 2013; Vic Health, 2015). The vastness of Australia and 
the selective dissemination of the disease raises a question as to whether there is a pattern in 
the disease spread. 
 
 
 
Figure 3 Google map image of likely areas of buruli ulcer infection in Victoria, Australia. Numbers in the red circles 
represents cases reported from that area (Vic Health, 2015) 
 
The Department of Health in Victoria within 2013-2014 (Fig. 2 &3) confirmed 163 cases 
which currently put the annual incidence rate at < 1 per 100,000 inhabitants in Australia,  
however in endemic regions this can be up to 100 times higher (Vic Health, 2015). In some 
countries in West Africa BU incidence has huge socioeconomic impact on the inhabitants 
(Asiedu et al., 1998). 
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1.1-2 Socioeconomic Burden of Buruli Ulcer Disease 
Buruli ulcer usually affects the rural poor in West Africa. These areas usually lack proper basic 
social infrastructure like proper road, hospitals and potable water. The inhabitants often are 
subsistent farmers growing crops to support their families and barely sell products for profit. 
The estimated cost of treating BU per patient in Ghana was $966.85 in 1994. In 1995 and 1996 
the cost reduced to $706.08 and $658.74 respectively. Due to a lack of proper social welfare 
programs system in rural areas in Africa, patients have to bear the full cost of treatment. This 
is an economic burden on an already impoverished rural population whose yearly per capita 
income is estimated to be $200.00 in 1996, and the average income for a farm laborer is less 
than $1.00 per day. Since many cannot afford the cost of treatment, they resort to alternative 
medicine. By the time the disease is reported to medical centres for proper care they had 
reached advance lesion stage and as such is difficult to manage.  
Complications such as vasculitis or osteomyelitis leads to contracture deformities or 
amputations. These complications imply that individual cannot work on their farms to feed 
their families as they used to 
Though the mortality rate is low, the morbidity in endemic areas cannot be overlooked. The 
long term impact of the infection leading to long hospitalization, results in disruption to the 
income stream of breadwinners and school attendance of affected children. (Zinsou, 1995; 
Asiedu et al., 1998). 
 
1.1-3 One Health Approach to Mitigate the Spread of Buruli Ulcer  
Current dynamics in infectious diseases have necessitated a multidisciplinary approach to 
solving them. Many of the infectious diseases that plague humans have a zoonotic origin e.g. 
haemorrhagic fever viruses, influenza, rabies and Bovine spongiform encephalopathy (BSE). 
In addition, the environments also harbours many harmful pathogens to humans and Mu is a 
classic example in this context. The impact of these infectious diseases has ripple effects on 
livestock production, wildlife and even food security. They also pose a biosecurity threat to 
many nations as terrorists can utilize them as biological weapons in time of conflicts. Therefore 
a holistic approach to tackling emerging infectious diseases must employ microbiology, 
veterinary medicine, human medicine, ecology, public health, epidemiology and sometimes 
biosecurity (GCEID ; Kahn et al., 2009). It is in this vein that we propose a multidisciplinary 
approach study regarding BU. 
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1.1-4 Application of Geographical information system in Buruli ulcer 
Large number of people are affected by vector-borne infection world-wide and often one 
approach epidemiologists take to understand the progression of the infection is developing risk 
maps ( Hay et al., 2006; Peterson et al.,  2006; Brooker et al., 2007). This helps to estimate 
geographically the risk based on the distribution of parasite, vector and reservoir taking into 
consideration the human population, social and behaviour structure of the area. Risk map 
generation has improved greatly with advancement in technology and with wide spread 
availability of computerized or digital environmental layers, ecological niche modelling tools 
and geographic information system (GIS). GIS is a tool used to analyse spatial and temporal 
trends in area of interest and to map. It is of great value in epidemiology in understanding 
disease outbreaks and controls. Such approaches have been used in predicting the geographic 
distribution of diseases like Chagas disease and leishmaniasis. This tool has also been use to 
understand vector and reservoir movement of dengue virus  and malaria (Peterson et al., 2005; 
2006; Brooker et al., 2007). 
There is no doubt that active surveillance is needed to understand the nature of transmission of 
Mu within Australia. Surveillance is the systematic progressive collection and collation of data 
and making sense out of them to the benefit of those who needs them. With the current spread 
of BU in Victoria, Australia, (Fig 2, 3) the current study will seek to explore GIS tools to map 
out the spatial distribution of BU cases to determine parameters that serve as risk factors. 
 
1.2-1 THE GENUS MYCOBACTERIUM  
 
Mycobacterium ulcerans belongs to the order-Actinomycetales, family-Mycobacteriaceae and 
genus-Mycobacterium (Draper,1971). An exemplar of this genus is Mycobacterium 
tuberculosis which was discovered in 1882 by Robert Koch before then it used to be referred 
to as tubercle bacillus. However  Mycobacterium leprae was the first genus member to be 
identified in this genus by Hansen in 1873 in Bergen, Norway (Barksdale et al., 1977; Kazda, 
2009).  
Mycobacteria in general are aerobic non-sporeformers. They are straight or slightly curved 
non- motile rods (approximately 0.2–0.6 µm wide by 1.0–10 µm long). The genus contains 
more than 170 species. The optimum growth condition varies considerably, ranging from pH 
4.6 -7.4 and temperature 32o - 37o. There are two main characteristics that stand out when 
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describing this genus, firstly, they are slow growers with generation time ranging from 2 hours 
for Mycobacterium smegmatis to 24 hours for M. tuberculosis. The second characteristic is the 
nature of the cell wall. Mycobacteria cell walls are composed of mycolic acid, these are 60-90 
carbon long chain fatty acid esters which gives bacterium a waxy appearance and behaviour. 
Mycolic acid cell walls tend to clump together when they form colonies and are difficult to 
stain though they are known to be Gram positive (Draper, 1971). Bacteria designated Gram 
positive usually appear purple-violet after Gram staining as a result of the retention of the 
crystal violet dye in the cell membrane even after rinsing with ethanol (Madigan et al., 2012. 
Brock Biology of Microorganisms, page 54, 13th Ed.).  Mycobacteria are also designated by 
the name acid fast bacillus (AFB) a property conferred by the presence of mycolic acid. Acid-
fastness is the ability of an organism to form acid-stable complexes with some arylmethane 
dyes. AFB are all group of organisms resistant to acid and alcohol during staining procedure 
(Draper, 1971; Portaels, 1982). 
The genus is of great medical importance both in humans (e.g. M. tuberculosis, Mu) and 
animals (e.g. Mycobacterium kansasii, Mycobacterium fortuitum, Mycobacterium para-
tuberculosis) causing different types of diseases from mild to severe. Infections could range 
from direct contact with bacteria to indirect contact through feeding on contaminated foods 
(Hruska, 2009).  
 
1.2-2 The Pathogen- Mycobacterium ulcerans 
The pathogen is also a member of the atypical or non-tuberculous mycobacteria (NTM). NTM 
are Mycobacteria species with the exception of M. tuberculosis, M. leprae, Mycobacterium 
avium and Mycobacterium africanum which are commonly recognized as human pathogens. 
The term is actually not agreed upon by all researchers (Brabois et al., 1999). Some NTM 
closely related to Mu include: Mycobacterium marinum, Mycobacterium pseudoschottsii and 
Mycobacterium liflandii (Merritt et al., 2010). The four species form a group called 
Mycobacterium marinum complex due to their phylogenetic similarity to M. marinum.  They 
share similar growth conditions and over 97% identity in the 16SrRNA gene sequences (Stinear 
et al., 2007). 
 
Recent phylogenetic analysis has revealed the common ancestor of Mu to be the fish pathogen: 
M. marinum. Phylogenetic analysis indicates that Mu has evolved from M. marinum-like 
ancestor, acquiring into it genome insertion sequence elements. Other genetic mutational 
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events in Mu includes transposon insertion which has resulted in genome rearrangement 
producing over 700 pseudogenes (Stinear et al., 2007). The other relationship between Mu and 
M. marinum includes their choice of aquatic habitats and also the pathophysiologic similarities 
of the disease they cause which involves subcutaneous skin infection (Chemlal et al., 2002).  
Careful studies have revealed a contradictory finding in the genetics and the growth capacity 
of Mu in that the genome lacks nitrate and fumarate reductase pathways and microorganisms 
lacking these metabolic pathways are usually unable to grow in low oxygen condition. 
However it is in micro-aerophilic conditions that Mu growth is enhanced in the BACTEC 
system (Palomino et al., 1998), this could be attributed to different strain types but requires 
more investigation. BACTEC system is a fully automated microbiology growth system. It is 
designed to accommodate Mycobacteria Growth Indicator Tube (MGIT). Thus bacteria in 
BACTEC is under continues monitoring which offers accurate measurement of conditions of 
growth necessary for the bacteria (Tortoli et al., 1999).  
Mu genome compared also with other members of the M. marinum complex is quite reduced 
and lacks the ion transport and lipid biosynthesis genes. In addition, Mu is sensitive to direct 
sunlight as a result of a mutation of a key gene-crtI in it genome. The gene -crtI is involved in 
the carotenoid biosynthesis. What makes Mu unique is the acquisition of pMUM001, a plasmid, 
which encodes for a toxin called mycolactone to which it owes its virulence (Stinear et al., 
2004).  
 
1.2-3 The Toxin-Mycolactone 
Mu is the third mycobacteria species known to be of human importance. The first two being 
M. tuberculosis and M. leprae of which none produces toxin, at least for it pathogenicity. This 
makes Mu the only known mycobacteria species that owes its virulence to a plasmid borne 
encoding toxin-mycolactone. Mycolactone is a   major secondary metabolite by M. ulcerans 
and it has been demonstrated in vitro and in vivo in mice and guinea pigs by injection of 100 
μg of the toxin resulted in  the debilitating lesions observed in the BU disease through 
cytotoxicity and immune-suppression and modulation (George et al., 1999; Gunawardana et 
al., 1999; Stinear et al., 2004). 
The isolation and characterization of mycolactone was done in 1999 by Small et al., who 
described it as two, lipid like in nature, polyketide-derived macrolides termed mycolactone A 
and B. Mycolactones are extremely virulent in biological activities and also exist   as C and D, 
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depending on the geographic origin of Mu isolates (Gunawardana et al., 1999; Pidot et al., 
2008; Kishi, 2011).  
Different strains of Mu exist in different geographic location. This was discovered not only by 
molecular sequencing but also by the severity of the mycolactone produced and subsequently 
the resulting inflammation and ulcer. The strains can be grouped into continental blocks. Africa 
strains, mainly isolates from Benin, Ghana, and Ivory Coast produces mycolactone A/B. 
Unique strain also exists in Australia which produces mycolactone C. Mycolactone D is 
observed in Asia (Japan, Malaysia, New Guinea) and Europe (France) and the American 
(Mexico) strain produces no mycolactone. The Africa strain has the severest virulence 
compared with the strains from America, Australia, Asia and Europe (Merritt et al., 2010) 
It is worth mentioning that mycolactone-like metabolite have also been observed in some 
mycobacteria species like M. liflandii (frog pathogen) and the fish pathogen M. marinum. This 
makes Mu technically not the only mycobacteria producing mycolactone (MPM). In order to 
avoid confusion in the nomenclature of Mu and other MPM, like M. shinshuense, M. 
pseudoshottsii, M. marinum, and M. liflandii, there is a proposal to consider all MPM including 
Mu as a single species (Pidot et al., 2008; 2010). The exact role of this toxin of these 
Mycobacteria is unknown, it has however been hypothesized that mycolactone protects Mu 
from predation by eukaryotes (George et al., 1999). This needs to be investigated using wild 
type and mutant strain (non-mycolactone producing Mu). 
 
1.2-4 Pathogenesis and Clinical Features of BU 
Buruli ulcer disease is a necrotizing skin infection. WHO has classified BU into two clinical 
forms, namely non-ulcerative and ulcerative. The non-ulcerative is the early stages of the 
disease, usually with no open lesions but may lead to ulcerative forms in about four weeks if 
not treated, four types can be identified. The non-ulcerative form initially appears as a painless 
papule about 1cm in diameter. The area around the papule usually appears reddened. This form 
is mostly reported from Australia. Another form is the appearance of a painless but itchy nodule 
or a swelling protruding from the subcutaneous skin layer. The area can be distinguished by 
the unique colourisation compared to the surrounding skin layer. The next is called plaque, is 
usually a firm well delineated lesion on the skin about 2cm in diameter and often also painless 
and characteristically reddened. Lastly the oedematous form of the disease has also been 
described. This is normal an extensive non-pitting swelling with no clearly defined margin. 
Fever has been reported to follow this form. 
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The ulcerative form is presented by extensive necrosis of the subcutaneous layer. The ulcers 
usually have undermined edges with peripheral indurations. The floor of the ulcer have a 
whitish appearance. WHO has categorized BU into three blocks for treatment and the 
distinction is based on the size of the ulcer (Table 2). 
Category I ulcers are usually single lesion < 5cm in diameter. Category I are usually treatable 
with only antibiotics. Ulcers with diameter 5-15cm are referred to as Category II. They can be 
treated with a combination of antibiotics. Multiple lesions > 15 cm and /or lesions present on 
eyes, breast and genitalia, and with a complication of osteomyelitis falls into Category III. 
Treatment regimen includes antibiotics and surgery (Table 2) (WHO, 2001, 2015). 
 
1.2-5 Diagnosis and Treatment of Buruli Ulcer 
Currently, WHO recommended diagnostic methods of BU includes: (i) direct smear 
examination (DSE) from lesions for Ziehl Neelsen AFB staining (ii) isolation of bacilli, (iii) 
Polymerase chain reaction (PCR) targeting IS2404 and (iv) histopathological analysis from 
tissues. To confirm BU in an individual, any two or more of these test is needed. Also in some 
cases external quality assurance (EQA) is encouraged and required from a reference laboratory. 
This is important for two main reasons: firstly many ulcers have the same physiopathological 
features of BU and secondly none of the diagnostic methods is of 100% sensitivity. Therefore 
performing at least 2 diagnostic methods and EQA removes any chance of misdiagnosis of BU. 
The manner in which specimen are taken from lesions for diagnosis is very important and 
requires experienced hands as this is enough to alter the results at the end.  
In the case of DSE, samples can be taken from open ulcers but not from the very centre of 
ulcers rather underlying edges of ulcers are likely to harbour the bacilli. In addition fine needle 
aspiration (FNA) or tissue biopsy can be taken from oedematous form for direct examination. 
The DSE method is quite simple and rapid to perform and does not require sophisticated 
instruments. However, it has low sensitivity (60%) and cannot determine the viability of the 
bacilli. In-vitro culture from specimen is the preferred method for diagnosis since we can infer 
viability by visible colony and as such infer causation and also monitor treatment regimens. 
This method has however many disadvantages; firstly being the slow-growing nature of Mu 
(6-12 weeks) which is not rapid for patients care. Secondly, it requires well-furnished 
laboratory with trained personnel for the culturing procedure. Lastly, it has low sensitivity (20-
60%). To conclude, PCR and histopathological examination are rapid diagnostic methods. 
They both have a good specificity and 90% sensitivity of finding bacilli in specimen if ever 
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present. The problem with this is the fact that they are expensive to perform. PCR also cannot 
distinguish between viable and non-viable bacilli and histopathology is undesirable for its way 
of specimen acquisition and requires trained personnel like the first two methods (WHO, 2001, 
2012, 2015). Buruli ulcer disease can be treated and most non-ulcerative forms are usually 
cured with antibiotics only. Ulcerative form depending on the category (I, II or III) can either 
be treated with antibiotic, surgery or both. For a better treatment, early diagnosis of BU is a 
key. Early detection of BU at the sub-clinical level or at the non-ulcerative form is able to 
reduce many of the contractures and deformities associated with the disease. It is in this vain, 
that the current study will be seeking to develop a method for sub-clinical detection of BU in 
Australian cohort through the production of antigens specific for Mu.  
Table 2- Summary of categories, diagnosis and recommended treatment of Buruli ulcer 
 
Treatment 
category 
Form of disease Diagnosis  Recommended 
treatment regimen 
 
 
 
Category I 
Single small ulcers 
e.g. includes; 
1. Nodules 
2. Papule 
3. Plaque 
4. Ulcers < 5cm in diameter 
 
 
 
Clinical 
diagnosis  
(e.g. DSE 
Histopathology  
Isolation  
PCR) 
 
Cure without surgery but  
Complete 8 weeks 
antibiotic treatment 
 
 
 
Category II 
 
Non-ulcerative and ulcerative plaque 
and oedeomatous forms 
 
Single large ulcers 
5-15cm in diameter 
 
 
Clinical 
diagnosis  
(e.g. DSE 
Histopathology  
Isolation  
PCR) 
 
Complete antibiotic 
treatment before surgery  
  
If ulcer is near a joint 
maintain same movement 
as on unaffected side 
 
 
 
 
 
Category III 
 
-Ulcers on the head, neck and on face 
 
-Mixed forms such as osteitis, 
osteomyelitis and joint involvement 
 
-Multiple lesions and osteomyelitis 
 
-Extensive lesions > 15cm diameter  
 
 
 
 
Clinical 
diagnosis  
(e.g. DSE 
Histopathology  
Isolation  
PCR) 
 
Complete antibiotic 
treatment before surgery 
(if possible) 
 
If ulcer is near a joint 
maintain same movement 
as on unaffected side 
 
  Table modified from (WHO, 2012) 
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In terms of medication, WHO recommends a full eight weeks with antimycobacterial drugs 
like rifampicin, streptomycin, clarithromycin and moxifloxacin however many clinician are 
discontinuing the administering of streptomycin due to the side effect of hearing impairment 
in patients. (WHO, 2003, 2015). 
 
1.2-1 HOST IMMUNE RESPONSE TO Mycobacterium ulcerans 
The progression of the disease is marked by the destruction of the subcutaneous skin layer and 
even sometimes affect nerves and blood vessels. There is also the characteristic nonappearance 
of inflammatory response during the early and acute phases of the disease, which is attributed 
to the immunosuppressive nature of mycolactone (Duker et al., 2006). 
Immune responses to mycobacteria antigens and host responses have long being studied, when 
the call for effective diagnostic test for tuberculosis was sought. This led to the development 
of the Tuberculin Skin test (TST) which is a simple diagnostic skin test made from purified 
protein derivative (PPD) of M. tuberculosis (Barksdale et al., 1977; Daniel & Janicki, 1978). 
TST diagnostic test quantifies cell mediated immunity (e.g. γ-IFN) arising from exposure to 
M. tuberculosis.  
Based on the TST researchers have proposed a similar diagnostic test which is hoped to be a 
quick, easy and inexpensive diagnostic test for exposure to Mu. Burulin, an antigenic substance 
produced from Mu was first attempted in 1975. The antigen was prepared from a series of 
ultrasonic disintegration and centrifugation. The efficacy of Burulin was tested in patients with 
leprosy, tuberculosis and BU disease. Patients with Tuberculosis (TB) and BU were 
simultaneously tested with Burulin and TST to check for cross-reactivity. The result revealed 
that Burulin showed strong reactivity among BU patients. However BU patients also responded 
positive to TST, which confirms the antigenic heterogeneity among mycobacteria species 
(Table 3). This was the first step to developing a skin test for Mu (Stanford et al., 1975). 
Research to decode antigens specific for various mycobacteria has since then gained grounds. 
A similar study to above using Mu cultural filtrate (MUCF) reported remarkable differences in 
humoral immune responses of BU patients compared to unaffected groups (Dobos et al., 2000). 
It has also been reported that BU patients have significantly reduced expression of γ-IFN in 
their peripheral blood mononuclear cells (PBMC) as compared to healthy controls. IFN is 
important mediator in innate and adaptive immunity. They are usually involved in the 
activation of macrophages and are produced by T-cells. On the other hand  Mu specific 
Page | 20 
 
antibody are detectable in serum of BU patients but not in healthy controls, which indicate 
patients show active immunological responses to Mu antigens but show -IFN or T-cell anergy. 
The reduced proliferation of cell mediated responses is what account for the pathophysiological 
features of the disease as seen by indolent and oedema at site of infection ( Roberts et al.,, 
1997; Gooding et al., 2002). In explaining the immune responses in BU patients, two 
parameters is worth considering, firstly the host response to the toxin, mycolactone (Roberts et 
al., 1997) and secondly the immune response to surface antigens of Mu (Stanford et al., 1975).  
A comparative study of mycolactone and Mu surface antigens might give a clue to appropriate 
diagnostic method. Attempt are however being made in the area of identifying Mu specific 
antigens. The main limitation has always being with cross-reactivity with other mycobacteria 
disease especially M. tuberculosis ( Stanford et al.,1975; Dobos et al., 2000; Gooding et al., 
2002; Diaz et al., 2006; Yeboah-Manu et al., 2012).  
A comparative genomic study aimed to solve this limitation by Pidot et al., identified seven 
specific proteins: MUP045, MUP057, MUL_0513, Hsp65, and the polyketide synthase 
domains ER, AT propionate, and KR A. In a screening study in Benin these proteins showed 
significant differences in the serologic responses in both endemic and control groups (Pidot et 
al., 2010). 
The current study seeks to replicate this using both Mu PPD and the seven proteins to screen 
cohort in Australia since such screening has not been done. The current study will consider a 
larger cohort within Victoria and will exploit a slightly modified approach in producing Mu 
PPD for screening Victoria population. This is needed to measure the level of exposure to Mu     
and to identify who is at risk. 
 
1.2-2 Comparison Burulin and MUCF 
Stanford et al., (1975), were the first to publish an article on Burulin. This was an attempt to 
identify antigen specific for M. ulcerans as TST-PPD was for M. tuberculosis.  This was 
necessary because as at 1975 the diagnosis of Buruli ulcer was only made on clinical grounds 
involving histopathological analysis of ulcers and isolation of the bacteria. Though these 
diagnostic methods were enough for early stages of the disease, they were not accurate enough 
for older lesions. 
Burulin is a complex antigenic proteins prepared from Mu.  Two strains, No. 297 and No.298 
(isolated from active lesions from Uganda) and No. 408 (Zaire) were cultured on Lowenstein-
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Jensen at 32°. After de-activation of growth Burulin was made through bacteria cell disruption 
using ultra-sonication and a series of centrifugation (Table 3) (Stanford et al., 1975). 
MUCF, was made from Mu strain,  S-WT (from the Centers for Disease Control and Prevention 
culture collection; Atlanta) (Table 3) after recovery from 10% glycerol, was incubated in 5 ml 
Middlebrook 7H9 with OADC supplement (Remel, Lenexa, KS) at 32.5°C for 7 days. The 
media of choice for the production of MUCF were protein and serum- free, as such any protein 
detected in the medium is from the bacteria. Mu were harvested at the mid-log phase growth 
through centrifugation. The amount of MUCF recovered from a 1L culture was 5mg (Dobos et 
al., 2000). 
 
 
Table 3-Summary of the production Burulin and MUCF 
Preparation  
conditions 
Burulin MUCF 
Strain No. 297, No.298 (Uganda)  
and No. 409 (Zaire) 
S-WT (Atlanta) 
 
Growth medium 
 
Lowenstein-Jensen 
Middlebrook 7H9 (supplemented with                  
proteins 
 
Temperature 
 
32o C 
  
        32.5oC 
 
pH 
 
6.4 
 
- 
 
Elution buffer 
phenol, 5g.; sodium chloride, 5g.; potassium 
dihydrogen phosphate, 1.81g.; di-sodium 
hydrogen phosphate dihydrate, 3.56 g.; 
glycerol, 80 ml.; distilled water, to 1L 
   isocratic 
  gradient of 0.1 M NH4HCO3 
Method of antigen  
extraction 
 
Ultrasonic disintegration 
Cultivation in protein- and serum-free 
media allows for expression  of antigens 
 
Incubation time 
 
35-56days  
 
27days then passage into  1L before 
harvesting 
 
Major findings  
 
1. Test positive for BU patients 
2. Test positive also for TB patients 
 
No correlation between BU stage and  
serum antibodies production  
 
 
Reference 
 
(Stanford et al., 1975) 
 
(Dobos et al., 2000) 
 
 
Though there are some similarity in the preparation of Burulin and MUCF, the procedure for 
their extraction is quite different (Table 3) which are potent enough to affect the type of 
proteins expressed and extracted from the mycobacteria (Daniel & Janicki, 1978).  
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1.3 ENVIRONMENTS ASSOCIATED WITH TRANSMISSION OF Mycobacterium 
ulcerans 
 
1.2-1  Water Bodies and Wetlands 
The outbreaks of BU have usually been reported from areas close to aquatic environments, i.e., 
wetlands, swamps, marshy areas, ponds, streams or rivers. The importance of ecological 
sampling from aquatic environments have long been known and was first conducted in Uganda 
in the 1970s, after it was observed that most patients reporting BU infection lived close to 
aquatic environment (Barker et al., 1972). Many researchers have since hypothesized that 
contact with infected aquatic environment is a high risk factor in Australia and Africa (Table 
4) (Hayman et al., 1991;Portaels et al., 1995 Merritt et al., 2010).  
In many endemic areas in Africa diverse water bodies such as, rivers, streams, lakes, dams and 
ponds have many direct uses (Fig 5). They serve as a source of drinking water to humans and 
livestock. In addition, they serve for bathing and washing as well as for irrigation, the same 
cannot be said in Australia because freshwater bodies does not have such direct usage. However 
an outbreak that occurred in 1993 and 1994 in east Cowes, Philip Island in Australia was 
attributed to indirect contact (aerosol) with golf course irrigation system that was contaminated 
with Mu. It is from this constant association of inhabitants with water bodies that it is believed 
they are and should be considered as risk factors (Table 2)  (Portaels et al., 2001). Till date no 
further studies have validated aerosols as a mode of transmission. 
The type of aquatic ecology where BU infections have been reported in Australia is quite 
different from that of Africa. In Australia, cases are concentrated along the coast (Fig 3) where 
salinity is high whereas in Africa cases are mainly reported from areas with freshwater (Fig 5)  
(van Ravensway et al., 2012). Such disparities need thorough investigation in these two regions 
to see how they impact on Mu transmission. 
Extensive environmental studies have been carried out in many countries in Africa where BU 
have been reported: Ghana, Nigeria, Benin, Cote d’Ivoire, Cameroun and Togo. Samples 
collected from the environments and tested positive for Mu DNA have included, soil, water, 
biofilms, detritus, snail, fish and aquatic bugs (Marsollier et al., 2002, 2004;Williamson et al., 
2008 Merritt et al., 2010; Ebong et al., 2012;Williamson et al., 2012; Benbow et al., 2014). It 
must be mentioned that such extensive sampling have not been conducted yet in the Australia 
region. 
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However sampling in Australia has mainly included swabs from ulcers of brushtail and ringtail 
possums, possum scats and mosquitoes (Johnson et al., 2007; Fyfe et al., 2010; Lavender et 
al., 2011).  Despite these efforts the exact mode of transmission is not known and the search 
for vector and environmental reservoir is continuing. The signature sequences targeted in 
samples for the presence of Mu are insertion sequence element (ISE) 2404 sometimes written 
as IS2404. ISE are mobile genetic elements that are found within genome of certain bacteria 
and are capable of causing genomic rearrangement (Stinear et al., 2007). 
 
 
Figure 4- Environments associated with Buruli ulcer. A- River in Benin) B. a pond in Ghana, showing two ladies 
fetching water. C- Lake in Benin, (Dr Chauty, AFRF)(WHO, 2000). 
 
 Samples from Africa screened for IS2404 are also screened for IS2606 another unique 
signature of Mu. This is important because, it has been observed that M. liflandii, isolated from 
a West African craw-frog is also known to possess IS2404, which makes IS2404 PCR not 
specific for Mu in some endemic localities, this however has not been reported in Australia or 
anywhere else (Merritt et al., 2010).  
Other sampling have also included protozoa (e.g. amoeba) and microscopic insects (Eddyani 
et al., 2008; Gryseels et al., 2012) this was borne from the fact that Acanthamoeba polyphaga 
is already known to serve as a reservoir to some Mycobacteria (Adékambi et al. 2006). The 
study by Eddyani (2008), isolated certain Mycobacteria, but no Mu were isolated from amoeba 
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spp (Vahlkampfiidae and Acanthamoeba spp). In addition, their samples were PCR negative 
for Mu IS2404. This however requires further investigation as amoeba is believed to serve as 
food for microscopic insects and are further eaten by aquatic bugs (Eddyani et al., 2008). 
Studies on protozoa have not been conducted in Australia yet. 
 
1.2-2 Aquatic Insects-Probable Hosts 
Aquatic bugs, in the Order: Hemiptera: Families Naucoridae and Belostomatidae species, Fig 
4) have repeatedly been found to be positive for M. ulcerans DNA. Is worth mentioning that 
the first successful environmental culture of M. ulcerans was from an aquatic bug: Gerris spp 
(water strider) (Portaels et al., 1999; 2008). Laboratory experimentation has gone ahead to 
prove that, through feeding on infected prey, Belostomatidae spp. are persistently colonized by 
Mu. In a later experiment the infected aquatic bug was able to cause BU in an animal model 
through bite. Though this  does not directly infer vectorial association, it however sheds light 
on the seamless movement of Mu through the trophic levels in the environment (Mosi et al., 
2008).  
 
 
Figure 5- Some aquatic bugs implicated as possible reservoir and vector of M. ulcerans. A- Naucridae spp. and B- 
Belostomatidae spp (Merritt et al., 2005). 
 
Though mechanical transmission are possible in the laboratory there is a caveat in trying to 
extrapolate it to what happens in-situ. The reason being that aquatic bugs (Belostomatidae and 
Naucoridae) do not actually feed on humans, neither has any BU patients attributed the onset 
of their disease to the bite of an aquatic bug (Benbow et al., 2008; WHO, 2003). And even if 
they did, how accurate would that be since the incubation period of Mu takes several months 
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(Walsh et al., 2008). In a transmission experiment recently done with mice tails coated with M. 
ulcerans, it was observed that mosquito bites or puncture wound by a needle create an entry 
point for Mu into the skin to cause BU. This suggest that puncture wounds are important in the 
mode of transmission (Prof. Tim Stinear personal communication at WHO 2015). The 
involvement of mosquitoes have only been reported in Australia (Johnson et al., 2007), with 
no correlation study anywhere, the same can be said about Naucoridae and Belostomatidae 
species ( Fig 3) which are mainly implicated in Africa transmissions (Marsollier et al., 2002; 
Silva et al., 2007). This raises question as to whether transmission is geographically dependent. 
This definitely warrants further research. 
 
1.2-3 Possums and other mammals 
In Australia, BU in mammal have been observed in ringtail and brushtail possums. There has 
also been observation of infection in koala, long-footed potoroo, horses, dogs, cat and alpaca. 
(Mitchell, 1984; Portaels et al., 1999Elsner et al., 2008; van Zyl et al., 2010). Among these 
animals possums are the most highly suspected as reservoir of Mu (Fig 6). Possums are native 
protected marsupial species in Australia and are found in most regions. The persistent 
association of BU and positive M. ulcerans DNAs in possum lesions and scats has led to the 
hypothesis that possum might act as reservoir or intermediary in the transmission of Mu. It has 
also been hypothesized that if an adult mosquito feeds on an infected possum blood and goes 
ahead to bite a human, transmission infection could occur. Infection could also occur if a cat, 
dog or any other animal was in contact with a dead infected possum (Fyfe et al., 2010;Paul 
Johnson personal communication,WHO 2015). 
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Figure 6-. A typical possum habitat in Point Lonsdale. B- common brushtail possum. C- ringtail possum. D-Faeces of 
a brushtail possume (left) and right shows faeces of a ringtail possums. E- ringtail possum lesion and F-  lesion on the 
nose of brushtail. (Fyfe et al., 2010) 
 
It must however be mentioned that despite many studies in Ghana, Benin and Uganda there 
was no reported case of Mu isolation from mosquitoes or rodents in Africa ( Portaels et al., 
1999; Durnez et al., 2008; Vandelannoote et al., 2010). Recently, a conference paper presented 
reported positive detection of IS2404 in the faeces of domestic animals in endemic area in 
Benin (personal communication with Rousseau Djouaka at WHO, 2015). This report definitely 
needs confirmation and if proven to be true, it will be the first time a significant amount of 
IS2404 would have been detected in mammals in Africa. Such finding may assist to elucidate 
the mode of transmission because it may point at a plausible link between domestic animals 
and humans. 
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1.2-4 Multi-host structure for M. ulcerans transmission   
A molecular approach in studying the diets of the African creeping water bug Naucoris sp. 
revealed that they prey on a wide range of materials including microorganisms, protozoa, 
detritus, fungi and plants, as such implicating any one organism as being the initial source of 
the infection is a complex task. Many attempts are being made to resolve the complex and 
multiple host structure of Mu transmission (Gamboa et al., 2012). Using mathematical model, 
efforts are being made to identify and isolate the Achilles heel or keystone host species 
involved in the transmission (Roche et al., 2013). A keystone species is an organism or a group 
of organisms that is/are critical for the dissemination of a pathogen (Mills, 1993). The first 
study using this model in Mu transmission implicated oligochaeta worms as the critical 
organism in the aquatic food web. This was because their removal from the model significantly 
reduced the prediction of the transmission to other trophic levels. This definitely needs further 
research on the field to draw any meaningful conclusion (Roche et al., 2013).  
 
1.2-5 Seasonal variation and incidence of Buruli ulcer 
Seasonal pattern in the epidemiology of BU have long been suggested by Barker (1972) in 
Uganda. He was working from the hypothesis that Mu thrives on vegetation close to slowing 
moving stream and as such when inhabitants come to fetch water and are in contact with 
infected vegetation, they contract Mu through existing scratches or skin trauma. He went on to 
propose that incidence of BU in Uganda will vary with seasonal variation of vegetation. After 
numerous seasonal sampling in Ibuje, an endemic area in Uganda from dry season (November-
March) to raining season, which starts from April till August he validated the hypothesis. In 
Ibuje, dry season leads to the drying out of most of the perennial grasses around river banks, 
which correlated with low incidence of the disease, the raining season leads to an increase in 
the disease (Barker, 1972). Seasonal variation in BU cases also exists in Australia. Winter, 
which starts June-August records more BU diagnosis compared with other seasons (Hughes et 
al., 2007). With the incubation period of Mu being six weeks to three months (Walsh et al., 
2008), probably implies that infection occurred in summer (December-February) or the fall 
(September-November). Monthly environmental sampling, e.g. possum scats and mosquitoes 
from endemic regions in Australia for a whole year could shed some light on the transmission 
trend, however this has not been done. 
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Seasonal variation of aquatic bugs in endemic areas have also been observed. Variation and 
abundance of aquatic bugs usually occurs even with circadian rhythm to prolong seasonal 
variations (Ebong et al., 2012). In contrast to what Barker found in Ibuje, where dry season 
saw reduction in BU incidence, Marion et al., have reported the opposite in a study conducted 
in Akonolinga in Cameroun where they observed that dry season and reduction of water level 
in the Nyong river favoured the transmission of Mu (Marion et al., 2010). Seasonal variations 
are known to be important in certain disease incidence and definitely warrant further 
investigation in BU. 
 
1.2-6 The role of landscape variation 
Heavy rains and floods causing landscape alteration have been reported to increase the 
incidence of BU. The first case of infection in Bairnsdale, Australia was in 1939 and was 
attributed to a severe rainfall in 1935. There was extensive flooding and washout from 
drainages through the whole district (Radford, 1975).  
In Papua New Guinea (PNG), the onset of BU came to fore after the eruption of Mount 
Lamington in 1951. BU was actually not reported until heavy rains and flood hit the region 
washing the residues of the volcanic eruption into the human settlements. Regions around 
Septik and Kumusi rivers were the most affected. The disease was named Kumusi Ulcer after 
the Kumusi River in PNG (Hayman, 1991).  
Barker (1972) also observed that the cases in Uganda were as a result of heavy flooding which 
had occurred from 1962 to 1964. The severe rains and flooding created many permanent 
swamps around Lake Victoria as well as increased soil fertility and grass proliferation, these in 
effect enhanced the growth of Mu (Barker, 1972).  
In terms of the impact of anthropogenic activities, a study conducted in Cote d’lvoire showed 
that people living close to dam and/or rice plantation presented more cases of BU than those 
who lived farther away (Brou et al. 2008). Other environmental alterations like dam creation, 
deforestation, agricultural activities and arsenic leakage into water bodies by mining activities 
have all been reviewed to increase incidence of BU (Merritt et al., 2010). Though these 
information does not directly give out the mode of transmission, it however does offer helpful 
indications where to look when an outbreak of BU occurs. 
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1.2-7 Age and gender as risk factors 
Age and gender are in some areas regarded as non-environmental risk factors (Table 4). In 
Africa it has being observed that children between the ages of 2-14 years old more are 
susceptible than the adults (Table 4). The likely explanation to this is that those in this age 
bracket, tends to be engaged in a lot of outdoor activities such as soccer, fetching water for 
household, etc. it is also not uncommon to find children walking bare footed whiles carrying 
out these activities and picking up injuries. Injuries and improper wound care have strongly 
been linked with the infection of the bacteria (Table 4).  (Debacker et al., 2004;2006). In 
Australia, the age bracket susceptibility is the exact opposite to that in Africa. BU is prevalent 
in the older population (≥ 60years), this has been attributed to weak immunity resulting from 
older age (Nielsen et al., 2013; O’Brien et al., 2013). 
Though gender has not conclusively being linked with BU, more studies report female being 
infected in Africa. This might be due to immunological or sociocultural factors. The 
sociocultural aspect can be reasoned from the fact that women tend to go for water from lakes 
and rivers more than their male counterpart. In Africa women also carry out some household 
chores like washing around water bodies, which might increase their exposure to infection. 
This has not been critical explored in Australia. Whichever the case, more research is needed 
to explore gender disparity in the transmission of the bacteria (Debacker et al., 2004; 2006). 
The current study will explore BU cases in Victoria to see if gender plays any role in 
transmission in Australia. 
In terms of the anatomical presentation of BU, more ulcers have been reported on the lower 
limbs than the upper limbs. The exact reason for this differential is not known but it has been 
suggested that because the lower limbs are close to the ground or soil is the likely answer. 
However ulcers have also been reported on the head, face, neck, buttocks, fingers and trunk of 
patients (Noeske et al., 2004; WHO, 2012).  
A number of preventive measures have been suggested from empirical studies that can help 
reduce the risk of Mu infection in endemic localities. First and foremost wearing of protective 
shoes when working on the farm or walking around water bodies significantly reduce risk. In 
addition long-sleeve shirt is recommended above short-sleeve ones. The second preventive 
measure is to avoid swimming or wading in rivers in endemic areas. The use of mosquito bed-
net is believed to be also  helpful (Johnson et al., 2007; Merritt et al., 2010). 
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Table 4-Summary of risk factors to Mu infection in some countries 
Country Risk Factor (s)  References  
Australia 1. Most patients > 60 years old 
2. Exposure to mosquitoes 
(Quek et al., 2007) 
Benin 
 
1. 5–14 years of age 
2. Unprotected water from swamps 
3. BCG-vaccinated patients > 5 years old 
4. Agricultural activities 
5. Improper wound care 
 
(Debacker et al., 2004; 
2006) 
 
(Merritt et al., 2010) 
 
Cameroo
n  
1. Living near cocoa plantation or woods 
2. Wading in swamps 
3. Improper wound care 
 
  
 (Pouillot et al., 2007) 
 
Ghana 1. Exposed skin 
2. Exposure to riverine areas (wading and swimming) 
3. Fishing 
4. Age 2–14 years of age 
5. Swimming in rivers 
6. Arsenic-enriched drinking water (from mining) 
 
(Raghunathan et al., 
2005) 
 
(Aiga et al.,2004) 
 
(Duker et al., 2004) 
Table modified from (Merritt et al., 2010) 
 
1.3 RESEARCH PRIORITY BY WHO 
Global Buruli Ulcer Initiative (GBUI) program was launched by WHO in 1998. The mandate 
of GBUI was to coordinate control and research efforts in understanding more about the 
epidemiology of BU. The first International Conference on Buruli ulcer control and research 
took place in Yamoussoukro, Côte d’Ivoire. The Yamoussoukro communiqué brought to fore 
the severity of the morbidity of BU and concerns about it emergence were discussed. GBUI 
has identified five key research areas as most likely to add to our knowledge of the BU: 
1.  Identification of the mode of transmission 
2.  Development of methods for early diagnosis 
3.  Improvement of treatment   
4. BCG trials and development of new vaccine and  
5. Cultural and socio-economic studies ( WHO, 2000;Merritt et al., 2005; Rondini, 2005). 
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Although significant research effort has been made in these five key areas, the full 
understanding of the disease is yet to be realized. It is therefore the interest of the current study 
to help in the first two points of the GBUI research key areas, which is about the transmission 
and early diagnosis of BU in Australian cohort. 
 
1.4 AIMS, HYPOTHESIS AND OBJECTIVE 
Buruli ulcer has been reported in Australia since the late 1930s and 1940s by Alopes and Searls 
in Bairnsdale, East area of Gippsland of Victoria. The incidence of the disease was almost non-
existent for several years until there was a sudden re-emergency of case in 1992-1994 around 
the Mornington Peninsula area, Western Port and Phillip Island and from the Bellarine 
Peninsula (BP). Current reports indicates that among all these areas, cases from BP have 
steadily rising since 2004-2014 with no apparent explanations (Fig. 2) (Vic Health). In 
Australia, it has been found that brushtail and ringtail possums show clinical signs of BU (Fig. 
6). In addition their scats contains high levels of M. ulcerans DNA. It has therefore been 
suggested possums acts as a host of the bacteria and spread it to mosquitoes that feed on them 
and in turn pass it on to humans (Johnson, et al., 2007; Fyfe et al., 2010). But with many 
patients not remembering the onset of their BU from a mosquito bites suggests other possible 
factors or parameters in the environments mediating the transmission (Benbow et al., 2008).   
The research question for this study therefore is to identify factors mediating the current rise 
of BU cases in the BP taking into consideration the environments and host immunity, this is 
recounted from the fact that in endemic areas BU has been found in members living in the same 
household while as other members are unaffected (Gooding et al., 2002).We therefore 
hypothesize that environmental factors coupled with host immuno-physiological determinants 
underpins susceptibility to BU. The aim of this study can be divided into three blocks; 
 
1. To map BU cases in the Bellarine Peninsula to understand distribution pattern and 
identify risk factors. 
2. To develop a diagnostic test for Mycobacterium ulcerans 
3. To understand level of exposure of Mu in the BP and also determine in co-morbidity 
in transmission. 
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CHAPTER 2- RESEARCH METHODOLOGY 
 
- Aim 1   
-To map BU cases in the BP to understand distribution pattern and identify risk factors. 
 
2.1- Background 
Victoria has the highest burden of BU case in Australia. Currently, the highest burden of BU 
cases are found on Bellarine Peninsula (BP), e.g. Point Lonsdale and Ocean Grove. Recent 
Case reports  indicate the geographical progression of transmission within this region (Huang 
et al., 2014). The mode of transmission is unknown but a previous study indicated that possums 
and mosquitoes might play a role in the transmission in BP (Fyfe et al., 2010). Although 
previous studies have shed some light on the disease in terms of possible reservoir and vector, 
many questions remain unanswered.  Previous studies failed to address the environmental niche 
of Mu and ecological or biological transmission to human. In addition previous studies failed 
to resolved the potential role of intermediate factors such as invertebrates that might be 
involved in the transmission of Mu  (Merritt et al., 2010). In this section we aim to understand 
the pattern of transmission of Mu; looking at spatial distribution of BU cases within the BP. 
This section will address the identification of environmental factors in the hypothesis in 
Section 1.4. To help me do this, we have a Geomatics and GIS expert on the project. 
 
2.1-2- Objectives 
The main objective in this section is to do descriptive epidemiology using Victoria wide BU 
database to identify transmission pattern and local risk factors. Specific objectives shall look 
at BU cases at following aerial scales using GIS tools; 
State level:  Victoria 
Regional:   Bellarine Peninsula 
State Suburbs:  Towns/suburbs 
Area of Residence:  Mesh block  
 
NB = (Mesh Blocks are the smallest geographic region in the Australian Statistical Geography Standard 
(ASGS), the smallest geographical unit for which Census data are available and that preserves privacy)
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We have chosen to work at these four scales (Victoria, BP, Suburbs and mesh block) to cull 
out any pattern that might not be obvious from the preceding scale. Summary of specific 
objectives to be carried out at the aerial scale include: 
1. BU cases in space: Shall identify spatial distribution patterns of BU cases and local 
environmental parameters serving as risk factor. 
2. BU cases in time: Will look into seasonal patterns and time events occurrences (e.g. 
dam or road constructions etc.) that might impact transmission.  
3. Possible new foci: Hypothesis on possible new foci, with environmental changes 
occurring by numerous new settlements in the BP. 
At the end of the study we hope to have answers to questions like; 
1. What are the demographic characteristics of BU patients in the Victoria? 
2. What is the spatial distribution (random, regular or clustered) of BU case in BP? 
3. What is the speed of spread and direction of BU within BP? 
4. Are there clusters in time and space? 
5. Where are the possible transmission sources (risk factors: soil, water, animals or 
insects) to humans? 
6. Will seasonal periodicity as described by Hughes et al. 2007 correlate with abundance 
of Mu in environmental samples (possum scats and mosquitoes) from January-
December? 
 
2.1-3- Methodology 
To achieve the objectives in Aim 1 the following study design shall be followed. 
 
2.1-4- Data collection and Storage 
A. Acquisition of State wide BU cases for descriptive epidemiology: The Victoria 
Health Department keeps a database of all infectious and communicable disease in the 
region including BU. They have already given access for this study to use information 
in the BU database. For explorative and descriptive analysis if the patients data is not 
stratified, we shall stratified them  according to the following criteria;  
a. Age group 
b. Gender 
c. Suburbs and/or Mesh block (for residence) 
Page | 34 
 
d. Probable place of exposure (if remembered by patients) 
e. Time of infection 
f. Category of lesion presented (I, II or III) 
Patient names will be substituted with number labels for data protection and anonymity.  
We shall also acquire the recent suburb population census data done in 2011 as well as the area 
size (square-kilometre) from the Australian Bureau of Statistics (ABS). The data obtained from 
ABS shall be used to compute parameters like population density and do epidemiological 
assessments (e.g. risk measurements). 
 
B. Spatial distribution and map layers collection; Stratification of Suburbs and/or Mesh 
block in (section 2.1-4-Ac) above shall be used for mapping BU in space (section 2.1-
2, no.1). The project has already acquired GIS map layers from Victoria State Council. 
The GIS layers to be used shall include;  
i. Regional boundaries (Australia and Victoria map layers) 
ii. Mesh block area of residence 
iii. Road networks 
iv. Water (River, lake, dam, etc.) courses 
v. Forest patches 
vi. Demographic data 
vii. Waste disposal areas 
viii. Recreational areas 
NB: bold indicated map layers already acquired 
 
 
C. Transmission and seasonality for BU case in time: More cases of BU have been 
reported in the winter in Australia from June-August with no clear explanation why this 
is so. With mosquitoes and possums haven been suggested to play a key role in the 
transmission process we shall identify collection areas and set up traps to collect 
possum scats and mosquitoes from 16th January-16th December 2016 in 3 transects of 
50 x 50m demarcated within mesh block residence of areas of highest BU cases in our 
data. This shall also be done for non-endemic areas. Our sampling shall  record; 
1. Identification of insects collected monthly. 
2. Monthly abundance of mosquitoes. 
3. Monthly Mu infected mosquitoes. 
4. Monthly possum scats collected. 
5. Monthly Mu infected possum scats  
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To check for Mu DNA in possum scats, each monthly scats collected will be pooled together 
and grinded into powder. Three (3) samples of 200mg will then be taken and checked for M. 
ulcerans DNA using RT-PCR.  Monthly mosquitoes collected will also be pooled into groups 
of 25 for RT-PCR. This is to enhance detection limit of the assay taking into consideration the 
small size of mosquitoes. RT-PCR conditions shall be as described by Fyfe et al., 2010. We 
shall also perform external quality assurances (EQA) for each monthly sample with our 
Melbourne University collaborators. The aim of the transmission and seasonality studies is to 
help answer questions in section 2.1-2. If correlation can be drawn from this study, 
environmental interventions needs to be taken to curtail further spread of BU. If no correlation 
exist between monthly BU cases and monthly environmental samples, then possums and 
mosquitoes may not be that important in playing active role in the transmission of Mu after all 
as such the search for transmission parameters must continue unabated; or the collection time 
and areas have to be redesigned and extended.  
2.1-5- DNA extraction of environmental samples  
There will also be environmental sampling in both endemic and non-endemic communities for 
the detection of Mu DNAs. Sampling will be done randomly from the environments. Water, 
insects, dead possums, possum scats, dominant vegetation (both dead and living) and soil will 
be collected. All collected samples will be transported on the same day to the laboratory, stored 
at 4oC and analysed within a week of collection. DNA will be extracted from each type of 
environmental samples using the FastDNA Spin kit for (MP Biomedical) according to the 
manufacturer’s instruction. 
 
2.1-6- Real Time Polymerase Chain Reaction (RT-PCR) 
Due to the weak sensitivity of conventional PCR, we will perform RT-PCR on the extracted 
DNA. TaqMan assay which is more specific and sensitive than sybre gold will be setup. The 
procedure and conditions for PCR and RT-PCR will be as previously described by Fyfe et al., 
2007. The table below describes the sets of primers and conditions to be applied in the RT-
PCR. The RT-PCR will be analysed using gel electrophoresis. We shall perform external 
quality assurances (EQA) of each sample type with our Melbourne University collaborators. 
The areas to be selected for the environmental sampling will be based on the explorative and 
descriptive analysis of the Suburb/Mesh block in section 2.1-4-Ac. The following criteria will 
be used for suburb inclusion: 
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1. Suburb of highest BU cases in Victoria- This is because area of highest BU cases 
might give a lead to the investigation on possible risk factors and mode of transmission. 
We shall expect to find environmental factors and social behaviours serving as risk 
factors in this suburb and also very positive serologic responses. 
2. Suburb of lowest BU cases in Victoria- We intend to explore this as a comparative 
study to (1) in regards to measuring the abundance of various sources that might serve 
as risk factors. 
3. Suburb with highest recent (2013-2014) BU cases- This area shall be investigated to 
describe the probable direction of transmission and predict possible new foci in 
Victoria. If the suburb in (1) is also the suburb of highest recent case, the second highest 
suburb will be chosen for screening in that order. 
4. Suburb with no recent (1998-2003) BU cases- If the suburb with no recent cases 
(1998-2003) is the suburb in (2) we shall move to next suburb in the data. 
5. Suburbs with no BU case report- This suburb will serve as the control (non-endemic 
area). We shall expect to find very low to no sources of Mu transmission and hopefully 
serologic assay would differentiate this group as the unexposed group in Victoria. 
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Table 5-Primers and probes designed for real-time PCR assays targeting IS2404, IS2606, and KR Primer 
Primer or probea Sequence (5'–3') Nucleotide positions b Amplicon size (bp) Putative gene function (reference)
No. of copies of amplicon per
plasmid/chromosome  c
IS2404  TF AAAGCACCACGCAGCATCT 27746–27762 59 Transposase 4/201d
IS2404 TR AGCGACCCCAGTGGATTG 27787–27804
IS2404 TP 6 FAM-CGTCCAACGCGATC-MGBNFQ 27768–27781
IS2606  TF CCGTCACAGACCAGGAAGAAG 28912–28932 58 Transposase 8\82                                            
IS2606  TR TGCTGACGGAGTTGAAAAACC 28947–28969
IS2606  TP VIC-TGTCGGCCACGCCG-MGBNFQ 28933–28946
KRTF TCACGGCCTGCGATATCA 3178–3195 65 KR-B domain 15/0
KRTR TTGTGTGGGCACTGAATTGAC 3222–3242
KRTP 6 FAM-ACCCCGAAGCACTG-MGBNFQ 3199–3212
 
 
 
a -TF, forward primer; TR, reverse primer; TP, probe. 
b -Numbering based on the first copy of the amplicon in pMUM001 (GenBank accession no. BX649209).  
c -Determined by BLAST analysis of the amplicon sequence in WASABI, an in-house, web-interfaced MySQL database for genome analysis. 
d -A total of 171 were identical copies, with an additional 30 copies identified with 1-nucleotide substitutions within the primer sites which would be unlikely to prevent amplification (Fyfe et al., 2007). 
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2.1-7- Ethics Approval 
The approval to use patient’s data and information were given by Victoria Department of 
Health after all the requirements for information usage and storage were met. All other 
procedures were in accordance with the National Health and Medical Research Council 
(NHMRC) Australia.  
All the results and descriptive maps will be checked to be sure to avoid any patient 
identification. 
2.1-8- Data analysis 
 
a. Statistical Analysis  
The statistic to be used in the data analysis will involve both descriptive analysis 
and explorative analysis. Basic statistics like, percentages, means or medians 
and standard deviations will be sufficient dependent on the project for patients’ 
data and risk assessment analysis. ANOVA will be used to find significance in 
the Mu DNA copy number in samples and the month of collection. The results 
will be considered significant if p≤ 0.05. We shall use STATA statistical 
software for these analyses.  
 
b. Spatial analysis will include areas of residence (Meshblock address of 
patients). Other layers to be included are road networks, agriculture lands, 
forests, rivers, water bodies, recreational centres, and waste disposal sites and 
sewage systems. All will be analysed against the location of transmission (Mesh 
block address of patients).  We shall perform GIS modelling using Quantum 
GIS (QGIS) software. Digital maps in section 2.1-4 B, shall be imported into 
QGIS workspace alongside coordinate reference system (CRS) of the 4 aerial 
scale in section 2.1-2 to develop a spatial distribution of BU cases in Victoria. 
CRS is a coordinate-based local, regional or global system used to locate 
geographical entities (e.g. Countries, Cities, Towns, etc.). Specific analyses to 
be carried out shall include distance matrix, buffering, and spatial queries, near 
neighbour and explorative analysis. These analyses explores pattern in 
locational data by comparing graphically the observed distribution functions of 
event-to-event or random point-to-event nearest neighbour distances, either 
with each other or with those that may be theoretically expected from various 
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hypothesized models, in particular that of spatial randomness (Upton & 
Fingleton, 1985), i.e. it describe distribution of points according to their spacing. 
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Aim 2 
-To develop a diagnostic test for Mycobacterium ulcerans 
 
2.2-1 Background  
Mycobacterium ulcerans is the causative organism of BU. It is the third mycobacteria species 
of human importance after M. tuberculosis and M. leprae. Over the years the incidence of BU 
infection has increased greatly in many countries especially in the West Africa regions. Some 
cases have also being reported in Australia with Bellarine Peninsula (BP) in Victoria having 
the highest prevalence. Currently, there are 4 methods of diagnosis for BU in medical centres, 
these include: 
 
1. Direct smear for AFB 
2. Isolation and in-vitro culture 
3. PCR assay on fine needle aspirate (FNA) 
4. Histopathological assay (tissue biopsy) 
 
It is recommended that at least two of the four methods be performed before diagnosing an 
ulcer as BU. Though these methods are known to work, there are many challenges surrounding 
their usage, some of which include: 
 
1. The need of well certified and equipped Laboratory. 
2. Well trained personnel required for specimen collection. 
3. Issues with the sensitivity of the method to detect Mu. 
4. The slow growing nature of the bacillus is not quick for rapid patient care. 
Many health centres are not equipped to overcoming all these challenges as such the need for 
a rapid, accessible and easy to use diagnostic test. Currently, BU cases are under reported 
globally,  due to lack of rapid diagnostic tools (WHO, 2012, 2015). It has been reported that 
BU cases are increasing in the BP with the reasons unknown (Vic Health, 2015). The aim of 
this section is to develop a diagnostic test for Mu. This study as such proposes a modified 
method for the production of purified protein derivatives (PPDs) from Mu which will serve as 
an antigen in serological survey in BP cohort. This section will address the host immunity as a 
risk factor in the hypothesis in section 1.4. To help me achieve aim 2 and aim 3 we have the 
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kind assistance of collaborators in Peter Doherty institute for infection and immunity in 
Melbourne, Australia, we also have on the team project co-supervisors from Australia Animal 
Health Laboratory (CSIRO).   
 
2.2-2 Objectives 
The main objective of this study is to produce purified protein derivatives (PPDs) from Mu to 
be used in a serological survey. Specific objectives include: 
1. To establish a culture of Mu for PPD and a stock culture for future use. 
2. Production of PPDs for whole blood stimulation of residents on the BP 
3. Expression of the seven recombinant proteins in Section 1.2-1 specific for Mu to be 
used in whole blood assay from residents on BP. 
At the end of this study we hope to have answers for questions like; 
1. What biomarkers from the PPDs and recombinant proteins are unique for diagnosis in 
Mu infection? 
2. Can these biomarker distinguish exposure to Mu in experimental murine models?  
The limitation in this section is the molecular heterogeneity among Mycobacteria species as 
such designing diagnostic tool is a cumbersome task. We hope to overcome this hurdle by 
comparing the PPD produced from our studies with other PPDs from other Mycobacteria 
species e.g. M. para-tuberculosis or M. marinum. 
2.2-3 Ethics Approval 
Approval for the culture of Mu in Deakin University PC2 laboratory was given by the 
Laboratory & Biosafety Committee (LBC). Risk Assessment for the production of PPDs was 
also approved by School of Medicine Laboratory technical Committee. All procedures used in 
the culture of Mu and the production of PPDs are in accordance with the guidelines of Safety 
in Laboratories, AS2243.3 Microbiology 2002.  
 
2.2-4 Methodology  
To achieve the objectives in Aim 2 the following study design shall be followed; 
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2.2-5 Mycobacterium ulcerans culture 
To produce enough PPD we needed to grow Mu in large volumes. Mu is an environmental 
pathogen, which cause skin ulcer called Bairnsdale ulcer. The mode of transmission to humans 
is unknown as such precautions must be taken in the laboratory when working with them. Basic 
safety standards will be followed including the use of gloves, gowns and the use of biosafety 
facilities (PC 2). Care will also be taken to limit the formation of aerosols. All other biosafety 
assessment and approval will be duly followed.  
2.2-6 Brown and Buckle Agar (BBA) 
This medium supports the growth of most mycobacteria.  It differs from the more traditional 
Lowenstein-Jensen medium in that it contains egg yolks and agar instead of whole eggs and 
therefore does not need to be inspissated which is quite complex and tedious. 
Table 6-Reagents for Brown and Buckle media 
For 6.5 litres For 1.625 litres 
(2 litre bottle) 
di-Potassium hydrogen orthophosphate anhydrous 
(K2HPO4) 
 
36g 
 
9g 
 
Potassium dihydrogen orthophosphate (KH2PO4) 12g 3g 
Agar No3 (Oxoid L13) 68g 17g 
50% Glycerol 100ml 25ml 
Distilled.Water (DW) 4800ml 1200ml 
Additives 
Sterile Egg Yolks (90-95 eggs) 1600ml 400ml 
2% Malachite green (Filtered sterilised) 64ml 16ml 
 
A pre-made BBA media slopes (6ml) were ordered from Media Preparation Unit (MPU) in 
Melbourne University for the start-up culture of Mu. Two type of media were ordered from 
MPU, BBA and LJ. Different type of media are known to influence protein expression in 
mycobacteria species. We chose these two media to assess that effect and also compare the 
quality of PPD that would be produced. The slopes have been inoculated with pure cultures 
and are currently under incubation at 32.5oC. The slopes will be monitored weekly for 3months 
to check for visibly colonies. 
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2.2-7 Batch Cultures 
For the production of PPD from Mu large volumes are required. After sufficient growth has 
been obtained on the slopes, bacteria will be scrapped from the slopes and transferred into a 
25ml protein free Middlebrook 7H9 broth supplemented with glucose and trypose (M-7H9TG) 
and incubated at 32.5°C for 10 days. It is important the media is protein and serum free so that 
any resulting proteins expressed during the process will be solely from the Mu culture. This 
will be followed by passage into 100ml M-7H9TG and incubated at 32.5°C for another 10 days. 
The 100ml M-7H9TG will serve as an inoculum for a 1L M-7H9TG which is the final passage, 
this will be incubated at 32.5°C for 10 days. Cultures will be incubated on a shaker, pH of 6.8-
7 will be maintained throughout the incubation. 
2.2-8 Workflow 
Pure culture (M. ulcerans) 
 
 
                                                     
         Incubated at 32.5oC for 3months 
 
 
 
         Incubated at 32.5oC for 10days 
 
 
 
         Incubated at 32.5oC for 10days 
 
 
 
           Incubated at 32.5oC for 10days 
 
Cells growth and density will be monitored weekly by measuring the absorbance of cultures at 
OD600nm. Pellicle score and pellicle height will also be recorded. These measurement will be 
used as measure of growth throughout the incubation period. 
BBA LJ 
M-7H9TG (25ml) M-7H9TG (25ml) 
M-7H9TG (100ml) M-7H9TG (100ml) 
M-7H9TG (1L) M-7H9TG (1L) 
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2.2-9 Time course secretome 
The protein composition in our batch culture will be determined and analysed pre and post 
harvesting for the production of the PPD. This is because the presence of any unaccounted 
proteins has the potential of interfering with the quality or quantity of the PPD generated at the 
end of production. The composition of secreted Mu within the culture media will be taken at 
two independent time points and recorded. The media will be concentrated and total protein 
will be quantified for each sample time point using the 2-D Quant Kit (GE Healthcare) as per 
the manufacturer’s recommendation.  
2.2-10 Purified Protein Derivate  Workflow for Mycobacterium ulcerans 
Freshly grown bacterial will be harvested for the preparation of PPD. The following outline 
will be followed; 
1. Cells will be vortexed for 10 seconds to de-clump the bacterial cluster. 
2. Bacterial cells will be inactivated in a steam autoclave at 100°C for 2h and cooled to 
4°C overnight. 
3. Cells will then be filter sterilized through sterile gauze and transferred into sterile 
centrifugation pots for centrifugation at 3,000 × g for 10 min.  
4. Resultant supernatants will be transferred into a new pre-weighed centrifuge pots and 
40% (w/v) TCA solution in distilled water will be added to a final concentration of 4%. 
5. Mixture will be stirred for at least 30 min with magnetic stirrer and placed (without 
stirring) in the dark room at room temperature for 15-18h. During this period the 
Burulin-proteins will be precipitated by the TCA. 
6. The precipitate will be centrifuged at 2,600 × g for 15 min. This step will generate a 
pellet. If the pellet is too soft to retain a second centrifugation will be done.   
7. The solution will be carefully decanted to retain the pellet. 
8. The pellet will be put in a centrifuge pot and washed with 5% NaCl (w/v) + 0.5% phenol 
(w/v) (adjusted to pH 3.0 with 40% (w/v) TCA). Centrifuged at 2,600 × g for 15 min 
and repeat washing three times until the pH of the supernatant is between 2 and 3. The 
wet-weight will be measured and recorded. 
9. The washed pellets will be dissolved in 1.8% (w/v) Na2HPO4.2H2O (pH 11) with the 
amount equalling approximately 2-2.5 ml per gram of wet-weight. 
10. Centrifuge the preparation at 2,600 × g for 10 min and mix the supernatants with an 
equal volume of phosphate buffer (1.5% (w/v) KH2PO4 + 3% (w/v) Na2HPO4.2H2O) 
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containing 19.4% (w/v) glucose and 0.5% (w/v) phenol, pH will be maintained at 6.7-
6.9. 
11. PPD generated will be quantified using the 2-D Quant Kit (GE Healthcare). 
12. Concentrated PPD will be stored at 4°C in the dark for later use. 
 
2.2-11 Recombinant Proteins Expression 
  
Recombinant proteins shall be expressed from the seven Mu specific gene constructs cloned 
into the plasmid vector pET-DEST42. The plasmid constructs which are MUL_0513, 
MUP045, MUP057, AT propionate, KR A, MUL_2232 (hsp18) and MUL_1393 (hsp65) will 
be transformed into an E. coli expression vector to produce Mu-antigen for the serologic assay. 
The plasmids have a C-terminal V5 epitope and 6xHis tag, are Ampicillin resistant and 
expression of the proteins is induced by Isopropyl β-D-1-thiogalactopyranoside (IPTG). The 
plasmid constructs used in this study were gotten from James Sacha Pidots (Department of 
Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia) and 
procedure for the protein expression used in this section is as described by Pidot et al.  2010 
(Pidot et al., 2010). 
 
2.2-12 Protein Analysis by Polyacrylamide Gel Electrophoresis: 
The recovered PPD and recombinant proteins will be run using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) using 12% gels under reducing conditions in 
Laemmli buffer for protein analyses.  
 
2.2-13 Cytokine Assay in Mice 
As a proof of principle, the proteins recovered in section 2.2-10 and 2.2-11 will be used in a 
mice model first. Mu infected and uninfected mice will be bled (0.5ml of blood) after 3 days 
for serum analysis. This will serve as an optimizing assay for the serological-survey assay for 
Victoria population. Analysis will be done using Enzyme-linked immunosorbent assay 
(ELISA) and Western blotting.  
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For the mice model, 5 BALD/c mice will be used in a pilot study to calibrate the setup. Mice 
have been chosen for this assay as their physiological makeup mimics that of humans, also 
previous BU models has shown mice to be easy to use and manipulate. The procedure will be 
as follows; 
1. Tails of healthy BALD/c mice will be dipped into 5 ml culture of 106 Mu/ml and then 
puncture wounds will be created on the tails using sterile needle sticks, this will be 
recorded as Time-0 (t0) and designated the name asymptomatic stage.  
2. The mice will later on be observed until ulcers appear on the tails, the time will be 
recorded and designated ulcerative/symptomatic stage (tbu). 
3. Average time (tbu1/2) designated subclinical BU will be calculated from t0 – tbu. 
4. From (3) we will thus have three time point for bleeding mice for serological assay 
which will seek to measure the expression of cell-mediated immunity (cytokines) and 
also possible antibodies specific for Mu. 
Time point for bleeding 
t0-   asymptomatic stage 
tbu1/2-   subclinical BU 
tbu-   ulcerative/symptomatic stage 
 
5. After the time points have clearly been defined 30 BALD/c mice will now be used for 
the PPD and Mu Recombinants serologic assay. 
6. Mice will be sacrificed after tbu, and their spleen and lyphmnodes will be harvested for 
further expression of cell mediated markers. Some of the analytes shall include; Th1 
cytokines: IL-2, IFN-c, IL-12p40, IL-12p70; Th2 cytokines: IL-4, IL-5, IL-10, and IL-
13; proinflammatory cytokines: TNF-a, IL- 1a, IL-1b, and IL-6; IL-9; IL-17; colony 
stimulating factors: GMCSF, GCSF, IL-3; and chemokines: CXCL-1, CCL-2, CCL- 3, 
CCL-4, CCL-5, and CCL-11. 
7. Concanavalin A (ConA) mitogen will be used as non-BU agent in control mice. 
 
2.2-14 Western blot analysis  
1. For the analysis of mice sera, PPD (antigen) and Mu recombinant proteins will be 
separated on electrophoretic gel (From Aim 2-PPD production). 
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2. Gels will be transferred to nitrocellulose membranes. Membranes will be blocked with 
skim milk and protein bands will be cut into strips.  
3. Antigen strips will be incubated with mice sera (0.5ml) samples at a 1:500 dilution in 
PBS-T for 1.5 hrs. Strips will be washed with PBS, 1% Tween 20 and incubated with 
alkaline phosphatase-conjugated fragment goat anti-human immunoglobulin. Nitro-
blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) will be used 
for colour development. 
 
2.2-15 Enzyme-linked immunosorbent assay (ELISA)  
1. ELISA 96-well plates will be coated with PPD also for per well in 100 ml PBS. This 
will be repeated for Mu recombinant proteins. 
2. Plates will be incubated at 4oC overnight.  
3. After incubation, plates will be washed with dH2O, 2.5% Tween 20 (dH2O-T) and 
blocked for 1 h with 200ul blocking buffer (5% skim milk in PBS) at 37oC.  
4. Serial 2-fold dilutions of serum from 1:100 to 1:12800 in 50ul blocking buffer per well 
will be incubated for 1.5 hrs at 37oC. 
5. The plates will be washed once more with dH2O-T.  
6. 50ul of 1:6000 diluted goat anti-human IgG (c-chain specific) coupled to horseradish 
Peroxidase will be added to each well and incubated for 1h at room temperature.  
7. 100ul TMB Microwell Peroxidase Substrate (KPL) will be added after the after the last 
washing step with dH2O- T. 
8. The reaction will be stopped after 5 min and absorbance measured using an ELISA 
plate reader at 450 nm.  
9. The ELISA plate will contain two-fold dilutions of a negative control comprising a pool 
of 5 negative sera from people living in BU non-endemic communities and a positive 
control consisting of 5 medium positive sera from people living in BU endemic areas. 
The cut-off value for positivity will be considered to be the mean optical density (OD) 
of negative and positive control at a 1:100 serum pool dilution as described by Yeboah-
Manu et al., 2012. 
10.  Statistical analysis will be done using some specific test like the nonparametric 
Kruskal-Wallis and also Dunn’s post-test shall be used to compare OD values for the 
different groups. The results will be considered significant if p≤ 0.05. 
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2.2-16 Comparative ELISA Assay 
The in-house generated PPD will be compared with other PPDs from mycobacteria species 
simultaneously e.g. M. tuberculosis, M. para-tuberculosis and M. marinum to assess cross-
reactivity and specificity of the PPD. The results from this assay will be compared using a One-
way analysis of variance (ANOVA). 
 
 
 
2.3-0 Aim 3- 
 
To understand level of exposure of Mu in the BP and also determine in co-morbidity in 
disease.  
 
2.3-1 Background 
A serological assay has been suggested by many researchers as a possible diagnostic tool for 
BU which might help to understand the full extent of exposure of Mu globally. Such tools have 
been used in studies in endemic and non-endemic areas in Uganda, Ghana and Benin but not 
in Victoria, Australia. (Stanford et al., 1975; Pidot et al., 2010; Yeboah-Manu et al., 2012) . It 
is worth mentioning however that serology assay has not received much support as efficient 
tool to screen Mu exposure due to cross-reactivity with other mycobacteria species. A major 
limitation of this study is that in Ghana and part of West Africa individuals receive BCG 
vaccine for tuberculosis which might result in the non-specificity the Mu assay (Diaz et al., 
2006; Yeboah-Manu et al., 2012). 
In this study we shall also explore co-morbidity factors in the Victorian database, specifically 
clinical history of BU patients on immunosuppressive medications to see if these have 
predisposed them to Mu infection. 
We hypothesize that areas like Victoria which do not report many cases of tuberculosis or BCG 
vaccination, serological-survey is a good tool to measure risk to the disease. BU cases in 
Australia and specifically Victoria has being increasing since 1998-2014. The reason for the 
rise is unknown and there is no data on the level of exposure or the environmental parameters 
driving such progression. We therefore propose a large serological-survey and environmental 
assessment in the Bellarine Peninsula to generate data on the level of exposure (18kDa shsp) 
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and cell meditated immunity. Our findings could help policy makers’ setup interventions to 
reduce the steady progression of the disease. The limitations of observational study applies in 
our project couple with cross-reactivity to serum proteins with other non-tuberculous 
mycobacteria (Barksdale et al., 1977; Pidot et al., 2010). This section will address the host 
immunity as a risk factor in the hypothesis in section 1.4 
 
 
 
2.3-2 Objectives 
The main objective of this study is to assess the level of exposure of residents on the BP to the 
Mu pathogen and co-morbidity factors. Specific Objectives include; 
1. Determining Mu specific antibody (18kDa shsp) titre in residents’ sera. 
2. Quantification of cell-mediated biomarkers (cytokines) in whole blood of residents to 
infer susceptibility. 
3. To explore co-morbidity in BU cases from the BP. 
 
2.3-3 Ethics Approval 
Ethical clearance for the study will be obtained from Victoria Health Department, Barwon 
Health and Deakin University. Written consent will also be obtained from all individuals 
involved in the study. Parents or guardians written consent on behalf of all child participants 
will also be considered. The research will be carried out in accordance with the guidelines 
specified by The National Statement on Ethical Conduct in Human Research (2007) (Updated 
May 2015) 
 
2.3-4 Methodology  
To achieve the objectives in Aim 3 the following study design shall be followed; 
 
2.3-5 Study Design 
The areas to be selected for the serologic screening of individuals will be based on the 
explorative and descriptive analysis of the Victoria wide BU data and the spatial distribution 
of cases in Aim 1. The criteria for suburb inclusion in Victoria will be based on section 2.1-6 
(no. 1-5) which lists the suburbs to be considered for environmental sampling. 
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Selection of individuals for the serologic screening will based on the mesh block scale. Any 
individual who answers “Yes” to the following questions will be included in the screening. 
1. Have you had BU before? 
2. Has any member of your family had BU? 
3. Have you shared an accommodation with a BU patient? 
4. Have you had an ulcer (not necessary BU) before? 
5. Have you had a pet with BU before? 
6. Do you encounter possums in your home or around your house often?                                                                                                                                          
2.3-6 Venepuncture 
 
To determine level of exposure to Mu we shall require whole blood samples from persons 
living in the study area for the PPD and recombinant protein stimulation. A qualified Nurse 
or Phlebotomist from Geelong hospital will be employed to do the venepuncture. Blood 
samples shall be collected using this protocol;   
 
1. Two millilitres of blood will be collected into vacutainer tubes from participants of 
communities described above.  
2. The participant will be de-identified but the following information will be recorded. 
a. Patients reference code 
b. Age group 
c. History with BU (in study design questions) 
d. Mesh block residence 
e. Endemic or non-endemic community 
 
3. Blood samples will be transported immediately at ambient temperature to the laboratory 
for separation of serum by centrifugation at 2,000g for 10 mins to remove the clot. Sera 
will be stored at -80oC until further analysis. The samples shall be analysed according 
to the procedure described in section 2.2-14 and 2.2-15. 
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2.4 OVERVIEW OF THE CURRENT STUDY 
 
 
 
 
Figure 7 - Summary of the Current project 
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2.5 RESEARCH DURATION  
 
 
 
Table 7-Research timeline 
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CHAPTER 3- RESULTS AND DISCUSSION  
 
 
In this report, we describe the spatial distribution of BU case from 1998-2014 as reported in 
the department of infectious diseases in Barwon Health, Victoria. We also show basic 
explorative analysis of BU cases. The spread of BU is rising steadily (Fig.2 & 8) although 
morbidity is low compared with other countries. In Victoria, BU cases is geographical 
restricted to the Bellarine Peninsula with no clear explanation  (P. Johnson, Hayman, et al., 
2007). Point Lonsdale reported the most case of BU (112) for the year under review. Barwon 
Heads, Queenscliff, Ocean Grove and St. Leonards follows with 63, 34, 30 and 19 cases 
respectively (Fig 8). 
 
Figure 8 -Suburbs of Reported cases of Bairnsdale ulcer in Victoria (Barwon Health) 
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3.1-1 Buruli Ulcer Cases by Year 
The year that saw the highest cases is 2012 (48 cases) which is quite recent with respect to the 
first case of BU in Victoria (1930s). Some areas like Indented heads, Clifton spring, Beaumaris 
and Seaford have only reported a case within 2002, 2004, 2012 and 2014 respectively, 
Beaumaris, Seaford and its environs might describe a new foci for BU due to the recency of 
their cases (Fig 11) which might require immediate intervention in terms of awareness creation 
to avert more cases. It is however very difficult to ascribe a concrete reason for the rise in cases 
since the mode of transmission of BU is still unknown ( Portaels et al., 1999; Hughes et al., 
2007; Huang et al., 2014). Though in Australia mosquitoes and possums have been implicated, 
more environmental investigations need to be done to establish a strong link with human 
infections (Johnson et al., 2007; Fyfe et al., 2010; Lavender et al., 2011). And such 
investigations must answer questions on increase in possum population and abundance of 
mosquitoes in a given time. The other parameters that will need to be investigated is whether 
these organisms were consistently infected with M. ulcerans to serve as agent of transmission 
to human.  
 
  
Figure 9 - BU cases by year. The highest case was in 2012. 
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3.1-2 Buruli Ulcer cases by Month 
July is the month that recorded more cases of BU (42 cases) ((Fig-10) a similar study in 2007 
reported June. (Hughes et al., 2007).  July is also the Victoria’s coldest month (winter). 
Temperatures ranges 13.4-15.4oC with some rain showers (van Ravensway et al., 2012). More 
cases have also been reported to occur at the end of autumn or winter (Duker et al., 2006). With 
the onset of BU cases often reported after heavy rain and flooding, it is not surprising that more 
case are thus reported in July. It is important to mention that the months indicated in Fig-9 is 
not the months of infection but rather the clinical diagnosis of the disease. M. ulcerans is a 
slow growing bacteria with incubation period of 6weeks-3months (Walsh et al., 2008). Thus 
reporting BU in July meant that infection would have occurred around March-June.  (Hughes 
et al., 2007) also reported 1-4months of latent BU.  
This implies that understanding the parameters of transmission has to span at least March to 
July. From Fig-9, another interesting trend can be identified in December and January. From 
July, BU cases (42 cases) steadily declines to December (10 cases) and picks up again in 
January (13 cases) if it can be understood as a cyclic trend. The probable explanation may lie 
in the seasonal variation and anthropogenic activities (i.e. reactional activities).  
 
Figure 10-BU case by month. July recorded highest BU cases 
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Australia winter is usually from June-August (van Ravensway et al., 2012). The weather is 
usually cold and there is less outdoor activities (BU cases decline). Spring - the three transition 
months September-November (holidays and outdoor activities gradually resumes with some 
Mu infection). The summer and hottest months are December-February (lots of Mu infections 
occurs here due to numerous outdoor activities) and BU cases begin to rise from February after 
incubation period. Continuous seasonal variation monitoring might give a clearer trend of BU 
incidence in Victoria.   
 
3.1-3   Areas of residence and Buruli Ulcer cases 
Though July is the month that recorded overall highest cases, when Point Lonsdale, Barwon 
Heads, Queenscliff, Ocean Grove and St. Leonards the five areas with highest cases among the 
16 areas  are observed closely they recorded highest cases in different months. And this raise 
the question as to whether the month of July alone is that important in Mu transmission (Fig 
11)? 
 
 
Figure 11-Area of Residence showing months of highest cases 
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Barwon Health has 16 different areas reporting BU cases from 1998-2014. Among these, Point 
Lonsdale, Barwon Heads, Queenscliff, Ocean Grove and St. Leonards seems to have a crude 
average outbreak every 2.3 years. Point Lonsdale however has been consistent in reporting BU 
case every year from 2000-2014 per the hospital data (Fig.12). This makes it still the most 
endemic point in Victoria (Hughes et al., 2007;Johnson et al., 2007; O’Brien et al., 2013; 
2014;). For further studies on environmental parameters Point Lonsdale is a good spot. The 
differences in months of highest cases (Fig.11) among the BU areas make transmission 
tracking quite difficult and expensive as this requires designing different methods for studying 
each area for their unique parameters (Merritt et al., 2005).  
 
 
Figure 12 - BU case by year and area of residence -The red boxes show suburbs that have reported cases for ≥ 7 
different years. The is a crude average case reports every 2.3 years 
 
3.1-4   Clinical Presentation of Buruli Ulcer 
There were more BU cases on the legs (83 cases) than anywhere else on the body. The ankles 
and elbows topped with clinical presentation of 46 and 40 cases respectively (Fig.13), almost 
twice less in the case of legs. This was also the trend reported by Hughes et al., 2007. The 
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remaining body site recorded less than 20 cases. This results is agrees with previous studies 
that found that the lower extremities reported more case than any part of the body followed by 
the upper extremities (Hayman et al., 1985; Noeske et al., 2004 Hughes et al., 2007). The 
reason for such dichotomy has not been investigated by research. It has however been 
suggested that since M. ulcerans is an environmental mycobacterium present in the soil and 
the lower limbs are closest to the ground transmission is thus aide. It has also been postulated 
that the nature of occupation might influence the site of BU on the body. The reason being that 
rural farmers in West Africa with less footwear protection are more prone to infection than 
those who wear shoes and long-sleeved clothing to farm (Raghunathan et al., 2005). 
 
 
Figure 13- Anatomical presentation of BU at Barwon Health 
 
3.1-5  Age of patients and category of Buruli Ulcer 
 
WHO has grouped BU into 3 categories. Category I, are ulcers < 5 cm in diameter. Category 
II ulcers are usually > 5cm and ≤ 15cm in diameters. Category III ulcers are those that > 15cm 
in diameter but also BU on multiple sites of the body (e.g. legs, head, breast and hand at the 
same time). Majority of BU present in our data are category I (81%). Category II and III 
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followed with 11% and 8% respectively (Fig.14). This result is opposite to what is observed in 
West Africa where category III ulcers are predominant ( WHO, 2012; Huang et al., 2014;). The 
possible reason for such difference might lie in the virulence of different strain of M. ulcerans. 
It has been observed that the strain found in Australia produces mycolactone-C which is less 
cytotoxic compared to the Africa strain which produces mycolactone-A and very virulent. This 
might play a role in the advancement of BU (Gunawardana et al., 1999; Kishi, 2011). The other 
reason is the ready access to medical centre and welfare system in Australia compared to rural 
suburbs of West African. BU patients in Australia are likely to visit hospital quicker to present 
BU cases for rapid treatment before reaching category II or III. Nutritional disparity might also 
account for the extreme lesions observed in other areas of BU compared to Australia (Asiedu 
et al., 1998; Duker et al., 2006; Hughes et al., 2007). 
 
 
Figure 14 – Age and category of BU case 
 
The mean age is (53.6 years) and the median age is (57.5years), the median age is closer to 
what was reported by Hughes et al., 2007 which was ≤ 60years. The age group that is mostly 
affected is 71-80years (16%) but is closely followed by 61-70years old group with 15%. The 
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next groups are 51-60 and 81-90years both with 14% of BU cases among patient’s data. Those 
aged 50 years and younger had below 10%. This makes the older folk the group (51-90years) 
more susceptible to BU in Victoria as reported also by (Hughes et al., 2007; Boyd et al., 2012; 
O’Brien et al., 2013). The reason for such age trend in Victoria could be due to 
immunosuppression related to advancement in age. Older folks are usually stricken with weak 
immunity and are more prone to infectious disease as evidenced by the Fig.13. The age trend 
is however not the case in West Africa where BU is prevalent among children in 5-15year 
groups (Debacker et al., 2004; Merritt et al., 2010; Boyd et al., 2012). Another trend that might 
support the weak immunity hypothesis among the older folks is the presence of all the BU 
categories (I, II and III) in that age bracket proving that they are likely to advance in category 
once infected (Fig.13).  
In conclusion the results presented in this report are cases from the Barwon Health, department 
of infectious diseases from 1998-2014. The current project is also working hard to acquire the 
entire BU patient’s data in Victoria to present a much big picture. Though there are some 
differences in what our data showed there is however some agreement with previous studies 
done elsewhere in Australia and other countries (Gooding et al., 2002; Quek et al., 2007; 
Hughes et al., 2007; Merritt et al., 2010). At the end of this project we hope our results will be 
of help to Victoria health department on intervention to make to curtail further spread of this 
flesh eating bacteria. 
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Abstract 
Background 
Buruli ulcer (BU) is a subcutaneous necrotic infection of the skin caused by Mycobacterium ulcerans. There 
has been increasing BU incidence in Victoria, Australia. The aim of this study to provide an epidemiological 
update of BU cases in Victoria to understand the pattern of distribution over time and space and attempt to 
identify local risk factors.  
Methods 
A comprehensive descriptive epidemiological analyses were performed on BU notification data from 1994 
to 2016. In addition, retrospective temporal, spatial and spatio-temporal analyses were conducted to 
understand the distribution of cases. Quantum GIS was used to generate maps. Demographic, new housing 
settlements and historical rainfall data were analysed to assess their effects on BU incidence in Victoria. 
Findings 
There were a total of 902 patients notified from 1994-2016. The incidence rate was 0.8/100,000 persons in 
Victoria. Space and time analyses showed that the most likely disease cluster was the Bellarine and 
Mornington Peninsulas with incidence rate 50 times higher than the State of Victoria rate. Gender was not 
a risk factor, but age was, with increased susceptibility among the over 60 year old group. There was an 
unusual high risk in the 15-24 age group in Point Lonsdale. Correlation analyses indicated that increase in 
population and construction of new settlements might be some of the reasons contributing to the rise in 
cases in Victoria.  
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/413542doi: bioRxiv preprint first posted online Sep. 10, 2018; 
2 
 
Interpretation 
The findings agreed with published works in Australia of the increase in BU cases in Victoria. However, 
our findings also highlights the endemic nature of cases. The identified spatial disease clusters could be 
relevant for future environmental sampling studies or screening tests for M. ulcerans exposure. 
Author Summary  
Buruli ulcer (BU) has been reported in 33 countries, mainly from the Tropics and Sub-tropics. Tropical 
cases are mainly within the West African region. Australia is the only country outside Africa in the top six 
highest incidence countries for BU. The exact mode of transmission remains unclear. Disease cases are 
rising in Australia, especially in Victoria for reasons that remains unclear. We have provided a descriptive 
epidemiological analyses in space and time of 22 years of recorded data on BU cases in Victoria from 1994 
to 2016. We have also discussed demographic and new settlement dynamics over the study period. There 
were a total of 902 PCR-confirmed BU cases from 245 suburbs. Five suburbs on the Bellarine and 
Mornington Peninsulas were identified as the most endemic locations in Victoria. Spatial analyses detected 
a wider disease cluster area on the Peninsulas. We propose environmental sampling for risk factors analyses 
should focus on the endemic regions and some secondary clusters.
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INTRODUCTION 
Buruli ulcer (BU) is a skin infection caused by Mycobacterium ulcerans. The progression of disease is 
marked by destruction of skin and subcutaneous tissue (1,2). While BU is the most common name, it is 
also known as Bairnsdale ulcer (2), Daintree ulcer (3), Kumusi ulcer (4), Mossman ulcer or Searle ulcer 
(5) depending on the geographical region (6). 
A geographically restricted disease, BU has been reported in 33 countries in the tropics and sub-tropics 
(7,8), with very few cases reported in temperate areas (9). In the tropics, the highest prevalence is in the 
West and Central African regions (10,11). The sub-tropical cases are mainly within Queensland in northern 
Australia (3). Cases in the temperate regions include a temperate region in southern Australia (i.e., Victoria) 
as well as Japan and China (12). Australia reported its first case in Bairnsdale (Victoria) in the late 1930s 
(13,14). In Australia, MacCallum et al., were the first to describe and publish reported cases of a skin ulcer 
caused by Mycobacterium cultivable only on Löwenstein-Jensen medium (2,14). The annual incidence rate 
as at 2016 is less than 1 per 100,000 inhabitants in Australia (15). Victoria is the state with highest number 
of cases reported in Australia (15).  
The exact mode of transmission remains unclear; however, outbreaks of BU have usually been reported 
from areas close to aquatic environments (6,16). Aquatic insects have repeatedly been found positive for 
the M. ulcerans DNA target sequence IS2404 (6,17,18). The involvement of mosquitoes as vectors and 
possums as reservoir have been suggested in Australia (12,19,20).  
Heavy rains and floodings causing landscape alteration have also been associated with BU incidence (6,21). 
Age and gender are regarded as non-environmental risk factors in some areas (6,22). In Australia, BU is 
prevalent in the population older than 60 years; this has been attributed to immunosenescence (23).  
BU cases are decreasing globally as per recent review (24), but Victoria has seen an increase in cases with 
shifting geographical distribution of disease (from the Bellarine to the Mornington Peninsulas) (15). Further 
studies are required to better understand this trend in Victoria. The main objective of this study was to 
provide an epidemiological profile and to perform space-time statistical analyses of BU cases in Victoria 
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to understand distribution patterns and identify possible local risk factors such as age, gender, annual 
rainfall, changes in population and construction of new settlements. 
METHODOLOGY 
 
Ethics statement  
Low risk ethics approval was obtained from Research Ethics, Governance & Integrity (REGI) Unit at 
Barwon Health for the use of the Victoria Buruli ulcer database. Project reference number:  BW HREC 
14/114. We were not required to obtain consent as data we were collating and analysing had already been 
notified to Department of Health and Human Services of Victoria (DHHS) under the Public Health and 
Wellbeing Act 2008 and patients were not re-contacted. All patient data analysed were anonymized. 
Buruli ulcer notifications for Victoria 
 
The study population included patients diagnosed with BU and notified to the DHHS from 1 January 1994 
to 31 December 2016. BU became a notifiable condition in Victoria in 2004, before which notification was 
voluntary. The BU confirmed cases involve detection from clinically suspected cases of IS2404 by 
polymerase chain reaction (PCR) or isolation and culture of the organism from specimens performed by 
the Mycobacterium Reference Laboratory (MRL), Victoria. Data were extracted from a centralized 
notifiable disease database and variables used in the analysis included: BU notification date (stratified by 
month and year), 5 year age group, gender, suburb of residence and meshblock address at the time of 
notification, “exposure to which endemic area”, and “type of contact with endemic area (Residents or 
Visitors)”. Meshblocks are the smallest geographic regions in the Australian Statistical Geography Standard 
(ASGS), for which census data are available and preserve privacy. For purposes of interpretation, a 
“Resident” as referred to in this study is a BU patient with recorded   exposure to M. ulcerans infection at 
their place of residence. There are two types of Residents: Residents living in a known endemic area and 
Residents who do not live in a known endemic area and never visited one. A “Visitor” is a BU patient who 
does not live in a known endemic area and have their exposure recorded outside their place of residence 
when visiting a known endemic area.  
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Dataset for geographic information system 
 
Geographic information system (GIS) map layers were acquired from the Government of Victoria website 
(https://www.data.vic.gov.au/) (25) and demographic data from Australian Bureau of Statistics (ABS) 
(26). Data sourced included: 
i. Regional boundaries (Australia and Victoria map layers) 
ii. Meshblocks in Victoria (2011) 
iii. Demographic data (2016 census data) 
iv. New settlements information (2006-2016 census data) 
Historical population and housing census data for Victoria from 1994 to 2016 has changed significantly. 
There has been the addition of new settlements and re-demarcation of meshblocks since 1994. Therefore, 
to provide a general epidemiological update, population census data used for all analyses were from the 
2016 census data. 
Rainfall dataset and analyses 
Since BU incidence has been linked to seasonal variations (6,21,27,28), historical rainfall data from 1994-
2016 were sourced from the Bureau of Meteorology website (29). Rainfall data for Rye was collected from 
the Rosebud country club station (#086213). Ocean Grove weather station (#087178) was also the source 
of Point Lonsdale and Queenscliff rainfall data. Barwon Heads rainfall data was collected from the Barwon 
Heads Golf Club station (#087135). The rainfall data quality were highly variable with 11 missing data 
points (1994, 1995, 1996, 1999, 2000, 2002, 2003, 2004, 2006, 2007 and 2009)  from Ocean Grove weather 
station from 1994 to 2016. There were eight missing data points (1994 to 2001) from Barwon Heads Golf 
Club station and one missing data point (2003) from Rosebud country club station. To assess rainfall pattern 
and BU incidence at the local level, the mean annual rainfall from the three weather stations were cumulated 
into three groups namely 1994-2006, 2007-2011 and 2012-2016. 
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This grouping was done for ease of comparison with changes in the addition of new settlements from the 
ABS website from 2006, 2011 and 2016 housing and population census data at the local level. 
Statistical analysis and epidemiological calculations 
 
GraphPad Prism (Version 7.03) was used to perform univariable analysis. The analyses included 
stratification by gender for age-group and temporal trend for entire Victoria as well as for the most endemic 
suburbs. Spearman correlation was performed for month of notification for BU cases stratified for Residents 
and the total number of places of residence as well as Visitors and total number of places of residence across 
Victoria. Nonparametric analyses was done using Kruskal–Wallis and Mann–Whitney tests on the variables 
at statistical significance at p-value of 0.05.  
We also identified most common exposure sites and assessed demographic, physical environment and 
rainfall pattern. Epidemiological calculations for the most common exposure sites included: number of 
cases (n) and percentage (%) of positive cases in the population (pop), cumulative incidence rate for a time 
period, and relative risk. Cumulative incidence is the proportion of new cases occurring during a specified 
time period per 1,000 inhabitants. Relative risk is the ratio of percentage of positive cases among the 
exposed (to a risk factor) on percentage of positive cases among the non-exposed (Table 1). Relative risk 
and cumulative incidence were calculated for each endemic suburb and other detected disease clusters 
compared to the total population at risk in Victoria. All calculations were as described in Basic 
epidemiology (2nd edition, World Health Organisation 2006) (30). 
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Mean annual cumulative incidence (Ci) = n ÷ (years under review) x 1,000 /population. 
Table 1: Relative risk contingency table. 
 Positive cases Negative cases 
Exposed  a b 
Non exposed c d 
 
Relative risk = a/(a+b)/c/(c+d) 
We also assessed the correlation between BU incidence and changes in demographic, physical environment 
and rainfall pattern in the most common exposure sites. 
GIS and data importation 
BU notification data containing the list of variables described above were imported into the GIS software 
by the meshblock unique identifier matching the Victoria meshblock layer. Extraction of the co-ordinates, 
latitude and longitude (WGS84 Geodesic reference system) of each polygon centroid from the two 
following layers: all meshblocks of Victoria and Victorian Buruli cases. Quantum GIS (qGIS) software 
(version 2.18.7, Las Palmas) was used. 
Organization of files for SatScan 
 
To conduct the spatial, temporal, and space-time analyses, latitudes and longitudes were extracted for each 
meshblock centroid point using qGIS from a polygon map of Victoria. All BU cases locations were geo-
coded and matched to the meshblock points and administration.  
SatScan analysis parameters 
 
The files created as input files for SatScan software were: 
1. Case file containing BU cases with meshblock location identification (Loc. id) and time of 
diagnosis in months and years. 
2. Population file containing Loc. id with number of inhabitants 
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3. Co-ordinates files containing Loc. id with latitudes and longitudes  
SatScan was programmed to report maximum cluster size of ≥ 25% of the population at risk. Spatial output 
was set to report hierarchical clusters with no geographic overlaps. Monte Carlo replications were set at 
999.  
Spatio-temporal analysis 
 
A retrospective purely temporal, purely spatial and space and time analysis under the Poisson probability 
model to detect significant clusters by exhaustively scanning over space, time and both space-time. Monte 
Carlo replication was performed using SatScan software (version 9.4.4). With a null hypothesis of no 
outbreak, the software algorithm searches the input data files to discover areas where cases exceed 
expectation and report a p-value and relative risk. In conjunction with qGIS,  maps were developed to 
represent cases in time (temporal trend), in space (spatial analysis) and in space and time (spatio-temporal 
trend) (31).   
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RESULTS 
Distribution of Buruli ulcer cases by residence in Victoria-1994-2016 
 
There were 902 confirmed BU cases notified from 1994 to 2016 with residential addresses from 245 suburbs 
in Victoria (Fig 1).  
Fig 1: Distribution of confirmed Buruli ulcer cases within Victorian Government regions in Victoria from 1994 to 2016. 
The coloured regions shown in the map represent the Government of Victoria regions in 2011. 
 
The highest concentration of reported cases lived in the Southern metropolitan region of Melbourne, 
Victoria, with 356 cases (39%). This was closely followed by Barwon South West region with 317 cases 
(35%). Northern/Southern and Eastern metropolitan had 91 (10%) and 74 (8%) respectively. Gippsland, 
Grampians, Loddon-Mallee and Hume regions reported < 30 cases (Fig 1). Of these cases, 523 (58%) had 
their exposure location recorded as their suburb of residence, 335 (37%) had their exposure location 
recorded outside their suburb of residence and 44 (5%) had no recorded exposure site. More males (509; 
56%) reported cases compared to females (392; 44%). The three age groups with most cases were 60-64, 
65-69 and 70-74 years recording 83 (9%), 78 (9%) and 72 (8%) cases, respectively. The remaining age 
groups had < 70 cases each (Fig 2A).There were no significant differences in age, when stratified by gender 
(p = 0.13). The same was observed for month of notification (p = 0.20) and year of case report (p = 0.61). 
Month of notification of BU cases correlate with Residents and the total number of different suburbs they 
resided as well as Visitors and the total number of different suburbs they resided across Victoria (Fig 2D). 
 
Fig 2: A: Age group stratified for gender. B: Year of cases report stratified for gender. C: Month of notification stratified 
for gender. D: Month of notification for BU cases stratified for Residents and the total number of places of residence as well 
as Visitors and the total number of places of residence across Victoria. 
 
Detected purely spatial and space-time clusters 
The purely spatial and space-time analysis showed an average annual reported incidence of BU cases per 
100,000 people of 0.8 from 1994 to 2016 in Victoria. The space-time analysis reported five spatial disease 
clusters (1, 3, 4, 5 and 6) and one temporal cluster (cluster 2). The purely spatial analysis identified 11 
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clusters. Four of the space-time clusters (1, 3, 4 and 5), as well as the purely spatial clusters (1, 2, 3 and 4) 
were reported to be significant clusters (p < 0.05, Fig 3). Both the purely spatial and space-time analysis 
had the most likely disease cluster (cluster 1), also known as the primary/candidate cluster geographically 
located on the Bellarine and Mornington Peninsulas (Fig 3). The annual incidence for cluster 1 (Fig 4) of 
reported cases/100,000 persons for the space-time and purely spatial was 40 (2001-2016) and 28, 
respectively. Temporal analysis detected significant rise in BU cases from 2011 to 2016 (red lines) (Fig 4). 
 
Fig 3: Detected patients’ clusters of purely spatial and space-time analyses.  
Both primary clusters of space-time and spatial analyses labelled “1” (Indigo circular window) are located on the Bellarine 
and Mornington Peninsulas. The remaining circular windows (Violet circular window: purely spatial clusters and Black 
circular windows: space-time clusters) seen on the map are secondary clusters. The numbers (1, 2, 3, 4, 5, 6 and 7) represent 
the order of cluster reporting. Some secondary clusters could not be shown on map due to small size. 
 
Fig 4: Purely temporal trend of BU cases from 1994 to 2016. The lines represent observed cases across time: Blue line shows 
observed cases only. Red line indicates observed cases that showed significant temporal clustering across time (also 
highlighted in red). Dark green line indicates the baseline expected cases based on the total population used in the analysis 
(default calculation by SatScan) and (iv) Light green line is the ratio of observed ÷ expected BU cases.
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Top five residence and exposure locations  
 
The top five suburbs for the place of residence and exposure location of most reported BU cases were 
located on the Bellarine and Mornington Peninsulas from 2002-2016 period (Fig 5).  
Fig 5: Number of BU cases in the top 5 residence (5A) and most visited/attributed exposure (5B) areas from 1994 to 2016. 
Fig 5B, shows the most visited or attributed M. ulcerans exposure areas. 
 
The suburb with most BU cases in Residents was Point Lonsdale with 103 (11%) cases, followed by Rye 
with 74 (8%), Barwon Heads with 61 (7%)  Ocean Grove with 39 (4%) and Queenscliff with 33 (4%) cases. 
All the patients in these suburbs had their exposure location recorded as their place of residence in the 
Bellarine or Mornington Peninsulas (Fig 5A).  Fig 5B shows the top five suburbs reported to be the place 
of probable exposure by patients (Visitors) not living in the area. Point Lonsdale was the suburb with the 
highest number of perceived exposure cases in Visitors with 89 (10%) cases followed by Barwon Heads 
with 42 (5%) cases. Rye, Ocean Grove and Queenscliff followed with 32 (4%), 24 (3%) and 24 (3%) cases, 
respectively.  
 
Fig 5: Five top suburbs of BU cases from 2002 to 2016.  
Number of diagnosed cases among Residents and Visitors in the top five residence and perceived exposure areas in each 
month from 1994-2016. Cases in Point Lonsdale (green) has shown a decrease since 2011, while Rye (blue), which started 
reporting cases in 2012 has shown a steady increase. BU cases in Barwon Heads (red), Ocean Grove (brown) and Queenscliff 
(black) have been dynamic since the onset of case reporting. 
 
 
Temporal trend in the top five Resident and most visited areas. 
 
The temporal trend of Residents and Visitors locations were compared as well as years of case report for 
each of the five suburbs (Fig 6). Since 2011, Point Lonsdale has been reporting a decrease in cases whereas 
Rye, has been reporting increasing cases since 2012 (Fig 6). The seasonal trend of BU reporting was 
generally similar in both Residents and Visitors (Fig 2D). 
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Age and gender of Residents and Visitors in the top five suburbs 
 
From the 2016 census data, the most populated suburb in the top 5 Residents’ locations was Ocean Grove 
(14, 165), followed by Rye (8, 416) (Table 2). Rye had almost twice as many males to females among both 
Residents and Visitors reporting BU. The proportion of males to females with BU cases among Resident or 
Visitors was similar within each of the other four suburbs (Table 2). There was no statistically significant 
difference in gender among Residents (p= 0.44) as well as Visitors (p= 0.52, Table 2). There was a 
significant difference in age group of Residents (Table 2, p= 0.04) and Visitors (Table 2, p= 0.00). 
 
 
 
 
 
 
 
 
 
 
 
 
 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/413542doi: bioRxiv preprint first posted online Sep. 10, 2018; 
13 
 
Table 2: Age and gender of Residents and Visitors in the top five suburbs. 
 
Character- 
istics 
 
Point Lonsdale 
 
Ocean 
Grove 
 
Barwon 
Heads 
 
Queenscliff 
 
Rye 
 
p-value 
 
Population (n) 
(2016) 
 
2,684 
 
14,165 
 
3,875 
 
1,315 
 
8,416 
 
       
Sex n (%)       
Female 54 52 51 53 50.5  
Males 46 48 49 47 49.5  
       
 
Median age 
(Year) 
 
59 
 
42 
 
43 
 
59 
 
47 
 
       
Resident (n) 103 39 61 33 74  
Sex n (%)       
Female 51 (49.5%) 18 (46.2%) 26 (42.6%) 15 (45.5%) 26 (35.1%) 0.44 
Males 52 (50.5%) 21 (53.8%) 35 (57.4%) 18 (54.5%) 48 (64.9%)  
       
Age group       
0-14 6 (5.8%) 2 (5.1%) 7 (11.5%) 3 (9.1%) 9 (12.2%) 0.04 
15-24 7 (6.8%) 2 (5.1%) 9 (14.8%) 0 (0.0%) 3 (4.1%)  
25-34 5 (4.9%) 3 (7.7%) 5 (8.2%) 1 (3.0%) 5 (6.8%)  
35-44 9 (8.7%) 3 (7.7%) 8 (13.1%) 2 (6.1%) 9 (12.2%)  
45-54 3 (2.9%) 3 (7.7%) 2 (3.3%) 2 (6.1%) 9 (12.2%)  
55-64 20 (19.0%) 8 (20.5%) 12 (19.7%) 11 (33.0%) 13 (17.6%)  
65-74 17 (17.0%) 8 (20.5%) 9 (14.8%) 4 (12.0%) 12 (16.2%)  
75+ 36 (35.0%) 10 (25.6%) 9 (14.8%) 10 (30.0%) 14 (18.9%)  
Median age 69.5 59.5 49.5 59.5 59.5  
Age mode 75+ 75+ 55-64 55-64 75+  
       
Visitors (n) 86 22 42 23 31  
Sex n (%)       
Female 42 (48.3%) 8 (36.4%) 20 (47.6%) 12 (52.2%) 12 (38.7%) 0.52 
Males 44 (51.7%) 14 (63.4%) 22 (52.4%) 11 (47.8%) 19 (61.3%)  
       
Age group       
0-14 23 (26.7%) 5 (22.7%) 11 (26.2%) 3 (13.0%) 5 (16.1%) 0.00 
15-24 10 (11.6%) 4 (18.2%) 6 (14.3%) 3 (13.0%) 0 (0%)  
25-34 6 (7.0%) 2 (9.1%) 2 (4.8%) 4 (17.4%) 0 (0%)  
35-44 6 (7.0%) 5 (22.7%) 9 (21.4%) 3 (13.0%) 3 (9.7%)  
45-54 7 (8.1%) 1 (4.5%) 2 (4.8%) 2 (8.7%) 2 (6.5%)  
55-64 16 (18.6%) 1 (4.5%) 5 (11.9%) 2 (8.7%) 3 (9.7%)  
65-74 13 (15.1%) 2 (9.1%) 5 (11.9%) 4 (17.4%) 13 (41.9%)  
75+ 5 (5.8%) 2 (9.1%) 2 (4.8%) 2 (8.7%) 5 (16.1%)  
Median age 39.5 29.5 39.5 39.5 69.5  
Age mode 55-64 35-40 0-14 25-34/65-74 65-74  
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Changes in demographics and physical environment of the top 5 exposure sites 
Within a ten year time period (i.e., 2006 to 2016), Barwon Heads and Ocean Grove have had the greatest 
population increases of 881 (21%) and 2,891 (20%) respectively (Fig 7).  Over the same time, the 
population at Point Lonsdale increased by 207 (8%) and Rye 79 (1%). There has been an 8% decrease in 
Queenscliff population in the same time period. Ocean Grove had the greatest number of new house 
constructions at 1,574 (21%). Rye, which had only 1% increase in population had a 590 (7%) new 
constructions. There was a significant correlation between the incidence rate of BU cases and the increase 
in population and new housing constructions in Barwon Heads (p = 0.02). There was also a significant 
correlation between incidence rate and new housing constructions in Queenscliff (Fig 7, p = 0.02). The 
remaining suburbs did not show any significant relationship between incidence rate of cases, population 
change and housing constructions. The rainfall pattern did not significantly affect incidence rate in top five 
areas at the local level (Fig 7). 
Fig 6: Incidence of BU cases with changes in population, new house constructions and rainfall data from 2006 to 2016. The 
year under review were considered for “2001 to 2006”, “2007 to 2011” and “2012 to 2016”. The blue, brown and green bars 
represent population (N), new house constructions (N) and rainfall historical data (mm/year), respectively. The incidence 
rate of BU cases is shown in red dots and lines. Correlation analyses was performed for each variable to understand how 
they relate to incidence rate. P-values (*) were reported where the relationship was significant (p < 0.05). 
Relative risk of living in the top 5 or disease cluster areas 
The relative risks recorded for BU in Residents in each of the top five patients’ locations and disease cluster 
areas compared to the rest of Victoria were high. The risk of having been diagnosed with a Buruli ulcer was 
274 (range: 224 - 335) times higher in Point Lonsdale compared to the rest of Victoria. This risk in 
Queenscliff and Barwon Heads were 171 (122-241) and 111 (86 -143), and for Ocean Grove and Rye, it 
was less than 100. Relative risk of those living in the top five areas (combined) was 101 (88 - 116).  
The highest absolute risk of BU cases was 4 % in Point Lonsdale, 3 % in Queenscliff and 2 % in Barwon 
Heads. Ocean Grove and Rye had less than 1% each. The highest mean annual cumulative incidence of 
2.6/1,000 persons was observed in Point Lonsdale. Queenscliff, Rye and Barwon Heads had 1.9, 1.8 and 
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1.4/1,000 persons respectively. The lowest cumulative incidence of 0.2/1000 persons was recorded in 
Ocean Grove (Table 3). 
Table 3: Relative risk of living in the top 5 or disease cluster areas. 
 
 
Location or 
cluster 
 
 
Resident 
Population 
(N) 
 
 
Period in 
review 
 
 
Total 
cases 
(n) 
 
 
Mean  cases 
number/ 
year 
 
 
Absolute 
risk  
(%) 
 
 
Mean annual 
incidence/ 1000 
inhabitants 
 
 
Relative risk  
(Ci 95%) 
Barwon Heads  3,875 2006-2016 61 5.5 2 1.4 111 (86 -143) 
Ocean Grove 14,165 2005-2016 39 3.3 < 1 0.2 19  (14 -26) 
Point 
Lonsdale 
2,684 2002-2016 103 6.9 4 2.6 274 (224 -335) 
Queenscliff 1,315 2004-2016 33 2.5 3 1.9 171 (122 -241) 
Rye 8,416 2012-2016 74 14.8 1 1.8 63 (50 -80) 
Combined (5) 30,455 2002-2016 310 20.7 1 0.7 101 (88 -116) 
        
Space-Time        
Cluster 1 61,723 2001-2016 399 26.6 < 1 0.4 75 (66 -86) 
Cluster 2 - 2011 2016 598 99.6 - - - 
Cluster 3 73,072 2005-2016 62 5.2 < 1 0.1 6 (5 - 8 ) 
Cluster 4 638,943 2016 50 50 < 1 0.1 1 (0 - 1) 
Cluster 5 18,033 2002-2010 14 1.6 < 1 0.1 5 (3 - 9) 
        
Purely spatial        
Cluster 1 61,723 1994-2016 402 17.5 1 0.3 76 (67 -87 ) 
Cluster 2 64,706 1994-2016 63 2.7 < 1 0.0 7 (5 - 9) 
Cluster 3 16,140 1994-2016 24 1.0 < 1 0.1 10 (7 -15) 
Cluster 4 101,677 1994-2016 53 2.3 < 1 0.0 4 (3 - 5) 
 
 
The Space-time and purely spatial primary cluster,  also known as the most likely cluster (Cluster 1, Fig 3) 
where observed cases are significantly higher than expected, which circumscribes areas on the Bellarine 
and Mornington Peninsulas had relative risk of 75 (66 - 86) and 76 (67 - 87) and mean annual cumulative 
incidence of 0.4 and 0.3/1,000 persons respectively. Relative risk of the remaining clusters was ≤ 10. 
Cumulative incidence recorded in cluster 2, 3 and 4 of the purely spatial analysis were less than 1 (0.0-
0.3/1,000 persons, Table 3). The same could be said for the remaining space-time clusters (3, 4 and 5, Fig 
3) with 0.1/1,000 persons (Table 3). 
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Absolute risk and incidence rate for age groups and gender within the top five Residents’ locations 
The highest absolute risk of 7% was found among the > 75 year group in Point Lonsdale (Table 4). 
Queenscliff had the next highest risk of 5% among the same age group. The next age group with the second 
highest absolute risk was among the 55-64 year group found in Point Lonsdale (5%) and Queenscliff (4%). 
The third highest absolute risk of 4% was found in Point Lonsdale among the 15-24 year group. The 
remaining absolute risk varied considerably among the rest of the suburbs (range: 0 to 4%) (Table 4). The 
absolute risk of 3% for all the suburbs combined was among the > 75 year group followed by 55-64 and 
65-74 year groups with both having 1% each (Table 5). Absolute risks and incidence rate among gender 
was not statistically significant (Table 6, p = 0.81). Age was a risk factor in the five endemic areas (Table 
4, p = 0.00). 
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 Table 4: Buruli ulcer absolute risk (%) for age groups within each of the top five Residents’ location using 2016 population 
census data 
 
 
n= number of BU cases for that age group 
pop= total number of Residents with that age group in the suburb 
% = absolute risk calculated for that age group in the suburb (n/pop) x 100. 
PL= Point Lonsdale 
OG= Ocean Grove 
BH= Barwon Heads 
QC= Queenscliff 
Age group is a risk factor in the endemic areas (p = 0.00)
  PL   OG   BH   QC   Rye  
Age group  
n 
 
pop 
 
% 
 
n 
 
pop 
 
% 
 
n 
 
pop 
 
% 
 
n 
 
pop 
 
% 
 
n 
 
pop 
 
% 
0-14 6 364 2% 2 2,904 <1% 7 928 1% 3 139 2% 9 1,393 1% 
15-24 7 168 4% 2 1,327 <1% 9 348 3% 0 100 0% 3 691 < 1% 
25-34 5 138 4% 3 1,358 <1% 5 237 2% 1 58 2% 5 775 1% 
35-44 9 233 4% 3 1,990 <1% 5 562 1% 1 77 1% 5 1,023 1% 
45-54 3 282 1% 3 1,844 <1% 2 523 <1% 2 167 1% 9 1,055 1% 
55-64 20 395 5% 8 2,011 <1% 12 566 2% 11 250 4% 13 1,218 1% 
65-74 17 542 3% 8 1,680 1% 9 450 2% 4 299 1% 12 1,325 1% 
75+ 36 543 7% 10 1,061 1% 9 246 4% 10 213 5% 14 933 2% 
 
Total 103 2,665  39 14,175  58 3,860  32 1,303  70 8,413  
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Table 5: Buruli ulcer absolute risk for age group for the top five Residents’ location combined using 
2016 population census data. 
 
 
 
Age group 
 
 
Total  BU cases 
 
Total 
number of 
age group 
 
 
Absolute 
risk 
   0-14 20 5,728 <1% 
15-24 21 2,634 1% 
25-34 19 2,566 1% 
35-44 31 3,885 1% 
45-54 17 3,871 <1% 
55-64 64 4,440 1% 
65-74 50 4,296 1% 
75+ 79 2,996 3% 
Total 301 30,416  
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Table 6: Buruli ulcer incidence rate and absolute risks for gender in the top five Residents’ locations 
 
 
Suburb 
 
 
Total pop 
 
 
n (Female) 
 
 
n (Male) 
 
 
Year under 
review 
 
 
BU cases 
(Female) 
 
 
BU cases 
(Male) 
 
 
Ci  
(Female) 
 
 
Ci  
(Male) 
 
 
Absolute risk  
%(Female) 
 
 
Absolute 
risk 
%(Male) 
Barwon Heads 3,875 1,976 1,899 2006-2016 26 35 < 1 < 1 1 2 
Ocean Grove 14,165 7,366 6,799 2005-2016 18 21 < 1 < 1 < 1 < 1 
Point Lonsdale 2,684 1,369 1,315 2002-2016 51 52 < 1 < 1 4 4 
Queenscliff 1,315 6,97 618 2004-2016 15 18 < 1 < 1 2 3 
Rye 8,416 4,250 4,166 2012-2016 26 48 < 1 < 1 1 1 
Total 30,455 15,658 14,797 2002-2016 136 174 < 1 < 1 1 1 
 
Mean annual cumulative incidence (Ci) and absolute risk among gender was not significant (p > 0.05).
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DISCUSSION 
 
Progression of disease in Victoria- Buruli ulcer continues to be reported in Victoria after the first cases in 
Bairnsdale area of East Gippsland in the 1930s (13,14). Previously  studies have concentrated in focal areas, 
especially in the Bellarine Peninsula and more specifically Point Lonsdale to understand the progression 
and transmission of the disease (12,19,32). The incidence rate in Victoria from 1994 to 2016 was 
0.8/100,000 persons. Cases in Point Lonsdale have been decreasing and there is a gradual movement of BU 
case towards south-eastern Victoria and the reason is unclear. Though the BU database provides disease 
cases from 1994, temporal analysis identified that disease clustering became significant in 2011 (Fig 4). 
However space-time analysis reports disease clustering in Bellarine and Mornington Peninsulas from 2001 
to 2016 (Fig 3). Some of the secondary clusters detected may indicate Residents’ not living in known 
endemic areas with exposure to new endemic regions (Fig 3). It is worth noting that increase in cases has 
not been uniform in Victoria and there are top five endemic locations (Fig 5). In addition, the most likely 
disease cluster detected circumscribed the Bellarine and Mornington Peninsulas (Fig 3).  The reason for 
such a shift is unclear. It is plausible that the high concentration of people in metropolitan areas, increase 
in population and construction of new settlements in these areas could play a role to recent rise in cases. 
This is evident from the demographic changes that have taken place since 2006. There was no direct 
correlation between incidence rate and rainfall data analysed at three data points at the local scale presented 
in this study. We are aware that, to expect incidence rate to rise with rainfall pattern alone, is an 
oversimplification as the transmission pattern of M. ulcerans to humans could be far more complex and 
may involve several critical points at larger scale (33) and intermediate hosts as described by Roche et al., 
2013 (34). 
The month with the highest notifications in the BU database was August. Previous studies have reported 
the median incubation period of BU to be 4.5 months (range: 1 to 9 months) after infection (35). This 
suggests that more people would have been exposed or infected in autumn, March-April (4.5 months 
median lag period) or November-February (9 months maximum lag period), which is the summer period in 
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Victoria. This was similar to previous studies (15,35,36). This is not surprising as more outdoor activities 
occur during the summer and autumn periods. Increased contact with the environment was observed from 
the activities undertaken by Visitors in the perceived exposure sites were mostly holiday related (data not 
shown). Comparison of the month of notification among Residents and Visitors for the top 5 exposure sites 
(Fig 6) showed close similarity to the trend in Victoria (Fig 2D). This may confirm that exposure sites of 
M. ulcerans is likely to be in the top five Residents’ locations (Fig 5A).  
However, Fig 2D may suggests that as cases increases in Victoria, more new suburbs are detected among 
(Residents). This trend could be interesting and may suggest wider foci of risk factors across Victoria than 
probably suspected. These new suburbs may describe breeding grounds for the next outbreak.  
Age and gender disparities in BU cases in Victoria- Though males reported more cases within the 
database, there was no statistically significant difference in incidence rate and absolute risk between 
genders. A closer look at Residents’ and Visitors’ profile of the top five endemic areas for gender, showed 
no significant difference as well (Table 2) indicating that gender did not appear to be  a risk factor for BU. 
Age was a risk factor in the endemic areas (Table 4, p = 0.00). The association of age and gender in BU 
transmission have previously been reported both in Africa and Australia (22,37). In Africa, gender was not 
a risk factor however, age was a risk factor especially among the less than 15 and over 79 year age groups 
(6,22). Previous studies in Victoria also showed no difference in gender, but the over 60 age group were 
most affected. In Australia, this has been attributed to immunosenescence (37,38) . Our findings agree with 
previous studies in Victoria. The findings in this study limits generalization of BU case reports in Victoria, 
because the trend observed in the State is heavily influenced by only a few suburbs and highly focal. 
Absolute risk was unusually high (4%) among the 15-24 age group in Point Lonsdale which has never been 
reported before. 
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CONCLUSION 
We acknowledge that BU incidence rate from 1994 to 2004 will be underestimated as in these years we 
relied on voluntary reporting (this would have missed a significant number of cases). After the identification 
of the first BU cases 86 years ago, BU still presents a major public health concern. There has been a dramatic 
increase in number of BU cases since 2010. The debilitating features and associated complication presents 
a significant burden to patients and subsequently high medical costs (39,40). This study has provided a 
detailed profile of the epidemiology of BU cases in Victoria utilizing the BU database (1994 to 2016). 
Increasing population and construction of new settlements may have contributed to the recent BU rise in 
some areas. Gender is not a risk factor, however age is. The age group most affected in Victoria were the ≥ 
60 years. This has been attributed to immunosenescence. The distribution pattern of BU cases or emergence 
observed in our study is not  random, as have previously been reported (33). Spatial disease clusters have 
been detected in Victoria and for the first time they have been tested and four spatial clusters have been 
found significant. The most likely cluster is on the Bellarine and Mornington Peninsulas. 
The incidence rate observed in the most likely disease cluster area was 40/100,000 persons from 1994 to 
2016 (space-time analyses). The relative risk for the top five locations combined was 101. There is a strong 
confirmation of the top five patients’ location (Residents) being the environmental source of M. ulcerans 
exposure. The identification of specific environmental factors is still lacking. It is plausible that behavioural 
patterns of Residents and Visitors could provide key information of specific risk factors. Analysing the daily 
activities or lifestyle pattern of Residents requires further study. Therefore, future case control studies could 
be designed to describe the daily activities of Visitors (e.g. hiking or swimming, where and when) during 
their stay. This could provide valuable information regarding identification of possible risk factors. In 
addition, since M. ulcerans is an environmental mycobacteria, extensive environmental sampling would be 
necessary to determine the exact source of transmission to humans for public health intervention. 
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Abstract
Mycobacterium ulcerans is recognised as the third most common mycobacterial infection
worldwide. It causes necrotising infections of skin and soft tissue and is classified as a
neglected tropical disease by the World Health Organization (WHO). However, despite
extensive research, the environmental reservoir of the organism and mode of transmission
of the infection to humans remain unknown. This limits the ability to design and implement
public health interventions to effectively and consistently prevent the spread and reduce the
incidence of this disease. In recent years, the epidemiology of the disease has changed. In
most endemic regions of the world, the number of cases reported to the WHO are reducing,
with a 64% reduction in cases reported worldwide in the last 9 years. Conversely, in a smal-
ler number of countries including Australia and Nigeria, reported cases are increasing at a
rapid rate, new endemic areas continue to appear, and in Australia cases are becoming more
severe. The reasons for this changing epidemiology are unknown. We review the epidemi-
ology of M. ulcerans disease worldwide, and document recent changes. We also outline and
discuss the current state of knowledge on the ecology of M. ulcerans, possible transmission
mechanisms to humans and what may be enabling the spread of M. ulcerans into new
endemic areas.
Background
Mycobacterium ulcerans is a slow-growing organism that causes necrotising infections of skin
and soft tissue and is classified as a neglected tropical disease by the World Health
Organization (WHO) [1]. Ulcers are the most common form of disease, but it can also mani-
fest as a subcutaneous nodule, plaque or as a diffuse and aggressive oedematous form, and can
be complicated by osteomyelitis [2–4] (Fig. 1). The disease is known internationally as Buruli
ulcer (BU) after the county in Uganda where cases were described in the 1960s. Previously,
wide surgical excision was the treatment of choice [5], but dual antibiotic combinations
have recently been shown to be highly effective at curing lesions [6, 7] and are now the recom-
mended first-line treatment [2, 8]. Surgery is used to aid wound healing and prevent deform-
ity, or if antibiotics are not tolerated, contraindicated or declined [8]. If diagnosed and treated
early, outcomes are excellent, but if left untreated, the disease can progress resulting in high
levels of morbidity and permanent disability [4, 9].
In Africa, the disease affects mainly children [4] with more than 50% of cases occurring in
those 5 to <15 years of age. Conversely in Australia, it affects mainly adults, with a median age
of about 60 years [10]. Nevertheless it can occur in all age groups, is found in males and
females equally [4, 11, 12], and in Africa it commonly affects those living in remote areas
with limited access to health care [4, 13]. The majority of people affected are overtly immuno-
competent, though there appears to be an increased risk in those who are HIV-positive [14],
and those who are immune suppressed are at risk of developing more severe disease [3, 15]. In
Africa, the disease occurs most commonly in rural and resource-limited settings where access
to safe water and sanitation is low, whilst in Australia, it occurs in high-income settings with
access to high-level sanitation and treated water. Sero-epidemiological surveys in Africa sug-
gest that only a small proportion of those exposed to M. ulcerans develop disease [16].
Emergence of BU worldwide
Although an outbreak of skin ulcers resembling BU was reported from Uganda in 1897, the
first confirmed reports of BU were from Australia in 1948 in patients residing in the
Bairnsdale region in south-eastern Victoria, where it is known as the Bairnsdale ulcer [17].
It has now been reported from 33 countries [1] and is the third most common mycobacterial
disease worldwide in immunocompetent people after tuberculosis and leprosy [18] (Table 1
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and Fig. 2). Confirmed cases of Buruli were then reported from
three countries in the 1950s; Democratic Republic of Congo
(DRC) [19], Mexico [20] and Uganda [21]. Nine countries across
three continents reported their first cases in the 1960s; in Central
Africa (Angola [20], Congo [22] and Gabon [23]), in West Africa
(Nigeria) [20], in Asia and the Pacific (Papua New Guinea [24],
Malaysia [25] and Indonesia [20]) and in South America (Peru
[20] and French Guiana [20]). During the 1970s, cases were
reported from West Africa for the first time (Benin [20], Ghana
[26], Sierra Leone [20] and Cameroon [27]). In the 1980s, Ivory
Coast [28] and Liberia [29] were added to the list of West
African countries recording their first cases, along with Japan
[30], Kiribati [31] and Suriname [32]. In the 1990s, four countries
were added from West Africa (Burkina Faso [33], Equatorial
Guinea [20], Togo [34] and Guinea [20]) as well as Sri Lanka
[20] and China [35] from Asia. In the 2000s, Brazil reported
cases for the first time [36] in addition to the East and Central
African countries Kenya [37], Malawi [20], South Sudan [20]
and Central African Republic [18].
Current epidemiological situation
The greatest burden of disease is found in West and Central
Africa where the highest number of cases are reported from
Cote D’Ivoire [39], Benin [40], Ghana [41], Cameroon [42] and
the DRC [43]. Estimated incidence rates include 21.5 per 100
000/year in parts of Benin [40] and 20.7 per 100 000/year in
Ghana overall with up to 158.8 per 100 000/year in some affected
districts [41]. Cases continue to be reported from South America
(mainly in French Guiana) [38, 44, 45], Asia and the Pacific
(mainly in Papua New Guinea) [18,20]. BU is predominantly
found in tropical and subtropical climates, apart from south-
eastern Australia [12, 46] (with estimated incidence rates of up
to 404 per 100 000/year) [47], China and Japan [48] (Table 1).
In Australia, it has also been reported from tropical areas in
Queensland, where it is known as the Daintree ulcer [49–51],
and in the Northern Territory [52]. Importantly, case numbers
reported by countries may be influenced by political stability,
access to health care, funding for case detection activities, quality
of reporting systems and availability of diagnostics. For example,
an exhaustive field survey conducted in DRC involving more
than 39 000 households showed that only 7% of active BU
cases were captured in the hospital-based reporting system [53].
In recent years, the number of disease cases reported to the
WHO worldwide has been steadily decreasing; from 5156 cases
in 2008 to 1864 cases in 2016 – a reduction of 64% (Fig. 3). This
mainly reflects reductions in Africa where there has been a decline
in most of the highest prevalence countries (Table 1). For example,
Cote D’Ivoire reported 2679 cases in 2009 and only 376 cases in
2016 (86% reduction), Ghana’s reported cases reduced from 1048
in 2010 to 371 in 2016 (65% reduction) and Benin’s from 1203
cases in 2007 to 312 in 2016 (74% reduction). An African country
going against the trend is Nigeria, where cases were first reported in
2009 and have increased from 24 in that year to 235 in 2016 (879%
increase). Case incidence reported from French Guyana has also
decreased from 6.07 cases per 100 000 person-years in 1969–1983
to 4.77 cases per 100 000 person-years in 1984–1998 and to 3.49
cases per 100 000 person-years in 1999–2013 [38].
Conversely, in Australia, the number of reported cases has
been increasing with 186 reported in 2016 compared with 42 in
2010 (343% increase). This mainly reflects a rapidly increasing
number of cases reported from the coastal regions of the south-
eastern state of Victoria where there has been a 248% increase
in cases in the last 4 years (79 cases in 2014 to 275 in 2017). In
this region, the disease has emerged in new geographical areas
including the Mornington Peninsula outside of Melbourne, and
the proportion of cases presenting with severe disease has doubled
since 2010 [10]. Paradoxically, in two adjacent peninsulas sepa-
rated by only a few kilometres of ocean with similar climate
and resident populations, there are diverging epidemics – increas-
ing case numbers on the Mornington Peninsula and reducing case
numbers on the Bellarine Peninsula [54].
Ecology of BU
Evidence indicates that M. ulcerans likely evolved from M. mari-
num by acquiring a virulence plasmid that produces its patho-
genic mycolactone toxin [55] and allowed it to adapt to a
specific environmental niche [56]. Laboratory conditions that
favour the growth of M. ulcerans are low oxygen [57], relatively
low temperatures (28–33 °C) [58, 59], moderately acidic environ-
ments (pH 5.4–7.4) [60] and low levels of ultra violet rays [58].
This may explain why M. ulcerans is often found at the bottom
of aquatic habitats or protected by biofilms [61]. However, despite
extensive research, the environmental reservoir of the organism
and mode of transmission of the infection remain unknown. A
major factor limiting this understanding is that the organism
can rarely be cultured from the environment [62], although
PCR testing of water, aquatic plants, soil and detritus from
swamps can show evidence of M. ulcerans [47, 63–67].
In endemic areas, the disease is highly focal with endemic and
non-endemic areas separated by only a few kilometres [12, 13]. It
is usually associated with wetlands, especially those with slow-
flowing or stagnant waters such as floodplains or swampy areas
[13, 65]. Studies have suggested that farming activities close to riv-
ers [39] and swimming in rivers in endemic areas [68] are risk
Fig. 1. A severe Mycobacterium ulcerans lesion on the knee of an 11-year-old boy.
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factors for acquisition of BU. The construction of dams and irri-
gation systems have also been associated with increased cases [69],
although in French Guyana, a reduction in cases has been
observed, likely related to reduced flooding of downstream
districts [70]. A major process of land-use change, deforestation,
is known to result in increased erosion, which has been speculated
to result in run-off contamination of water bodies with M. ulcer-
ans [71]. Deforestation has also been found to alter the
Table 1. Countries with published reports of Buruli ulcer cases including year of initial report and changes in numbers of cases reported over time
Country
Year cases first
reported and
reference
Year of peak disease
cases reported to WHO
2002–2016
Peak number of cases
reported to WHO in a
year
2016 cases
reported to
WHO
Percentage change in 2016
from peak reported cases in
a year
Angola 1960 [20] NA NA NA –
Australia 1940 [17] 2016 186 186 Peak
Benin 1977 [20] 2007 1203 312 −74%
Brazil 2007 [36] NA NA NA –
Burkina Faso 1998 [33] NA NA NA –
Cameroon 1973 [27] 2004 914 85 −91%
Central African
Republic
2008 [18] 2008 3 NA –
China 1997 [35] NA NA NA –
Congo 1966 [22] 2006 370 NA –
Democratic
Republic of
Congo
1950 [19] 2004 487 175 −64%
Equatorial Guinea 1998 [20] 2005 3 NA –
French Guiana 1969 [20] 2002 27 [38] NA –
Gabon 1968 [23] 2005 91 39 −57%
Ghana 1971 [26] 2006 1048 371 −65%
Guinea 1993 [20] 2006 279 72 –74
Indonesia (not
confirmed)a
1960 [20] NA NA NA –
Ivory Coast 1980 [28] 2009 2679 376 −86%
Japan 1989 [30] 2011,2013 10 2 −80%
Kenya 2008 [37] NA NA NA –
Kiribati (not
confirmed)
1987 [31] NA NA NA –
Liberia 1981 [29] 2015 105 NA –
Malawi (not
confirmed)a
2001 [20] NA NA NA –
Malaysia 1964 [25] NA NA NA –
Mexico 1953 [20] NA NA NA –
Nigeria 1967 [20] 2016 235 235 Peak
Papua New
Guinea
1962 [24] 2004 31 16 –48
Peru 1969 [20] NA NA NA –
Sierra Leone 1975 [20] 2011 28 NA –
South Sudan 2001 [20] 2002 568 NA –
Sri Lanka (not
confirmed)a
1992 [20] NA NA NA –
Suriname 1984 [32] NA NA NA
Togo 1996 [34] 2004 800 83 −90%
Uganda 1958 [21] 2002 117 NA
aThe presence of M. ulcerans was not microbiologically confirmed in this report.
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composition of freshwater communities in French Guiana,
impacting the abundance of M. ulcerans [72].
In Victoria, Australia, native and domestic mammals including
possums, dogs, cats, koalas, horses and alpacas have developed
disease [47], but whether they are intimately involved in transmis-
sion, or accidental hosts, remains unclear. Outside of Australia,
M. ulcerans has rarely been detected in vertebrates, although
lesions on a wild mouse (Mastomys sp.) from Ghana [73] and
on a goat and dog from Benin have been found PCR-positive
for M. ulcerans [74], as have domestic duck faeces in Cameroon
and wild agouti faeces in Ivory Coast [75, 76]. In contrast, a
range of aquatic invertebrates from numerous taxa representing
several orders have been found positive for M. ulcerans DNA
from many locations in Africa [65, 77].
Recent evidence from Australia suggests that whatever the
source in the environment, it may only persist for a short time
[78]. In 21 patients with M. ulcerans who were part of a family
cluster, the median time to diagnosis between family members
was 2.8 months, and none were diagnosed more than 23 months
apart in a cohort spanning 18 years and nearly 2000 combined
years of elapsed time since diagnosis. This suggests that in this
setting the exposure risk is short term, and thereafter diminishes.
Environmental studies in Cameroon found that samples from a
water hole used by local people remained PCR-positive for
more than 2 years, and at least 12 months after all local human
M. ulcerans disease cases were treated and cured [75]. This sug-
gests that although the risk of disease transmission has dimin-
ished, the organism may continue to persist for longer periods
in some environments.
Spread of BU into new areas
The mechanism by which M. ulcerans is introduced into new
areas is unknown. However in Australia, research using popula-
tion genomics suggests that the organism has moved from east
to west in the southern state of Victoria, and that this relates to
the introduction and expansion of M. ulcerans into new environ-
ments rather than an awakening of quiescent pathogens [79]. Also
by analysing the population genomics of isolates from 11 different
countries in Africa, Vandelannoote et al. concluded that the
spread of M. ulcerans across Africa was a relatively modern phe-
nomenon and one that had escalated since the late 19th and the
early 20th centuries [80]. Their work suggested human-induced
changes and activities were behind the expansion of M. ulcerans
in Africa with humans with active BU lesions inadvertently con-
taminating aquatic environments during water contact activities.
In Australia, it is possible that the dispersal of possums or their
active transfer by humans from one area to another may promote
the introduction of M. ulcerans into new areas. Urban develop-
ment may also increase the disease risk because possums can
reach high population densities in remaining refuge habitats
(e.g. parks, ‘bush-style’ gardens) due to their generalist nature
and ability to utilise human environments and food sources
[81, 82]. Regardless of whether they are directly involved in intro-
ducing disease, as possums themselves develop BU, they could act
as sentinel animals for detecting the emergence of M. ulcerans
disease in new areas in Australia [83].
Transmission of BU to humans
Insects such as mosquitoes [84, 85] and aquatic biting arthropods
[59, 86] have been proposed as vectors for transmission, but this
remains an open question [66]. Mosquitoes in Australia have
tested positive for M. ulcerans by PCR [85] and there are epi-
demiological links such as the use of insect repellent on exposed
body surfaces and the use of mosquito nets being associated with
a reduction in M. ulcerans incidence [84, 87]. Additionally, in
Australian towns in an endemic area, a strong dose–response rela-
tionship was found between the detection of M. ulcerans in mos-
quitoes and the risk of human disease [88]. Possible mechanisms
for infection may involve direct inoculation of the organism
under the skin via a bite, as suggested by a recent study showing
Fig. 2. Map of countries reporting Buruli ulcer cases, stratified by year of first report. Note that each country is represented by its administrative area and that Buruli
ulcer did not occur throughout each country. France is represented for its overseas department French Guiana – there has been no case in metropolitan France.
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that if the skin already surface contaminated with M. ulcerans is
subjected to a puncturing injury in the form of a needle or a
bite from a live mosquito, then M. ulcerans lesions can develop
at the puncture site [89]. Alternatively, infection may result
from a bite leading to a wound which is secondarily infected by
M. ulcerans from environmental sources such as soil. Although
arguing against this is evidence from a guinea pig model where
applying M. ulcerans organisms directly to abraided skin did
not establish infection – instead infection was only established
when organisms were inoculated under the skin [90]. It has
been proposed that mosquitoes carry the organism on their pro-
boscis following contact or feeding with contaminated environ-
mental sources and then directly transmit it through their bite
[85], although the widespread nature and potential travel of mos-
quitoes both inside and outside the restricted geographic regions
affected by BU argues against this. Nevertheless, it is possible that
mosquito movements between the affected and unaffected areas
may be limited as some implicated mosquito species, such as
Aedes notocsriptus, have short flight distances and low dispersal
ability [91], whilst specific larval habitat requirements can also
restrict distribution [92]. If affected mosquito populations in
BU endemic areas were relatively isolated from other populations,
this could result in the geographic restriction observed.
The strongest evidence for a zoonosis comes from Australia
involving native mammal species; the common ringtail
(Pseudocheirus peregrinus) and common brushtail (Trichosurus
vulpecula) possums. Research has found that 19% of these ani-
mals in an endemic area (Point Lonsdale on the Bellarine
Peninsula) had M. ulcerans clinical disease, whilst a further 14%
were asymptomatic but had high levels of M. ulcerans DNA
detected on PCR examination of their faeces [47]. In addition,
the location, proportion and concentration of M. ulcerans DNA
in possum faeces strongly correlated with that of human M. ulcer-
ans disease cases in at least two outbreaks where it has been mea-
sured: Sorrento on the Mornington Peninsula [83] and Point
Lonsdale on the Bellarine Peninsula [47]. Additionally, in nearby
areas with no cases of human disease possum faeces were not
found to containM. ulcerans DNA [47]. It is theoretically possible
that infected possums amplify the organism in the environment
[93], leading to an increased risk of infection via contact with a
contaminated environment, or an intermediate vector such as a
mosquito could mechanically transmit the bacteria from infected
possums to humans via a bite. Further research is required to
investigate these potential transmission mechanisms and
determine if possums play a pivotal role in the transmission of
disease to humans or whether they are simply accidental hosts.
In Africa, M. ulcerans has been detected by PCR in aquatic
insect species in the order Hemiptera (families: Naucoridae and
Belostomatidae), which are known to bite humans, suggesting
that transmission may occur through these bites [59]. This is sup-
ported by the detection of M. ulcerans in the salivary glands of
these insects after eating snails containing the organism [94],
and the finding that it can also be transmitted to laboratory
mice via their bite [86]. In an outbreak in Philip Island,
Australia, it was postulated that aerosols generated by spray irriga-
tion using contaminated water may have disseminated M. ulcer-
ans and infected humans via the respiratory tract, or through
contamination of skin lesions and minor abrasions [95], but
this has not been proven.
Another recent study on an Australian cohort [78] confirms
previous suggestions that human-to-human transmission does
not occur [96]. Although cases were often clustered amongst fam-
ilies (6.5% of cases had another family member affected), the
short time period between the diagnosis of family clustered
cases (median 2.8 months) was shorter than the estimated incu-
bation period of the disease (4.5 months) [78]. Additionally,
whole genome SNP analysis of isolates from three paired family
clusters revealed isolates derived from two of the three family
clusters were not genetically identical and family cluster isolates
were not any more genetically related than those of six random
isolates from the same geographic region [78].
The location of clinical M. ulcerans lesions provides some
information about possible transmission mechanisms. A study
of 649 lesions in 579 Australian patients revealed that most lesions
were on exposed body areas, notably upper and lower limbs, and
were commonly over a joint. Few lesions were found on the head
and neck, palms of hands, soles of feet and trunk [97].
Furthermore, the distribution was non-random, with a strong pre-
dilection for ankles, elbows and calves. Differences in the pattern
of lesion distribution were also found between genders (men had
more lesions on upper limbs and less on lower limbs than
women), age groups (those aged ⩾65 years were less likely to
have proximal upper limb lesions compared with those <65
years) and season of likely acquisition (lesions on the arm and
shoulder were more common amongst those likely acquired in
the warmer months). Age, gender and seasonal differences may
relate to exposure risk via such mechanisms as trauma, insect
bites or soil contact relating to differences in clothing worn or
Fig. 3. Number of Buruli ulcer cases worldwide reported to the
WHO from 2002 to 2016.
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activities undertaken. Similar findings have also been reported
from a smaller study in Cameroon [98]. Case–control studies in
Africa have also identified wearing short lower body clothing
whilst farming as risk factors for M. ulcerans [99] and covering
limbs during farming as protective for M. ulcerans [100]. These
findings suggest that M. ulcerans transmission and pathogenesis
may be similar across the world despite very different geograph-
ical and climatic conditions.
Transmission also appears to be seasonal. In Australia, the
large majority of cases (>70%) are likely acquired in the warmest
6 months of the year [97], and in Cameroon, the likely time of
infection was seasonal and highest between the months of
August and October [101]. Studies have also reported an associ-
ation with rainfall; studies from Ghana and Cameroon report
that the proportion of M. ulcerans-positive samples from the
environment was higher during the months with higher rainfall
levels than during the dry season months [101, 102] and reports
from French Guyana [70] and Australia suggest an increase in
cases associated with periods of high rainfall followed by dry per-
iods [103].
Future prospects
The epidemiology of M. ulcerans has clearly changed over time
and is expected to continue evolving into the future. Although
the explanations for this are not fully understood, the processes
associated with increasing anthropogenic land-use change such
as deforestation, road construction, flooding and population
settlement may have significant impacts on this environmental
pathogen, affecting both its future distribution and human expos-
ure risk [93]. For example, the increase in cases in recent years
observed in south-eastern Victoria, Australia, may be reflective
of the impact of new residential developments which may have
altered the environment and impacted both aquatic and terrestrial
communities, including a proposed reservoir of M. ulcerans, the
possum.
Flooding, through environmental disturbance and contamin-
ation of aquatic habitats, has regularly been linked to outbreaks
of BU [93]. As dams alter the degree and frequency of down-
stream flooding, the increase in dam building occurring in
many regions where BU is endemic, may also alter the distribu-
tion of this pathogen. Climate change will likely also be influen-
tial, through altered temperatures, increased frequency of
extreme weather events and intense flooding events, and inunda-
tion of coastal foci, such as the Victorian hot-spot, through
changes in sea level. The increased mobility of today’s societies
may additionally help to modify the distribution of M. ulcerans,
by altering the genetic variants of this pathogen present in an
area (as found in the Offin river valley in Ghana) [104], and by
providing opportunities for the establishment of new foci where
suitable environmental conditions exist.
Conclusions
The reasons for the changing epidemiology of BU worldwide are
unknown. Possibilities include changing environmental condi-
tions such as rainfall and temperature in the era of climate
change, changes in population dynamics and land use, improved
sanitation and access to healthcare or reduction in exposure
through such things as increasing mosquito net use, or spill-over
into humans from epidemics in animal reservoirs. Additionally, if
humans represent the disease reservoir, it has been speculated that
a reduced burden of disease in humans through improved case
detection and increasing antibiotic use may be responsible for
the reduction in cases in Africa [80]. However, the situation of
increasing cases in Australia, where there is good access to med-
ical care and antibiotic treatment is widely used argues against
this explanation. An alternative explanation may be that improve-
ments in the accuracy of diagnosis since PCR confirmation was
introduced have reduced over-reporting of cases [105].
Importantly, cases of disease have been decreasing in most
countries in recent years indicating a hopeful, positive trend.
However, despite recent insights, it still has not been conclusively
determined how this pathogen circulates in the environment, or
how transmission to humans occurs. This requires the availability
of robust scientific knowledge acquired by a thorough and
exhaustive examination of the environment, local fauna, human
behaviour and characteristics, and the interactions between
them [106]. Only with this knowledge can control strategies or
early warning systems be designed and implemented that effect-
ively and consistently prevent the spread and reduce the incidence
of this disease.
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